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Human cytochrome P450 (CYP) enzymes belong to a family of monooxygenase enzymes 
that are responsible for the metabolism, in a stereo-specific and stereo-selective manner, 
of diverse chemicals. These chemicals are often referred to as xenobiotics which are 
usually harmful and toxic to the human organism. CYP enzymes play a key role in the 
metabolism of pharmaceutical drugs, making them more soluble for excretion from the 
human body. Human CYPs are also naturally involved in the biosynthesis of vitamins, 
steroids, fatty acids, lipids and cholesterol.  
A CYP enzyme requires a CYP reductase (CPR) for it to be active. Both CYPs and CPR 
are bound to the intracellular endoplasmic reticular (ER) membranes. The presence of a 
CPR is absolutely essential for membrane-bound CYP activity. It seems another ER-
bound protein, cytochrome b5, is required for the activity of some CYPs. However, 
cytochrome b5’s role in CYP activity is not clearly understood.  
Drug metabolism research in pharmaceutical industry involves accurately (a) determining 
the potential of a drug and its metabolites to inhibit CYP enzymes and (b) identifying its 
metabolites which are formed through CYP-mediated biotransformation reactions. The 
degree of success in drug metabolism research is a crucial measure for approval/rejection 
of a drug by regulatory authorities. However, drug metabolism studies take place only in 
the pre-clinical – clinical interface which is quite late in the drug discovery process for a 
failure to occur, which unfortunately happens quite often. Drug metabolism studies are 
not performed any earlier primarily because CYP enzymes are extremely costly and are 
difficult to use because of their inherent instability at room temperature. The experiments 
performed in this thesis attempt to address these issues. The main aim of the work was to 
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create a new set of tools that would facilitate the drug discovery process in general but, 
more specifically, allow these reagents to be used by chemists/biologists in early pre-
clinical phase, where they are most needed, by trying to overcome the major hurdles of 
CYP’s costs and stability.  
There are five experimental Chapters (Chapters 3 to 7) of this thesis.  
Chapter 3 describes the expression of 17 human CYP enzymes in baker’s yeast, using 
human CYP genes chemically synthesized with yeast-biased codons. There are 61 codons 
which code for the 20 amino acids that are essential for protein syntheses. It is known that 
the highly expressed genes, in a particular organism, use specific codons which would 
indicate that there is codon bias. Hence, codons used by highly expressed genes in baker’s 
yeast were used to create genetic sequences for human CYP enzymes. These codon-
optimised human CYP genes, in theory, should provide high expression in yeast. 
Therefore, expression of synthetic genes, from episomal (i.e. ‘extra-chromosomal’) 
plasmids, was compared with the expression of native genes, isolated from a human liver 
cDNA library to assess the assumption that yeast-biased codons would provide better 
expression of human CYPs. It was clearly shown that, per constant number of yeast cells, 
the synthetic genes expressed far more CYP activity than the native genes. It was also 
shown that some CYPs which have been claimed to require cytochrome b5 for their 
activity may not require its presence.  
Chapter 4 describes the expression of one copy of synthetic genes (chemically 
synthesized with yeast-biased codons), from a single yeast ‘chromosomal’ locus to find 
out which locus gives the best expression of human CYP proteins. Expression of genes 
from chromosomal loci allows growth of yeast cells in cheap, ‘non-selective’ growth 
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media, continuously over 5 days, or longer, in shake-flasks or fermentors. In contrast, 
expression from extra-chromosomal, episomal plasmids demand growth of yeast cells in 
‘selective’ growth media, which are expensive, where cell numbers are relatively low, 
and cell growth is restricted to 24 h. It has been speculated that, heterologous (i.e. foreign) 
gene expression from yeast depends on the yeast proteins that reside in the neighbourhood 
of the human protein that is being expressed from a particular yeast chromosome. Hence, 
CYP gene expression cassettes (consisting of a promoter, the gene of interest and a 
transcription terminator) were integrated into different chromosomal loci, using 
homologous recombination, a technology which also facilitates gene therapy in human 
cells. The results obtained clearly show that there is differential expression of a human 
CYP enzyme when expressed from the neighbourhood of the yeast ADE2, HIS3 and 
URA3 genes. Indeed, the best human CYP expression occurs from a particular locus of 
chromosome XV, where the yeast HIS3 gene resides.  
Chapter 5 is a continuation of Chapter 4 where two copies of chromosomally integrated 
human CYP genes (chemically synthesized with yeast-biased codons and integrated at 
two different chromosomal loci, via homologous recombination), have been used to 
express human CYPs from baker’s yeast. The goal was to obtain high yields and activities 
of human CYP enzymes. In order to achieve this, a new process was developed for 
isolation of microsomal [i.e. endoplasmic reticular (ER) membrane bound] enzymes. 
CYPs are totally inactive when shorn off these ER membranes. The activities of the 
baker’s yeast produced human CYP enzymes have been compared, head-to-head, with 
the three commercially available enzymes which are produced either from insect cells or 
bacterial cells and which are sold worldwide. Global market size of recombinant CYPs is 
considered to be at least $250 million. The results obtained show that the human CYP 
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enzymes, produced from baker’s yeast, are much more active than the commercially 
available enzymes. The results also suggest that, without embarking on production of 
these enzymes in a cheaper environment, the human CYP enzymes could easily be 
produced in the UK and sold at half the price quoted by the current manufacturers. Yet 
these cheap, highly active enzymes, if marketed, could still provide a profitable margin. 
Because of their cheapness, they could be made widely available for early pre-clinical 
research. 
Chapter 6 explores the use of three CYP-producing recombinant cells for 
biotransformation reactions. It has been reported that, until now, whole cell mediated 
biotransformation reactions generally yield, at best, no more than 10-15% of the product. 
Whole recombinant yeast cells, expressing (a) CYP1A1, (b) variants of human CYP2D6 
and (b) human CYP3A4 have been used to transform (i) chrysin, a natural product, (ii) 
codeine, a CYP2D6 substrate, and (ii) the CYP3A4 substrate, AZD-2014, an Astra-
Zeneca drug in multicentre Phase II/Phase III clinical trials. The results from LC/MS, 
HPLC and TLCs clearly show that there is >80% product formation. They also indicate 
that, in future, organic chemists in pre-clinical drug discovery could use this type of robust 
whole yeast cells, harbouring human CYPs, for bioorganic reactions.  
Chapter 7 describes the successful simultaneous co-production of two or three different 
human CYPs within the same cells. It is likely that two specific CYPs function, in tandem, 
on a substrate. There is also a necessity of determining inhibition of a particular human 
CYP, in the presence of another CYP or other CYPs. It is believed that the inhibition of 
a CYP is likely to be altered in the presence of another CYP through a biochemical 
process known as the ‘crowding effect’. These hypotheses can, in future, be tested using 
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the recombinant cells reported in this Chapter. The cells, co-expressing two or three 
human CYPs, could also be used for both biotransformation reactions and isolation of 
microsomal enzymes. The concept of co-expression of CYPs could also be used, in the 
future, as a stepping stone for creation of liver-like yeast cells which have the ability to 
express multiple CYPs of choice.   
In summary, this thesis describes various yeast systems that have been created for 
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CHAPTER 1 Introduction 
 
1.1 Background 
Every single living creature is exposed to different chemicals. They are known as 
xenobiotics. A xenobiotic is a chemical not produced by the human body ors such, a living 
organism. Essentially, it is foreign to an organism. After assimilation of these hazardous 
chemicals into the human body, the absorbed xenobiotics are eliminated from the body 
effortlessly through bodily liquids like the sweat, urine or faeces. However, the 
xenobiotics that are fat-soluble can build up in the lipid-rich tissues which have no 
mechanism to remove them. This could be lethal to the body. The conversion of 
xenobiotic chemicals to soluble substances helps the body to fight against their 
accumulation and, at the end, avoid any harm. The process of conversion (i.e. 
metabolism) includes transformation of xenobiotics into more polar (i.e. hydrophilic) 
substances which encourages their expulsion from the body, a process known as 
detoxification (Masters 1998). 
The detoxification process happens in three stages. Xenobiotics undergo solubilisation 
via biotransformation reactions directed by Phase I, II and III metabolising enzymes. The 
Phase I enzymes are involved in chemical reactions that catalyse oxidation, reduction or 
hydroxylation. Usually functional groups, such as –OH, –NH2, or –COOH, are added to 
the parent compound (i.e. the xenobiotic) to make it more polar. Mono-oxygenation 
reactions that allow hydroxylation are the most common amongst the Phase I enzymes. 
Hydroxylation involves addition of –OH group(s) to unreactive carbon atoms. They are 
catalysed by cytochrome P450 (CYP) enzymes. Phase II detoxification includes 
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conjugation with a small endogenous substance like glutathione, glucuronic acid, or 
cysteine. Responses in Phase II make the metabolites, obtained from reactions in Phase I, 
considerably more hydrophilic and help in their removal by means of bile or urine. 
Usually, Phase II metabolism further diminishes the pharmacological activity of the 
metabolite obtained in Phase I. Phase III reactions use products gotten from Phase II 
conjugation reactions. These are catalysed by similar enzymes which are dynamic both 
in Phase I and II metabolism (Danielson 2002) . 
Chemical Reactions Involved in different stages of xenobiotic metabolism:  
• Phase I – Oxidation, reduction and hydrolysis, 
• Phase II – Conjugation, 
• Phase III – Oxidation, hydrolysis and deamination.  
 
1.2 The birth of CYP450 (CYP) Enzymes 
The existence of cytochrome P450 (a CYP) was first recognized by Martin Klingenberg, 
(Klingenberg 1958)  who was studying the spectrophotometric properties of pigments in 
a microsomal fraction prepared from rat livers. The term ‘cytochrome P450’ was coined 
in 1962, what was thought to be at that time, as a temporary name for a coloured substance 
in the cell (Mason 1957, Cooper et al. 1965) . This pigment, when reduced and bound 
with carbon monoxide (CO), produced an unusual absorption peak at a wavelength of 450 
nm. Cytochrome is a misnomer given that a CYP is an enzyme rather than a true 
cytochrome. Despite this, the name ‘cytochrome P450’ has remained and is now widely 
accepted. At first, it was believed that there was only a single CYP enzyme. However, 
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today human and other mammals are known to have more than 50 distinct CYP enzymes. 
The total number present in plants is much more than 50, often as high as several hundred 
(usually 400-500). Over the last 15 years, CYP research has largely been concerned with 
defining the multiplicity of CYP enzymes in humans and diverse ranges of organisms. In 
more recent years, with CYP multiplicity having largely been determined, functional 
studies with CYP enzymes have begun to take precedence. 
 
1.3 Naming of CYP450 Enzymes  
Over 1000 different CYPs have partially been characterized in different organisms of the 
biological kingdom. A standardized nomenclature is used to describe the different CYPs 
that have been identified (Nelson et al., 1996). A P450 enzyme is denoted by the acronym 
"CYP" (cytochrome P450), an Arabic number denoting the family, a letter s t a n d i n g  
for the subfamily followed by an Arabic numeral that represents individual enzymes in 
the subfamily.  This nomenclature does not indicate any function of a CYP family 
member.  
There are at least 12 CYP gene families found in humans. Three of these families are 
involved in the metabolism of important drugs (i.e. pharmaceuticals), mainly through 
hydroxylation, which allows excretion of soluble metabolites of the drugs from the body. 
The three CYP families involved in most drug metabolism reactions are CYP1, CYP2 
and CYP3 (Zanger, Schwab 2013) . The family members are identified by the amino acid 
sequences that they have in common. As mentioned earlier, each family consists of sub-
families. Uppercase letters (e.g. 1B, 2C, 3A, 2B) represent the subfamily and each enzyme 
can be further differentiated by Arabic numerals (e.g. 3A4, 2B6, etc.). CYP3A4 is the 
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most abundant CYP enzyme in humans. 30% of all CYP enzymes in the liver and 70% 
of those in the gut consist of CYP3A4. 
As industrial-scale technologies have evolved, organisms including humans have 
continued to be more and more exposed to dangerous chemicals collectively known as 
xenobiotics (Bezirtzoglou 2012) . Xenobiotics are found everywhere. They could consist 
of chemicals which are pollutants, pesticides, medicines, plant alkaloids and toxins, all of 
which human beings have to imbibe during their day-to-day existence. Most of these 
xenobiotics are easily absorbed, due to their lipophilic nature, into the human body via 
the skin, lungs and intestines. If absorbed and not metabolised, they become toxic. A 
xenobiotic has to be converted into a more water-soluble compound before it is excreted. 
The Phase I and Phase II enzymes that are responsible for the metabolism of xenobiotic 





Table 1.1. Reaction and groups of enzymes involved in the metabolism of 
pharmaceutical drug substances. 
 
Class of Reaction Phase I or II Enzymatic Activities 
Oxidation 
Phase I 














Gluthathione conjugation Glutathione S-transferase 




In 1956, JK Grant discovered that in mammalian steroidal hydroxylase systems the 
electron donor is NADPH. Later, it was found that the enzymes that performed steroid 
hydroxylation and which are also involved in cholesterol metabolism are proteins that 
belong to the cytochrome P450 (CYP) family. Some of them are associated with the 
mitochondria while others to the endoplasmic reticulum, which are intracellular 
compartments of a eukaryotic cell. Their activities are all supported by NADPH and two 
other electron-transfer proteins (Manson 1957) .  
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In 1957, Manson introduced the term mixed-function oxidase for oxygenase reactions in 
which the substrate, oxygen and electron donor come together in a tripartite reaction to 
produce (a) a hydroxylated substrate, (b) the oxidised form of the electron donor and (c) 
water. 
In sterol metabolism, hydroxylase enzymes perform irreversible reactions, which often 
results in the conversion of a ubiquitous sterol substrate into a metabolite with selective 
and potent properties. Microsomal (i.e. endoplasmic reticular) fraction of certain cells is 
where the biosynthesis of cholesterol occurs through the anaerobic reaction between 
acetate and squalene. The reaction requires the involvement of oxygen and NADPH (Van 
Tamelen et al. 1966, Cory, Russey & Ortiz de Montellano, P R 1966)  and is catalysed by 
a CYP450 enzyme. This result seems to be in conflict with the data published by (Shozo 
Yamamoto, Konrad Bloch 1970) where they claimed that epoxidation, mediated by an 
enzyme of the CYP family, was not inhibited by carbon monoxide (CO). CYPs ought to 
be inactivated by CO since coordination (binding) of CO to ferrous haem iron de-activates 
its hydroxylase activity.  
Bergstrom, in 1959, provided more evidence for the involvement of CYPs in sterol 
biosynthesis showing that one route for the conversion of cholesterol into bile acids 
involves the hydroxylation of cholesterol to 7α-hydroxy-cholesterol. This process occurs 
mainly in the liver microsomal fractions, the hydroxylation reaction again requiring 
NADPH and oxygen. Although the reaction, which is now known to be mediated by a 
CYP, was inhibited by carbon monoxide, the inhibition was shown to be reversed by light 
at 450 nm (Scholan, Boyd 1968) . 
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In 1995, Mason, Fowlks and Peterson published that in specific enzymatic hydroxylation 
reactions mediated by diverse hydroxylases, molecular oxygen donates an oxygen atom 
that is transferred to the substrate. These hydroxylases formed the basis of the cytochrome 
P450 (CYP) family of enzymes. 
 Cytochrome P450 (CYP) enzymes in humans 
Although there are a number of oxidative enzymes capable of undertaking xenobiotic 
metabolism (e.g. alcohol dehydrogenase, xanthine oxidase and the amine oxidases), the 
main oxidative enzyme system in xenobiotic metabolism involves the family of 
cytochrome P450 (CYP) enzymes.  The CYP enzymes are haem-containing membrane 
proteins that metabolize both foreign chemicals (xenobiotics) and endogenous 
compounds. CYPs are known to act in humans as drug metabolizing enzymes, but in 
human cells the primary purpose of these enzymes is to make essential chemicals, such 
as steroids (i.e. cholesterol) and other important lipids such as prostacyclins and 
thromboxaneA2 (Daum et al. 1999) .  It has been found that some CYPs are intimately 
involved in vascular autoregulation, particularly in the brain (Fleming 2001) . Mutations 
in cytochrome P450 genes or deficiencies at the enzyme levels are responsible for several 
human diseases.  Some CYPs may activate pro-carcinogens to carcinogens (Code 1997; 
Su 2000); many are also involved in the removal of carcinogens from the body(Gonzalez, 
Kimura 2003) ; and reports indicate that certain CYPs are involved in the promotion of 
lung cancer in cigarette smokers(Antariksa Budhi 2003) . 
Most of the known CYPs are found at different constitutive levels in the liver of the 
human body (Nelson et al. 1996) , which is the main organ involved in drug and toxin 
removal. However, substantial amounts of CYPs are also found in extrahepatic tissues 
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such as, the small intestine, the lungs(Simon D. Spivack et al. 2001) , kidney, skin, heart 
and brain(Gonzalez, Kimura 2003, Rieder et al. 2000) .  In the human liver there are at 
least 12 distinct CYP enzymes. At present it appears that only six isoenzymes from 
families CYP 1, 2 and 3 are involved in hepatic metabolism of most of the marketed 
pharmaceutical drugs. They are CYP1A2, CYP3A4, CYP2C9, CYP2C19, CYP2D6 and 
CYP2E1. These CYPs account for about 70% of the human hepatic microsomal CYPs, 
with CYP3 isoenzymes accounting for approximately 30%. The major pharmaceutical 
drugs that they metabolise (R H Levy 1995)  are listed in Table 1.3.   
 
 
 Mechanism of action of CYP450 enzymes 
There are two subunits which are required for the activity of human cytochrome P450 
(CYP) enzymes. They are the haem containing catalytic subunit, cytochrome P450 
(CYP), and the activating subunit which consists of NADPH-dependent P450 reductase 
(CPR). NADPH is the reducing agent which reduces atmospheric oxygen (O2), inserting 
an atom of oxygen into the CYP substrate (which could be a potential medicine), with the 
other oxygen atom being reduced to water. The stoichiometry of the reaction is depicted 
below (White, Coon 1980) :  
RH + NAD (P) H + H+ +O2 → ROH + NAD (P) + + H2O 
 
 NADPH-cytochrome P450 reductase (CPR) 
CPR, a flavo protein, is situated on the endoplasmic reticulum (ER), functioning as a 
redox partner to a CYP also embedded on the ER, supplying electrons necessary to 
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catalyse CYP-dependent oxygenations. In some cases, CPR may have a conformational 
role on a CYP, affecting the latter’s function by changing a step in the reaction cycle 
which is not involved in electron transfer (open and close conformational changes). When 
it is in close conformational form, the electron passes through FAD and then to FMN 
before it gets to the haem-protein because FMN-binding site is covered by the FAD 
binding domain whereas if they are in open conformation (close proximity), there will be 
a direct passage of the electron from NADPH to FMN and to the haem-protein (Guiterrez 
et al., 2002). 
The crystallographic structure of CPR suggests that this protein may have emerged from 
gene fusion. CPR is one of only four mammalian proteins known to contain both FMN 
(flavin mononucleotide) and FAD (flavin adenine dinucleotide) domains in a single 
polypeptide chain. The simplest system that supports NADPH-dependent oxygenation 
reaction in vitro involves the three major components, namely, 
(a) A CYP450 (CYP) catalytic subunit, 
(b) The NADPH-cytochrome P450 reductase (CPR), and 
(c) A phospholipid (Lu, Junk & Coon 1969, Lu, Coon 1968, Henry W. Strobel et al. 
1970) . 
The reaction between the CPR and CYP is required to ensure that electrons from NADPH 
passes through CPR to the CYP in two single-electron transfer steps (Figure 1.1; (White, 
Coon 1980, Loida, Sligar 1993) . 
There is another protein that contributes to the monooxygenase function of CYP450s 
(CYPs). It is the cytochrome b5. The b5 protein can serve as an allosteric effector of CYP 
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activity without supplying electrons for CYP-dependent substrate metabolism (Hiroyuki 
Yamazaki et al. 1996, Porter 2002) . 
There is only one CPR that exists in humans whereas in plants there are multiple forms 
of the enzyme.  
 
 
Figure 1.1.  Cytochrome P450 redox system. P450s receive electrons by one of 
two major routes for oxygenation of substrate (R).  Most P450s generate 
hydroxylated product (ROH). The two electrons are delivered through 
NADPH. In the class I P450 system (e.g. bacterial and mammalian adrenal 
mitochondria), the electrons are shuttled through flavin adenine dinucleotide 
(FAD), via ferredoxin reductase (FDR) and a ferredoxin (FD), to the P450. In 
the class II P450 system, (e.g. mammalian hepatic drug-metabolising 
isoforms) electrons are delivered by a FAD and Flavin mononucleotide (FMN)-
containing P450 reductase (NADPH-cytochrome P450 reductase (CPR) to the 
P450.( HEME in red, NADP+ in dark blue , FAD in yellow, FAD in orange and 





 The role of cytochrome b5 in cytochrome P450 
(CYP) mediated reactions 
Cytochrome b5 has a role in electron donation to microsomal desaturases that are 
involved in the synthesis of unsaturated fatty acids (Vergères, Waskell 1995) . It is a 17-
kDa haem-protein present in the endoplasmic reticulum (ER) of all eukaryotic cells. 
Together with NADPH, it helps in CYP450 monooxygenase reactions. Recent studies 
have demonstrated that in the expression of some recombinant CYP enzymes (CYP2A6, 
CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1, CYP4F3, CYP4F2, CYP2J2, 
CYP4A11 and CYP3A4) b5 is required for maximal catalytic activities. In the same 
study, it was also suggested that the condition for reconstitution of activities vary 
depending on the CYP450 enzymes that are expressed (Hiroshi Yamazaki, Tsutomu 
Shimada, 2006). This study has shown that: 
 CYP2C8, CYP2C9, CYP2C19, CYP4F3, CYP4F2, CYP2J2, CYP4A11, CYP2E1 
and CYP3A4 have increased activities when cytochrome b5 (b5) was co-
expressed along with the CYP450 reductase (CPR), and 
 Although CYP2C19 is closely analogous to CYP2C18 in the protein sequence, 
the latter may not require cytochrome b5 to manifest activity.  
In the past, it has been reported that CYP3A4 co-expressed with b5 reductase and b5 
produce greater rates of reaction than when CYP3A4 is co-expressed just with CYP450 
reductase (CPR) (Figure 1.2; Yamazaki et al). In 1971, Hildebrandt and Estabrook 
established that stimulation of P450 drug oxidations with the addition of NADH to 
microsomes shows that cytochrome b5 contributes the second electron to the CYP450 
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catalytic cycle. Activity of CYP2B4 inhibited by cytochrome b5 at higher concentration 
which suggested that cytochrome b5 was occupying the cytochrome P450 reductase-
binding site on cytochrome P450 2B4 (Haoming et al., 2008). However, in the studies 
reported here, I was able to show that not all CYPs require this extra electron from 
cytochrome b5.  
 






NADPH Cytochrome P450 reductase
e- +
 
Figure 1.2.  The electron pathway transport system of cytochrome P450 in the 
endoplasmic reticulum. The cytochrome b5 is readily reduced upon addition 
of NADPH, and that cytochrome reductases (purple and light blue colours) 
serve as electron donors to both cytochrome b5 (green colour) and the 
cytochrome P450 (deep blue). The cytochrome b5 serves as an additional 
electron donor to P450-mediated reaction. (Adapted from Todd D. Porter, 
2002) 
 
1.4 Stress Response, Stress Genes and Protein 
Expression 
There are different conditions that cells are subjected to during cell division. These 
conditions prevent cells to produce maximum amounts of cellular proteins when 
required. Increase of temperature, increase or decrease in pH, salinity or oxygen 
concentration could be stressful for cells. The result of cellular stress can lead to protein 
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denaturation which involves proteins losing their native, functional configuration and 
ultimately leading to aggregation. 
This process is likely to be reversible to some extent but cells die when they suffer from 
stress beyond a certain limit. Another factor that prevents cells from producing more 
cellular protein is the down-regulation of the house keeping genes. This machinery may 
be shut off or inactive due to the nature of proteins that are being over-expressed or over- 
produced. 
Part of the response towards cellular stress is the activation of stress genes leading to 
higher expression of stress proteins. These stress proteins protect cells from the effect of 
the protein denaturation and help cells to recover from the effects of denatured cellular 
proteins. Most of the stress proteins include heat shock proteins (HSPs) but also several 
others which function similarly to protect cells. Most stress proteins act in the absence 
of stress, under normal conditions. They play roles in 
a) Protein biogenesis, 
b) Assisting correct folding of proteins, 
c) Metabolism and metabolite transport 
d) Aiding translocation of proteins across membranes of intracellular compartments 
(organelles) guiding to places where they live and function, and 
e) Supporting assembly of protein complexes allowing them to acquire multi-subunit 




1.5 Codon Bias and Heterologous Protein 
Expression 
Genentech scientists and their collaborators (1977) produced the first recombinant human 
protein (somatostatin) in a bacterium. They were the first who were able to express a 
human protein in a heterologous host which played a vital role in the development of 
future biotechnology industries. With only the amino acid sequence available, the group 
was able to synthesize 14 codon long somatostatin, using oligonucleotides, instead of 
cloning it from the human genome. In the absence of technology for constructing cDNA 
libraries, it was the only way to clone a gene in those days. But now, genes are cloned 
from tissue (or organism)-specific cDNA libraries directly using gene-specific primers 
and the polymerase chain reaction (PCR). 
There are 61 nucleotide triplets (codons) that code for 20 essential amino acids. There are 
three more which are nonsense codons, also known as stop codons, which help to end 
gene transcription. An amino acid can be coded by a single triplet (codon) as in the case 
of Methionine (Met, M) and Trytophan (Trp, W) or it could be coded by up to six codons 
as in the case of Arginine (Arg, R), Leucine (Leu, L) and Serine (Ser, S). 
The degeneracy of the genetic code enables alternative nucleic acid sequences to code for 
the same protein. The usage of specific codons varies 
 From one organism to the other, 
 Between proteins highly expressed and at low levels within the same organism,  
 Often many times within the same operon, and  
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 In response to GC content of the gene. 
The level of gene expression depends on various factors such as  
• Gene copy number, transcriptional control elements,  
• The site of chromosomal integration,  
• mRNA stability, and  
• Translational efficiency.  
Several efforts have been made to improve the level of protein expression in mammalian 
cells. They have concentrated on the elements involved in the gene copy number and 
transcription/translation determining elements. 
Gross and Hauser (1995) have shown that translational events play a vital role in limiting 
the expression of a gene. Protein coding system for gene expression can be adjusted by 
manipulating the vector construction, gene transfer method and selection protocol. In 
contrast, the control of genes at the translational levels is controlled by coding gene 
structure. Although the mechanisms controlling this type of gene regulation are still 
unknown, there has been some success towards understanding by introducing  
(a) an intron sequence that directs the pre-mRNA into the splicing pathway (Petitclerc 
et al. 1995) , and  
(b) the sequences that facilitate mRNA such as a Kozak consensus sequence (Kozak 
1987) .  
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Kim et al. (1997) suggested that comparison of performance of genes re-engineered with 
either human or yeast favoured codons will provide more useful information about the 
factors affecting gene expression with respect to codon usage and mRNA secondary 
structure. Experimental evidence showed that the highest protein expression was obtained 
with ‘hybrid’ codon usage where part of the genetic sequence was optimised for codons 
specific for the organism in which the protein was being expressed. 
 
1.6 Expression of human genes synthesised using 
yeast biased codons 
Codon usage bias is a phenomenon in which synonymous codons encoding the same 
amino acids are used at different frequencies. It has been suggested that codon distribution 
often occurs due to mutations or natural selection equilibrium between similar codons in 
each organism. 
In this report, I will be describing experiments which lead to the production of CYP 
enzymes that could be used  
(a) for drug metabolism studies, and/or  
(b) as potential targets for the treatment of breast cancer and prostate cancer.  
We have chosen to use yeast biased codons to recreate sequences of different human 
cytochrome P450 (CYP) genes. The codons used are utilized by highly expressed genes 
in baker’s yeast. The aim was to find out the consequence on CYP protein expression 
levels when chemically synthesised human CYP genes, using ‘yeast biased’ codons, were 
expressed in yeast. The conjecture was that, perhaps the human CYP genes would be 
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expressed more at the mRNA level than the genes isolated from a human cDNA library. 
This may result in higher protein levels. The concept relies on more ‘stable’ transcription, 
that is, if CYP mRNAs are transcribed in a way that the yeast cells do not recognize the 
human genes as foreign, there should be more human CYP proteins produced in yeast 
cells provided there is no block during translation. CYP activities could then be 
monitored. Higher CYP activities could be assumed to correlate with higher protein 
production. 
 
1.7 Role of CYP450s in Drug Metabolism 
Drug metabolism is a major determinant of pharmacokinetics, a process that regulates 
drug action. The vast majority of small molecules and biotechnological drugs are 
metabolized while some others are excreted as unchanged parent drug. Drug metabolism 
plays a very important role in the inter-individual differences in drug response and also 
drug interactions which may result in adverse effects leading to the failure of a therapeutic 
drug. 
Most clinically used drugs are chemicals which do not belong to the normal composition 
of the human body. Hence, they are also referred to as xenobiotics. The principle of 
elimination of drugs that are foreign substances from the body is through metabolism, a 
form of biotransformation. As described earlier, this elimination occurs via Phase 1 and 
Phase 2 drug metabolism enzymes. These enzymes add functional groups to make 
lipophilic molecules more hydrophilic in order to make them easier to eliminate. The 
oxidative reaction is mainly catalysed by the Phase 1 cytochrome P450 (CYP) enzymes 
and the rest by the Phase 2 conjugating enzymes. 
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The CYP enzymes that play vital roles in the removal of xenobiotic pharmaceutical drugs 
from the human body belong to CYP 1, 2 and 3 sub-families. CYP metabolizing drugs 
are CYP 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4. 70% of these CYPs are localized in 




Figure 1.3. The CYP subfamily enzymes play different roles by acting on 
diverse sets of substrates.  Besides being used for drug metabolism studies, 
the CYP 1, 2 and 3 sub-families of enzymes have other roles in the human body. 
Members of certain sub-families have been shown to have overlapping 
functions in being able to act on two different sets of substrates (MEDCH, 
2013). 
 
CYPs play important roles in endogenous biochemical pathways such as steroid hormone 
biosynthesis, metabolism of polyunsaturated fatty acids (such as arachidonic acid and 
prostaglandins) and activation of vitamins A and D3 to biologically active hormones. 
They also participate in the activation and detoxification of a variety of different types of 
exogenous chemicals, some of which possess medicinal properties and others which are 
known to contaminate or pollute the environment (Figure 1.3; Estabrook 2003).  
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Mutations in CYP genes that correlate with deficiencies in enzyme activities are 
responsible for several human diseases (Murata 2001). CYPs can also show great inter-
individual variability mainly due to environmental factors (e.g. CYP2E1 being induced 
in individuals who drink ethanol and CYP1A1/CYP1A2/CYP1B1 being induced in 
individuals who are exposed to aromatic hydrocarbons), genetic factors (that could result 
in specific CYP enzyme deficiencies) and patho-physiological factors (CYP2E1 being 
induced in diabetics).   
Induction of CYP1 family of genes (which is induced by polycyclic hydrocarbons found 
in cigarette smoke and charred food) is a risk factor in several cancers such as lung and 
colon cancers because these enzymes can convert pro-carcinogens to carcinogens. 
Mutations in the CYP1B1 gene (leading to defects in CYP1B1 activity) are linked to 
congenital glaucoma possibly because of the enzyme’s major role in steroidogenesis. A 
metabolite formed from acetaminophen (Paracetamol) by CYP2E1 can cause severe toxic 
effects in humans. People who are alcoholic are at high risk to Paracetamol toxicity 
because they possess alcohol-induced high levels of CYP2E1. CYP2C8 is selectively 
responsible for inactivation of the anti-cancer drug paclitaxel (Taxol) through oxidation 
to 6α-hydroxypaclitaxel. Specific alleles of CYP2C8 are known to have a great influence 
on the pharmacokinetics of paclitaxel (Nakajima et al. 2005). CYP2C19 is known to 
metabolise a proton pump inhibitor, omeprazole, which is used to treat peptic ulcer. 
Omeprazole has been used as a CYP2C19 marker to assess gene-dosage effects and its 
intra-subject variability (Yin et al. 2004).  
Some drug molecules can activate or inhibit the CYP enzymes. This can lead to adverse 
effects of drugs on the human body. For example if ketoconazole (an antifungal 
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compound), a CYP3A4 inhibitor, is administered together with Triazolam (sedative to 
treat insomnia) which is metabolised by CYP3A4, it will result in an overdose of 
Triazolam. This is an example of drug-drug interaction which often can cause major 
problems in the clinic. New drug candidates with poor metabolism profile or which cause 
drug-drug interactions often do not survive the drug development process which involves 
a lot of expense often leading to expenditures of $1 billion or more. Therefore, choosing 
drugs that do not interact with CYP enzymes is very important at an early stage of drug 
development.  In recent years, the area of drug metabolism has become crucial to the drug 
discovery process.  Use of drug metabolising enzymes early in the drug discovery process 
can save significant amount of costs and time required in pre-clinical and clinical studies, 
thereby greatly facilitating the process. That is the reason why introduction of drug 
metabolism screens as early as possible in the drug discovery process is gaining appeal. 
Drug metabolism studies have become as important as primary screening of a library of 
compounds against a therapeutic target, in the drug discovery process.  
It appears that certain CYP enzymes have a high affinity towards chemical structures 
commonly found in pharmaceutical drugs. CYP2D6 and its genetic variants are known to 
metabolise a quarter of all known pharmaceutical entities (Werck and Feyereisen 2000). 
This subset of CYP isozymes is also considered to be highly important in drug 
metabolism studies because of their presence in the human liver, – the main organ 
involved in metabolism (see Table 1.3).  
CYP3A4 is the most abundant CYP at ~30% of the total CYPs present in the human liver, 
the others existing in lower yet substantial amounts (1-15%) (Gonzalez 1992; Beaune 




Table 1.2.  Pharmaceuticals, as substrates for different CYPs.   
 
CYP Xenobiotics Metabolised 
Xenobiotics 
Activated Inducers Inhibitors 
CYP1A
2 
Caffeine;           7-ethoxy-
resorufin;          7-
methoxy- resorufin;  
imipramine; phenacetin; 

































































































1.8 CYP19A1 (Aromatase) – Its Role in Breast 
Cancer 
 
Breast cancer is the most common type of cancer in women in Western countries. 
Estrogens (i.e. estradiol and estrone which is a derivative of estradiol) are key factors in 
the pathogenesis and progression of breast cancer. The key enzyme aromatase is required 
for the conversion of 
• Androstendione to estrone, and 





Testosterone Estradiol  





Aromatase converts the ‘A’ ring of the steroids, androstendione and testosterone, to the 
aromatic state. These reactions take place primarily in ovarian granulosa cells but also in 
many other tissues (S.E. Bulun et al., 2005).  The aromatase enzyme is coded by the 
cytochrome P450- gene, CYP19A1. The CYP19A1 protein, like most other CYPs, is 
anchored to the endoplasmic reticular membranes of estrogen producing cells. Again, like 
other human CYPs it is activated by NADPH-dependent cytochrome P450 reductase 
(CPR). 
Aromatase inhibitors block the peripheral conversion of androgens (androstendione and 
testosterone) to estrogen (estrone and estradiol) and thereby reduce estrogen levels in 
tissue and plasma. There are two major types of aromatase inhibitors, type 1 steroidal (i.e. 
exemestane) drugs which bind competitively and irreversibly to the enzyme and are 
inactivators. The other type consists of non-steroidal inhibitors (i.e. anastrazole) and bind 
reversibly. 
The main primary source of estrogen in the postmenopausal women is the conversion of 
circulating androgens via aromatization at peripheral sites (i.e. adipose tissue, skin) 
(Montagna et al., 2013). One of the focuses of this study was to create DNA constructs 
that would allow overexpression of CYP19A1 and its isolation as a microsomal enzyme. 
The aim was, with the ready availability of CYP19A1 enzyme in abundance, new non-
toxic inhibitors could be identified from natural product libraries derived perhaps from 
edible plants. Aromatase inhibition is currently the most effective treatment of 
postmenopausal breast cancer, as they reduce aromatase activity throughout the body, 
resulting in breast cells also being deprived of estrogens.  
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Treatment of breast cancer with the currently available aromatase inhibitors, over a long 
period of time, often leads to resistance due to over-activation of specific kinases related 
to cell signalling, MEK, RAF, P13K, mTOR (mammalian target of rapamycin), and Akt 
(Chumsri et al., 2011). Hence, second generation inhibitors are widely sought and are of 
great interest.  
 
1.9 CYP17A1 (17α-hydroxylase/17, 20 desmolase) 
– Its Role in Prostate Cancer 
 
Another aspect of this study was to produce the human CYP17A1 enzyme in baker’s 
yeast. CYP17A1 is over-expressed in prostate cancer and plays a major role in its 
development. Inhibition of this enzyme which activates genes, required for normal male 
sexual function, can prevent prostate cancer development in men. 
Under normal conditions, dihydrotestosterone [DHT; also known as androstanolone (5α-
androstan-17β-ol-3-one] is synthesized predominantly by 5α-reduction of testosterone. 
This depends on the affinity binding of DHT (an androgen) to the androgen receptor (AR), 
which is a transcription factor that controls androgen-dependant gene transcription. 
CYP17A1 enzyme has dual function in the intracrine synthesis of testosterone and DHT 
from progesterone via the cholesterol pathway (see Figure 1.5). 
Its 17α-hydroxylase function acts on pregnenolone, a progesterone precursor, by adding 
a –OH group on carbon 17 of the steroid D ring. Its 17,20-lyase activity acts on 17-
hydroxyprogesterone and 17-hydroxypregnenolone to split the side chain of the steroid 
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Figure 1.5. The pathways that lead to the synthesis of androgens that act as 
ligands for the androgen receptor which is mis-regulated in prostate cancer 
(Mula-Abed et al, 2013). 
 
Recently, abiraterone has been approved for the treatment of prostate cancer. It selectively 
inhibits the CYP17A1 enzyme that is vital for androgen synthesis. Several studies have 
shown that abiraterone blocks the growth of prostate cancer cells (Siegal at al., 2012). 
The forces behind the progression to metastatic castration-resistant prostate cancer 
(CRPC) are multi-factorial but the main contribution is the persistence of androgen from 
non-gonadal sources that leads to intra-tumoral AR (androgen receptor) signalling (De 





1.10 Expression of Human CYPs in Baker’s Yeast 
 
Cytochrome P450s (CYPs) are present in all mammalian tissues and is involved in the 
synthesis of endogenous compounds such as steroids, fatty acid and prostaglandins. They 
also participate in activating and detoxification of foreign compounds, namely chemical 
pro-carcinogens, environmental pollutants and many therapeutic drugs. CYP enzymes 
partake in the oxido-reductive catalysis cycle on the endoplasmic reticular membranes. 
As an electron donor, it has been suggested that the cytochrome P450 reductase (CPR) is 
surrounded by a circle of multiple CYPs. Using NADPH as a substrate, the CPR 
contributes once to the transfer of one electron to a particular CYP, and then unlinks itself 
from the first CYP to contribute an electron to the next one (Backes and Eyer, 1989; Eyer 
and Backes, 1992; Taniguchi and Pyerin, 1988; Taniguchi et al., 1979). 
When a mammalian CYP is expressed in heterologous cells (i.e. in an organism different 
from the one where it naturally occurs), its activity is affected greatly by the amount of 
CPR present in the recombinant expression system. It has been reported that CPR is the 
key rate limiting factor for the catalytic activities of CYPs while phospholipids act as 
matrices for the interaction of CYPs and CPR that allow modulation of CYP activities 
(CYPs = enzymes, CPR = electron donor, and phospholipids = provide the membrane 
structure for binding of a CYP and the CPR). 
Among heterologous expression systems, Saccharomyces cerevisiae was the first yeast 
that was used and applied further for the study of drug metabolism of human CYPs in 
vitro (Cheng et al., 2006). Although other organisms (such as E. coli, mammalian and 
insect cells) have been used for human CYP expression, yeast has specific advantages 
over the other expression systems: 
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• Ease of growth of yeast cells, 
• Low endogenous CYP activity level, 
• Intracellular membrane structure similar that bear phospholipids, and 
• Endogenous CPR activity which can couple with human CYPs to provide CYP 
activity (Andrew. 2002). 
Regardless of the advantages in yeast, one major problem of using yeast as well as other 
expression systems is the insufficiency of CPR activity in host cells. The endogenous 
level of the yeast CPR does not exceed a molar ratio of 0.05-0.1 relative to heterologous 
CYPs, and the in vitro activity is poor. Co-expression of CYPs with CPR, driven by strong 
yeast promoters, was reported as an approach to improve CYP activities. Besides, the co-
expression of cytochrome b5 during expression in yeast has helped to stimulate the 
activities of certain CYPs towards some substrates (Murataliev et al., 2004). The stability 
of the heterologous expression system is a key factor for obtaining accurate in vitro data 





 CYP expression from episomal, extra-chromosomal 
vectors versus from chromosomally-integrated 
genetic copies 
 
CYP protein levels may vacillate when human CYP genes are expressed from episomal 
vectors (such as pYEP plasmids) from yeast cells which contain the CPR gene expression 
cassette on a chromosomal locus. The vacillation depends on how toxic the human CYP 
protein is for the host organism in which it is being expressed. This is because the 
autonomously replicating sequence based on the yeast 2µ-plasmid allows for fluctuation 
of the CYP gene copy number depending on the cells’ ability to cope with expression of 
a relatively toxic protein. Moreover, episomal plasmids are maintained within the cell 
during cell division through selection pressure using selective minimal media for growth 
of yeast cells. 
In contrast, expression of heterologous CYP proteins from genomic copies of CYP genes, 
integrated into the yeast genome via homologous recombination, is likely to be far ‘more 
stable’ than expression from episomal vectors because 
• There would not be any copy number fluctuations when CYP gene expression 
cassette(s) are integrated into the yeast genome (the copy number will solely 
depend on how many copies of the CYP gene expression cassette have been 
introduced into different chromosomal loci), and 
• There would not be any necessity of growing cells in selective minimal media 
once the CYP gene expression cassette has stably integrated into one or more of 
yeast’s chromosomes, hence allowing cells to be grown in a full nutritious 
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medium without any selection. 
This would permit use of such chromosomally integrated expression systems for 
• High-throughput screening of potential CYP inhibitors using whole cells, and 
• Production of CYP proteins on a large scale. 
As a proof of concept, 
• Integrative plasmids for integration of the human CYP3A4 gene (synthesized 
using yeast biased codons) were constructed and integrated into the yeast genome 
at different chromosomal loci, and then 
• The CYP activities of yeast transformants, obtained from CYP3A4 gene 
integrations, were compared with transformants that expressed the same gene 
from an episomal plasmid. 
Both integrative and episomal expression systems used a modified, non-toxic (patented) 
version of human CPR for co-expression with CYP. Both systems used the inducible 
ADH2 promoter (derived from one of the two alcohol dehydrogenase genes present in 
yeast) for expression of heterologous proteins. 
 
 Homologous recombination 
 
This is a type of genetic recombination where genetic sequences are exchanged between 
two or more similar or identical molecules of DNA. The traditional use of baker’s yeast 
S. cerevisiae in alcoholic fermentation has over time resulted in enormous accumulated 
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knowledge concerning genetics, physiology and biochemistry as well as genetic 
engineering and fermentation technologies. Yeast is widely being used in the sysntheses 
of new metabolic products through the development of new yeast strains (Nevoigt, 2008). 
The emergence of synthetic biology has introduced new ideas on how foreign DNA can 
be inserted into the yeast genome. Incorporating complete natural or synthetic pathways 
to the production of a chemical into yeast has been attained but still remains a major 
challenge that is currently hindering the synthesis of any new therapeutic molecule of 
choice. The optimization of a newly developed technology is always hard to achieve. 
Different combinatorial methods for inserting foreign genes into yeast’s genome have 
been deployed. The major advantage in using homologous recombination comes from the 
observation that proteins can be stably expressed with correct folds independent of the 
proteins’ primary sequence which can be sometimes a problem during expression from 
an extra-chromosomal plasmid (Martina et al., 2007) 
 
1.11 CYP1 Family of Enzymes 
Three genes are members of the CYP1 family: CYP1A1, CYP1B1 and CYP1A2. 
According to Nelson, (1996), this family has no pseudogenes and they all share the same 
features of regulation; all are transcriptionally controlled by the AhR-ARNT  
transcription factor complex (Scmidt, 1996). AhR (aryl hydrocarbon receptor) is a 
hormone receptor which acts as a transcription factor upon binding to its ligand. ARNT 
(aryl hydrocarbon receptor nuclear translocator) is a co-activator of AhR. Induction of 
gene transcription by the AhR-ARNT complex occurs through binding of polycyclic 
aromatic hydrocarbons (PAHs) to AhR which act as ligands to the transcription factor 
58 
 
complex. The AhR-ARNT transcription activator complex activates genes of the CYP1 
family (Figure 1.6).  
 
 
Figure 1.6. Transcription activation of CYP1A1, CYP1B1 and CYP1A2 genes 
through induction by the AhR-ARNT transcription activator complex, bound 
to a PAH (a polyaromatic hydrocarbon), (Vasilis P et al., 2009). 
 
CYP1A1 activates mainly two different types of pro-carcinogens, PAHs and heterocyclic 
amines, to carcinogens. 
CYP1A1’s mechanism of activation of the pro-carcinogen benzo[a]pyrene (a PAH) is 
through its oxidation to benzo[a]pyrene 7,8-oxide [β(a)P-7,8-oxide], and subsequent 
hydrolysis to the two enantiomeric diols (+)-β(a)P-7,8-diol and (-)-β(a)P-7,8-diol (Vasilis 
P et al., 2009).  
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CYP1A1’s mechanism of activation of the pro-carcinogen 2-amino-1-methyl-6- 
phenylimidazo[4,5-b]pyridine (PhIP) is depicted in Figure 1.7. 
 
 
Figure 1.7. Activation of the potential pro-carcinogen 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP) to the N-hydroxylated metabolite which 
is a carcinogen (Vasilis P et al., 2009). 
 
The expression of CYP1A1 in the human liver is very low (Edward, 1998) compared to 
the expression of CYP1A2 which is liver specific. The CYP1A2 protein has not been 
detected in any other tissue besides the liver. CYP1A2 constitutes about 13% of the total 
hepatic CYP content (Imoka, 1996). 
Similar to CYP1A1, CYP1B1 occurs at very low levels in the liver, kidney, prostate, 
mammary gland and the ovary (Murray, 1997). Like CYP1A1, CYP1B1 is also regulated 
by several key transcription factors, such as AhR-ARNT complex, the SpI transcription 
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factor, a cyclic AMP (Camp)-response element-binding protein (CREB), and possibly the 
estrogen receptor (Chang et al., 1998; Chen et al., 1996; Zheng et al., 2003). Once 
CYP1B1 is up-regulated, it catalyses the conversion of steroid hormones and exogenous 
substrates into toxic metabolites that increase the genotoxic and oxidative load on the cell 
and modulate cell signalling (Sissung et al., 2006). Hence, CYP1B1 has been thought to 
be a target for the discovery of new anticancer agents.  
 
1.12 CYP2 Family of Enzymes 
 
The human CYP2 proteins are a heterogeneous group of enzymes and do not seem to be 
regulated at the transcriptional level. The substrates and tissue specificity of the CYPs are 
also different from other CYP families. This study will focus on the CYP2C9, CYP2C18, 
CYP2C19, CYP2B6, CYP2J2 and CYP2D6 isozymes (together with the three SNPs of 
CYP2D6). I have successfully cloned genes coding for all these CYP genes in expression 
vectors that would allow production of these proteins in the yeast Saccharomyces 
cerevisiae.  
I have shown that CYP2C18 does not require cytochrome b5 but its close homologue 
CYP2C19 requires b5 for superior activities.  
The CYP2C subfamily contains four highly homologous proteins, 2C8, 2C9, 2C18, and 
2C19, which are located in a cluster on chromosome 10 and this subfamily accounts for 
20% of the human total liver CYP content (Imoka, 1996).  
CYP2D6, a xenobiotic metabolizing cytochrome P450, less significantly present in the 
liver (only about 2% of the human hepatic CYP enzymes) but is significantly found on 
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the surface of the cell plasma membrane (Jacqueline et al., 1998). In the present study, I 
have explored the role of yeast-produced CYP2D6 as a drug metabolising enzyme using 
whole yeast cells for the biotransformation of codeine in the production of its metabolite, 
morphine. Although the amount of CYP2D6 in the liver is low, it is still involved in about 
25% of the metabolism of drugs currently in use (Martina et al. 2012) . A suitable 
expression system has been devised in this study to express wild-type CYP2D6 and five 
other variants in whole cells. Microsomal CYP2D6 enzymes have been isolated from two 
of these variants, the wild-type (Met374) and the Val374 counterpart. It has been reported 
that CYP2D6 does not require the co-expression of cytochrome b5 for its enzymatic 
activity. Here, I present evidence that if CYP2D6 is co-expressed with another enzyme 
(e.g. CYP3A4 in the presence of cytochrome b5), the expression of both these enzymes 
(CYP2D6 and CYP3A4) is much higher than when CYP2D6 is expressed on its own. An 
explanation to support this observation is provided in Chapter 7. 
Another important family of CYP2 family member, CYP2B6, is present in the human 
liver. It is involved in the biotransformation of drugs (e.g. anticancer drugs such as 
cyclophosphamide) and other xenobiotics. In the past, CYP2B6 was reported to be 
present only in part of the general population but recent studies have shown that it is 
present in all adult human livers (Hoffmann et al., 2008). CYP2B6 is about 1-10% of the 
total hepatic CYP protein in individuals (Zanger et al., 2007). In Chapter 3 of this study, 






1.13 CYP3A Subfamily of Enzymes 
 
The human subfamily CYP3A plays a dominant part in the metabolic elimination of 
pharmaceutical drugs. CYP3A enzymes are localized in the liver and the small intestine. 
Family members contribute to first-pass and systemic metabolism of drugs. The CYP3A 
subfamily consists of the proteins: CYP3A4, CYP3A5, CYP3A7 and CYP3A43. 
Although there is no systematic analysis of the true extent of its contribution, it is 
generally accepted that the CYP3A4 enzyme plays the most important role in the 
metabolic elimination of more drugs than any other CYP isozyme. CYP3A4’s major role 
in drug metabolism maybe due to its large active site that permits the binding of 
structurally diverse molecules (i.e. different molecules derived from different scaffolds). 
Among adults, CYP3A4 is the dominant CYP3A enzyme in the liver and other organs.  
CYP3A5 and CYP3A7 are polymorphically expressed in the foetal liver where CYP3A4 
is totally absent. Because both CYP3A4 and CYP3A5 share substrate specificity (e.g. 
midazolam), it is difficult to segregate the relative contribution of the two enzymes in 
CYP3A mediated metabolism. The catalytic activities of both CYP3A4 and CYP3A5 are 
affected significantly by the presence of cytochrome b5. The level of CYP3A4 activity 
expressed in a yeast expression system, with the yeast strain containing the human 
cytochrome b5 gene has shown a 40-fold higher level of activity compared to the one 
expressed without cytochrome b5 (Zanger et al., 2013). 
Expression of CYP3A4, and its stability and inhibition are regulated by different 
mechanisms (Figure 1.8). Many factors which include nuclear receptors, hormones, 
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Figure 1.8. Pathways through which CYP3A4 are activated/deactivated, and 
the enzyme’s role in deactivation and detoxification of substrates (Chen et al., 
2014). 
 
1.14 CPY4 Subfamily of Enzymes 
 
CYP4 subfamily of enzymes is one of the oldest CYP450 sub-families which are thought 
to have been evolved about 1.25 billion years ago. It comprises of about 22 isoenzymes 
encoded by genes that are expressed either in a constitutive or an inducible manner. CYP4 
enzymes are related to two functional aspects: (a) as cholesterol metabolizing enzymes 
and (b) as membrane integrity maintaining enzymes (Nebert and Gonzalez, 1985). I have 
constructed expression cassettes for the three CYP4 sub-family genes, CYP4A11, 
CYP4F3 and CYP4F2 genes, for expression in yeast. In this study, I have shown the 




 The 4A Subfamily 
 
The CYP4A set of isozymes is a sub-family of CYP4. Thirteen CYP4A genes have been 
identified in humans (Kawashima et al, 1992). They code for proteins that have the 
capability of hydroxylating terminal ω-carbon atoms of both saturated and unsaturated 
fatty acids (Figure 1.9). The CYP4A proteins also participate in prostaglandin synthesis 
(Yemamato et al., 1984). When the first member of the CYP4 gene family was isolated, 
cloned and sequenced (Hardwick et al., 1987), its amino acid sequence revealed that it 
was far less homologous (< 36%) to the CYP family of proteins known at that time. These 
enzymes are expressed constitutively in the liver, kidney and their expression is induced 
by clofibrate, a hypolipidemic, which lowers plasma triglyceride together with cholesterol 
levels.  
 
Figure 1.9. Human CYP4 enzymes that are involved in the metabolism of 
arachidonic acid. The diagram shows the CYP4 enzymes that metabolise 





It has been reported that CYP4A-mediated conversion to metabolites often occurs with 
high degree of regioselectivity (Kroetz et al ,. 2005; Cosima et al 2010). For example, in 
humans, CYP4A11 uniquely hydroxylates lauric acid. It seems that CYP4A enzymes 
generally require cytochrome b5 for maximal turnover. It has been reported that 
CYP4A11 has a role in the formation of 20-hydroxyeicosatetraenoic acid (20-HETE) as 
a metabolite in the human liver and kidney (Cosima et al 2010), HETE serves as a second 
messenger different hormones and growth factors and plays partial opposing roles in the 
regulation  of vascular, renal and cardiac function (Fleming , 2008).  CYP4A11, which is 
also referred to as 20-HETE synthase, is considered to be a major contributor to the 
formation of 20-HETE in the human liver rather than the kidney. In contrast, CYP4F2 
may be the dominant 20-HETE synthase in both liver and kidney.  
 
 CYP4F Subfamily 
 
The genes of the human CYPF subfamily are mostly located on chromosome 19p13.1-2 
(Kikutal et al., 2002). The CYP4FA11 gene is the exception, being located on 
chromosome 1 (Nelson et al., 1996). The major genomic difference between CYPF3 and 
CYPF4 genes is that the pre-mRNAs of the former set of genes alternatively use exons 3 
or 4 which lead to the formation of the 2 variants CYP4F3A and CYP4F3B.  
In this study, I have elaborated on the construction of the plasmids that express the 
CYP4F3A enzyme. The CYP4F3A mRNA uses exon 4. The CYP4F3A enzyme 
metabolises mainly leukotriene B4 rather than arachidonic acid but the variant CYP4F3B 
66 
 
which preferentially uses exon 3 shifts the metabolism towards synthesis of arachidonic 
acid (Christmas et al., 1999).  
Mutations in the human CYP4F2 gene have been linked to elevated blood pressure. This 
enzyme also contributes to the biosynthesis of 20-HETE. The natriuretic and anti-
hypertensive effects of the unsaturated fatty acid, 20-HETE, fail to be manifested in 
humans carrying this genetic disorder. CYP4F2 gene mutations have been reported to 
induce a change in warfin doses (Matthew et al., 2009). Cardwell et al., (2008) have 
suggested that the reaction was mediated indirectly through 20-HETE production, a 
reaction catalysed by CYP4F2.  
Vitamin K1 has been shown to be a substrate of the CYP4F2 enzyme. It was found to 
catalyse formation of a new metabolite of vitamin K1 when screening against other 
recombinant CYP450 enzymes (Figure 1.10; Rettie and Tai, 2006, Sontag and Parker 






Figure 1.10. Role of CYP4F2 in vitamin K1 homeostasis. Vitamin K1 
dihydroquinone, a cofactor of glutamyl carbonxylase, is responsible for 
activation of several blood factor proteins through carboxylation of key 
glutamic (Glu; E) amino acid residues that initiate the blood coagulation 
cascade response. Both CYP2C9 and CYP4F2 enzymes affect warfarin dose 
responses by controlling clearance of warfarin and removal of vitamin K1 
from the system (Rettie and Tai, 2006). 
 
1.15 Microsome preparation from human liver 
tissues 
 
Many early studies have utilized CYP450 enzymes purified from the human liver 
(Distlerath 1985; Yun 1991).  Human liver microsomes are available, although not very 
widely, from a few commercial companies that sell these preparations. If properly 
handled, liver tissues obtained after surgery or from organ donors can be frozen in liquid 
nitrogen and held at -80ºC essentially indefinitely without apparent loss of P450 enzyme 
activity (Pearce 1996). The microsomal preparations can also be stored for long periods. 
But the availability of tissues and the technical difficulties in purifying individual or total 
enzyme activities are a big problem. Moreover, the total CYP activity in isolated livers 
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seems to disappear very quickly. These problems have caused a shift to heterologous 
methods that allow production of CYPs in specific cell systems for diverse practical 
applications in drug metabolism studies (Guengerich 1991; Miners 1994). 
Catalytically active cytochrome P450 enzymes have been successfully expressed in 
bacteria (Escherichia coli), insect cells, yeast (Saccharomyces cerevisiae, and to a lesser 
extent Schizosaccharomyces pombe) and mammalian cells. These heterologous systems 
can be used to express human CYP enzymes along or conjunction with one or both of 
their redox partners. All expression systems have their unique advantages and 
disadvantages.  The following section will discuss and compare the different heterologous 
recombinant systems. 
 
1.16 Recombinant P450 expression systems 
 
 Expression systems based on mammalian cells 
 
In theory, a mammalian cell expression system should be the ideal system to express CYP 
enzymes. In mammalian cells, only the catalytic part needs to be produced. This is the 
part which disappears (or is non-existent) in most mammalian cells in culture (Crespi 
1993).  The P450 reductase (CPR) remains functional in mammalian cells but in tiny 
amounts. Therefore, extra amounts usually need to be produced for CYP overexpression 
in mammalian cells. Unfortunately, by the nature of its biochemical activity (i.e. ability 
to generate free electrons), CPR is toxic for cells.  
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Stable heterologous expression of individual human CYP450s have been achieved in 
several cell lines, including V79 Chinese hamster (Doehmer 1991), Chinese hamster 
ovary (CHO) cells (Ding 2001), HepG2 cells (Aoyama 1990), NIH3T3 cells (Battula 
1987), and human lymphoblastoid cells (Crespi 1991). At some yet undefined level 
(which is very small), most CYP enzymes appear to adversely affect the growth of host 
mammalian cells (Crespi 1993). Because of their effect on growth, these low levels would 
represent the upper limit of expression that can be achieved in mammalian cells. Within 
the bounds of this limitation, there is the possibility to exploit the presence of native levels 
of CPR and cytochrome b5/ cytochrome b5 reductase for the expression of CYP enzymes, 
without the need for co-expression of the co-factor proteins. However, mammalian 
systems that constitutively express CYPs are quite unstable for reasons which are not 
clear. Instability implies that either the genetic information is quickly discarded by the 
cells (i.e. it is lost) or cells fail to express any recognizable level of CYP enzymes.  
However, a distinct advantage of the mammalian cell expression system is that it offers 
the possibility to couple CYP metabolite formation to toxicological endpoints that is, 
cytotoxicity, malignant transformation, or mutagenesis investigations (Sakaki 2000). It 
should be noted that similar toxicological endpoints could also be measured in yeast based 
systems if such systems were to be available. 
The disadvantages of a mammalian cell expression system are that expression levels are 
low, work in mammalian cell culture is extremely expensive and sensitive assays are 
needed. For reasons that are also poorly understood, most human CYP cDNAs do not 
yield any significant level of expressed protein in the mammalian cell expression systems 




 Bacterial cell expression systems 
 
Bacteria (Escherichia coli) are the most commonly used host organism for expression of 
cytochrome P450 enzymes. There are many advantages for using a bacterial expression 
system. Firstly, development of a bacterial system is rapid and the culture medium is 
inexpensive relative to mammalian or insect cell systems. Secondly, the bacterial system 
is ideal for the isolation of large quantities of enzyme for spectroscopic or structural 
studies. Thirdly, purification of bacterially-expressed CYPs is relatively straightforward. 
The purified CYPs can be used with CPR and, when necessary, with cytochrome b5 to 
reconstitute catalytic activities at expected rates. 
CYPs made in bacteria have been used for a variety of purposes. For example, readily 
available large amounts of CYPs, purified from bacteria, have been used as antigens for 
the preparation of polyclonal antibodies. The oxidation products generated via a relatively 
short 20 min incubation of a substrate (bufuralol) with large amounts (35 nmol) of a 
recombinant CYP (i.e. CYP1A2) can rapidly be isolated and characterized by mass and 
1H-NMR spectroscopy (Yamazaki 1994; Dong 1996). However, the greatest 
disadvantage of the bacterial system is that bacteria lack the endoplasmic reticulum to 
which both mammalian microsomal CYPs and CPR (the electron transfer partner for 
microsomal CYP activity) bind to manifest their activities. 
At least 35 mammalian CYPs (human and non-human) have now been expressed in E. 
coli.  Bacterial expression uses two distinct approaches: either (a) the sequence of the 
proteins is modified at the N-terminus (through minor changes in the amino acid sequence 
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and often truncation of the 35-51 amino acid membrane anchor domain that lies at the N-
terminus) so as to obtain soluble, unanchored proteins (Iwata 1998) or (b) ompA targeting 
sequences are incorporated at the N-terminus to direct CYPs and the CPR to the 
periplasmic membranes of bacteria, where the signal sequence is removed by proteolytic 
cleavage (Princhard 1998). With either approach, appropriate choice of the host strain is 
essential for efficient cDNA expression. Although it is believed that modifications at the 
N-terminal region of the CYP protein and the CPR are not important for substrate 
recognition or catalysis, extensive validation of kinetic properties of expressed protein is 
definitely prudent. In general, the reported rates of catalysis for isolated bacterial 
expressed CYPs are lower than those observed with proteins obtained from other systems.  
In human cells, the two subunits, CYP and CPR, are always separate (i.e. they are not 
physically associated but act in “trans”). However, often fusion proteins between a 
particular CYP and the CPR have been produced in bacteria and some of them have been 
purified (Shet 1993; Parikh 1997; Iwata 1998). A fusion protein is a single-chain protein 
that contains both the P450 (CYP) and NADPH-P450 reductase (CPR) subunits 
covalently joined together. The catalytic activities of these available fusion proteins have 
not been extensively investigated. Initial investigations that have been reported indicate 














 Expression systems based on yeast cells 
 
The first system used to successfully express a mammalian P450 was yeast. Heterologous 
expression of mammalian P450 enzymes in yeast was first reported by Ohkawa and his 
colleagues in Japan (Sakaki 1985).  In principle, yeast has the possibility of becoming 
one of the best cell systems for expressing or producing P450 enzymes. Yeast is the only 
heterologous system that contains very similar intracellular organelles to that present in 
human cells (Pompom 1997).  Mammalian P450 proteins are found in subcellular 
membranes in human cells, such as mitochondria and endoplasmic reticulum and require 
electron transfer enzymes, NADPH-ferredoxin reductase for mitochondrial P450-s, and 
NADPH-P450 reductase for microsomal (i.e. endoplasmic reticular) P450 enzymes, to 
exhibit their catalytic activities. It is highly desirable that heterologous host cells contain 
human cell-like intracellular compartments and electron transfer enzymes in order for the 
human P450 enzymes to be produced with activities that are very similar to that present 
in human cells. In this respect, baker’s yeast (Saccharomyces cerevisiae) is very similar 
in its intra-cellular architecture and electron transfer enzymes to that of human cells. 
Yeast also has its own NADPH-P450 reductase (CPR) and cytochrome b5 indicating that 
yeast has the perfect machinery to produce active human CYPs and CPR.  Therefore, one 
can envisage co-producing the catalytic partner (i.e. a CYP) along with one or both 
reductases (i.e. the yeast and the human CPR genes) in yeast. While the expression of 
human CYPs in Schizosaccharomyces prombe (Ehmer 2002), Pichia pastoris (Anderson 
2002) and Yarrowia lipolytica (Nthangeni 2004) has been reported, the baker’s yeast 
Saccharomyces cerevisiae (Ching 1991; Pompon 1996; Pompom 1997; Hayashi 2000) 
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has proved to be the yeast most often used for heterologous expression of human CYP 
proteins. 
Lower cost of growing yeast compares very favourably with mammalian cells and insect 
cell based systems. Moreover, yeast can be grown to comparable densities to bacterial 
cells and much higher densities than insect cells. The observed P450 expression levels 
are high enough to allow both spectrophotometric and detailed biochemical analysis of 
single human CYPs directly in yeast microsomal fractions.  
Based on the above, yeast is potentially a better host cell than bacteria and insect cells for 
expression of P450 enzymes. In the past, the activities of human CYP enzymes, expressed 
in yeast, were the major problem. In the present study, I have been able to use the concept 
of expressing human genes, synthesised with yeast biased codons, to avert this problem. 
The results have provided a good response with high CYP enzymes activities. 
 
 Baculovirus Expression System 
 
First foreign gene expression with a baculovirus was demonstrated more than 20 years 
ago (Smith et al., 1983). Traditionally, recombinant baculovirus generation is carried out 
in two steps (Berger, 2004): (1) gene of interest is cloned into a small transfer vector and 
propagated in E. coli and, (2) later cloned into the baculovirus genome by homologous 
recombination in insect cells yielding 30-80 recombinant progenies (O’Reilly et al., 
1994). The major drawback of the baculovirus system is that, once a composite 
baculovirus is constructed, it cannot be modified easily, partly due to its large size (130 
kb). Moreover, proteins produced by the baculovirus system are not always amenable to 
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X-ray crystal studies. The proteins need to be truncated or mutated before they can be 
coaxed into forming highly order single crystals (Trowitzcsh wt al., 2010). 
 
1.17 Introduction to the yeast expression system 
 
 Saccharomyces cerevisiae is a model eukaryote 
 
Although yeasts have greater genetic complexity than bacteria, containing 3.5 times more 
DNA than Escherichia coli cells, they share many of the technical advantages that 
permitted rapid progress in the molecular genetics of prokaryotes and their viruses. Some 
of the properties that make yeast particularly suitable for biological studies include rapid 
growth, dispersed cells, the ease of replica plating and mutant isolation, a well-defined 
genetic system, and most importantly, a highly versatile DNA transformation system 
(Daum 2000; Buschini 2003). Unlike many other microorganisms, S. cerevisiae is viable 
even after introduction of numerous auxotrophic markers. Being non-pathogenic, baker’s 
yeast (henceforth will be referred to simply as “yeast”) can be handled with fewer 
precautions. Moreover, large quantities of yeast can be grown in fermentors and therefore 
yeast-produced heterologous proteins can be a cheap source for further biochemical 
studies on human proteins (Nishihara 1997; Masimirembwa 1999). 
Unlike most other microorganisims, strains of S. cerevisiae have both a stable haploid 
and diploid state. Thus, recessive mutations can be conveniently isolated and manifested 
in haploid strains, and complementation tests can be carried out in diploid strains. The 
development of DNA transformation has made yeast particularly accessible to gene 
cloning and genetic engineering techniques. Structural genes corresponding to virtually 
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any genetic trait can be identified by complementation in yeast with wild type genes from 
plasmid libraries since the majority of the 6000 genes identified in yeast have homologues 
in human cells. Also, plasmids can be introduced into yeast either as extra-chromosomal 
replicating entities or by integration into the genome.   
Integrative recombination of DNA through transformation (i.e. transfection) in yeast 
proceeds exclusively via homologous recombination. Techniques (i.e. protocols) similar 
to that developed for yeast have been used for genomic integration of genes in mammalian 
cells (Adams 1997).  Via homologous recombination, exogenous DNA with segments 
homologous to that present in the organism’s genome can be directed at will to specific 
locations in the host’s genome. Homologous recombination, coupled with yeast’s high 
levels of gene conversion, has also led to the development of techniques for the direct 
replacement of genetically engineered yeast DNA sequences into their normal 
chromosomal locations. Thus, normal wild type genes, even those having no previously 
known mutations, can be conveniently replaced with altered or disrupted alleles. The 
phenotypes arising after disruption of yeast genes have contributed significantly toward 
understanding the function of certain proteins in vivo.   
Yeast transformation can be carried out directly with synthetic genes, permitting the 
convenient production of numerous altered forms of proteins. These techniques have been 
extensively exploited in the analysis of gene regulation, structure-function relationships 
of proteins, chromosome structure, and other general questions in cell biology. The 
overriding virtues of yeast are illustrated by the fact that mammalian genes can be 




In addition, yeast has proved to be invaluable for studies of proteins from other organisms 
which includes the use of the two-hybrid screening system for general detection of 
protein-protein interactions (Field 1989).  Yeast artificial chromosomes (YACs) have 
been used for cloning large fragments of DNA. Yeast has also been used for elucidation 
of biochemical pathways in humans and other organisms. Most notably, these involve the 
cancer cell division cycle, elucidation of the function of protein kinases, proteolysis and 
protein degradation, protein folding/misfolding, apoptosis, chalking out the mechanism 
of action of a pharmaceutical drug, a toxic chemical or an agricultural herbicide (Bähler 
2005). Besides the above, yeast expression systems have been used for lab and 
commercial scale preparations of heterologous proteins.  
 
 Yeast transformation 
 
Saccharomyces cerevisiae is unique among eukaryotes in the ease with which it can be 
transformed with DNA, and the high frequency with which the introduced DNA can 
undergo homologous recombination with genomic DNA. There are several requirements 
for a successful transformation experiment (Adams 1997): (1) a means of introducing 
yeast DNA into cells; (2) a selectable marker on the introduced DNA with corresponding 
non-reverting mutations in the chromosomes that would allow generation of the 
auxotrophic markers; and (3) a vector system (i.e. a shuttle vector) that would allow 








 Yeast selectable markers 
 
Although the frequency of transformation of yeast can be quite high compared to other 
similar organisms, only a small fraction of the total number of cells in a transformation 
experiment are transformed. It is essential to have in yeast a selectable marker that would 
allow selection of cells that become transformed. All standard yeast vectors have a 
bacterial origin of replication and a bacterial selectable marker, usually the ß-lactamase 
gene that confers ampicillin resistance. At the same time, all standard yeast vectors also 
have a yeast selectable marker, such as a fully functional LEU2, URA3, ADE2, HIS3, 
TRP1 or LYS2 gene etc.(Sikorski 1989). In addition, all yeast strains contain markers that 
allow selection of transformants containing the desired plasmid.  The most commonly 
used yeast markers consist of inactive (i.e. defective) LEU2, URA3, ADE2, HIS3, TRP1 
and LYS2 genes which are usually represented as ura3, his3, leu2, trp1 and lys2 (the 
defective genes are always represented in lower casing). Mutations in these particular 
genes are chosen because of their low reversion rate. Plasmids containing functional 
LEU2, URA3, ADE2, HIS3, TRP1 or LYS2 gene can complement the corresponding 
inactive genes in the yeast strain. Moreover, these yeast markers can complement specific 
E. coli auxotrophic mutations and can thereby be used sometimes directly for selection in 
bacteria.  
In this project, the basic yeast strain BC300 (derived from W303-1a; ATCC #208352) 
has been used extensively to generate BC300 derivatives. For example, the gene 
expression cassettes for a modified human reductase, ∆hRDM, have been introduced at 
the LEU2 locus of BC300 to generate the strain YY7. Similarly, the two gene expression 
cassettes for a modified human reductase, ∆hRDM, and human cytochrome b5 were 
78 
 
introduced at the LEU2 and TRP1 chromosomal loci of BC300 to generate the strain 
YAB79.  
The strain BC300 is defective in the five nutritional marker genes, LEU2, HIS3, ADE2, 
TRP1 and URA3, a functional copy of each being essential for growth in minimal 
medium. These individual genes allow synthesis of the amino acids leucine, histidine and 
tryptophan, the nucleoside uracil and the nucleoside base adenine. This means that 
because there are inactivating mutations in the LEU2, HIS3, ADE2, TRP1, URA3 genes, 
BC300 cells can only grow in minimal medium to which leucine, histidine, adenine, 
tryptophan and uracil are added. Therefore, selectable markers are essential elements for 
any yeast transformation procedure. For example, a yeast vector (i.e. plasmid), that 
contains the desired CYP gene and has the functional URA3 gene as a selectable marker, 
has been transformed into BC300. Those cells which grow on minimal medium plates 
that contain leucine, histidine, adenine, tryptophan but lack uracil must contain the yeast 
plasmid. The functional URA3 gene on the vector complements the URA3 gene defect 
(i.e. ura3) in the cell and thereby restores cell growth in the absence of uracil.   
One can use similar strategies to introduce multiple genes in a relatively stable manner 
using the other ‘selectable markers’ LEU2, HIS3, ADE2 or TRP1. And that is how a gene 
copy of the modified NADPH P450 reductase (CPR; ∆hRDM) or the cytochrome b5 
protein (substrate of cytochrome b5 reductase, CBR, which exists within yeast) can be 
co-introduced into the BC300 cells.  
In addition, selection of yeast transformaants using a suitable antibiotic resistance gene, 
as a marker, has also been used for: (a) introducing new genes into the yeast genome and 




 Yeast vectors 
 
A wide range of vectors are available to meet various requirements for insertion, deletion, 
alteration and expression of genes in yeast. Most plasmids used for yeast studies are 
shuttle vectors, which contain sequences permitting them to be selected and propagated 
in E. coli, thus allowing for convenient amplification and subsequent alteration in vitro.  
The yeast vectors used in this project originate from the bacterial vector pBluescript and 
contain (a) pBluescript’s bacterial origin of replication (ColE1ori) that can promote high 
copy number maintenance in E. coli and (b) the selectable antibiotic marker, the β-
lactamase gene (bla or Amp-r) that confers resistance to ampicillin.  The bacterial vector 
pBR322 derived yeast vectors have relatively low copy numbers and can confer resistance 
to either ampicillin (because of the presence of the Amp-R gene) or tetracycline (because 
of the presence of the Tet-R, tetracycline resistance gene) depending on the way that the 
yeast vector was constructed.   
In addition, as mentioned before, all yeast vectors (Table 1.4) contain markers that allow 
selection of transformants containing the desired plasmid. They either bear an 





Table 1.3. Components of the commonly used yeast plasmid vectors. 
 
Plasmid YIp YEp YRp YCp 
E. coli genes or segments 









Yeast genes or segments 
URA3; HIS3; LEU2; TRP1; LYS2; etc. 
2 µm; 2µm-ori REP3 
ARS1; ARS2; ARS3; etc. 





















Host (yeast) markers 










Stability +++ + + + 
 
 
 YIp vectors 
 
The YIp integrative vectors do not replicate autonomously, but integrate into the genome 
at low frequencies by homologous recombination. The site of integration can be targeted 
by cutting the yeast segment in the YIp plasmid with a restriction endonuclease and 
transforming the yeast strain with the linearized plasmid. The linear ends are 
recombinogenic and allow direct integration to the site in the genome that is homologous 
to these ends. In addition, linearization increases the efficiency of integrative 
transformation from 10 to 50 fold. Once integrated, the transforming DNA is part of the 
chromosome and segregate in mitosis and meiosis with the same high fidelity as a 
chromosome. Plasmids used for integration have a yeast selectable marker, but no other 
yeast elements (Sikorski 1989; Funk 2002).  Strains transformed with YIp plasmids 
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(Table 1.4) are extremely stable, even in the absence of selective pressure.  However, 
plasmid loss can occur at approximately 10-3 to 10-4 frequencies by homologous 
recombination between tandemly repeated DNA (if there be any in such sequences), 
leading to looping out of the vector sequence.   
 
 YEp vectors 
 
The YEp yeast episomal plasmid vectors replicate autonomously in yeast because of the 
presence of a segment of the yeast 2 µm (µ) plasmid that serves as an origin of replication 
(2µ ori). The 2µ ori is responsible for high copy-number and high frequency of 
transformation of YEp vectors (Murray 1983; Sikorski 1989).  
YEp vectors contain either a full copy of the 2µ plasmid, or, as with most of these kinds 
of vectors, a region which encompasses the ori and the REP3 gene. The REP3 gene is 
required in cis to the ori for mediating the action of trans-acting REP1 and REP2 genes 
which encode products that promote partitioning of the plasmid between cells at division. 
Therefore, the YEp plasmids containing the region encompassing only ori and REP3 must 
be propagated in cir+ (i.e. circle-positive) hosts containing the native 2µ plasmid which 
provides the trans-acting REP1 and REP2 genes (Sherman et al., 1991).   
Most YEp plasmids are relatively unstable under non-selective growth conditions, being 
lost in approximately 10-2 (i.e. 1 in 100) or more cells after ten generations of growth 
(each generation lasting around 90 min). Even under conditions of selective growth, only 
60% to 95% of cells retain the YEp plasmid. The copy number of YEp plasmids ranges 
from 10-200 per cell of cir° hosts.  However, the plasmids are not equally distributed 
among the cells, and there is a high variance in the copy number per cell in populations. 
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In this project, I have engineered the cir° yeast cells, from the strain BC300, which already 
contain stably integrated copy/copies of a modified human reductase (∆hRDM) and/or 
cytochrome b5 to take up  
(a) A YEp plasmid which encodes a variety of different human CYP genes, so that a 
CYP and its activating subunit (CPR; ∆hRDM), with or without cytochrome b5, 
will simultaneously be expressed within the same yeast cells, and  
(b) One or two copies of YIp plasmids encoding human CYP genes, so that a CYP 
and its activating subunit (CPR; ∆hRDM), with or without cytochrome b5, will 
simultaneously be expressed within the same yeast cells.  
 
 YRp vectors 
YRp vectors, containing ARS but lacking functional CEN elements, can be transformed 
into yeast at high frequencies. But these vectors are lost at too high a frequency, over 10% 
per generation, making them undesirable as vectors of choice (Sikorski et al., 1989; 
Sherman et al., 1991). 
 
 YCp vectors 
The YCp yeast centromere plasmid vectors are autonomously replicating vectors 
containing centromere sequences, CEN, and autonomously replicating sequences, ARS. 
The YCp vectors are typically present at very low copy numbers, usually 1 per cell and 
are lost in approximately 10-2 cells per generation without any selective pressure. In most 
instances, the YCp vectors segregate to two of the four ascospores from an ascus, 
indicating that they mimic the behaviour of chromosomes during meiosis, as well as 
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during mitosis. The ARS sequences are believed to correspond to the natural replication 
origin of yeast chromosomes, and all share a specific consensus sequence.  The CEN 
function is dependent on three conserved domains, designated I, II, and III; all three 
elements are required for mitotic stabilization of YCp vectors. 
The stability and low copy-number of YCp vectors make them ideal as cloning vectors, 
for construction of yeast genomic DNA libraries, and for investigating the function of 
genes altered in vivo. ARS1, which is in close proximity to TRP1, is the most commonly 
used ARS element for YCp vectors, although others have been used. CEN3, CEN4 and 
CEN11 are the commonly used centromeres that can be conveniently introduced into YCp 
vectors. 
 
1.18 Vector systems for heterologous expression of 
proteins in Saccharomyces cerevisiae 
The yeast episomal plasmid, pSYE263 (created in Professor Chaudhuri’s laboratory), 
contains a sequence that would allow autonomous replication in yeast. It was derived 
from yeast’s endogenous 2µ-plasmid and contains an origin of replication which could 
promote high copy number if the gene expressed from the plasmid was non-toxic. 
Episomal 2µ-based plasmids are known to have fluctuating copy numbers depending on 
the gene that is expressed. Gene expression from pSYE263 is driven by the yeast ADH2 
promoter and contains the URA3 gene as a marker for selection of yeast transformants in 
minimal medium that lacks uracil. 
The yeast integrating plasmids do not contain the 2µ sequence but contain only one of the 
yeast genes ADE2, HIS3, LEU2, TRP1 or URA3 as a selection marker for growth of yeast 
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transformants in minimal medium that lacks adenine, histidine, leucine, tryptophan or 
uracil. New yeast integrating plasmids (Yip-s), which contain the ADH2 promoter and 
which encode ADE2, HIS3, TRP1 genes, were constructed by me for this project and are 
described in later Chapters of this report. 
 
1.19 Prologue to the contents of this thesis 
 
The aim of my investigation was to devise new systems for expression of human 
cytochrome P450 enzymes (CYPs) in baker’s yeast, so that they are produced, as 
‘intracellular membrane bound’ proteins, in high yields and activity. It is essential that 
CYPs bind to intracellular membranes to manifest activity. The goals were to find out the 
effects on ‘activity’ and ‘yields’ of CYP enzymes with the use of (1) human CYP genes 
(~1500 bps in length) which are ‘chemically synthesised’ using ‘yeast biased codons’, 
and (2) a non-toxic variant of the human P450 reductase gene (∆hRDM; ~2000 bps; 
Patent WO2007129050A3) which had been genetically engineered before this work 
began. This was to test the concept that ‘codon usage’ is a crucial factor in expression of 
inherently toxic proteins.  
A large number of plasmids (~100) have been constructed during the course of conducting 
the work described in this thesis. In the experimental Chapters 3 to 7, the construction of 
some of these plasmids and their applications will be discussed in detail.  
Chapter 3 compares the expression of CYP genes, chemically synthesized using yeast 
biased codons, with the expression of native CYP genes isolated from a human liver 
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cDNA library. Expression of both types of genes, synthetic and native, was from an 
episomal plasmid.  
Chapter 4 compares the expression of the synthetic human CYP genes from (a) an 
episomal plasmid with (b) single copies integrated at different sites of the yeast genome. 
Chapter 5 describes the consequence of expressing synthetic human CYP genes from two 
separate copies integrated at two different sites of the yeast genome. Activities of 
microsomal enzymes, isolated from cells expressing two copies of the synthetic genes, 
have been compared with commercially available microsomal enzymes that are sold 
worldwide. 
Chapter 6 describes the use of whole cells, expressing synthetic human CYP genes, for 
highly efficient biotransformation reactions of a starting chemical to a product or 
products.  
Chapter 7 provides details of the significance of co-expressing two or three different CYP 
enzymes, from synthetic genes, within the same cohort of cells, in drug metabolism 
studies.  
In summary, unique platform systems, based on bakers’ yeast, have been devised that 
allows construction of ‘stable’ yeast strains that permit production of levels of highly 






Chapter 2 Materials and Methods 
 
2.1 Chemicals, common reagents and equipment 
Chemicals 
All chemicals used were analytical and molecular grade. New England Biolabs, Sigma 
Chemicals, Fisher, Invitrogen Life Technologies, Becton Dickinson, Melford 
Laboratories, Roche and Bio-Rad UK were the main suppliers.  
Water 
All solutions used were made from Ultra-pure (18-Milli-Q) water obtained from a pure 
water system (Mllipore Q synthesis A-10, Millipore). For all yeast cell culture 
experiments, the media used were made from pure water and were autoclaved at 121°C, 
15-psi pressure for 15 min. 
 
2.2 Common reagents, solutions and media 
TEG 
50 mM glucose, 10 mM EDTA, 25 mM Tris-HCl, pH 7.5. 
50X TAE 
242 g Tris base, 57.1 ml glacial acetic acid, 18.6 g EDTA, made up to 1 L with pure water.  
10X TE 




A pre-mixed stock powder consisting of 10 g tryptone, 5 g yeast extract, 10 g NaCl, in 1 
L pure water.  
YP medium 
1% Bacto-yeast extract, 2% Bacto-peptone. 
YPD Broth 
A pre-mixed powder from Difco (Cat No 242820), consisting of 1% Bacto-yeast extract, 
2% Bacto-peptone, 2% glucose. 
Synthetic Dextrose minimal medium (SD) 
0.67% Bacto-yeast nitrogen base without any additional supplements, 2% glucose. 
Supplemented minimal medium (SMM) 
A SD medium that contains nutrients, depending on the auxotrophic markers required for 




The pieces of equipment used were the ones commonly used in a molecular biology/ cell 







Table 2.1. Equipment list. 
 
Equipment Supplier Model / Catalogue Number 
-20ºC Freezer Sadia Sadia 310 
4ºC Fridge Sadia Sadia 310 
Autoclave machine Fisher Scientific Classic 2100 
Balance Fisher Scientific Op-1500 
Bench-top Centrifuge SANYO MSE Micro-Centaur 
Centrifuge (JA-17) Beckman Coulter AvantiTM J-20 XP 
Dispensing Pipettor Fisher Scientific Eppendorf Mulltipette 2-
10000µl 
Double distilled water supply Millipore Milli-Q synthesis A10 
Fluorescence microscope Olympus BX51 
Fluorescence spectrophotometer Shimadzu UV-2401PC 
Heated incubator Fisher Scientific Sanyo, MIR-163 
Incubator 30oC Fisher Scientific Sanyo, INA-320-010Y/MIR-
162 
Magnetic Stirrer/Heater Fisher Scientific IKA, SWT-750-030A 
Microscope Olympus CKX41 
Micro centrifuge MSE Fisher Scientific Sanyo, CEK-113-010P 
Microwave oven SANYO 800w compact microwave 
PCR machine Anachem Biometra thermocycler, T3 
Combi   
 pH meter Mettler Toledo Severn Multi 
Sonicator Hielscher UP50H 
Thermo mixer Fisher Scientific Eppendorf, BLD-455-010C 
UV Illumination UVP C-80 
Ultracentrifuge Beckman Coulter Optima L-100 XP 
Ultra-low (-80oC) freezer Triple Red Nuaire, NU6512E 
Vortex mixer Fisher Scientific IKA, MPR-550-010H 
Water Bath Fisher Scientific TYP E DMU 5 





2.4 Basic Molecular Biology Techniques 
 
Molecular techniques were important in every aspect of this project. Coding sequences 
of the human CYPs were chemically synthesized using yeast-biased codons. The CYPs 





5) CYP2B6,  
6) CYP2C8,  
7) CYP2C9,  
8) CYP2C9 Arg (R144C SNP),  
9) CYP2C9 Ile (I359L SNP),  
10) CY2C18,  
11) CYP2C19,  
12) CYP2D6_variant 1 (CYP2D6-1; Val374),  
13) CYP2D6_variant 2 (CYP2D6-2; Met374),  
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14) CYP2D6_SNP2 (CYP2D6_*2),  
15) CYP2D6_SNP10 (CYP2D6_*10),  
16) CYP2D6_SNP39 (CYP2D6_*39),  
17) CYP2R1,  
18) CYP3A4,  
19) CYP3A4_variant 2 (CYP3A4-2),  
20) CYP2J2,  
21) CYP4F3,  
22) CYP4F2,  
23) CYP4A11,  
24) CYP7A1,  
25) CYP17A1  
26) CYP19A1.  
At first, 80-100 base DNA fragments (Genewiz, USA) of each gene were chemically 
synthesized. The DNA fragments were then assembled using PCR with the help of a high-
fidelity DNA polymerase. The amplified CYP coding sequences were cloned in a basic 
bacterial vector, pUC57 (Thermo Fisher Scientific), and the resultant plasmids were used 
for the work described in this report.  
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The plasmids were (a) digested with appropriate restriction enzymes, (b) the digests were 
loaded on to agarose gels, (c) the vector and the gene inserts were fractionated, (d) the 
inserts were isolated from agarose gel pieces, and (d) purified for further cloning in a 
yeast expression vector. After the genes were cloned into the yeast vector, the resultant 
plasmids were isolated using the alkaline lysis protocol (please see below). After that, 
pure plasmid DNA was isolate on commercially available silica-gel columns.  
Yeast expression plasmids, encoding chemically synthesized CYP genes, were 
transformed (transferred) into yeast cells that contained a modified (non-toxic) mutant of 
the human CPR (∆hRDM), and (in some cases) cytochrome b5. The transformed yeast 
cells (i.e. yeast strains) had the potential to produce active human CYP enzymes. 
 
2.4.1 Molecular Cloning 
 
2.4.1.1 Preparation of bacterial competent cells using 
CaCl2 
 
DNA manipulation generally requires good competent bacteria. The E. coli DH5α strain 
is widely used in cloning applications due to its reliability, stability and improved quality 
of plasmid DNA obtained from mini preparations (mini-preps). The chemistry involved 
in the uptake of DNA by the cell is not yet fully understood. The cell is enabled to take 
up the circular DNA after treatment with cold calcium chloride (CaCl2). The method was 




Preparation of bacterial competent cells involved (a) streaking out DH5α cells from a 
glycerol stock on to LB agar plates (Sigma-Aldrich, Cat No L3147) that contained no 
antibiotic (i.e. ampicillin), (b) incubating plated cells over-night at 37°C, (c) picking an 
individual colony and inoculating it into a 5 ml LB broth (Sigma-Aldrich, Cat No L3147) 
contained in a 25 ml conical flask, and (d) growing cells over-night in an orbital incubator 
(shaking at 37°C, 220 rpm). 
200 µl of cells from the overnight culture was added to 200 ml of LB broth that contained 
1 ml of 50% glucose and cells were grown for about 4-5 h until OD600 (i.e. absorbance of 
cell suspension at 600 nm) reached 0.3-0.4. The culture was left for 10 min on ice. The 
centrifuge (Beckman Coulter Avanti™ J-17 XP) was chilled and the cells were 
centrifuged at 3500 rpm for 15 min at 4°C; the supernatant was discarded and the pellet 
was gently re-suspended in ice-cold 20 ml MgCl2 (0.1M) and incubated for 20 min on ice 
to soften the cell wall. The cells were then centrifuged for 15 min, the supernatant was 
discarded and re-suspended in ice-cold 20 ml CaCl2 (100 mM), incubated for 20 min and 
finally centrifuged for another 15 min when all supernatant was removed. The pellets 
obtained were gently re-suspended in 6 ml ice-cold CaCl2 (100 mM) which contains 15% 
glycerol. 100 µl of cell suspension was aliquoted into Eppendorf tubes which were flash 















2.4.1.2 Construction of recombinant DNA molecules 
 
One of the main aims of the project was to devise new systems for expression of human 
CYP enzymes in baker’s yeast. 
Within this aim, the first goal was to find out how ‘chemically synthesized’ human CYP 
genes, with codons that are yeast-biased, fare against CYP cDNAs isolated from a human 
liver cDNA library in terms of (a) ‘CYP enzyme activity’ and (b) ‘CYP yield’. 
For the above comparative analyses, 17 human CYP genes (13 of which are widely used 
for Drug Metabolism studies, and 4 which have crucial roles in the synthesis of steroids 
that are essential for human cells) were chosen. All the genes were synthesized using 
yeast-biased codons and were cloned into the basic vector, pUC57. 
The pUC57 plasmids, bearing ‘synthetic’ CYP genes, were amplified by transforming 
into bacterial DH5α cells. The CYP genes were isolated from the pUC57 plasmids using 
restriction enzymes that cut at specific recognition sites at the 5’ and 3’ ends of the genes. 
The CYP genes were then ligated into a shuttle vector of choice (i.e. pSYE263) which has 
the ability to replicate inside both bacterial and yeast cells. 
 
2.4.1.3 Plasmid vectors 
 
One of the yeast vectors used, in the construction of recombinant DNA for yeast 
expression studies in this project, was the episomal 2µ-based vector pSYE263 (Figure 
2.1). It contains the promoter from the yeast alcohol dehydrogenase gene 2, ADH2, which 
is one of the two alcohol dehydrogenase genes of yeast. Alcohol dehydrogenases are 
responsible for oxidation of ethanol to enable its removal from living cells. 
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The vector pSYE263 was already available in the lab and a small aliquot (10 µl) of 
bacterial stock from -80°C was inoculated into LB broth, which was grown overnight at 
37°C and the plasmid was then isolated. Another plasmid used in this study was 
pBluKS(+)/ADH2p (Figure 2.2), which contained the ADH2 promoter fragment 
(Saccharomyces Genome Database; YMR303C). The promoter DNA was isolated from 
this plasmid by growing cells from bacterial stocks, kept at minus 80°C, to construct a set 
of yeast integrative vectors for cloning CYP genes. These vectors permit integration of 
CYP gene expression cassettes into yeast cells’ different chromosomal loci on the 
genome.  
Both the plasmids (Figures 2.1 and 2.2) bear a β-lactamase gene which confers resistance 






Figure 2.1. Map of the plasmid pSYE263, a 2µ-based episomal plasmid, which 
contains the yeast ADH2 promoter for inducible expression in yeast. The 
restriction sites that are shown occur in the plasmid only once. 
 
 
Figure 2.1. Map of the basic plasmid that contains the yeast ADH2 promoter 
which was isolated from this plasmid for further cloning in yeast integrative 












































































2.4.1.4 Restriction enzyme digests 
 
To be able to clone a DNA insert into a cloning or expression vector, both insert and 
vector have to be treated with restriction enzymes that create compatible ends. It is 
preferable that at least one of the enzymes used creates a sticky end to ensure that the 
insert is incorporated in the correct orientation. 
All restriction enzymes used for this report were purchased from New England Biolabs, 
UK; they were supplied with their appropriate buffers. Amongst all the restriction digests 
carried out, only the Xbal site (TCTAGA) was found to be methylated which results in 
the site being resistant to cleavage. This occurs when the recognition sequence is preceded 
by GA or followed by TC. Hence, plasmids were passed through a dam-minus bacterial 
strain (SCS170) to prevent methylation, so that the site could be digested again with XbaI. 
Coding sequence of all the genes began with an ATG (coding for Methionine, the Start 
site) and ended with a Stop codon (TAA, TAG or TGA). A restriction site (BamHI or 




This involves the ligation of the insert to the linearized vector. It comprises the formation 
of covalent phosphodiester bonds between the 5’ nucleoside phosphates of one fragment 
with the 3’-hydroxyl residue of another. The formation of the bonds can be catalysed by 
two different ligases, (a) bacterial DNA ligase or (b) bacteriophage T4 DNA ligase. The 
97 
 
latter (New England Biolabs, Cat No M0202S) was used because it also helps to join 
blunt-ended DNA fragments. 
The ratio of amounts of insert to vector fragments ratio used is critical for high efficiency 
ligation. Powell (2001) calculates the ratio as: 
 (ng of vector) x (kb size of insert) X molar ratio of insert/vector  = ng of insert  
Kb size of vector 
The total reaction volume used for ligation was 20 µl and consisted of:  
2µl 10x ligase buffer 
2µl Digested vector DNA (50 ng/µl) 
 Equivalent amount of insert DNA 
0.5 µl T4 DNA ligase (20 NEB units/µl 
 Sterile water to volume of 20 µl 
 
Ligase was added last and gently mixed. A ligation mixture was incubated at 19°C (i.e. 
room temperature) on the bench, or 4°C overnight (in a cold room or a refrigerator). The 
reaction mixture was then used directly for transformation in competent cells (mostly 
DH5α, sometimes JM109). Through ligation, a new recombinant plasmid was created. 
 
2.4.1.6 Transformation of ligation mixtures in CaCl2 
competent bacterial cells 
 
The process of introducing foreign recombinant DNA into living cells is called 
transformation or transfection. 
Competent cells are thawed on ice for 10 min. 5 ng of DNA from ligation mixture was 
introduced to the thawed competent cells and incubated for 30 min on an ice bucket. The 
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mixture was then heat-shocked at 42°C for 45 sec, and immediately transferred back to 
ice for recovery for 2 min.  800 µl of LB broth was added and incubated, shaken for 1 h 
at 37°C. 
LB agar containing ampicillin (100 µg/ml, Fisher BioReagent, Cat No BPE1760-5) were 
poured on10 cm-diameter sterile plastic dishes and allowed to set. After 1 h, 50 µl of the 
cells from the transformation mixture were spread on the LB agar plates which contained 
ampicillin. The plates were incubated overnight at 37°C. The cells which grew on the 
plate contained plasmids that bear the β-lactamase (ampicillin resistant) gene. 
 
2.4.1.7 Isolation and purification of recombinant plasmid 
DNA from transformants (mini preparations) 
 
After the recombinant DNA was constructed via ligation, the clones were identified and 
confirmed through restriction enzyme digests. The cells, bearing the plasmid DNA (i.e. 
transformants), were then amplified through growth of bacterial cells (i.e. bacterial cell 
division). There were two types of plasmid DNA which were prepared in this study:  
1. Crude DNA which were obtained via alkaline lysis preparations, and  
2. Pure DNA which were obtained using commercially available mini silica-gel 
columns. 
The alkaline lysis method was usually used to obtain relatively large amounts of DNA 
while the columns (commercially available from Qiagen or York Bio) have an advantage 
of yielding plasmids with reduced RNA which can accurately be quantified (i.e. 
concentrations of DNA can be determined in µg/µl) and stored longer. 
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The plasmids obtained by either of the two methods were used to 
(1) Confirm that the insert and vector have the correct sizes, and that the plasmid has 
the correct restriction patterns after restriction enzyme digests. 
(2) Transform yeast cells so that yeast transformants could be grown in cell culture 
and analysed for expression of active CYP enzymes. 
 
2.4.1.8 Plasmid DNA preparation via alkaline lysis (crude 
preparation) 
 
For this purpose, usually 4 individual bacterial colonies were picked from an LB agar 
ampicillin plate and inoculated into 5 ml LB broth containing 5 µl ampicillin (100 µg/ml). 
The cultures were grown overnight at 37°C, with shaking at 220 rpm inside an orbital 
shaker. The cultures were taken out and 1.5-3 ml of cells was spun down for 1 min at 
13,000 rpm; the supernatants were discarded. The pellets were first re-suspended in 
Solution 1 and then the other two Solutions were added one after the other.  They were:  
(1) Solution 1 (4.5g glucose,12.5ml Tris-HCl pH 8, 10 ml EDTA pH 8, 4mg/ml 
RNase, made up to 500 ml with distilled water). 
(2) Solution 2 (10 ml NaOH 10N, 50 ml 10% SDS, filled up to 500 ml with water); 
SDS is a detergent that lyses cells, whereas NaOH is a strong base that works 
to neutralize the strong acidity in Solution 3 to cause bacterial DNA to 
precipitate leaving the plasmid DNA in solution. 
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(3) Solution 3 (89 g potassium acetate, 58 ml acetic acid, filled up to 500 ml with 
distilled water. 
100 µl of Solution 1 was used to re-suspend the pellet. Then 200 µl of Solution 2 was 
added and immediately placed on ice for 5 min. Then 150 µl of Solution 3 was added and 
inverted up and down six times, again incubated on ice for another 5 min; this neutralized 
the effect of Solution 2.  The mixture was then spun down at the maximum speed 13,000 
rpm for 10 min.  Usually, a good pellet is formed from a slimy colourless solution that 
looks like starch. The supernatant was transferred into a new Eppendorf tube and 450 µl 
isopropanol was added, incubated for 10 min at room temperature. This was spun at 
13,000 rpm for 10 min. The supernatant was discarded gently without disturbing the pellet 
and 500 µl of 70% ethanol was added and spun down for 8 min. The supernatant was 
removed gently and the pellet was air dried for 10-15 min at room temperature. 50 µl of 
1xTE buffer was used to dissolve the dried pellet. Digest with restriction enzymes were 
performed on 2 µl of DNA to check the correct size of the insert DNA and authenticity 
of the newly created plasmid.  The rest of the plasmid DNA was stored in a minus 20˚C 
freezer.  
 
2.4.1.9 Preparation of pure plasmid DNA, using columns 
 
Pure plasmids are prepared so that they could be stored for a longer period of time and 
the procedure followed was as specified by the manufacturer.  
1.5-3 ml of overnight culture was spun down at 13,000 rpm for 1 min and the supernatant 
was discarded gently. With York Bio columns, there are three solutions that are used 
sequentially: Solution 1, Solution 2 and Solution 3.  100 µl of Solution 1 was added to 
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the pellet and re-suspended gently, 200 µl of Solution 2 was added immediately followed 
by 300 µl of Solution 3. The mixture was allowed to incubate for not more than 1 min 
and then centrifuged at 13,000 rpm for 10 min. The column was assembled inside the 
collection tube and the supernatant was transferred gently without disturbing the residue 
on the wall of the tube.  700 µl of washing solution containing 70% ethanol was added 
and spun down for 30 sec at 8,000 rpm; this step was repeated and the supernatant was 
discarded. The column was taken off and transferred into a new Eppendorf tube and eluted 
in 50 µl of nuclease free water (allowed to incubate for 2 min), spun down for 1 min at 
13,000 rpm. 
Digestions with restriction enzymes were performed using 1 µl (~4 µg) of plasmid DNA. 
The rest of the plasmid DNA was stored at minus 20˚C. After the plasmid was isolated, 
its concentration was determined by measuring absorbances at 260 nm and 280 nm in a 1 
ml quartz cuvette with 1 cm path length. The ratio of the two absorbances gives the level 
of purity of the plasmid. Nucleic acids and proteins have absorbance maxima at 260 and 
280 nm, respectively. Historically, the ratio of absorbances at these wavelengths has been 
used as a measure of purity in both nucleic acid and protein extractions. A ratio of ~1.8 
is generally accepted as “pure” for DNA. High 260/280 purity ratios are not indicative of 
an issue whereas low values may indicate RNA/protein impurities. 
The following formula was used to determine the concentration (amount) of DNA in 









2.4.1.10 Gel electrophoresis 
 
After restriction digests, horizontal agarose gel electrophoresis was used to analyse the 
band size of insert DNA and restriction patterns of the plasmids. DNA fragments separate 
based on their molecular sizes. Since DNA is negatively charged and in solution it 
migrates to the positive pole in an electric field, higher the molecular weight of a linear 
DNA, the slower it migrates to the opposite end of the pole. 
Gels are run for 20-25 min at 90 V, stopped and viewed under ultra-violet (UV) light. 
Presence of a fluorescent dye (Sybro Safe DNA Gel Stain, Life Technologies Cat No 
S33102) in the gel detects DNA bands in UV light at 260-310 nm.  The gel composition 
may affect the visibility of the band size and its movement.  Most gels were 1% w/v of 
agarose (Life Technologies, Cat No 15510027) in a 1 X TAE buffer (50x TAE, 40 mM 
Tris, 20 mM acetic acid and 1 mM EDTA, pH 8.4). The set gel was transferred into a tank 
containing the same electrolyte, 1X TAE, filled up to the maximum to cover the gel. 
Samples and DNA ladder (2–log DNA ladder; NEB, Cat No N3200L) were loaded (in 
50% glycerol, 2% Ficol, 50 mM EDTA and 5% bromophenol blue in sterile water) onto 
the wells of the gel, and a potential difference was set to 90 V. After the gel ran for 30 
min, it was taken out and viewed under UV light (BioRad, ChemDoc System). 











Figure 2.3. A typical agarose gel showing the different DNA fragments that 
were isolated to allow ligation between ‘insert’ and ‘vector’ fragments to 
obtain plasmids that were used for expression of CYPs. 
 
2.4.1.11 Purification of DNA from agarose gels 
 
Following gel electrophoresis, excised DNA fragments from gels were placed in a 1.5 ml 
Eppendorf tube, and DNA was isolated (using a kit from Promega; Wizard SV Gel and 
PCR Clean up System). 100 µl of membrane binding solution per 10 mg of gel slice was 
added and incubated at 65°C for 10 min on a Thermo-mixer (Fisher Scientific) shaking 
at 300 rpm until the gel completely dissolved in solution. The mini column was inserted 
into the collection tube and the dissolved gel was transferred, incubated for 1 min to allow 
the DNA to bind to the membrane.  After centrifugation at 13,000 rpm for 1 min, the 
flow-through was discarded and the column was re-inserted into the collection tube, 700 
µl membrane wash solution (containing ethanol) was added centrifuged at 13,000 rpm for 
5 min and again the flow-through was discarded.  The last step was repeated to ensure 
that a clean DNA fragment was obtained. The tube was centrifuged for 1 min at the same 
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speed and the column was transferred into a new Eppendorf tube. 50 µl of nuclease free 
water was added and incubated for 2 min at room temperature and centrifuged at 
maximum speed for 1 min. The flow through was checked by running a quick agarose gel 
to see the band fragment of 1 µl DNA.  The isolated DNA was stored at -20°C until further 
use. 
 
2.5 Yeast Molecular and Cell Biology 
 
The yeast Saccharomyces cerevisiae was chosen as the heterologous host organism for 
the production of human CYP proteins. Yeast is a single-celled microbe that can be 
cultured and manipulated using techniques that have been published. Plasmids obtained 
from bacterial cells were introduced (via transformation) into yeast. The aim was to grow 
yeast transformants, containing the constructed plasmids which encoded different CYP 
genes, for production of active CYP enzymes using 
a) Published general protocols and 
b) More specific CYP-related protocols/ techniques that would be developed over 
the course of the work performed for this doctoral dissertation. 
 
 
2.5.1 Yeast vectors 
 
Some of the basic plasmids used in this study were available in the laboratory. In order 
to meet various requirements, such as for insertion, deletion, alteration and expression of 
genes in yeast, new plasmids were created during the course of this work.  
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The yeast vectors (both episomal and integrative) that were used in this study were 
derived from the basic plasmid pBluescript. This permitted selection on LB-agar plates 
that contained ampicillin. Since pBluescript contains the β-lactamase gene, bacterial cells 
that do grow in ampicillin must contain the yeast expression plasmid which was derived 
from pBluescript. Thus, ampicillin-resistant bacteria could also be grown in larger liquid 
cultures for amplification of plasmid DNA which could be used for further transformation 
into yeast. 
The yeast episomal plasmid, pSYE263 contains a sequence that would allow autonomous 
replication in yeast. It was derived from yeast’s endogenous 2µ-plasmid and contains an 
origin of replication which could promote high copy number provided the gene expressed 
from the plasmid was non-toxic. Episomal 2µ-based plasmids are known to have 
fluctuating copy numbers depending on the gene that is expressed. Gene expression from 
pSYE263 is driven by the yeast ADH2 promoter and contains the URA3 gene as a marker 
for selection of yeast transformants in minimal SD medium that lacks uracil. 
The yeast integrating plasmids do not contain the 2µ sequence but contain only one of the 
yeast genes ADE2, HIS3, LEU2, TRP1 or URA3 as a selection marker for growth of yeast 
transformants in minimal medium that lacks adenine, histidine, leucine, tryptophan or 
uracil. New yeast integrating plasmids (YIp-s), which contain the ADH2 promoter and 
which encode ADE2, HIS3, TRP1 genes, were constructed by me for this project and are 








2.5.2 Yeast media and culture conditions 
 
The full medium (non-selective) YPD medium consists of 1% Bacto-yeast extract, 2% 
Bacto-peptone, 2% glucose. The mixture is available as a pre-mixed powder from Difco 
(Cat No 242820). 
Synthetic (selective) SD minimal medium, used during this study, consisted of yeast 
nitrogen base without any amino acids. Different media were then prepared based on the 
supplementary nutrients (depending on the particular yeast strain’s auxotrophic markers). 
The carbon source was glucose or raffinose (sugars that repress the ADH2 promoter); 
mostly glucose has been used during the course of this thesis.  
Exhaustion of glucose, through conversion of glucose to ethanol, induces the ADH2 
promoter and allows expression of CYP proteins. The stocks of all solutions and reagents 





Table 2.2.  Nutrient concentrations for drop-out powders.  
 
Nutrients Final con. µg/ml * Liquid stock Sigma Aldrich Cat No 
Adenine 40 500 A9126 
L-Histidine 20 240 H8125 
L-Leucine 60 720 L8000 
L-Tryptophan 40 480 T0254 
Uracil 20 240 U0750 
* 8.3 ml/L of a stock solution that contained histidine, uracil, tryptophan or uracil, and 
12.5 ml/L from an adenine stock solution were used. The tryptophan and histidine 
containing solutions were stored at 4°C.  
 
2.5.3 Yeast strains and their manipulation 
 
The yeast S. cerevisiae strains used during this research are derivatives of the basic strain 
W303-1a (MATa ade2-1 can-his-3-11, 15 leu2, 112 trp1-1 ura3-1) which is referred to in 
the lab as BC300. All yeast strains were freshly grown from a glycerol stock solution 
(which are stored at -80°C) before they are used for (a) transformation or (b) CYP 
expression studies. They were streaked out on a freshly prepared synthetic defined (SD) 
media with appropriate supplements and incubated at 30°C for 2-3 days.  Single colonies 
were picked from the plates and inoculated into YPD liquid media. The culture was 
shaken overnight in an orbital shaker at 30°C, 220 rpm. The optical densities of cultures 
were measured at 600 nm (OD600). This was done to monitor cell growth. Cells were also 
counted under a microscope, using a haemocytometer (Sigma-Aldrich, Cat No Z359629), 
108 
 
to check their viability before any further use. The haemocytometer chamber and the 
cover slip were sterilized and dried before use. 
Cell suspensions (1 to 4 dilutions) were gently dropped on to the grid uniformly. Cells 
were counted within a 1 mm2 ruled area which was divided into 25 squares centrally 
located within the chamber (Figure 2.4). Cells falling on the top or the right of the 
boundary were not counted but cells touching the left or bottom were all counted. Also 
all the yeast buds were counted as separate from their mother cells if they were one-half 
the size of their mother cells. 
The total cell count was calculated as: 
Total cell count/ml = [(total cell count x dilution factor)/number of squares] X 10000  
 
 






2.5.4 Yeast transformation with lithium acetate 
 
The yeast S. cerevisiae has a very distinct way through which foreign DNA is introduced. 
The process involves the DNA attaching to the cell wall and entering the cell by 
endocytotic membrane invagination. One of the important elements for a successful yeast 
transformation is polyethylene glycol (PEG) which acts on the membrane to increase the 
transformation efficiency.  The chemical lithium acetate and heat shock helps the DNA 
to pass through the cell wall. There are several ways to carry out yeast transformation but 
in this report, the lithium acetate (LiAc) method was adopted. 
A yeast colony from a strain, streaked out on a fresh plate (as described above), was 
inoculated into 5 ml of liquid YPD yeast cell culture medium and incubated overnight in 
an orbital shaker at 30°C, with shaking at 220 rpm. The OD600 was determined after 16 h 
of growth and then 100 µl of the culture was added to fresh 100 ml of YPD in a separate 
flask. The cell titre should reach 2x 107 cells per ml after 3-5 h, after which the cells were 
harvested by centrifugation at 300 g for 5 min, washed twice in sterile water. 5X 107 cells 
was re- suspended in 1ml of 0.1 M LiAc. The carrier DNA (from salmon sperm) was 
boiled for 5 min and chilled on ice while harvesting the cells. The cell suspension was 
transferred into a new 1.5 ml Eppendorf tube, centrifuged for 1 min at 3000X g and the 
supernatant was discarded. The cell pellet was re-suspended in 1 ml of 0.1M LiAc and 
incubated for 10 min.  100 µl of cells were then transferred into a new 1.5 ml Eppendorf 
tube and centrifuged for 1 min. A master mix was prepared for yeast transformation 








w/v 250 µl 
LiAc 1.0 M 36 µl 
SS DNA 5 µl 
DNA 3-5 µl 
WATER 64 µl 
TOTAL 360 µl 
The items must be added one after the other as it appears on the Table. 
 
After 360 µl of the mixture was prepared, it was mixed by vortexing for a few seconds 
and then it was incubated for 30 min at 30°C and transferred immediately for heat-shock 
to 42°C for another 30 min on water bath. The cells were then incubated on ice for 3 min 
and centrifuged for 2 min. The supernatant was discarded and 50 µl of sterile water was 
added to the cell pellet and the re-suspended cells were plated out on an SD plate to which 
appropriate supplements had been added. The plate was incubated at 30°C for 2-3 days. 
The transformants are picked and further streaked out on YP-glycerol (2%) plates to 
eliminate petites. The yeast S. cerevisiae is one of the very rare organisms that can exist 
without functional mitochondria and grow via a fermentative pathway. These mutant 
yeast cells are known as ‘petites’. Petites may form, through the formation of free radicals, 
when a toxic protein is being expressed in yeast. Petites are slow growing and do not 
grow in glycerol which is a non-fermentative carbon source. Hence, the slow growing 




2.5.5 Chromosomal integration of plasmids into yeast 
 
Integrative plasmids are first linearized (by cutting the gene that is used as a nutritional 
selection marker in a way that at least 200 bps are in both 5’ and 3’ segments of the 
fragmented gene) before the DNA is introduced into yeast cells. The DNA then undergoes 
homologous recombination with the genomic DNA at the chromosomal locus of the 
linearized gene (i.e. the gene coding for the nutritional selection markers available in the 
strain BC300, that is, ADE2, LEU2, HIS3, TRP1 or URA3).  
 
2.5.6 Yeast live cell assays to measure CYP activities 
 
The live yeast cell assays are rapid and relatively inexpensive compared to assays related 
to analysis of CYP microsomal activities. They are used to determine the expression 
levels of various CYPs via enzyme kinetic measurements. The assays were used to 
determine the expression levels of CYPs 1A1, 1A2, 1B1, 2D6(1), 2A6, 2B6, 2C8, 2C9, 
2C18, 2C19, 2D6(2), the 3 SNPs of 2D6 (*2, *10, *39), 2E1, 2J2, 3A4, 3A5, 4F3A, 17A1, 
and 19A1 produced from different expression plasmids created for this project. 
 
2.5.7 Methods for live cell assays 
 
The yeast strains containing the genes of interest were streaked out on minimal medium 
SD-agar plates with appropriate nutritional requirements. The plates were allowed to 
incubate for 2-3 days at 30°C. Three colonies were generally picked (to screen for high 
CYP producers often ~50 colonies were picked) and were grown according to the 
protocols available for expression of a particular CYP. The clones were cultured in 
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selective SW6 medium (SMM + glucose + casamino acids + nutrients required for 
auxotrophs) overnight at 30°C in an orbital incubator shaking at 220 rpm. On the next 
day, the OD600 of this pre- culture was recorded so that an appropriate number of cells 
could be seeded into full (non-selective) YPD medium. This main culture, to be used for 
expression of a CYP, was grown overnight for 18 h when cells were 
(a) still in the exponential growth phase but 
(b) at a time when all glucose in the medium was full exhausted. 
Both aspects are important. Aspect (a) is essential for monitoring optimal levels of CYP 
activities; in stationary phase, CYP activities start decaying. Aspect (b) is crucial for the 
CYP protein to be produced at the highest levels; only after all glucose is converted to 
ethanol does the ADH2 promoter allow full-blown expression (i.e. production) of a human 
CYP enzyme in yeast. 
Cells from the main culture were counted so that a defined number of cells could be used 
for the fluorescence-based CYP activity assays. 
 
2.6 Measuring CYP activities using a fluorescence 
plate reader 
 
Cells grown up to the late exponential growth phase (16-20 h of incubation) were 
aliquoted into 1.5 ml Eppendorf tubes (labelled correctly) and centrifuged for 1 min on a 
bench-top centrifuge at 3,200 rpm. The pellets were then re-suspended in 500 µl 1xTE 
(50 mM Tris-HCl pH.7.4, 1 mM EDTA) and centrifuged for 1 min at the same speed as 
above. This was repeated twice. The supernatants were removed carefully and the pellets 
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were finally re-suspended in 450 µl of 1X TE. 50 µl of cell suspensions were transferred 
into a sterile 96-well microtiter plate to which 50 µl of a substrate mixture (depending on 
the substrate for a specific CYP) was added. The parameters for the fluorescence plate 
reader (Synergy HT BioTek) were set using the appropriate extinction/emission filters 
and appropriate gain sensitivity setting to obtain the best kinetic output from the plate 
reader (Table 2.4). The plate was incubated at 30°C for 30 min before the fluorescence 
emissions were measured.  
 
Table 2.4. Excitation and Emission filters used in monitoring the amount of 
fluorescence emission.  
 
Substrates Excitation/Emission (nm) Reference 
CEC 410/460 White (1998) 
Coumarin 355/460 Donato et al.(1998) 
BFC 410/510 Butters et al. (1993) 
DBF 485/520 Stresser et al. (2000) 
BOMCC 410/460 Liu et al.(2010) 
EROD 530/590 Afshin (2014) 
 
2.6.1 Preparation of TE buffer (100 ml) 
 
5 ml of 1 M Tris-HCl pH 7.4 + 200 µL of 0.5 M EDTA pH 7.5, the volume was topped 





2.7 Bradford Assay 
 
In 1976, Bradford developed a method for measuring protein concentrations which 
involves the binding of Coomassie brilliant blue G-250 dye to proteins. The dye exists in 
three forms: cationic, neutral green and anionic blue (Compton and Jones, 1985). 
Immediately after the dye binds to the protein(s), the dye changes from protonated red 
(Amax=470 nm) to stable un-protonated blue (Amax= 595 nm).  
 
2.7.1 Dye reagent for Bradford assay 
 
The protein standard was bovine serum (BSA) (Sigma-Aldrich, Cat No A6003). The 
concentration for BSA stock solution was 10 mg/ml to draw a standard curve (Table 2.5; 
Figure 2.6). The protein assay dye concentrate (Bio-Rad, Cat No 500-0006) contains 450 
ml of dye solution, phosphoric acid, and methanol. 
Initially, 4 µl of microsomes (see Section 2.8) were diluted in 800 µl of sterile water. This 
was used for making further dilutions. For example, for the CYP19A1 microsomes, two 
dilutions were made: 
1 in 5 200 µl (from 4/800 stock) + 800 µl water 






Table 2.5. For BSA standard curve, 0.1mg/ml BSA solution was prepared 
from the 10mg/ml stock solution. 
 
Tube No. 1 2 3 4 5 6 7 
Volume of BSA (0.1mg/ml) 0 25 50 100 150 200 250 
Volume of H20 in µl 1000 975 950 900 850 800 750 
BSA amount in µg 0 0.5 1 2 3 4 5 
BSA BioRad reagent added in µl 250 250 250 250 250 250 250 
Different amounts of BSA (in a total volume of 150 µl) were added per well. End point 
absorbance was read at 590 nm.  The BSA standard curve is shown in Figure 2.6. 
 
 
Figure 2.6.  The BSA standard curve.  The concentrations refer to the values in 






2.8 CYP microsome preparation from yeast cell 
cultures using PEG precipitation 
 
For microsome preparations, the protocol that was used was similar to the one described 
by Mecellan et al. (2000), only the amounts of cells grown were scaled up. Depending on 
the amounts of microsomes required, the final volume of main culture was between 400 
ml and 1600 ml. The cells were harvested washed with DMB-A buffer that contained a 
Serine protease inhibitor (0.266 mM DTT, 2.66 mM of AEBSF), and the cell pellets were 
stored at -80°C. The protease inhibitor AEBSF has been shown to inhibit trypsin, 
chymotrypsin, plasmin, kallikrein and thrombin. As an alternative to PMSF, AEBSF 
offers lower toxicity, improved solubility in water and improved stability in aqueous 
solutions. 
 
2.8.1 Cell disruption 
 
The protocol for preparation of microsomes used a combination of continuous cellular 
disruption under pressure, followed by differential centrifugation. The liberated 
membrane-bound CYP proteins were then concentrated using a combination of NaCl and 
PEG precipitation. The devised protocol has been adapted from the methodology detailed 
by McLellan et al.  (2000). 
Cell pellets were removed from the -80˚C freezer and kept on ice for 30 min. The cell 
pellet was re-suspended in DMB A buffer (to 1g of wet cell pellet, 1.4ml of DMB-A 
buffer was added). The cell suspension was centrifuged on a bench-top Sorvall centrifuge. 
~35 g cell pellet was gently re-suspended (with the help of a glass rod) in 50 ml DMB-A 
buffer to which 1.33ml (100 mM AEBSF) and + 0.133ml (100 mM DTT) were added. 
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Ensuring homogeneity of cell suspension is essential for cell disruption.  Failure to add 
AEBSF and DTT is likely to result in degraded CYP proteins. 
Before the cell pellet was disrupted, the Constant Cell Disruption equipment (Constant 
Systems Basic Z model with continuous processing head) was chilled for 30 min at 4°C 
before use. Pressure was set to 22.5 KPSI (Kilo-Pound per Square Inch). Disruptor was 
washed with about 50 ml of DMB-A buffer to ensure that the system was operating 
correctly. Cell suspension was added into the cell disruptor gently. The cells were then 
processed in the cell disruptor.   
The cell lysates obtained were collected from the cell disruptor and were centrifuged at 
4,600 rpm (4,302 g) for 20 min at 4˚C using a Sorvall bench-top centrifuge [this was to 
remove all cell debris and broken cell membranes]. The resulting supernatants were then 
transferred into chilled 30 ml JA17 tubes for use in the high-speed Beckman Coulter JA 
17 rotor in an Avanti J-20XP centrifuge and spun at 16,000 rpm (35,267X g) for 15 min 
at 4°C (this was to remove cell debris, nuclei, peroxisomes, lysosomes and mitochondria). 
Percentage disruption was calculated by comparing the known cell pellet wet weight with 
that which remained after disruption. Centrifugation was repeated twice into freshly 
cooled JA17 tubes. 
 
2.8.2 PEG3500 precipitation of cytosolic fraction 
performed at 4°C 
 
The supernatants were transferred into large capacity chilled buckets for the high-speed 
Beckman Coulter JLA 10.5 rotor for centrifugation in an Avanti J-20XP centrifuge. 
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The supernatants were then diluted with ice cold DMB-TES buffer containing both DTT 
and AEBSF [0.4 mM AEBSF (4.0µg/ml), 0.04 mM DTT (0.4µg/ml)]. The bucket was 
then placed on a magnetic stirrer in the cold room and stirred at approximately 1-2 rpm. 
NaCl was then added to this mixture to give a final concentration of 0.125 M, and mixed 
gently. 
The required volume of ice-cold 50% PEG solution was transferred into a separating 
funnel and added drop-wise (1-2 drops per second) to the above solution whilst gently 
stirring the solution.  
 
2.8.2.1 An example of a typical microsome preparation  
 
100 ml of supernatant diluted with 375 ml DMB-TES to which had 11.88 ml (5 M NaCl). 
To this mixture, 118.8 ml (50% PEG) was added drop-wise. . 
After addition of PEG4000, the magnetic flea was removed from the bucket and the 
supernatant mixture was then left on ice in the cold room for 20 min, and then spun at 
12,000X g, (8,034 rpm), for about 20 min at 4°C in the high-speed Beckman Coulter JLA 
10.500 rotor in the Avanti J-20XP centrifuge. This step pelleted the microsomal fraction 
of the cells. The supernatant (cytosolic fraction) was poured off very gently. The surface 
of the pellet was washed twice with roughly the same volume of DMB-buffer B as that 
of the size of the pellet.  
The pellets were transferred (using long, thin spatulas) into a 15 ml homogeniser and re- 
suspended in DMB-buffer B. Depending on the size of pellet this volume varied. The 
pellets were very gently re-suspended by passing the plunger of the homogeniser up and 
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down four to five times avoiding excessive frothing.  Microsomes were aliquoted out, 
snap-frozen using liquid nitrogen, and stored at -80˚C. A 50 µl aliquot of microsomes 
was used to check for amounts of CYPs produced using carbon monoxide (CO)-
difference spectroscopy. 
 
2.8.3 Reduced CO difference spectra for calculation of 
cytochrome P450 enzyme concentration in 
microsomes 
 
Microsomes are turbid suspensions made up of several membrane-containing structures 
within a cell and are obtained after opening up the cell wall and isolating the intracellular 
membrane fraction.  These suspensions are opaque to standard spectroscopy, because 
they scatter light so badly.  The only way to measure a spectrum on a turbid sample like 
this was to make a special instrument with the light detector very close to the cuvette, and 
to use dual beams and perform difference spectroscopy.  Cytochrome P450 is 
haemoprotein.  When the haem Fe3+ is reduced to Fe2+ by the addition of sodium 
hydrosulfite and complexed with carbon monoxide, a characteristic absorption spectrum 
can be measured (Klingenberg, 1958). The carbon monoxide (CO) binding assay (Omura 
and Sato 1964) is a method for quantifying the amounts of CYP holoproteins (i.e. active 
proteins) in microsome preparations. The reduced, carbon monoxide complexed, 





2.8.3.1 CO biding spectrum procedure 
 
Difference spectra of microsomal preparations were measured in a spectrophotometer 
(Shimadzu, UV-2401PC) using disposal plastic cuvettes (Sarstedt, Cat. No. 67.742).  850 
µl of 100 mM potassium phosphate and 20% glycerol, pH 7.5, was added in cuvette, and 
left for one min.  Then a ‘few grains’(usually 3-5 mg) of sodium hydrosulfite powder was 
added; mixed gently to prevent any bubble formation into the cuvette and then left for 
one min on the table at room temperature. 150 µl of microsomes was added into the 
cuvette and mixed gently.  Two cuvettes (one containing buffer with sodium hydrosulfite 
without microsomes and another with microsomes were prepared and a baseline of light 
absorption of the buffer and microsome mixture was recorded in the dual-beam 
spectrophotometer from 400 nm to 500 nm.  Carbon monoxide was bubbled slowly into 
one sample cuvette for about one min, 1 bubble/sec.  Light absorption was recorded again 
from 400 nm to 500 nm.  The concentration of cytochrome P450 in the cuvette was 
calculated from the absorption change at 450 nm relative to the absorbance change at 490 
nm, using the formula below: 
CYP content (nmole/ml) = [(A450nm – A490 nm) X dilution factor X 1000]/ 91  
Specific CYP content (nmole/ mg protein) = CYP content/ total protein in the reaction 
Extinction coefficient (91 mM-1cm-1) is the fraction of light lost to scattering and 
absorption per unit distance in a participating medium.  It is the sum of absorption 





2.8.3.2 Reagents and Media used for microsome preparations 
 
All solutions were autoclaved unless otherwise stated. 
 
DMB A Buffer 
• 162.5ml (4M sorbitol) final conc 0.65M, 
• 10ml (1M Tris-HCl pH 7.5) final conc 10mM, 
• 200µl (0.5M EDTA pH 8.0) final conc 0.1mM, made up to 1 litre. 
Microsome Buffer A 
• 162.5ml of 4 M Sorbitol, final concentration 0.65 M, 
• 10 ml of 1 M Tris pH 7.5, final concentration 10 mM, 
• 200 µl of 0.5 M EDTA pH 8.0, final concentration 0.1 mM, made up to 1 litre 
with MQ water and stored at 4°C. 
Microsome Buffer C 
• 1 ml (1 M Tris-HCl pH 7.5) final concentration 10 mM, 
• 200 µl (0.5 M EDTA pH 8.0) final concentration 1.0 mM, 
• 40 ml of 50% (v/v) glycerol final concentration 20%, 
made up to 100 ml with MQ water and stored at 4°C. 
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100mM AEBSF [4-(2-Aminoethyl)-benzenesulfonyl fluoride, HCl], Protease 
Inhibitor Working Solution 
239.7 mg of AEBSF (Melford, Cat No MB2003) was dissolved in 10 ml of MQ water 
and the solution was stored at -20°C. The solution is corrosive and causes burns. 
DL-Dithiothreitol Working Solution (100 mM) 
154.2 mg of dithiothreitol (Sigma, Cat No. D9779-SG) was dissolved in 10 ml MQ water. 
500 µl aliquots were stored at -20°C. 
Sutter’s Buffer B 
• 250 ml 4 M sorbitol, final concentration 2.0 M, 
• 5 ml 1 M Tris-HCl pH 7.5, final concentration 10 mM, 
• 100 µl 0.5 M EDTA pH 8.0, final concentration 0.1 mM, 
• 500 µl 1.0 M MgCl2, final concentration 1 mM made up to 500 ml. 
Sutter’s Buffer C 
• 1 ml 1 M Tris-HCl pH 7.5, final concentration 10 mM 
• 200 µl 0.5 M EDTA pH 8.0, final concentration 1.0 mM 
• 40 ml 20% glycerol, (from 50% glycerol stock) made up to 100 ml. 
Pefabloc (100mM) 




SD Min Agar (500 ml) 
• 3.35 g YNB (BD Cat No MD21152), 
• 10 g Glucose (Melford Cat No G1400),  
• 7.5 g Agar (Oxoid Cat No LP0013), 
• 1 pellet of NaOH (Fisher Cat No 359-500). 
SW6 Min broth (SW6) (1 Litre) 
• 6.7 g YNB BD Catalogue number: MD21152 from Becton Dickinson, 
• 40 ml of a 50 % glucose solution Catalogue number: G1400 from Melford. 
Buffer for Harvesting Cells (1 Litre) 
• 118.6 g/L Sorbitol, final conc. 0.65 M (Melford Cat No S0807) 
• 10 ml 1M Tris-HCl pH 7.5, final concentration 10 mM (Fisher Cat No BP152-
1), 





2.9 CYP assays 
 
2.9.1 Stock solutions for all CYP assays  
 
Solution A: 200 mg NADP+ (Sigma-Aldrich Cat No N0505, MW 765.4), 200 mg D-
glucose-6-phosphate disodium salt hydrate (Sigma-Aldrich Cat No F7250, MW 304.1), 
1M MgCl2 solution (Sigma-Aldrich Cat No M1028) were used to make a 10 ml solution 
in deionized water which gave final concentrations of 26.13 mM, 65.77 mM, and 65.42 
mM of the three constituents.  The solution was stored in aliquots at –20°C.  
Solution B. 250 g U glucose-6-phosphate dehydrogenase (Sigma-Aldrich Cat No G6378) 
was dissolved in 6.25 ml solution of 5 mM trisbasic sodium citrate (Sigma-Aldrich Cat 
No S46410) and stored in aliquots at –20°C.  
Solution C. Solution C was freshly prepared just before the assay by mixing 1.5 ml of 
0.5 M KPO4 pH 7.4, 1.5 ml of solution A and 0.3 ml of solution B.  The final volume was 
made up to 15 ml with deionised water.   
0.5 M Potassium Phosphate (KPO4) buffer pH 7.4 (Kpi buffer). 19.8 ml of buffer A 
and 80.2 ml of buffer B (see below) were mixed and the final volume was made up to 200 
ml with deionised water and pH was adjusted to 7.4 (using 0.5 M HCl and 0.5 M NaOH).  
Buffer A = 136.1 g KH2PO4/L (1 M), autoclaved.  
Buffer B = 174.2 g K2HPO4/L (1 M), autoclaved.  
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0.1 M Potassium Phosphate (KPO4) buffer, pH 7.4. 1.98 ml of buffer A and 8.02 ml 
of buffer B were mixed and the final volume was made up to 100 ml with deionised water 
and the pH was adjusted (using 0.5 M HCl and 0.5 M NaOH).  
Buffer A = 136.1 g KH2PO4/L (1 M), autoclaved.  
Buffer B = 174.2 g K2HPO4/L (1 M), autoclaved.  
50 mM Tribasic Sodium Citrate. 147 mg of tribasic sodium citrate (Sigma-Aldrich Cat 
No S4641) was dissolved in deionized water and the final volume was made up to 10 ml.  
 
2.9.2 Assay procedures 
 
The substrates for enzymes assays used in this study are CYP isozyme-specific 
fluorogenic substrates which upon oxidative cleavage yield fluorescence at specific 
excitation-emission wavelength. The substrates are light sensitive. Therefore, all assays 
were set up in the laboratory with yellow lights switched on.  
The reactions were performed in black 96-well plates with clear flat bottom (Fisher Cat 
No, FB86083).  The assay plate and the solutions were pre-warmed at 37ºC before 
initiation of the assay.  The plate layout, reaction temperature (37°C), reaction time (20 
to 40 min), fluorescence sensitivity, the wavelength parameters and other kinetic assay 
parameters (i.e. excitation-emission wavelengths) were set as is indicated in the following 
chapters.  Each reaction was performed in triplicate.  Each 100 µl reaction contained a 
specific concentration of Kpi buffer (as indicated in respective chapters), solution C, CYP 
isozyme and an isozyme-specific fluorogenic substrate.  Blank values were measured in 
reactions where CYP isozyme was not added.  The known concentrations of metabolites 
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were used to plot standard curves.  The fluorescence was measured in terms of relative 
fluorescence unit (RFU) in kinetic reactions over a period of 30 to 60 min.  Finally, the 
CYP activities were calculated as product formed/ min/ pmole of CYP or product formed/ 
min/ ml.   
 
 
2.9.2.1 EOMCC Assay 
 
Kinetic studies with CYP2D6 and CYP2E1 microsomes (i.e. measurement of activities) 
were performed using the Vivid® fluorogenic substrate EOMCC (3-cyano-7-
(ethoxymethoxy) coumarin) as per the standard Invitrogen Screening Kit protocol (Marks 
et al, 2002 and 2003).  Human CYP2D6 and CYP2E1 de-methylate EOMCC to form the 
fluorescent product 3-cyano-7-hydroxycoumarin (CHC).  The reactions were carried out 
in a reaction volume of 100 μl/ well in 96-well black plates (Fisher Scientific, Catalogue 
No FB86083).  All reactions were performed at 37ºC in 100 mM potassium phosphate 
buffer pH 8.0, containing 10 μM EOMCC, 1 pmol (CYP2D6 or CYP2E1) and the 
NADPH regenerating system (1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 3.3 mM 
MgCl2, 0.4U/ml glucose-6-phosphate dehydrogenase).  The fluorescent values of the 
product were recorded on the Biotek Synergy HT plate reader using an excitation 
wavelength of 410 nm (± 20 nm) and emission wavelength of 460 nm (± 50 nm).  Changes 
in fluorescence were measured as relative fluorescence units (RFU).  Kinetic progression 





2.9.2.2 CEC Assay 
 
CYP1A2, 4F3A and CYP2C19 activities were measured using the fluorogenic substrate, 
3-cyano-7-ethoxycoumarin (CEC).  CEC is metabolised mainly by CYP2C19, CYP4F3A 
and CYP1A2 to a fluorescent product 3-cyano-7-hydroxycoumarin (CHC) (Donato et al. 
2004). The reactions were carried out in a reaction volume of 100 μl/ well in 96-well 
black plates (Fisher Scientific, Catalogue No FB86083).  The reactions were performed 
at 30ºC in 100 mM potassium phosphate buffer pH 7.4, containing 10μM CEC, 1 pmol 
CYP1A2, 4F3A or CYP2C19 and the NADPH regenerating system (1.3 mM NADP+, 
3.3 mM glucose-6-phosphate, 3.3 mM MgCl2, 0.4U/ml glucose-6-phosphate 
dehydrogenase).  The fluorescent values were recorded on the Biotek Synergy HT plate 
reader using an excitation wavelength of 410 nm (± 20 nm) and emission wavelength of 
460 nm (± 50 nm).  Changes in fluorescence were measured as relative fluorescence units 
(RFU).  Kinetic progression of reactions was measured over 30 to 60 min. 
 
2.9.2.3 EROD Assay 
 
The catalytic activities of CYP1A1 and CYP1B1 were measured using the 
ethoxyresorufin-O-deethylase (EROD) assay (Klotz et al. 1984).  CYP1A1 and CYP1B1 
convert 7-ethoxyresorufin (7-ER) to resorufin in the presence of NADPH and oxygen and 
the assay is known as the EROD assay.  The amount of resorufin produced is measured 
fluorometrically and it reflects the level of 7-ethoxyresorufin o-deethylase activities of 
the two enzymes.  Both CYP1B1 and CYP1A1 can catalyse de-ethylation of the substrate 
7-ethoxyresorufin  (7-ER) to form the product resorufin, which exhibits fluorescence at 
excitation wavelength of 530 nm and emission wavelength of 590 nm. 
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The production of the metabolite resorufin, by deethylation of the fluorogenic substrate 
7-ethoxyresorufin was measured over 30 to 60 min.  The assay was performed as 
described before (Klotz et al. 1984).  The reaction kinetics was carried out at 30ºC in a 
reaction volume of 100 µl/ well in 96-well black plates with transparent flat bottom 
(Fisher, Catalogue No FB86083).  The assay mixture contained 100 mM Potassium 
phosphate buffer pH 7.4, containing 5 µM 7-ethoxyresorufin, 1 pmole CYP1B1 or 
CYP1A1 and the NADPH regenerating system (1.3 mM NADP+, 3.3 mM G6P, 3.3 mM 
MgCl2, 0.4U/ml G6PDH).  Resorufin formation was measured fluorometrically on the 
Biotek Synegy HT plate reader (excitation wavelength of 528 ± 20 nm and emission 
wavelength of 590 ± 20 nm).  Changes in fluorescence were recorded over 30 to 60 min 
as relative fluorescence units (RFU).  
 
2.9.2.4 DBOMF Assay 
 
CYP3A4, CYP2C8, and CYP3A5 activities were measured using DBOMF as the 
fluorogenic substrate. The production of the metabolite fluorescein, by dealkylation of 
Vivid® fluorogenic substrate dibenzyl-oxymethyl-fluorescein (DBOMF) was measured 
over 30 to 60 min at 30ºC.  The assay was performed as per the standard Invitrogen 
Screening Kit protocol.  The reactions were carried out at 30ºC in a reaction volume of 
0.1 ml/well in 96-well black plates.  The assay mixture contained 100 mM Potassium 
phosphate buffer pH 8.0, containing 4 µM DBOMF, 1.0 pmole CYP3A4, CYP2C8, or 
CYP3A5 and the NADPH regenerating system (1.3 mM NADP+, 3.3 mM G6P, 3.3 mM 
Mg Cl2, 0.4U/ml G6PDH).  Fluorescein formation was measured fluorometrically on the 
Biotek Synegy HT plate reader (excitation wavelength of 485 ± 20 nm and emission 
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wavelength of 528 ± 20 nm).  Changes in fluorescence were recorded over 30 to 60 min 
as relative fluorescence units (RFU). 
 
2.9.2.5 7-MFC Assay 
 
CYP2C9 activity was measured using 7-MFC as the fluorogenic substrate. The 
production of the metabolite HFC, by dealkylation of Vivid® fluorogenic substrate 7-
methoxy-4-(trifluoromethyl)-coumarin(7-MFC) was measured over 30 to 60 min at 30ºC.  
The assay was performed as per the standard Invitrogen Screening Kit protocol.  The 
reactions were carried out at 30ºC in a reaction volume of 0.1 ml/well in 96-well black 
plates.  The assay mixture contained 100 mM Potassium phosphate buffer pH 8.0, 
containing 50µM 7-MFC, 1.0 pmole CYP3A4, CYP2C8, or CYP3A5 and the NADPH 
regenerating system (1.3 mM NADP+, 3.3 mM G6P, 3.3 mM Mg Cl2, 0.4U/ml G6PDH).  
HFC formation was measured fluorometrically on the Biotek Synegy HT plate reader 
(excitation wavelength of 431 ± 9 nm and emission wavelength of 535 ± 20 nm).  Changes 
in fluorescence were recorded over 30 to 60 min as relative fluorescence units (RFU). 
 
2.9.3 Inhibition of CYP enzymes bound to microsomes 
and expressed within whole cells 
 
Cells were taken during the exponential growth phase at ~18 h of incubation. 4×108 cells 
were taken from the overnight culture and aliquoted into an Eppendorf tube (this is 
equivalent to approximately 25 ODs). These cells were then centrifuged in a bench top 
centrifuge for 1 min at 13,200 rpm (16.1X g). The supernatants were removed carefully. 
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The cell pellets were then re-suspended in 1000 µl of TE buffer (50 mM Tris-HCl, pH 
7.4, 1 mM EDTA). The re-suspended cells were centrifuged again at 13,200 rpm (16.1X 
g) for 1 min. The supernatants were one again removed by careful pipetting and again re-
suspended in 900 µl TE buffer and centrifuged for 1 min at 13,200 rpm (16.1X g). This 
step was repeated once again. The supernatants were again removed by careful pipetting 
and the cell pellet was re-suspended in 900 µl of TE buffer bringing the end volume up 
to 1000 µl. 
These cells were diluted further 1 in 10 before carrying out an IC50 assay with compound 
concentrations in serial dilutions.  
 
2.9.3.1 Preparation of CYP inhibitors 
 
For most inhibitors, a master stock at 400 µM concentration was prepared.  
The working concentrations of inhibitor were obtained by diluting the stock in 1X TE 
buffer. The working concentrations were 4X stronger than the final concentration as only 
25 µl of inhibitor solution was added to each well to obtain a final volume of 100 µL per 






Table 2.6. Concentrations of inhibitors used for IC50 determinations. 
 












2.9.3.2 Substrate mixture preparation  
 
0.5 µL of substrate was added to 24.5 µl of TE buffer. 25 µl of substrate mix was added 
to each well of the plate. Final concentrations of substrates used are mentioned in the 
Figures of the Chapters that describe the experimental results. 
 
2.9.3.3 General procedure for CYP inhibition studies 
 
50 µl of cells was added to each well. 25 µl of each inhibitor concentration was added to 
three wells on the plate (triplicate). The plate was placed in the incubator at 30°C for 10 
min. After the 10 min incubation, 25 µl of substrate was added to each well on the plate. 
 The plate was then placed in the BioTek plate reader and read for 30 to 60 min. 
 
2.9.3.4 CYP inhibition assay parameters 
 
The assay is carried out between time periods of 30 to 60 min using appropriate filters 
that would monitor extinction/emission of the fluorescent products formed. Appropriate 
gain sensitivity settings were used to obtain the best kinetic output from the Synergy HT 
BioTek plate reader. These parameters varied depending on the level of CYP expression 
within the recombinant yeast cells. 
The plate reader is set up to shake the plate for 3 sec at an intensity of 4 (in a scale of 1 
to 10) between each reading. Kinetic analysis is carried out at 30°C. Table 2.7 provides 





Table 2.7. An example outlining the parameters with which CYP1A1 



























The data at 60 min of inhibition for each concentration of inhibitor was used to determine 
IC50 values of a CYP1A1 inhibitor, using GraphPad Prism. 
 
Reagents and Media 
• Tris-HCl  
• EDTA  
• 7-Ethoxyresorufin (7-ER). 
 
TE Buffer (50 ml) 
500 µl of 1 M Tris-HCl pH 7.4 was added to 100 µl of 0.5 M EDTA pH 7.5 and was made 




2.10 Western blot of CYP proteins expressed in yeast 
 
2.10.1 Protein quantification in yeast 
 
Recombinant yeast cells, containing CYP genes, were grown in 3-4 ml of YPD complete 
medium, without any selection, overnight (~18 h) at 30°C by shaking at 200 rpm. 5X 106 
cells were usually spun down at 13,000 rpm for 1 min to remove supernatant which was 
essentially the exhausted YPD medium. The cell pellet was washed 3X in 1 ml 1X TE 
buffer. The cell pellet was re-suspended by vortexing in 200 µl of cell lysis buffer (5.7 µl 
10X SDS, 1 ml 10X TE buffer and made up to 10 ml with deionized pure water). 
The suspension was sonicated (Grant Ultrasonic bath XUBA1) twice for 10 sec, to enable 
efficient release of proteins by the yeast, Saccharomyces cerevisiae. The sonicated cell 
suspension was incubated in 99°C for 10 min to open the yeast membrane. 
The suspension was centrifuged in a centrifuge, pre-cooled to 4°C, at 16000X g for 20 
min and immediately was placed on ice gently. The supernatant was transferred to a new 
Eppendorf tube. 
The proteins in the lysed cells were diluted 1:20 (to each 5 µl cell lysate was added 95 µl 
1X TE buffer). This allowed calculation of total protein concentration in each sample of 
cell lysate. All protein samples obtained from cell lysis were stored at -20°C when not in 





2.10.2 Preparation of protein sample for Western blots 
 
Proteins from 2X 106 cells (i.e. 20-30 µg of protein), after cell lysis, contained in 20 µl 
was added to 20 µl of 5X loading sample buffer. The mixture was heated to 95°C for 5 
min, for denaturation of proteins, and then centrifuged at 16000X g for 1 min. The 
Eppendorf tubes containing denatured proteins were returned on ice and the contents were 
centrifuged for 15 min at maximum speed. 20 µl of this mixture was loaded on to wells 
of an SDS-polyacrylamide gel. Standard protein ladder (5 µl; Bio-Rad Catalogue No 
1610398) was loaded on one of the extreme left or right hand side well of the gel.  
 
2.10.3 Buffers used for Western blotting 
 
10X TBS: 87.6 g of NaCl + 60.5 g Tris Base + 800 ml water to make up to 1 L, pH 
adjusted to 7.4 by adding around 10 ml 1M HCl.  
1X TBST: (50 mM Tris-Cl, pH 7.4; 150 mM NaCl).  8.76 g of NaCl + 6.05 g Tris Base 
+ 800 water to make up to 1 L adjusted to pH 7.4 by adding around 10 ml 1M HCl; 1 ml 





2.10.4 Gel Castings 
 
Table 2.8.  Polyacrylamide gel for resolution of proteins in cell lysate, via 
Western blotting; volumes of reagents required for 10 ml solutions are 
shown. 
 
Water  4.7 ml 
1.5M Tris-HCl(p H 8.8) 2.5 ml 
30%Acrylamide mix 2.5 ml 
10% SDS 100 µl 
10% Fresh Ammonium persulfate 100 µl 






Table 2.9.  Stacking gel for Western blotting.  
 
Water  3.1ml 
0.5M Tris-HCl (pH 6.8) 1.25ml 
30% Accrylamide mix 600µl 
10% SDS 500µl 
10% Fresh Ammonium persulfate 50µl 





2.10.5 Introduction to Western Blotting 
 
Western blotting or immunoblotting allows investigators to determine, with a specific 
primary antibody, if a protein antigen at all exists in a particular cell environment and, if 
it did, at what relative levels.  Often, the relative amounts of a protein in different samples 
are gauged to a rough approximation using Western blots. 
Briefly, 1) The sample is prepared from microsomes or yeast cells that are homogenized 
in a buffer that protects the protein of interest from degradation; 2) The sample is 
separated using SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and then 
transferred to a synthetic membrane for detection; 3) The membrane is incubated with 
generic protein (such as milk proteins or bovine serum albumin) to bind to any remaining 
unoccupied places on the membrane.  A primary antibody is then added to the solution 
which is able to bind to the specific protein; 4) A secondary antibody-enzyme conjugate, 
which recognizes the primary antibody is added to illuminate the location where the 
primary antibody was bound.   
 
2.10.6 SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) 
 
This technique was based on a modified version of that described by Laemmli (Laemmli, 
1970).  The Mini-PROTEAN 3 Electrophoresis system purchased from Bio-Rad was used 
in my studies.  10% separating gels consisted of final concentration of 7.5% 
acrylamide/bis-acrylamide (30%) (Sigma-Aldrich, Cat No A6050), 1.5 M Tris-HCl pH 
8.8, 0.1% SDS, 0.001% N-,N’-Tetramethylethylenediamine (TEMED) (Sigma-Aldrich, 
Cat No T7024) and 0.001% ammonium persulphate (APS) (Sigma-Aldrich, Cat No 
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A3678), and were poured into the casting stand units to within 0.5-1.0 cm from the bottom 
edge of the well comb and the gels were left to polymerise for about an hour. The stacking 
component of the gel was made immediately prior to electrophoresis. The stacking gel 
consists of 4% acrylamide/bis-acrylamide (30%), 0.5 M Tris-HCl pH 6.8, 10% SDS, 10% 
TEMED and 10% APS and was poured over the separating gel 0.25 cm from the top of 
the gel kit, the well comb was then inserted before the gel sets.  Polymerisation of the gel 
takes about an hour.  The completed gel running apparatus was then placed into its gel 
tank and the upper and lower reservoirs were filled with appropriate amounts of running 
buffer which consisted of 25 mM Tris-HCl pH 8.6, 192 mM glycine and 0.1 SDS (w/v).  
Samples for electrophoresis were prepared at required dilutions using the sample buffer 
consisting of 2% SDS, 10% glycerol, 5% 2-mercaptoethanol, 0.002% Bromophenol blue 
and 0.125 M Tris-HCl pH 6.8.  The diluted samples were then boiled for 2-3 min to 
denature the proteins and then cooled on ice.  Up to 20 µl of boiled samples were loaded 
on each well.  5-10 µl Bio-Rad standards (Bio-Rad, Cat No 161-0309) were loaded 
usually on one side of the SDS-polyacrylamide gel.  Electrophoresis was performed using 
constant current, using a power supply (Bio-Rad, Cat No 164-5050).  For stacking the 
proteins, the gels were run at 8 mA per gel until the loading dye had concentrated at the 
top of the separating gel.  The current was then increased to 16 mA per gel until the blue 
running dye had reached the bottom of the gel or the marker had reached a suitable 






2.10.7 Western blotting 
 
Once the proteins were separated using SDS-PAGE on a 10% SDS-polyacrylamide gel 
as described above, the gel was carefully taken off from the tank.  The stacking gel was 
scraped away from the separating gel and discarded.  The separating gel was then soaked 
in Cathode buffer (25 mM Tris, 20% methanol, 40 mM 6-aminohexanoic acid), and 
placed onto 3X Whatman chromatography paper (Whatman, Cat No 3030335) pre-
soaked with Cathode Buffer on blotter.  A piece of nitrocellulose membrane (Millipore, 
Cat No VX 466008), roughly the size of the gel, was soaked in Anode buffer II (25 mM 
Tris, 20% methanol, pH 10.4) for 2-3 min, and then layered over the separating gel, 
ensuring that no air bubbles were trapped between the gel and the nitrocellulose sheet.  
Three more pre-soaked Whatman papers in Anode buffer II were placed over the top of 
the nitrocellulose sheet, and three Whatman papers soaked in Anode buffer I (300 mM 
Tris, 20% methanol, pH 10.4) were placed on top of previous sheet of Whatman paper.  
The blotter cover was gently placed and the blotter was run at a constant current of 0.8 
mA/ cm2 for 2-3 h.  Once transfer was completed, the nitrocellulose sheet was placed in 
a plastic tray containing 50 ml of PBS/ 0.1% Tween (polyoxyethylene-sorbitan 
monolaurate) for 10 min with gently shaking, and PBS/ 0.1 Tween solution was poured 
off, 5 ml blocking solution (10% fat free milk (Bio-Rad, Cat. No. 170-6404) in PBS) was 
added, and incubated for 1 h with gently shaking.  The nitrocellulose sheet was rinsed 
briefly with PBS/0.2% Tween and washed once in PBS/0.2% Tween for 15 min followed 
by three 5 min washings in PBS/0.2% Tween.  The blot was then incubated in 25 ml of 
antibody solution that contained the primary antibody and incubated at 4ºC overnight with 
gentle shaking.  The antibody was diluted in 1% milk, PBS/0.2% Tween solution at least 
at 1:1000 dilution.  The blot was then washed three times with PBS/0.2% Tween each 
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time for a period of 10 min.  After washing, the blot was incubated in 30 ml of secondary 
antibody solution that contained secondary antibody at 1:3000 dilution in 1% milk, 
PBS/0.2% Tween for 2 h at room temperature with gentle shaking.  The secondary 
antibody was discarded and the blot was washed twice in PBS/ 0.2% Tween followed by 
washing twice with PBS.  Finally, the blot was rinsed twice with sterile water.  The blot 
was placed on the reagent bath containing 5 ml of enhanced chemiluminescence Western 
blotting detection reagent solution A and solution B (Santa Cruz Biotechnology, Cat No 
SC-2048), mixed by inversion, the water was poured off from the blot and the mixed 
Luminol reagent solution was added to the membrane with protein side facing up for 2 
min at room temperature.  The excess Luminol reagent was poured off and the membrane 
was lifted with a pair of forceps to drain excess reagent.  The membrane was tightly 
covered, protein side facing up, with a single layer of plastic wrap.  The 
chemiluminescence was detected with the Gel Doc™ system (Bio-Rad) with multiple 
exposures of 15 seconds, up to a period of 10 min. 
 
2.11 Biotransformation with CYP-expressing 
recombinant yeast cells under the control of the 
ADH2 promoter 
 
2.11.1 A Typical Biotransformation Experiment  
 
(1) Pre-culture-1: A scoopful of CYP-containing ‘stable’ yeast cells were 
inoculated, from a fresh YPD (complete medium) plate, into 50 ml 1X YPD in 
a 500 ml conical baffled flask; shaken at 30°C, 220 rpm, ~17 h; baffled flasks 
were used for vigorous aeration; after all a CYP enzyme would have to utilize 
oxygen to metabolize the starting material.  
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(2) Pre-culture-2: Pre-culture- cells were harvested and re-suspended in 50 ml 1X 
YPD in a 500-ml conical baffled flask; shaken at 30°C, 220 rpm, 14 h; 
(3) Pre-culture-3: Pre-culture- cells was harvested from and re-suspended in 50 ml 
1X YPD in a 500 ml conical baffled flask; shake at 30°C, 220 rpm, 14 h; 
A gradual increase of OD600 (optical density measured at 600 nm) was observed 
with each day of culture and this also translated to an increase of CYP activity 
(using pro-fluorescent substrate), from pre-culture 1 to pre-culture 3.   
(4) Main culture (i.e. the cells that are involved in biotransformation). 
a. Cells harvested from Pre-culture-3, were re-suspended (~100 OD600 of cells) in 
5 ml 1X SD (minimal medium) in four 50 ml baffled flasks;  
b. Codeine was added to cultures (final concentration, 50 µM) from a 50 mM stock 
solution in 100% DMSO; the final concentration of DMSO in the cultures was 
< 0 
c. Flasks were shaken at 30°C, 220 rpm, 24, 48, 72, 96 h;  
d. Cells were harvested every 24 h for assessing biotransformation (i.e. amounts of 
bio-transformed products).   
e. For the 48 h, 72 h, 96 h cultures, 0.2 ml of 50% glucose was added every 24 h 
of growth, to replenish levels of glucose to 2%.  
Note: Glucose is exhausted after 12 h of growth.  Hence, every other 12 h, cells make the 
CYP enzyme.  The ADH2 promoter (ADH2p) is repressed in the presence of glucose and 
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induced in the presence of ethanol.  As glucose is converted to ethanol during yeast cell 
division (i.e. yeast cell growth), the ADH2p is induced (i.e. when CYP proteins are made).  
Therefore, over a 96 h time period, 48 h will be spent by the cells on growth (cell division) 
and the other 48 h on CYP production.  During the time CYP enzyme is produced, 
(codeine to morphine) biotransformation will take place.  
 
2.11.2 Composition of YPD and SD Medium for growth of 
cells for biotransformation 
 
YPD = 5 g of Yeast extract(LP0021,  OXOID)+10 g Proteosepeptone (LP0085 OXOID) 
+10 g Glucose add up 500 ml pure water and autoclave 
SD-agar = 3.35 g yeast nitrogen base(BD291940, DIFCO) 10 g glucose 10 g agar 1 pellet 
of NaOH add up to 500 ml pure water 
SD-MM = 3.35 g yeast Nitrogen base (291940, BD DIFCO) + 480 ml pure water+ 20 ml 
50%. 
 
2.11.3 Thin Layer Chromatography Procedures 
 
1) The cells were spun down from each flask for 5 min at 13,000 rpm. 
2) Transferred the total amount of the recovered supernatant into separation funnel 
with a glass stopper.  
3) 200 µl of 0.1M ammonia was gently added.  
144 
 
4) Butanol was used to extract codeine/morphine; extracted 3X with 5 ml pf 1-
butanol.  I made sure the layers were well separated before removing the aqueous 
layer.  
5) The organic layer was passed through 0.2 µm Ministart high-flow syringe filter to 
remove cell debris; alternatively, paper filters could be used.  
6) Eluent was transferred from the filter into the Büchi evaporator flask and 
evaporated at 65°C. 
7) The extracted residue was re-suspended in 5 ml of methanol.  
 
 







2.11.4 TLC Buffer 
 
For detection of codeine and morphine, the solvent systems that were attempted were:  
1) Dichloromethane (DCM) : Methanol : Ammonia = 24 : 2.8: 0.4 
2) Ethyl acetate : Methanol : Ammonia = 85 : 10 : 5 
3) Toluene : Acetone : Ethanol : Ammonia = 40 : 40 : 6 : 2 
Solvent system (3) provided the best separation.   
All solvents were HPLC grade.   
• Dichloromethane (DCM), Sigma Cat No 1.13713, 
• Methanol solution contains 0.1 %( v/v) formic acid, Sigma Cat No 632546, 
• Chloroform for HPLC 0.5-1% ethanol as stabilizer, Sigma Cat No 439142, 
• Toluene, Sigma Cat No 648566, 
• Acetone, Sigma Cat No 439126, 
• Water with formic Acid Hypergrade for LC-MS Sigma Cat No 1.59013, 
• Ethyl acetate Sigma Cat No 1.03649, 
• 1-Butanol for liquid chromatography Cat No 1.01988, 





Chapter 3 Cloning and construction of yeast 
plasmids for expression of 17 human 
CYP genes (most of which used for 
Drug Metabolism studies), synthesized 




Cytochrome P450 (CYP) enzymes belong to a large superfamily of proteins that exist in 
all eukaryotic and some prokaryotic organisms. The first heterologous expression of a 
functional human CYP was demonstrated in the baker’s yeast, Saccharomyces cerevisiae 
(Ton et al., 2004). Yeast was preferred as a heterologous system for expression of 
eukaryotic CYP450 proteins because of  
(1) Yeast cells’ high efficiency and easy mode of growth which is economically much 
cheaper compared to other higher eukaryotic cells,  
(2) Vector availability with strong constitutive or inducible promoters (GAPDH or 
GAL promoters) that would allow proficient gene transcription of heterologous 
genes, such as CYP450 genes, during cell division (Qin et al., 2011),  
(3) Availability of robust host strains that can overexpress membrane integrated 
proteins, such as cytochrome P450 reductase (CPR) which is absolutely essential 
for CYP enzyme activity (Kandel et al., 2014), and most importantly the 
(4) Presence of endoplasmic reticular (ER) membranes in yeast, similar to that in 
human cells, which normally house most eukaryotic CYPs enzymes; a few human 
CYPs, however, are associated with mitochondrial membranes which also play 
similar roles in both human and yeast cells (Schuck et al., 2009).  
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Although these traits underline yeast’s advantages compared to other eukaryotic hosts, 
the level of expression of most human CYP enzymes in yeast is low and most of the 
proteins that are produced have low enzymatic activity (Walmsley et al., 2002). In this 
thesis, attempts have been made to overcome these flaws so that yeast systems that 
produce CYP enzymes could be made available for wider commercial use. The main aim 
was to address the persistent problems of low expression and activity of human CYP 
enzymes produced in yeast.  
Codon optimized genes have commonly been used to enhance heterologous gene 
expression of proteins specifically in the context of synthetic biology, where cells are 
manipulated for optimal synthesis of chemicals and their metabolites. The strategy used 
in the codon optimization process involves replacement of rare codons with more 
frequently occurring ones in highly expressed genes that code for native proteins of host 
cells. It is well documented that production of functional heterologous proteins in a host 
organism is enhanced with the use of host-biased codons and that this influences protein 
yields (Milda and Alma, 2012). The questions that come to mind are:  
(1) Why do different organisms prefer different codons?  
(2) How does one envision codon bias?  
(3) How does codon bias affect protein expression? and  
(4) Does codon bias somehow modify the host to improve protein expression? 
There are 61 nucleotide triplets that code for 20 essential amino acids that are used by 
most organisms to synthesise proteins. Besides the 61 triplets, there are 3 nonsense 
codons, also known as stop codons where transcription stops during gene transcription. 
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In the ribosome, the codons are read by complementary tRNA coupled with the charged 
amino acids. How the codons are used and their frequency of use differs from one species 
to another and also even between proteins, expressed at low or high levels, within the 
same organism. In the past, it was strongly believed that evolutionary forces have evolved 
in the usage of certain codons by an organism (which is also referred to as selective 
equilibria between codons of the same species; Sharp et al., 2010). 
The adaptation index in the expression of a foreign protein in a host organism is identified 
with the help of correlation between codon bias of the expressed gene and its expression 
levels (Sharp et al., 1987; Chung et al., 2012). The index predicts the expression levels of 
endogenous genes present in the genome to which they belong but it does not measure 
the nature of adaptation or preference and this makes it more difficult to assess the likely 
compatibility between a gene that is expressed and the host candidate. To establish the 
codon preference, some major components can be used to compress the multi-
dimensional information into two-dimensional maps. This enables a convenient way to 
see the dissimilarities in the codon preferences between organisms. Therefore, this study 
is based on the strategy to improve expression of foreign genes by altering their rare 
codons so that they will be more reflecting the codons of baker’s yeast without any 
changes in the amino acid sequence of the encoded protein. 
It is likely that codon usage and iso-acceptor tRNA concentrations have co-evolved 
suggesting that the selection for this co-evolvement gives rise to a greater chance of 
increased induction of transcription of genes which can lead to higher expression of 
proteins (M. Bulmer, 1987). It was believed that the more the codons of rarely used 
codons appear in a gene the higher the possibility that the heterologous protein will have 
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a low expression level (Del Tito et al., 1995). It was also reported, in a similar study, that 
two to five of the codons from CGG, AUA, CUA, CGA and CCC that may occur in 
tandem, and in clusters, have significant up-regulatory effects on expression of test 
proteins (Rosenberg et al., 1993). 
Yeast biased codons may not be the only factor which contributes to the increased levels 
of expression of foreign genes in yeast. The particular yeast strain which acts as a host 
may play a very huge role in achieving high expression levels together with the 
transcriptional promoter which lies upstream of the gene to be expressed (X. Wu 2004). 
If there is efficient translation, it is absolutely imperative that the folding of the 
polypeptide chain occurs correctly for the protein to manifest appropriate activity. 
 
3.2 Outline of Chapter 3 
 
The goals of this chapter were to: 
(1) Construct episomal 2µ (multi-copy) plasmids for expression of human CYP 
proteins in yeast, using CYP genes that were chemically ‘synthesised’ with yeast 
biased codons, 
(2) Express ‘synthesised’ human CYP genes using yeast biased codons (referred to as 
CYP_yc), as CYP proteins within yeast cells using episomal plasmids, 
(3) Express ‘native’ human CYP genes which were earlier isolated from a human 
liver cDNA library (CYP) within yeast cells using episomal plasmids, 
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(4) Compare expression of activities of a specific CYP enzyme produced from 
‘synthesised’ CYP_yc gene, as in (2), with CYP enzyme produced from ‘native’ 
CYP_na gene, as in (3). 
Results from experiments (1) to (4) would answer the question, do ‘synthesised’ genes 
produce active enzymes that are as good as (or, better than) the enzymes produced from 
‘native’ genes? The results, presented in this Chapter, show that the enzymes produced 
from ‘synthesised’ human CYP genes are more active than the ones produced from the 
‘native’ genes. Most likely, this is because a CYP_yc gene produces more CYP protein 
than a CYP_na gene, per unit number of cells. The methodologies, used in this Chapter, 
were earlier described in Chapter 2 (Material and Methods). The protocols in Chapter 2 
were followed to clone and express a specific CYP_yc gene, chemically synthesised with 
yeast biased codons. 
 
3.3 Construction of recombinant DNA molecules 
 
One of the main aims of the project was to devise new systems for expression of 
functionally active human CYP enzymes in baker’s yeast. 
Within this aim, the first goal was to find out how a ‘chemically synthesized’ human 
CYP gene, with codons that are yeast biased (_yc), fare against a CYP cDNA (‘native’; 
_na) isolated from a human liver cDNA library in terms of (a) ‘CYP enzyme activity’ 
, (b) ‘CYP yield’ and (c) ‘co-expression with cytochrome b5 for some CYPs’. It has 
been reported that co-expression of the cytochrome b5 protein with a CYP and a 
cytochrome P450 reductase (CPR) provides higher enzyme activity to certain CYPs. A 
CPR is essential for the activity of all CYPs (Kendel et al., 2014).  
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For the above comparative analyses, 17 human CYP genes were chosen. Most of the 17 
genes are used for Drug Metabolism studies, others having crucial roles in the synthesis 
of steroids and fatty acids that are endogenous to human cells. All the genes were 
synthesized using yeast biased codons and were first cloned into the commercially 
available basic vector, pUC57 (Thermo Fisher, UK).  
The pUC57 plasmids, bearing ‘synthetic’ CYP genes, were amplified by transforming 
into bacterial DH5α cells. All seventeen CYP genes were isolated from the pUC57 
plasmids using restriction enzymes that cut at specific recognition sites at the 5’ and 
3’ end of the genes. The CYP genes were then ligated into a shuttle vector of choice 
(i.e. pSYE263) which had been constructed in-house previously. The resultant 
pSYE263 derived plasmids were amplified in bacterial cells and were then 
transformed into yeast. During yeast cell division, the transformants replicate extra-
chromosomally within yeast cells. For maintenance of plasmid, the yeast cells must 
be grown in selective synthetic defined (SD) medium. Extra-chromosomal plasmids 
cannot be maintained in complete YPD (yeast + peptone + dextrose) medium. A 
plasmid is gradually lost after 10 generations of growth, each yeast generation being 
of 90 min duration.  
 
3.3.1 Yeast transformation 
The yeast transformation protocol, used in this Chapter, has been described in Chapter 
2, Section 2.5.4.  
The yeast strains that were used were:  
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(1) YAB79 that contains ∆hRDM and cytochrome b5 genes at the LEU2 and TRP1 
loci; and  
(2) YY7 that contains only ∆hRDM at the LEU2 locus). 
The constructions of these strains are described in more detail in Chapter 4, Section 
4.4.4.  
 
3.3.2 Plasmid vectors 
 
The yeast extra-chromosomal vector used, in the construction of recombinant DNA 
plasmids for expression studies in this project, was the episomal 2µ-based vector 
pSYE263 (Figure 3.1). It contains the yeast ADH2 promoter which belongs to one of the 
two alcohol dehydrogenase genes of yeast. Alcohol dehydrogenases are responsible for 
oxidation of ethanol to enable its removal from living cells.  
The vector pSYE263 was already available in the lab and a small aliquot (10µl) of a 
bacterial glycerol stock from -80°C was inoculated into LB broth, grown overnight at 
37°C and the vector plasmid was isolated. The 573 bp ADH2 promoter fragment in the 
plasmid pBluKS(+)/ADH2p (Figure 3.2) was used to construct the episomal plasmid 
pSYE263, containing the ADH2 promoter. In order to isolate the 573 bp fragment from 
the plasmid, it was first extracted from bacterial cells which were grown from a glycerol 
stock kept at minus 80°C.  
Both the plasmids, pSYE263 and pBluKS(+)/ADH2p, bear a β-lactamase gene and a 





Figure 3.1. The plasmid map of pSYE263, the 2µ-based episomal plasmid 
containing the yeast ADH2 promoter which was isolated from the plasmid 
pBluKS(+)/ADH2p (Figure 3.1). The restriction sites shown on the map occur 










































Figure 3.2. Shows the map of the basic plasmid that contains the 573bp-ADH2 
promoter. This was isolated to create the plasmid pSYE263 (Figure 3.1). The 
restriction sites shown on the map occur in the plasmid only once. 
 
 
3.4 Cloning of CYP3A4_yc gene in the episomal 
plasmid pSY263 for expression of human 
CYP3A4 enzyme  
 
3.4.1 Cloning of CYP3A4_yc gene in the episomal plasmid 
pSY263 
 
CYP3A4 is one of the ten to twelve CYP enzymes which are widely used for Drug 
Metabolism studies during the process of drug development (Zanger et al., 2013). At first, 
the plasmid pUC57/h_CYP34_yc (Figure 3.3) was digested with the restriction enzymes 
BamHI and XbaI. The 1524 bp insert fragment containing the human CYP3A4_yc gene 
was isolated from an agarose gel and the 2700 bp pUC57 vector fragment was ignored 






































digested also with BamHI and XbaI restriction enzymes (Figure 3.5) to obtain the plasmid 
pSYE263/h_CYP3A4_yc (Figure 3.6).  
At this point one should emphasise that all CYP_yc genes, containing yeast biased codons, 
were constructed in-house (by Professor Chaudhuri, my supervisor) but were chemically 
synthesised by GeneWiz (USA). After receipt of the synthetic genes, all further DNA 




Figure 3.3. The plasmid map for pUC57/h_CYP34_yc, which contains the 
human CYP3A4 gene synthesised using yeast biased codons (h_CYP34_yc), 
cloned at the BamHI and XbaI sites of the plasmid. The BamHI-XbaI h_CYP34_yc 
insert fragment was isolated for further cloning in the episomal vector 
pSYE263 and integrative vectors described in Chapter 4. The restriction sites 
shown on the map occur in the plasmid only once.  
 
Similar pUC57 based plasmids were constructed for the rest of the CYP genes described 






































Lanes           1                                                2
1524 bp-
 
Figure 3.4. It shows the agarose gel that has fractionated the DNA fragments 
obtained after digestion of the plasmid pUC57/h_CYP34_yc after digestion 
with restriction enzymes, BamHI and XbaI.  
 
The 1524bp h_CYP34_yc gene fragment (Figure 3.4) was isolated from the gel and cloned 
in the yeast expression vector pSYE263, a 2u-based episomal plasmid that contains the 
ADH2 promoter and the CYC1 transcription terminator. In between the promoter and the 
terminator are the multi-cloning sites in which the gene h_CYP34_yc was cloned through 
DNA ligation. In order to clone the gene, pSYE263 was first digested with BamHI and 
XbaI and the vector fragment was isolated (Figure 3.5). 
 
Lanes            1       2                 3
5699bp-
 
Figure 3.5. The BamHI-XbaI digested pSYE263 linearised vector fragment 
(5699 bp) was isolated from the agarose gel. Lane 1, DNA ladder of established 
DNA fragments (commercially available; New England Biolabs). Lane 2, uncut 
vector; lane 3, digested vector which was isolated from the gel for ligation with 
the insert (Figure 3.4) obtain the plasmid pSYE263/h_CYP3A4_yc.  
 
The 5699 bp pSYE263 vector fragment and the 1524 bp h_CYP34_yc insert fragment 
were ligated with the help of the enzyme DNA ligase. After ligation and transformation 
in E. coli DH5α cells, individual colonies were grown for preparation of DNA using the 
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alkaline lysis method (Chapter 2, Section 2.4.1.8). The resultant plasmid DNA was named 
pSYE263/h_CYP3A4_yc (Figure 3.6). The authenticity of the plasmid was confirmed by 




Figure 3.6. It shows the restriction enzyme map of the episomal, 2µ-plasmid 
pSYE263/h_CYP3A4_yc that was used for expression of the h_CYP3A4_yc gene, 
to produce active human CYP3A4 enzyme. The restriction sites that are shown 















































Lanes      1     2       3      4       5      6
 
Figure 3.7. The agarose gel that shows the expected DNA fragments when the 
plasmid pSYE263/h_CYP3A4_yc was digested with the restriction enzyme NdeI 
(lanes 2, 4, 6). Lanes 3, 5 show the uncut plasmid. Lane 1, DNA ladder of 
established DNA fragments (commercially available; New England Biolabs).  
 
 
3.4.2 Comparison of CYP3A4 enzyme activities expressed 
by ‘synthesised’ CYP3A4_yc and ‘native’ CYP3A4_na 
genes, both encoded by the episomal plasmid 
pSY263, using a fluorescence-based assay 
 
The plasmid pSYE263/h_CYP3A4_yc (Figure 3.6) and pSYE263/h_CYP3A4_na 
(containing the native CYP3A4 gene; plasmid map not shown; published in an earlier 
thesis from this laboratory) were transformed in the yeast strain YAB79 that contains 
∆hRDM and cytochrome b5 genes at the LEU2 and TRP1 loci. The gene h_CYP3A4_na 
represents the human CYP3A4 gene isolated from a human liver cDNA library. The 
transformants obtained after transformation of the two plasmids in the yeast strain YAB79 
were designated as:  
(a) Episomal 3A4_yc, and  
(b) Episomal 3A4_na.  
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Transformants from the empty plasmid pSYE263, which does not encode any foreign 
CYP gene, were used as a control for comparison of human CYP3A4 enzyme activities 
from the CYP3A4_yc and h_CYP3A4_na genes (Figure 3.8).  
 
 
Figure 3.8. The graph shows the kinetics of activity (i.e. enzyme activity with 
progression of time) of the CYP3A4 enzyme which was expressed in yeast from 
(a) the ‘synthesised’ CYP3A4_yc gene (blue) and (b) the ‘native’ CYP3A4 gene 
(grey) using the same number of cells (1X 107); both genes were co-expressed 
with the modified human CPR gene, ∆hRDM, and cytochrome b5. Rate was 
measured in terms of relative fluorescence units (RFUs), using 
dibenzylfluorescein (DBF) as substrate. DBF is de-alkylated by CYP3A4 to 
form the fluorescent product flourscein. The empty plasmid (pSYE263 
containing no CYP3A4 gene), when expressed in yeast, showed no activity, as 
















Comparison of human CYP3A4 activities 
produced by the chemically synthesised and 
native genes (kinetics of reaction of enzymes 







Figure 3.9. The bar chart shows a comparison of human CYP3A4 enzyme 
activity obtained from same number of yeast cells (1X 107), expressing 
‘synthesized’ CYP3A4_yc and CYP3A4_na genes, obtained at 60 min of reaction 
of cells with DBF, the fluorogenic substrate. The data represent mean ± S.D. of 
three independent experiments.  
  
 
The chart in Figure 3.9 shows the relative CYP3A4 activity of three different cell types: 
cells which contain (a) an episomal plasmid bearing the CYP3A4_yc gene, (b) an episomal 
plasmid bearing the CYP3A4_na gene, and (c) an empty episomal plasmid. The cells that 
do not express any CYP3A4 gene show basal residual fluorescence from the substrate 
DBF (beige bar).  
The results from Figures 3.8 and 3.9 would indicate that there is more protein expressed 
from the ‘synthesized’ CYP3A4_yc gene than from the ‘native’ CYP3A4_na gene 
because, firstly, both genes would produce exactly the same enzyme and therefore the 
















Comparison of human CYP3A4 activities produced 
by cells harbouring (a) the chemically synthesised 
and (b) native genes at 60 min of enzymatic 






would be expected, the gene with the yeast biased codons should provide a more stable 
mRNA (i.e. more mRNA would be transcribed relative to what would be transcribed from 
the ‘native’ gene). More mRNA would translate to more protein, relative to what would 
be produced by the ‘native’ mRNA. This would have need to be confirmed by performing 
Western blot analysis on equal number of cells that express the two variants 
(‘synthesized’ and ‘native’) of the CYP3A4 gene (Figure 3.10). 
 
Lanes         1                   2                    3
60.0 kDa –
 
Figure 3.10. Western blot showing the amounts of CYP3A4 protein being 
expressed by equal number of cells (1X 106). The total cellular protein 
obtained from these cells was loaded on wells of an SDS polyacrylamide gel. 
Cells which contain the empty vector pSYE263 (lane 1), pSYE263/CYP3A4_na 
plasmid (lane 2), and pSYE263/CYP3A4_yc (lane 3). The expected size of 
CYP3A4 protein is 57.3 kDa. The blot was probed by a human CYP3A4 specific 
monoclonal antibody (Santa Cruz Biotechnology, Cat no: sc-27639).  
 
The results shown in Figure 3.10 do indicate that the CYP3A4_yc gene produces more 
CYP3A4 protein than the CYP3A4_na gene. Densitometric quantification (results not 
shown) suggests that ~4 times more protein is produced by CYP3A4_yc gene than by the 
native gene isolated from a human liver cDNA library. For all Western blots shown in 
this thesis, the housekeeping protein actin was used as a control. Actin blots showed equal 





3.5 Cloning of CYP2C9_yc gene in the episomal 
plasmid pSY263 for expression of human 
CYP2C9 enzyme 
 
3.5.1 Cloning of CYP2C9_yc gene in the episomal plasmid 
pSY263 
 
CYP2C9 is another one of the ten to twelve CYP enzymes which are widely used for 
Drug Metabolism studies during the process of drug development (Zhang et al., 2013). 
The human CYP2C9_yc gene, with yeast biased codons, was cloned in the yeast 
expression vector pSYE263 (Figure 3.1) in a way that was similar to the cloning of the 
CYP3A4_yc gene described in Section 3.4.1. 
The resultant plasmid was named pSYE263/h_CYP2C9_yc (Figure 3.12). 
A 1485 bp BamHI-XbaI CYP2C9_yc gene fragment (Figure 3.11) was isolated from the 
plasmid pUC57/BamHI-XbaI/h_CYP2C9_yc for further ligation (mediated by DNA 
ligase) to the 5699 bp BamHI-XbaI fragment of vector pSYE263 (Figure 3.5), to create 
the episomal, 2µ-plasmid pSYE263/h_CYP2C9_yc (Figure 3.12) for expression of the 




Lanes          1                          2                              3
1485bp-
 
Figure 3.11. The agarose gel shows fractionation of the DNA fragments 
obtained after digestion of the plasmid pUC57/BamHI-XbaI/h_CYP2C9_yc with 
BamHI and Xbal. Lane 1, DNA ladder with defined sizes of DNA fragments; lane 
2, pUC57/BamHI-XbaI/h_CYP2C9_yc digested with BamHI, Xbal; lane 3, uncut 
plasmid pUC57/BamHI-XbaI/h_CYP2C9_yc. The lower 1485 bp band (lane 2) 
was isolated from the gel for further ligation with the vector pSYE263, 
digested with BamHI and Xbal to obtain the plasmid pSYE263/h_CYP2C9_yc.  
 
 
Figure 3.12. Shows the plasmid map of pSYE263/h_CYP2C9_yc, with restriction 
sites that occur in the plasmid only once. The BamHI and XbaI sites of pSYE263 
were used for cloning the synthetic h_CYP2C9_yc gene with yeast biased 













































After ligation and transformation of ligation mixtures in E. coli DH5α, individual colonies 
were grown for preparation of plasmid DNA using the alkaline lysis method (Chapter 2, 
Section 2.4.1.8).  
The authenticity of the resultant plasmid DNA, pSYE263/h_CYP2C9_yc was 
confirmed by digesting with the restriction enzymes BamHI and XbaI. It was 
verified that the correct size insert (1485 bp) existed within the newly constructed 




Lanes           1          2           3          4           5
 
Figure 3.13. An agarose gel that shows the expected DNA fragments when the 
plasmid pSYE263/h_CYP2C9_yc was digested with the restriction enzymes 
BamHI and XbaI. Lane 1, DNA ladder; lanes 2 to 5, pSYE263/h_CYP2C9_yc 





3.5.2 Comparison of CYP2C9 enzyme activities expressed 
by ‘synthesised’ CYP2C9_yc and ‘native’ CYP2C9_na 
genes, both encoded by the episomal plasmid 




Figure 3.14. (A) The graphs show the rate at which the activity of CYP2C9 
enzyme, expressed in yeast from the ‘synthesised’ CYP2C9_yc gene and the 
‘native’ CYP2C9_na gene (co-expressed only with the human CPR gene, ∆hRDM 
but in the absence of cytochrome b5), increases over 50 min. Rate was 
measured in terms of relative fluorescence units (RFUs), using CEC (3-cyano-
7-ethoxycoumarin) as the substrate. CEC is de-alkylated by CYP2C9 to form the 
fluorescent product 3-cyano-7-hydroxycoumarin (CHC). The empty plasmid 
pSYE263 (containing no CYP2C9 gene), when expressed in yeast, showed basal 
levels of activity which equates to no activity (green). (B) Depicts the 
comparison of fluorescence emitted by the three yeast strains at 45 min of 
reaction of enzyme with substrate. The data represent mean ± S.D. of three 












(A) Comparison of enzyme activities obtained from 
CYP2C9_yc 'synthesised' gene and that obtained from 

















(B) Comparison of enzyme activities obtained from 
CYP2C9_yc 'synthesised' gene and that obtained from 








The results in Figure 3.14 (shown above) would indicate that there is slightly more protein 
expressed from the ‘synthesised’ CYP2C9_yc gene than from the ‘native’ CYP2C9_na 
gene. Again, as expected the gene with the yeast biased codons provides mRNA more 
stable than transcribed by the ‘native’ gene. This would translate to more protein relative 
to what would be produced by the ‘native’ mRNA. The results also show that active 
CYP2C9 can be expressed from yeast, in the absence of cytochrome b5. Recently, 
Corning-Gentest (the leading manufacturer of human enzymes in insect cells) have 
started distributing human CYP2C9 microsomal enzyme which has been produced in the 
absence of cytochrome b5.  
The results in Figure 3.14 was also confirmed by performing Western blot analysis using 
equal number of cells (1X 106) that express the two variants, ‘synthesised’ and ‘native’, 
of the CYP2C9 gene (Figure 3.15).  
 
Lanes    1          2
60.0 kDa –
 
Figure 3.15. Western blot shows CYP2C9 proteins expressed from equal 
number of cells (1X 106). The total cellular protein obtained from these cells 
was loaded on wells of an SDS polyacrylamide gel. Lane 1, cells expressing 
human CYP2C9 protein from a ‘synthetic’ gene; Lane 2, cells expressing human 
CYP2C9 protein from a ‘native’ CYP2C9 gene. The expected size of CYP2C9 
protein is 55.6 kDa. The blot was probed by a human CYP2C9 specific 




Densitometric measurements (results not shown) of the blot shown in Figure 3.15 indicate 
that there is ~2 times more protein obtained from CYP2C9_yc gene than from the 
CYP2C9_na gene.  
 
3.6 Cloning of CYP2C19_yc gene in the episomal 
plasmid pSY263 for expression of human 
CYP2C19 enzyme 
 
3.6.1 Cloning of CYP2C19_yc gene in the episomal plasmid 
pSY263 
 
CYP2C19 is another CYP enzyme, which is widely used for Drug Metabolism studies in 
the process of drug development (Zanger et al., 2013). The human CYP2C19_yc gene, 
with yeast biased codons, was cloned in the yeast expression vector pSYE263 using 
methodologies similar to cloning of the CYP3A4_yc gene in the same vector (this Chapter, 
Section 3.4.1). The resultant plasmid was named pSYE263/h_CYP2C19_yc.  
A 1485 bp BamHI-XbaI CYP2C19_yc gene fragment (Figure 3.16) was isolated from the 
plasmid pUC57/BamHI-XbaI/h_CYP2C19_yc for DNA ligase mediated ligation to the 
5699 bp BamHI-XbaI fragment of vector pSYE263 (Figure 3.5), to create the episomal, 






Lanes     1         2         3    4        5
 
Figure 3.16. The agarose gel shows fractionation of the DNA fragments 
obtained after digestion of the plasmid pUC57/BamHI-XbaI/h_CYP2C19_yc 
with BamHI and Xbal. Lane 1, DNA ladder with defined sizes of DNA fragments; 
lanes 2 & 5, pUC57/BamHI-XbaI/h_CYP2C19_yc digested with BamHI, Xbal; 
lanes 3 & 4, uncut plasmid pUC57/BamHI-XbaI/h_CYP2C19_yc. The lower 
1485 bp band (from lanes 2 & 5) was isolated from the gel for further ligation 




Figure 3.17. Shows the plasmid map of pSYE263/h_CYP2C19_yc, with 
restriction sites that occur in the plasmid only once. The BamHI and XbaI sites 
of pSYE263 were used for cloning the synthetic h_CYP2C19_yc gene with yeast 









































After ligation and transformation of the ligation mixture in E. coli DH5α competent cells, 
individual bacterial transformants were grown for preparation of plasmid DNA using the 
alkaline lysis method (Chapter 2, Section 2.4.1.8). 
The authenticity of the resultant plasmid DNA, pSYE263/h_CYP2C19_yc was confirmed 
by digesting with the restriction enzymes BamHI and XbaI. Thus, it was verified that the 
correct size insert (1485 bp) existed within the newly constructed plasmid (Figure 3.18).  
 




Figure 3.18. An agarose gel that shows the expected DNA fragments when the 
plasmid pSYE263/h_CYP2C19_yc was digested with the restriction enzymes 
BamHI and XbaI. Lane 1, DNA ladder; lanes 2 to 5, pSYE263/h_CYP2C19_yc 
digested with BamHI and XbaI.  
 
3.6.2 Comparison of CYP2C19 enzyme activities 
expressed by ‘synthesised’ CYP2C19_yc and ‘native’ 
CYP2C19_na genes, both encoded by the episomal 
plasmid pSY263, using a fluorescence-based assay 
 
The results shown in Figure 3.19 (which follows) indicate that there is much more protein 
expressed from the ‘synthesised’ CYP2C19_yc gene than from the ‘native’ CYP2C19_na 
gene because. Once again, the gene with the yeast biased codons should provide mRNA 






Figure 3.19. (A) The graphs show the rate at which the activity of the CYP2C19 
enzyme, expressed in yeast from the ‘synthesised’ CYP2C19_yc gene and the 
‘native’ CYP2C19_na gene (co-expressed with a modified human CPR  and 
cytochrome b5 genes), increases over 75 min. Rate was measured in terms of 
relative fluorescence units (RFUs), using 3-cyano-7-ethoxycoumarin (CEC) as 
the substrate. CEC is de-ethylated by CYP2C19 to form 3-cyano7-
hdroxycoumarin (CHC). The empty plasmid pSYE263 (containing no CYP2C19 
gene), when expressed in yeast, showed no activity (brown). (B) Depicts the 
comparison of fluorescence emitted by the three yeast strains at 75 min of 
reaction of enzyme with substrate.The data represent mean ± S.D. of three 
independent experiments.  













(A) Comparison of enzyme activities obtained from 
'synthesised' CYP2C19_yc gene and that obtained from 
CYP2C19_na 'native' gene, with the 'empty plasmid' as a 

















(B) Comparison of enzyme activities obtained from 
'synthesised' CYP2C19_yc gene and that obtained from 
'native' CYP2C19_na gene, with the 'empty plasmid' as a 







The mRNA derived from yeast biased codons CYP2C19 coding sequence should translate 
to more protein relative to what would be produced by the ‘native’ mRNA. This would 
have to be confirmed by Western blotting, using equal number of cells (1X 106), that 
express the two variants, ‘synthesised’ and ‘native’, of the CYP2C19 gene (Figure 3.20). 
 
Lanes          1               2              3 
60 kDa–
 
Figure 3.20. Western blot that shows the amounts of CYP2C19 protein being 
expressed by equal number of cells (1X 106) from different yeast strains. The 
total cellular protein obtained from these cells was loaded on wells of an SDS 
polyacrylamide gel. Cells which contain the empty vector pSYE263 (lane 1), 
pSYE263/CYP2C19_na plasmid (lane 2), and pSYE263/CYP2C19_yc plasmid 
(lane 3). The expected size of CYP2C19 protein is 55.9 kDa. The blot was 
probed by a human CYP2C19 specific monoclonal antibody (Santa Cruz 
Biotechnology, Cat no:sc25581).  
 
The results shown in Figure 3.20 would indicate that the CYP2C19_yc gene indeed 
produces more CYP2C19 protein than the CYP2C19_na gene. Densitometric 
quantification (results not shown) suggests that ~5 times more protein is produced by 
CYP2C19_yc gene than by the native CYP2C19_na gene isolated from a human liver 





3.7 Cloning of CYP2B6_yc gene in the episomal 
plasmid pSY263 for expression of human 
CYP2B6 enzyme 
 
3.7.1 Cloning of CYP2B6_yc gene in the episomal plasmid 
pSY263 
 
CYP2B6 is another CYP enzyme which is widely used for Drug Metabolism studies in 
the process of drug development (Zanger et al., 2013). The human CYP2B6_yc gene, with 
yeast biased codons, was cloned in the yeast expression vector pSYE263 using 
methodologies similar to cloning of the CYP3A4_yc gene in the same vector (this Chapter, 
Section 3.4.1). The resultant plasmid was named pSYE263/h_CYP2B6_yc.  
A 1491 bp BamHI-XbaI CYP2B6_yc gene fragment (Figure 3.21) was isolated from the 
plasmid pUC57/BamHI-XbaI/h_CYP2B6_yc for DNA ligase mediated ligation to the 
5699 bp BamHI-XbaI fragment of vector pSYE263 (Figure 3.5), to create the episomal, 




Lanes              1                             2
 
Figure 3.21. An agarose gel that shows the fractionation of DNA fragments 
obtained after digestion of the plasmid pUC57/BamHI-XbaI/h_CYP2B6_yc 
with enzymes BamHI and Xbal. Lane 1, uncut plasmid pUC57/BamHI-
XbaI/h_CYP2B6_yc; lane 2, pUC57/BamHI-XbaI/h_CYP2B6_yc digested with 
BamHI, Xbal. The lower 1491 bp band (from lane 2) was isolated from the gel 
for further ligation with the vector pSYE263, digested with BamHI and Xbal to 





Figure 3.22. The map of plasmid pSYE263/h_CYP2B6_yc, with restriction sites 
that occur in the plasmid only once. The BamHI and XbaI sites of pSYE263 were 
used for cloning the synthetic h_CYP2B6_yc gene with yeast biased codons, in 
the episomal, 2µ-plasmid pSYE263. 
 
After ligation and transformation of the ligation mixture in E. coli DH5α competent cells, 
individual bacterial transformants were grown for preparation of plasmid DNA using the 
alkaline lysis method (Chapter 2, Section 2.4.1.8). 
The authenticity of the resultant plasmid DNA, pSYE263/h_CYP2B6_yc was confirmed 
by digesting with the restriction enzymes BamHI and XbaI. It was verified that the newly 


















































Lanes         1            2             3           4          5
 
Figure 3.23. An agarose gel that shows the expected DNA fragments when the 
plasmid pSYE263/h_CYP2B6_yc was digested with the restriction enzymes 
BamHI and XbaI. Lane 1, DNA ladder; lanes 2 to 5, pSYE263/h_CYP2B6_yc 
digested with BamHI and XbaI.  
 
3.7.2 Comparison of CYP2B6 enzyme activities expressed 
by ‘synthesised’ CYP2B6_yc and ‘native’ CYP2B6_na 
genes, both encoded by the episomal plasmid 
pSY263, using a fluorescence-based assay 
 
The results shown in Figure 3.24 (that follows) indicate that there is more protein 
expressed from the ‘synthesised’ CYP2B6_yc gene than from the ‘native’ CYP2B6_na 
gene because. The gene with the yeast biased codons provides mRNA which is likely to 
be more stable than the mRNA transcribed by the ‘native’ gene. The mRNA derived from 
yeast biased codons CYP2B6 coding sequence would translate to more protein relative to 
what would be produced by the ‘native’ mRNA. This would have to be confirmed by 
Western blotting, using equal number of cells (1X 106), that express the two variants, 





Figure 3.24. (A) The graphs show the rate at which the activity of the CYP2B6 
enzyme, expressed in yeast from the ‘synthesised’ CYP2B6_yc gene and the 
‘native’ CYP2B6_na gene (co-expressed with a modified human CPR and 
cytochrome b5 genes), increases over 50 min. Rate was measured in terms of 
relative fluorescence units (RFUs), using dibenzylfluorescein (DBF) as 
substrate. DBF is de-alkylated by CYP2B6 enzyme to form the fluorescent 
product flourscein. The empty plasmid pSYE263 (containing no CYP2B6 gene), 
when expressed in yeast, showed no activity (brown). (B) Depicts the 
comparison of fluorescence emitted by the three yeast strains at 50 min of 
reaction of enzyme with substrate. The data represent mean ± S.D. of three 












(A) Comparison of enzyme activities obtained from 
'synthesised' CYP2B6_yc gene and that obtained from 
CYP2B6_na 'native' gene, with the 'empty plasmid' as a 

















(B) Comparison of enzyme activities obtained from 
'synthesised' CYP2B6_yc gene and that obtained from 
CYP2B6_na 'native' gene, with the 'empty plasmid' as a 








The results in Figure 3.24 would indicate that there is more protein expressed from the 
‘synthesized’ CYP2B6_yc gene than from the ‘native’ CYP2B6_na gene because, as 
would be expected, the gene with the yeast biased codons would provide a more stable 
mRNA (i.e. more mRNA relative to what would be transcribed from the ‘native’ gene) 
which would translate to more protein (relative to what would be produced by the ‘native’ 
mRNA). This would have to be confirmed by performing Western blot analysis on equal 
number of cells that express the two variants (‘synthesized’ and ‘native’) of the CYP2B6 
gene. 
 
Lanes     1                           2 
60 kDA–
 
Figure 3.25. Western blot that shows the amounts of CYP2B6 protein being 
expressed by equal number of cells (1X 106) from different yeast strains. The 
total cellular protein obtained from these cells was loaded on wells of an SDS 
polyacrylamide gel. Cells which contain pSYE263/CYP2B6_na plasmid (lane 
1), and pSYE263/CYP2B6_yc (lane 2). The expected size of CYP2B6 protein is 
56.3 kDa. The blot was probed by a human CYP2B6 specific monoclonal 
antibody (Santa Cruz Biotechnology, Cat no: sc18852).  
 
The results shown in Figure 3.25 indicate that indeed the CYP2B6_yc gene produces more 
CYP2B6 protein than the CYP2B6_na gene. Densitometric quantification (results not 
shown) suggests that at least 6 times more protein is produced by CYP2B6_yc gene than 
by the native CYP2B6_na gene isolated from a human liver cDNA library. We are not 
sure why this is not reflected in the enzyme activity results shown in Figure 3.24; 
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however, the microsomal CYP2B6 enzyme isolated from strain expressing CYP2B6_yc 
does show more activity than enzyme isolated from the strain expressing CYP2B6_na 
(data not shown).  
3.8 Cloning of CYP2C18_yc gene in the episomal 
plasmid pSY263 for expression of human 
CYP2C18 enzyme 
 
3.8.1 Cloning of CYP2C18_yc gene in the episomal plasmid 
pSY263 
 
CYP2C18 is another one of the CYP enzymes which is used for Drug Metabolism studies 
during the process of drug development (Meyer et al., 2010). The human CYP2C18_yc 
gene, with yeast biased codons, was cloned in the yeast expression vector pSYE263 using 
methodologies similar to cloning of the CYP3A4_yc gene in the same vector (this Chapter, 
Section 3.4.1). The resultant plasmid was named pSYE263/h_CYP2C18_yc.  
A 1488 bp BamHI-XbaI CYP2C18_yc gene fragment (Figure 3.26) was isolated from the 
plasmid pUC57/BamHI-XbaI/h_CYP2C18_yc for DNA ligase mediated ligation to the 
5699 bp BamHI-XbaI fragment of vector pSYE263 (Figure 3.5), to create the episomal, 




Lane             1
 
Figure 3.26. Agarose gel showing the fractionation of DNA fragments obtained 
after digestion of the plasmid pUC57/BamHI-XbaI/h_CYP2C18_yc with 
178 
 
enzymes BamHI and Xbal. Lane 1, pUC57/BamHI-XbaI/h_CYP2B6_yc digested 
with BamHI, Xbal. The lower 1488 bp band (lane 1) was isolated from the gel 
for further ligation with the vector pSYE263, digested with BamHI and Xbal to 
obtain the plasmid pSYE263/h_CYP2C18_yc.  
 
 
Figure 3.27. The map of plasmid pSYE263/h_CYP2C18_yc, with restriction 
sites that occur in the plasmid only once. The BamHI and XbaI sites of pSYE263 
were used for cloning the synthetic h_CYP2C18_yc gene with yeast biased 
codons, in the episomal, 2µ-plasmid pSYE263. 
 
After ligation and transformation of the ligation mixture in E. coli DH5α competent cells, 
individual bacterial transformants were grown for preparation of plasmid DNA using the 
alkaline lysis method (Chapter 2, Section 2.4.1.8). 
The authenticity of the resultant plasmid DNA, pSYE263/h_CYPC18_yc was confirmed 
by digesting with the restriction enzymes BamHI and XbaI. It was verified that the newly 
















































Lanes    1      2         3         4         5
 
Figure 3.28. An agarose gel showing the expected DNA fragments when 
plasmid pSYE263/h_CYP2C18_yc was digested with the enzymes BamHI and 
XbaI. Lane 1, DNA ladder; lanes 2 to 5, pSYE263/h_CYP2C18_yc digested with 
BamHI and XbaI.  
 
 
3.8.2 Comparison of CYP2C18 enzyme activities 
expressed by ‘synthesised’ CYP2C18_yc encoded by 
the episomal plasmid pSY263, in the presence or 
absence of cytochrome b5, using a fluorescence-
based assay 
 
The results shown in Figure 3.29 (which follows) indicate that roughly similar levels of 
CYP2C18 enzyme activity are expressed from the ‘synthesised’ CYP2C18_yc gene in the 
absence or presence of cytochrome b5. Western blotting confirms that the CYP2C18 
protein is expressed at similar levels in the absence and presence of cytochrome b5 






Figure 3.29. (A) The graph shows the rate at which the activity of the CYP2C18 
enzyme, expressed in yeast strains from the ‘synthesised’ CYP2C18_yc gene, 
increases over 30 min. Two of the strains co-express only ∆hRDM but two 
others co-express not only ∆hRDM but also cytochrome b5. Rate of reactions 
was measured in terms of relative fluorescence units (RFUs), using 
dibenzylfluorescein (DBF) as the substrate. DBF is dealkylated by CYP2C18 
enzyme to form the fluorescent product flourscein. The empty plasmid 
pSYE263 (containing no CYP2C18 gene), when expressed in yeast, showed 
more or less no activity. (B) Depicts the comparison of fluorescence emitted by 
the yeast strains (in the presence/absence of cytochrome b5) at 30 min of 
reaction of enzyme with substrate. The data represent mean ± S.D. of three 













(A) Comparison of enzyme activities obtained from different yeast 
clones expressing 'synthesised' CYP2C18_yc gene, with cells containing 
the 'empty plasmid' as a control; all strains co-express ∆hRDM, in the 


















(B) Comparison of enzyme activities obtained from different yeast 
clones expressing 'synthesised' CYP2C18_yc gene, with cells containing 
the 'empty plasmid' as a control; all strains co-express ∆hRDM, in the 








The results shown in Figure 3.30 suggest that all clones from the CYP2C18-producing 
yeast strains express similar amounts of CYP2C18 protein, in the presence or absence of 
cytochrome b5. It appears from Figure 3.29 that cytochrome b5 may not be helpful at all 
in augmenting CYP2C18 enzyme activity. However, It has been published that 
cytochrome b5 is essential for activity of CYP2C enzymes, and specifically CYP2C18 
(Zhang et al., 2015).  
 
Lanes   1         2        3         4
60 kDa–
 
Figure 3.30. Western blot showing that CYP2C18 protein is expressed from 
cells of all yeast strains containing the CYP2C18_yc gene. The total cellular 
protein obtained from these cells (1X 106) was loaded on wells of an SDS 
polyacrylamide gel. Lanes 1, 2: CYP2C18 protein expressed from cells co-
expressing cytochrome b5. Lanes 2, 4: CYP2C18 protein expressed from cells 
that did not co-express cytochrome b5. The expected size of CYP2C18 protein 
is 55.9 kDa. The blot was probed by a human CYP2C18 specific monoclonal 





3.9 Cloning of CYP1A2_yc gene in the episomal 
plasmid pSY263 for expression of human 
CYP1A2 enzyme 
 
3.9.1 Cloning of CYP1A2_yc gene in the episomal plasmid 
pSY263 
 
CYP1A2 is another CYP enzyme which is used for Drug Metabolism studies in the 
process of drug development (Zanger et al., 2013). The human CYP1A2_yc gene, with 
yeast biased codons, was cloned in the yeast expression vector pSYE263 using 
methodologies similar to cloning of the CYP3A4_yc gene in the same vector (this Chapter, 
Section 3.4.1). The resultant plasmid was named pSYE263/h_CYP1A2_yc.  
A 1563 bp BamHI-XhoI CYP1A2_yc gene fragment (Figure 3.31) was isolated from the 
plasmid pUC57/BamHI-XhoI/h_CYP1A2_yc for DNA ligase mediated ligation to the 
5711 bp BamHI-XhoI fragment of vector pSYE263, to create the episomal, 2µ-plasmid 
pSYE263/h_CYP1A2_yc (Figure 3.32) for expression of human CYP1A2 enzyme.  
 
1563bp-
Lanes      1           2          3  
 
Figure 3.31. An agarose gel that shows the fractionation of DNA fragments 
obtained after digestion of the plasmid pUC57/BamHI-XhoI/h_CYP1A2_yc 
with enzymes BamHI and Xhol. Lane 1, DNA ladder of DNA fragments with 
known molecular weight; lanes 2 and 3, pUC57/BamHI- Xhol/h_CYP1A2_yc 
digested with BamHI, Xhol. The lower 1488 bp band (from lane 2) was isolated 
from the gel for further ligation with the vector pSYE263, digested with BamHI 





Figure 3.32. The map of plasmid pSYE263/h_CYP1A2_yc, with restriction sites 
that occur in the plasmid only once. The BamHI and XhoI sites of pSYE263 were 
used for cloning the synthetic h_CYP1A2_yc gene with yeast biased codons, in 
the episomal, 2µ-plasmid pSYE263. 
 
After ligation and transformation of the ligation mixture in E. coli DH5α competent cells, 
individual bacterial transformants were grown for preparation of plasmid DNA using the 
alkaline lysis method (Chapter 2, Section 2.4.1.8) 
The authenticity of the resultant plasmid DNA, pSYE263/h_CYP1A2_yc was confirmed 
by digesting with the restriction enzymes (a) BamHI, XhoI and (b) BamHI, XbaI. It was 










































(A) Lanes           1         2        3         4        5
5699bp-
1575bp-
(B) Lanes     1        2        3         4        5
 
Figure 3.33. Agarose gels that show the expected DNA fragments when the 
plasmid pSYE263/h_CYP1A2_yc was digested with restriction enzymes (A) 
BamHI, XhoI and (B) BamHI, XbaI. Lane 1, DNA ladder; lanes 2 to 5, 
pSYE263/h_CYP1A2_yc digested with either BamHI-XhoI (A) or BamHI-XbaI 
(B). 
 
3.9.2 Comparison of CYP1A2 enzyme activities expressed 
by ‘synthesised’ CYP1A2_yc and ‘native’ CYP1A2_na 
genes, both encoded by the episomal plasmid 
pSY263, using a fluorescence-based assay 
 
The results shown in Figure 3.34 (which follows below) indicate that, in the absence of 
cytochrome b5, there is more CYP1A2 protein expressed from the ‘synthesised’ 
CYP1A2_yc gene than from the ‘native’ CYP1A2_na gene. The gene with the yeast biased 
codons should provide mRNA is probably more stable than the mRNA transcribed by the 





Figure 3.34. The graphs show the rate at which the activity of the CYP1A2 
enzyme, expressed in yeast from the ‘synthesised’ CYP1A2_yc gene and the 
‘native’ CYP1A2_na gene (co-expressed with only ∆hRDM but in the absence of 
cytochrome b5), increases over 30 min. Rate was measured in terms of 
relative fluorescence units (RFUs), using 3-cyano-7-ethoxycoumarin (CEC) as 
the substrate. CEC is de-ethylated by CYP1A2 to form 3-cyano7-




The graphs (Figure 3.34) show the rate at which the activity of the CYP1A2 enzyme, 
expressed from the ‘synthesised’ CYP1A2_yc gene, increases over 30 min (purple) is 
faster than the rate of the enzyme expressed from the native gene CYP1A2_na (red). The 
results in Figure 3.34 also indicate that there is more protein expressed from the 
‘synthesized’ CYP1A2_yc gene than that from the ‘native’ CYP1A2_na gene when 












Comparison of CYP1A2 enzyme activities obtained from 
'synthesised' CYP1A2_yc geneand that obtained from the 







Figure 3.35. (A) The graphs show the increase in rate of activity, over 30 min, 
of the CYP1A2 enzyme expressed in yeast from the ‘synthesised’ CYP1A2_yc 
gene which is co-expressed with ∆hRDM in the presence or absence of 
cytochrome b5. The rates were compared with rate of the enzyme produced 
from the ‘native’ CYP1A2_na gene co-expressed with only ∆hRDM but not 
cytochrome b5. Rate was measured in terms of relative fluorescence units 
(RFUs), using 3-cyano-7-ethoxycoumarin (CEC) as the substrate. CEC is de-
ethylated by CYP1A2 to form 3-cyano7-hdroxycoumarin (CHC). (B) Depicts the 
comparison of fluorescence emitted by the three yeast strains at 30 min of 
reaction of enzyme with substrate. The data represent mean ± S.D. of three 












(A) Comparison of CYP1A2 enzyme activities obtained from 
'synthesised' CYP1A2_yc gene and obtained from the 'native' 

















(B) Comparison of CYP1A2 enzyme activities obtained 
from 'synthesised' CYP1A2_yc gene and obtained from 






The results in Figure 3.35 indicate that in the presence of cytochrome b5, slightly more 
protein is expressed from CYP1A2_yc than in its absence. This may suggest cytochrome 
b5 may provide a protective influence on CYP1A2 protein. This was confirmed by 
performing Western blot analysis (Figure 3.36) on equal number of cells which express 
the variants (‘synthesized’ and ‘native’) of the CYP1A2 gene.  
 
Lanes     1        2       3 
60 kDa–
 
Figure 3.36. Western blot that shows the amounts of CYP1A2 protein which is 
expressed by equal number of cells (1X 106) from different yeast strains. The 
amount of total cellular protein obtained from these cells was loaded on wells 
of an SDS polyacrylamide gel. Cells which contain pSYE263/CYP1A2_yc + 
cytochrome b5 (lane 1), only pSYE263/CYP1A2_yc – cytochrome b5 (lane 2), 
and only pSYE263/CYP1A2_na – cytochrome b5 (lane 3). The expected size of 
CYP1A2 protein is 58.4 kDa. The blot was probed by a human CYP1A2 specific 
monoclonal antibody (Santa Cruz Biotechnology, sc-30085).  
 
The results shown in Figure 3.36 indicate that the CYP1A2_yc gene, when co-expressed 
with cytochrome b5, produces slightly more CYP1A2 protein than when it is expressed 
in its absence (compare lanes 1 & 2, Figure 3.36). Densitometric quantification (results 
not shown) shows that there is 50% more CYP1A2 protein, in the presence of cytochrome 






3.10 Cloning of four CYP2D6_yc variant genes [three 
bearing single nucleotide polymorphisms 
(SNPs)] and one the Val374 variant in the 
episomal plasmid pSY263 for expression of 
human CYP2D6 variant enzymes 
 
3.10.1 Cloning of CYP2D6_yc gene in the episomal plasmid 
pSY263 
 
Like CYP3A4, CYP2D6 is one of the major CYP enzymes which is widely used for Drug 
Metabolism studies in the process of drug development (Zanger et al., 2013). The human 
CYP2D6_yc gene variants, all synthesized with yeast biased codons, were cloned in the 
yeast expression vector pSYE263 using methodologies similar to cloning of the 
CYP3A4_yc gene in the same vector (this Chapter, Section 3.4.1). The resultant plasmids 
had the following names:  
(a) pSYE263/h_CYP2D6(1)_yc (bearing Met374Val mutant), 
(b) pSYE263/h_CYP2D6*2_yc (bearing the Arg296Cys; Ser486Thr mutant), 
(c) pSYE263/h_CYP2D6*10_yc (bearing the Pro34Ser; Ser486Thr mutant), 
(d) pSYE263/h_CYP2D6*39_yc (bearing the Ser486Thr mutant). 
1506 bp BamHI-XhoI CYP2D6_yc gene fragments [a typical example is provided in 
Figure 3.37 using the h_CYP2D6(1)_yc gene] were isolated from pUC57 based plasmids. 
A 1506 bp BamHI-XhoI CYP2D6(1)_yc (Figure 3.37) fragment from one such plasmid 
pUC57/BamHI-XhoI/h_CYP2D6(1)_yc was ligated to the 5711 bp BamHI-XhoI 
pSYE263 vector fragment, to create the episomal, 2µ-plasmid 
189 
 
pSYE263/h_CYP2D6(1)_yc (Figure 3.38) for expression of human CYP2D6(1) [Val374] 
enzyme. Similar approaches were taken to create expression plasmids for the other 
CYP2D6 variant genes. 
 
1506bp-
Lanes         1       2
 
Figure 3.37. An agarose gel that shows the 1506 bp gene insert fragment that 
was isolated from the plasmid pUC57/BamHI-Xhol/h_CYP2D6(1)_yc after 
digestion with enzymes BamHI-Xhol (lane 2). The fragment was isolated for 
ligation to the pSYE263, vector which had already been digested with BamHI-
Xhol, to obtain the plasmid pSYE263/h_CYP2D6(1)_yc. DNA ladder showing 
DNA fragments with defined base pairs. 
 
 
Figure 3.38. The map of plasmid pSYE263/h_CYP2D6(1)_yc, with restriction 
sites that occur in the plasmid only once. The BamHI and XhoI sites of the 
episomal, 2µ-plasmid pSYE263 were used for cloning the synthetic 










































The authenticity of the resultant plasmid, pSYE263/ BamHI-Xhol/h_CYP2D6(1)_yc was 
confirmed by two sets of digestions (A) with BamHI, Xhol and (B) with BamHI, XbaI 
restriction enzymes (Figure 3.39).  
 





(B) Lanes     1        2       3      4     5
 
Figure3.39. Agarose gels that show the expected DNA fragments when the 
plasmid pSYE263/h_CYP2D6(1)_yc was digested with restriction enzymes (A) 
BamHI, XhoI and (B) BamHI, XbaI. Lane 1, DNA ladder; lanes 2 to 5, 
pSYE263/h_CYP2B6_yc digested with either BamHI-XhoI (A) or BamHI-XbaI 
(B). 
 







3.10.2 Comparison of CYP2D6 enzyme activities expressed 
by ‘synthesised’ CYP2D6_yc mutant genes, all genes 
encoded by the episomal plasmid pSY263, using 
fluorescence-based assays 
 
The results shown in Figures 3.40 to 3.43 (which follow below) indicate that, in the 
absence of cytochrome b5, there is more CYPD6 protein expressed from the ‘synthetic’ 
CYP2D6_yc genes (coding for the three different SNPs and the Val374 mutant) than from 
the ‘native’ CYP2D6_na gene. All genes with the yeast biased codons should provide 
more mRNA because they are more stable than the mRNA transcribed by the ‘native’ 
gene and thereby should produce more protein, provided there is no translational block 
because of the structure of the mRNA.  
 
  
Figure 3.40. The graph compares the rate of reactions of (a) CYP2D6*39 
enzyme expressed from a synthetic gene consisting of yeast biased codons, 
and (b) CYP2D6_na enzyme expressed from the native CYP2D6 cDNA isolated 
from the human liver cDNA library. 7-ethoxymethoxy-3-cyanocoumarin 
(EOMCC) was used as substrate. EOMCC is converted to the fluorescent 
product 7-hydroxy-3-cyanocoumarin (HCC) upon reaction with CYP2D6. Rate 
was measured, over 30 min, in terms of relative fluorescence units (RFUs). The 














Comparison of enzyme activities obtained from 'native' 
CYP2D6_na gene and that obtained from the 'synthesised' 




Both the ‘synthesised’ CYP2D6*39_yc and the native CYP2D6_na genes were co-
expressed with the modified human CPR gene, ∆hRDM, but in the absence of cytochrome 
b5. The results in Figure 3.40 above show that the ‘native’ CYP2D6_na gene when 
expressed in yeast, possesses relatively lower activity (blue) than the gene encoding SNP 
*39 (Ton et al., 2004).  
 
 
Figure 3.41. The graph compares the rate of reactions of (a) CYP2D6*10 
enzyme expressed from a synthetic gene consisting of yeast biased codons, 
and (b) CYP2D6_na enzyme expressed from the native CYP2D6 cDNA isolated 
from the human liver cDNA library. 7-ethoxymethoxy-3-cyanocoumarin 
(EOMCC) was used as substrate. EOMCC is converted to the fluorescent 
product 7-hydroxy-3-cyanocoumarin (HCC) upon reaction with CYP2D6. Rate 
was measured, over 30 min, in terms of relative fluorescence units (RFUs). The 
data represent mean ± S.D. of three independent experiments.  
 
 
Both the ‘synthesised’ CYP2D6*10_yc and the native CYP2D6_na genes were co-













Comparison of enzyme activities obtained from 'native' 
CYP2D6_na gene and that obtained from the 





results in Figure 3.41 indicate that the ‘native’ CYP2D6_na gene when expressed in yeast, 
is produced much less (blue) than the gene encoding SNP *10 (Ton et al., 2004).  
 
 
Figure 3.42. The graph compares the rate of reactions of (a) CYP2D6*2 enzyme 
expressed from a synthetic gene consisting of yeast biased codons, and (b) 
CYP2D6_na enzyme expressed from the native CYP2D6 cDNA isolated from the 
human liver cDNA library. 7-ethoxymethoxy-3-cyanocoumarin (EOMCC) was 
used as substrate. EOMCC is converted to the fluorescent product 7-hydroxy-
3-cyanocoumarin (HCC) upon reaction with CYP2D6. Rate was measured, over 
30 min, in terms of relative fluorescence units (RFUs). The data represent 
mean ± S.D. of three independent experiments.  
 
 
Both the ‘synthesised’ CYP2D6*2_yc and the native CYP2D6_na genes were co-
expressed only with the modified human CPR gene, ∆hRDM, without any cytochrome 
b5. The results in Figure 3.42 reveal that the ‘native’ CYP2D6_na gene when expressed 














Comparison of enzyme activities obtained from 'native' 
CYP2D6_na gene and that obtained from the 






Figure 3.43. The graph compares the rate of reactions of (a) CYP2D6(1) 
enzyme expressed from a synthetic gene consisting of yeast biased codons, 
and (b) CYP2D6_na enzyme expressed from the native CYP2D6 cDNA isolated 
from the human liver cDNA library. 7-ethoxymethoxy-3-cyanocoumarin 
(EOMCC) was used as substrate. EOMCC is converted to the fluorescent 
product 7-hydroxy-3-cyanocoumarin (HCC) upon reaction with CYP2D6. Rate 
was measured, over 30 min, in terms of relative fluorescence units (RFUs). The 
data represent mean ± S.D. of three independent experiments.  
 
 
Both the ‘synthesised’ CYP2D6(1)_yc and the native CYP2D6_na genes were co-
expressed only with the modified human CPR gene, ∆hRDM, but without any cytochrome 
b5. The results in Figure 3.43 show that the ‘native’ CYP2D6_na gene when expressed 
in yeast is produced less (blue) than the CYP2D6 gene coding for the Val374 variant (Ton 
et al., 2004).  
In the results from Figures 3.40 to 3.44, it has been assumed that the enzyme activities 












Comparison of enzyme activities obtained from 'native' 
CYP2D6_na gene and that obtained from the 'synthesised' 







Figure 3.44. Comparison of activities of CYP2D6 enzyme, after 30 min of 
reaction obtained from (a) CYP2D6_na, (b) CYP2D6(1)_yc, (c) CYP2D6*2_yc, (d) 
CYP2D6*10_yc, and (e) CYP2D6*39_yc genes in strains derived from the yeast 
strain YY7. The bar plot compares the fluorescence emitted by 7-hydroxy-3-
cyanocoumarin (HCC) after 30 min of reaction of CYP2D6 enzymes with 7-
ethoxymethoxy-3-cyanocoumarin (EOMCC). The data represent mean ± S.D. of 
three independent experiments.  
 
 
The results in Figure 3.44 would again indicate that there is more protein expressed from 
all the ‘synthesized’ CYP2D6_yc genes than from the ‘native’ CYP2D6_na gene because, 
as would be expected the gene with the yeast biased codons would provide more stable 
mRNA molecules (i.e. more stable mRNA relative to what would be transcribed from the 
‘native’ gene) which would translate to more protein (relative to what would be produced 
















Comparison of enzyme activities obtained from the 
'native' CYP2D6 gene and that obtained from the 
'synthesised' variant CYP2D6 genes synthesized with 








equal number of cells that express the variants (‘synthesized’ and ‘native’) of the CYP2D6 
gene. 
 
Lanes       1         2       3        4         5 
60 kDa–
 
Figure 3.45. A Western blot which shows the CYP2D6 protein that is being 
expressed by equal number of cells (1X 106) from yeast strains that contain an 
episomal plasmid that bears ‘chemically synthesized’ genes CYP2D6*10 (lane 
1), CYP2D6*2 (lane 2), CYP2D6*39 (lane 3), CYP2D6(1) [i.e. CYP2D6(Val374); 
lane 4], and ‘native’ CYP2D6_na (lane 5). The expected size of CYP2D6 protein 
is 55.8 kDa. The blot was probed by a human CYP2D6 specific monoclonal 
antibody (Santa Cruz Biotechnology, Cat no: sc130366). 
 
The results shown in Figure 3.45 indicate that all the CYP2D6_yc genes produce similar 
amounts of CYP2D6 protein which is higher than that produced by the CYP2D6_na gene. 





3.11 Cloning of CYP2E1_yc gene in the episomal 
plasmid pSY263 for expression of human 
CYP2E1 enzyme 
 
3.11.1 Cloning of CYP2E1_yc gene in the episomal plasmid 
pSY263 
 
CYP2E1 is another one of the CYP enzymes which is used for Drug Metabolism studies 
during the process of drug development (Zanger et al., 2013). The human CYP2E1_yc 
gene, with yeast biased codons, was cloned in the yeast expression vector pSYE263 using 
methodologies similar to cloning of the CYP3A4_yc gene in the same vector (this Chapter, 
Section 3.4.1). The resultant plasmid was named pSYE263/h_CYP2E1_yc.  
A 1494 bp BamHI-XhoI CYP2E1_yc gene fragment (Figure 3.46) was isolated from the 
plasmid pUC57/BamHI-XhoI/h_CYP2E1_yc for DNA ligase mediated ligation to the 
5711 bp BamHI-XhoI fragment of vector pSYE263, to create the episomal, 2µ-plasmid 
pSYE263/h_CYP2E1_yc (Figure 3.47) for expression of human CYP2E1 enzyme.  
 
1494 bp–
Lanes   1   2        3             4
 
Figure 3.46. An agarose gel that shows the expected DNA fragments when 
plasmid pUC57/BamHI-Xhol/h_CYP2E1_yc was digested with enzymes BamHI 
and Xhol (lanes 2, 3, 4). The lower 1494 bp insert fragment (lanes 3 and 4) was 
ligated to the vector pSYE263 already digested with BamHI and Xhol to obtain 
the plasmid pSYE263/h_CYP2E1_yc. Lane 1, DNA ladder showing DNA bands of 





Figure 3.47. The map of the plasmid pSYE263/h_CYP2E1_yc, with restriction 
sites that occur in the plasmid only once. The BamHI and XhoI sites of pSYE263 
were used for cloning the synthetic h_CYP2E1_yc gene with yeast biased 
codons, in the episomal 2µ-plasmid pSYE263. 
 
After ligation and transformation of the ligation mixture in E. coli DH5α competent cells, 
individual bacterial transformants were grown for preparation of plasmid DNA using the 
alkaline lysis method (Chapter 2, Section 2.4.1.8). 
The authenticity of the resultant plasmid DNA, pSYE263/h_CYP2E1_yc was confirmed 
by two separate digests with restriction enzymes (a) BamHI, XhoI and (b) PvuII. It was 
verified that the newly constructed plasmid contained the correct size fragments (e.g. 










































(A) Lanes    1    2    3    4    5
7201 bp–
(B) Lanes    1    2    3    4    5
 
Figure 3.48. Agarose gels that show the expected DNA fragments when the 
plasmid pSYE263/h_CYP2E1_yc was digested with restriction enzymes (A) 
BamHI, XhoI and (B) PvuII. Lane 1, DNA ladder; lanes 2 to 5, 






3.11.2 Comparison of CYP2E1 enzyme activities expressed 
by ‘synthesised’ CYP2E1_yc and ‘native’ CYP2E1_na 
genes, both encoded by the episomal plasmid 
pSY263, using a fluorescence-based assay 
 
 
Figure 3.49. (A) The graphs show the rate at which the activity of the CYP2E1 
enzyme, expressed in yeast strain YAB79 from the ‘synthesised’ CYP2E1_yc 
gene and the ‘native’ CYP2E1_na gene (co-expressed with ∆hRDM and 
cytochrome b5 genes), increases over 30 min. Rate was measured in terms of 
relative fluorescence units (RFUs), using 7-ethoxymethoxy-3-cyanocumarin 
(EOMCC) as substrate. EOMCC is de-ethylated by CYP2E1 to form 7-hydroxy-3-
cyanocoumarin. (B) Depicts the comparison of fluorescence emitted by the 
two yeast strains at 30 min of reaction of enzyme with substrate. The data 











(A) Comparison of enzyme activities obtained from 
'synthesised' CYP2E1_yc gene and that obtained from 



















(B) Comparison of enzyme activities obtained from 'synthesised' 
CYP2E1_yc gene and that obtained from CYP2E1_na 'native' gene; 





The results shown in Figure 3.49 (above) indicate that the ‘synthesised’ CYP2E1_yc gene 
produces more CYP2E1 enzyme than the ‘native’ CYP2E1_na gene. Once again the 
results prove that the yeast biased codons are providing more mRNA because it is more 
stable than the mRNA transcribed by the ‘native’. Hence, CYP2E1_yc gene is producing 
more protein.  
That the mRNA derived from yeast biased codons CYP2E1 coding sequence translates to 
more protein, relative to what is produced by the ‘native’ mRNA, was confirmed by 
Western blotting, using equal number of cells (1X 106), that express the two variant 
CYP2E1 genes, ‘synthesised’ and ‘native’ (Figure 3.50). Densitometric quantification 
(results not shown) suggests that ~4 times more protein is produced by CYP2E1_yc gene 
than by the native CYP2E1_na gene isolated from a human liver cDNA library. 
 
Lanes      1        2
60 kDa–
 
Figure 3.50. Western blot that shows the amounts of CYP2E1 protein being 
expressed by equal number of cells (1X 106) from different yeast strains. Lane 
1: protein from cells which contain the plasmid pSYE263/CYP2E1_na (lane 1); 
lane 2: protein from cells which contain the plasmid pSYE263/CYP2E1_yc 
(lane 2). The expected size of CYP2E1 protein is 56.9 kDa. The blot was probed 
by a human CYP2E1 specific monoclonal antibody (Santa Cruz Biotechnology, 





3.12 Cloning of CYP2A6_yc gene in the episomal 
plasmid pSY263 for expression of human 
CYP2A6 enzyme 
 
3.12.1 Cloning of CYP2A6_yc gene in the episomal plasmid 
pSY263 
 
CYP2A6 is the ninth CYP enzyme which has been cloned during the work conducted for 
this thesis. As pointed out earlier there are ten to twelve CYP enzymes which are 
commonly used for Drug Metabolism studies in the process of drug development, 
CYP2A6 being one of them (Zanger et al., 2013). The human CYP2A6_yc gene, with 
yeast biased codons, was cloned in the yeast expression vector pSYE263 using 
methodologies similar to cloning of the CYP3A4_yc gene in the same vector (this Chapter, 
Section 3.4.1). The resultant plasmid was named pSYE263/h_CYP2A6_yc.  
A 1497 bp BamHI-XhoI CYP2A6_yc gene fragment (Figure 3.51) was isolated from the 
plasmid pUC57/BamHI-XhoI/h_CYP2A6_yc for DNA ligase mediated ligation to the 
5711 bp BamHI-XhoI fragment of vector pSYE263, to create the episomal, 2µ-plasmid 






Lanes           1                   2
 
Figure 3.51. An agarose gel that shows the expected DNA fragments when the 
plasmid pUC57/BamHI-Xhol/h_CYP2A6_yc was digested with BamHI and Xhol 
(lane 2). The 1497 bp insert fragment was isolated from the gel and ligated to 
the pSYE263 vector which had also been digested with BamHI and Xhol to 
obtain the plasmid pSYE263/h_CYP2A6_yc. Lane 1, DNA ladder with DNA 
fragments with defined base pairs. 
 
 
Figure 3.52. The map of the plasmid pSYE263/h_CYP2A6_yc, with restriction 
sites that occur in the plasmid only once. The BamHI and XhoI sites of pSYE263 
were used for cloning the synthetic h_CYP2A6_yc gene with yeast biased 










































After ligation and transformation of the ligation mixture in E. coli DH5α competent cells, 
individual bacterial transformants were grown for preparation of plasmid DNA using the 
alkaline lysis method (Chapter 2, Section 2.4.1.8). 
The authenticity of the resultant plasmid DNA, pSYE263/h_CYP2A6_yc was confirmed 
by two separate digests with restriction enzymes (a) BamHI, XhoI and (b) BamHI, XbaI. 
It was verified that the newly constructed plasmid contained the correct size fragments 




(A) Lanes     1      2       3         4          5
5699 bp–
1509 bp–
(B) Lanes     1      2       3         4        5
 
Figure 3.53. Agarose gels that show the expected DNA fragments when the 
plasmid pSYE263/h_CYP2A6_yc was digested with restriction enzymes (A) 
BamHI, XhoI and (B) BamHI, XbaI. Lane 1, DNA ladder; lanes 2 to 5, 







3.12.2 Comparison of CYP2A6 enzyme activities expressed 
by ‘synthesised’ CYP2A6_yc and ‘native’ CYP2A6_na 
genes, both encoded by the episomal plasmid 
pSY263, using a fluorescence-based assay 
 
 
Figure 3.54. (A) The graphs show the rate at which the activity of the CYP2A6 
enzyme, expressed in yeast strain YAB79 from the ‘synthesised’ CYP2A6_yc 
gene and the ‘native’ CYP2A6_na gene (co-expressed with ∆hRDM and 
cytochrome b5 genes), increases over 30 min. Rate was measured in terms of 
relative fluorescence units (RFUs) using 7-methoxy-3-cyanocoumarin (CMC) 
as substrate. CMC is de-ethylated by CYP2A6 to form 7-hydroxy-3-
cyanocoumarin (HCC). (B) Depicts the comparison of fluorescence emitted by 
the three yeast strains at 30 min of reaction of enzyme with substrate. The 










(A) Comparison of CYP2A6 enzyme activities obtained from 'native' 
CPY2A6_na gene and that obtained from 'synthetic' CYP2A6_yc


















(B) Comparison of CYP2A6 enzyme activities obtained from 'native' 
CPY2A6_na gene and that obtained from 'synthetic' CYP2A6_yc






The results shown in Figure 3.54 (above) indicate that the ‘synthesised’ CYP2A6_yc gene 
produces much more CYP2A6 enzyme than the ‘native’ CYP2A6_na gene. Since the gene 
with the yeast biased codons should provide mRNA more stable than the mRNA 
transcribed by the ‘native’ gene, production of more protein from the synthetic gene was 
expected.  
The mRNA derived from yeast biased codons CYP2A6 coding sequence should translate 
to more protein relative to what would be produced by the ‘native’ mRNA. This was 
confirmed by Western blotting, using equal number of cells (1X 106), that express the 
two variants, ‘synthesised’ and ‘native’, of the CYP2A6 gene (Figure 3.55). 
Densitometric quantification (results not shown) suggests that at least 10 times more 
protein is produced by CYP2A6_yc gene than by the native CYP2A6_na gene isolated 
from a human liver cDNA library. 
 
Lanes     1        2 
60 kDa–
 
Figure 3.55. Western blot that shows the amounts of CYP2A6 protein being 
expressed by equal number of cells (1X 106) from different yeast strains. Lane 
1: protein from cells which contain the plasmid pSYE263/CYP2A6_na (lane 1); 
lane 2: protein from cells which contain the plasmid pSYE263/CYP2A6_yc 
(lane 2). The expected size of CYP2A6 protein is 56.5 kDa. The blot was probed 
by a human CYP2A6 specific monoclonal antibody (Santa Cruz Biotechnology, 




3.13 Cloning of CYP2C8_yc gene in the episomal 
plasmid pSY263 for expression of human 
CYP2C8 enzyme 
 
3.13.1 Cloning of CYP2C8_yc gene in the episomal plasmid 
pSY263 
 
CYP2C8 is the tenth CYP enzyme which was cloned during the work conducted for this 
thesis. As pointed out earlier there are ten main CYP enzymes which are commonly used 
for Drug Metabolism studies in the process of drug development. This is the tenth enzyme 
in that list of enzymes ((Zhang et al., 2013)). The human CYP2C8_yc gene, with yeast 
biased codons, was cloned in the yeast expression vector pSYE263 using methodologies 
similar to cloning of the CYP2C8_yc gene in the same vector (this Chapter, Section 3.4.1). 
The resultant plasmid was named pSYE263/h_CYP2C8_yc.  
A 1485 bp BamHI-XhoI CYP2C8_yc gene fragment (Figure 3.56) was isolated from the 
plasmid pUC57/BamHI-XhoI/h_CYP2C8_yc for DNA ligase mediated ligation to the 
5711 bp BamHI-XhoI fragment of vector pSYE263, to create the episomal, 2µ-plasmid 








Lanes      1         2          3
 
Figure 3.56. An agarose gel that shows the expected DNA fragments when the 
plasmid pUC57/BamHI-Xhol/h_CYPC8_yc was digested with BamHI and Xhol. 
The 1485 bp insert fragment was isolated from the gel and ligated to the 
pSYE263 vector which had also been digested with BamHI and Xhol to obtain 
the plasmid pSYE263/h_CYPC8_yc.  
 
 
Figure 3.57. The map of the plasmid pSYE263/h_CYP2C8_yc, with restriction 
sites that occur in the plasmid only once. The BamHI and XhoI sites of pSYE263 
were used for cloning the synthetic h_CYP2C8_yc gene with yeast biased 











































After ligation and transformation of the ligation mixture in E. coli DH5α competent cells, 
individual bacterial transformants were grown for preparation of plasmid DNA using the 
alkaline lysis method (Chapter 2, Section 2.4.1.8). 
The authenticity of the resultant plasmid DNA, pSYE263/h_CYP2C8_yc was confirmed 
by digestion with restriction enzymes BamHI, XhoI. It was verified that the newly 
constructed plasmid contained the correct size gene insert fragment (e.g. 1485 bp BamHI, 




Lanes     1      2                   3                     4
 
Figure 3.58. An agarose gel that shows the expected DNA fragments when the 
plasmid pSYE263/BamHI-Xhol/h_CYP2C8_yc was digested with BamHI and 
XhoI restriction enzymes (lanes 2, 3, 4). The 1485 bp gene insert fragment was 
isolated from the gel and ligated with the pSYE263 vector which had been 
digested with BamHI and XhoI to obtain the plasmid pSYE263/ h_CYP2C8_yc. 





3.13.2 Comparison of CYP2C8 enzyme activities expressed 
by ‘synthesised’ CYP2C8_yc and ‘native’ CYP2C8_na 
genes, both encoded by the episomal plasmid 




Figure 3.59. (A) The graphs show the rate at which the activity of the CYP2C8 
enzyme, expressed in yeast strain YAB79 from the ‘synthesised’ CYP2C8_yc 
gene and the ‘native’ CYP2C8_na gene (co-expressed with ∆hRDM and 
cytochrome b5 genes), increases over 30 min. Rate was measured in terms of 
relative fluorescence units (RFUs) using 7-ethoxymethoxy-3-cyanocoumarin 
(EOMCC) was used as substrate. EOMCC is de-ethylated to the fluorescent 
product 7-hydroxy-3-cyanocoumarin (HCC) upon reaction with CYP2C8. (B) 
Depicts the comparison of fluorescence emitted by the two yeast strains at 30 
min of reaction of enzyme with substrate. The data represent mean ± S.D. of 













(A) Comparison of CYP2C8 enzyme activities obtained 

















(B) Comparison of CYP2C8 enzyme activities obtained 






The results shown in Figure 3.59 (above) indicate that the ‘synthesised’ CYP2C8_yc gene 
produces a lot more CYP2C8 enzyme than the ‘native’ CYP2C8_na gene in YAB79 
derived strains. Since the gene with the yeast biased codons should provide mRNA more 
stable than the mRNA transcribed by the ‘native’ gene, production of more protein from 
the synthetic gene was expected.  
The mRNA derived from yeast biased codons CYP2C8 coding sequence should translate 
to more protein relative to what would be produced by the ‘native’ mRNA. This was 
confirmed by Western blotting, using equal number of cells (1X 106), that express the 
two variants, ‘synthesised’ and ‘native’, of the CYP2C8 gene (Figure 3.60). 
Densitometric quantification (results not shown) suggests that at least 6 times more 
protein is produced by CYP2C8_yc gene than by the native CYP2C8_na gene isolated 
from a human liver cDNA library. 
 
Lanes     1          2 
60 kDa–
 
Figure 3.60. Western blot that shows the amounts of CYP2C8 protein being 
expressed by equal number of cells (1X 106) from different yeast strains. Lane 
1: protein from cells which contain the plasmid pSYE263/CYP2C8_na (lane 1); 
lane 2: protein from cells which contain the plasmid pSYE263/CYP2C8_yc 
(lane 2). The expected size of CYP2C8 protein is 55.8 kDa. The blot was probed 
by a human CYP2C8 specific monoclonal antibody (Santa Cruz Biotechnology, 





3.14 Cloning of CYP1A1_yc gene in the episomal 
plasmid pSY263 for expression of human 
CYP1A1 enzyme 
 
3.14.1 Cloning of CYP1A1_yc gene in the episomal plasmid 
pSY263 
 
CYP1A1 is another CYP enzyme whose gene was cloned during the work conducted for 
this thesis. Only recently it has been pointed out that CYP1A1 has a role in drug 
metabolism. Moreover is a target for finding anticancer agents that can act as chemo-
preventives. Some new chemical scaffolds have been identified by our group (where I 
was part of the discovery) using CYP1A1 microsomal enzyme produced in yeast (Mohd 
Siddique et al., 2016). This is the eleventh enzyme in that list of enzymes that was cloned 
for the work described in this thesis.  
The human CYP1A1_yc gene, with yeast biased codons, was cloned in the yeast 
expression vector pSYE263 using methodologies similar to cloning of the CYP3A4_yc 
gene in the same vector (this Chapter, Section 3.4.1). The resultant plasmid was named 
pSYE263/h_CYP1A1_yc.  
A 1551 bp BamHI-XhoI CYP1A1_yc gene fragment (Figure 3.61) was isolated from the 
plasmid pUC57/BamHI-XhoI/h_CYP1A1_yc for DNA ligase mediated ligation to the 
5711 bp BamHI-XhoI fragment of vector pSYE263, to create the episomal, 2µ-plasmid 







Lanes      1               2                3
 
Figure 3.61. An agarose gel that shows the expected DNA fragments when the 
plasmid pUC57/BamHI-Xhol/h_CYP1A1_yc was digested with BamHI and XhoI 
(lanes 2, 3). The 1551 bp gene insert fragment was isolated from the gel and ligated 
to the vector pSYE263 already digested with BamHI and XhoI to obtain the 
plasmid pSYE263/h_CYP1A1_yc. Lane 1, DNA ladder with DNA fragments with 
defined base pairs.  
 
 
Figure 3.62. The map of the plasmid pSYE263/h_CYP1A1_yc, with restriction 
sites that occur in the plasmid only once. The BamHI and XhoI sites of pSYE263 
were used for cloning the synthetic h_CYP1A1_yc gene with yeast biased 











































After ligation and transformation of the ligation mixture in E. coli DH5α competent cells, 
individual bacterial transformants were grown for preparation of plasmid DNA using the 
alkaline lysis method (Chapter 2, Section 2.4.1.8). 
The authenticity of the resultant plasmid DNA, pSYE263/h_CYP1A1_yc was confirmed 
by two separate digests with restriction enzymes (a) BamHI, XhoI and (b) BamHI, XbaI. 
It was verified that the newly constructed plasmid contained the correct size fragments 




(A) Lanes    1       2      3      4      5
5699 bp–
1656 bp–
(B) Lanes    1         2        3        4        5
 
Figure 3.63. Agarose gels that show the expected DNA fragments when the 
plasmid pSYE263/h_CYP1A1_yc was digested with restriction enzymes (A) 
BamHI, XhoI and (B) BamHI, XbaI. Lane 1, DNA ladder; lanes 2 to 5, 






3.14.2 Comparison of CYP1A1 enzyme activities expressed 
by ‘synthesised’ CYP1A1_yc and ‘native’ CYP1A1_na 
genes, both encoded by the episomal plasmid 
pSY263, using a fluorescence-based assay 
 
 
Figure 3.64. (A) The graphs show the rate at which the activity of the CYP1A1 
enzyme, expressed in yeast strain YY7 from the ‘synthesised’ CYP1A1_yc gene 
and the ‘native’ CYP1A1_na gene (co-expressed with only ∆hRDM gene), 
increases over 16 min. Rate was measured in terms of relative fluorescence 
units (RFUs) using 7-ethoxy resorufin (7-ER) as substrate. 7-ER is de-ethylated 
by CYP1A1 to form resorufin. (B) Depicts the comparison of fluorescence 
emitted by the three yeast strains at 16 min of reaction of enzyme with 












(A) Comparison of CYP1A1 enzyme activities obtained from 'native' 
CPY1A1_na gene and that obtained from 'synthetic' CYP1A1_yc















(B) Comparison of CYP1A1 enzyme activities obtained from 'native' 
CPY1A1_na gene and that obtained from 'synthetic' CYP1A1_yc gene, 






The results shown in Figure 3.64 (above) indicate that the ‘synthesised’ CYP1A1_yc gene 
produces much more CYP1A1 enzyme than the ‘native’ CYP1A1_na gene in YY7 
derived yeast strains. Since the gene with the yeast biased codons should provide mRNA 
more stable than the mRNA transcribed by the ‘native’ gene, production of more protein 
from the synthetic gene was expected.  
The mRNA derived from yeast biased codons CYP1A1 coding sequence again did 
transcribe/translate to more protein relative to what was produced by the ‘native’ mRNA. 
This was confirmed by Western blotting, using equal number of cells (1X 106), that 
express the two variants, ‘synthesised’ and ‘native’, of the CYP1A1 gene (Figure 3.65). 
Densitometric quantification (results not shown) suggests that ~2 times more protein is 
produced by CYP1A1_yc gene than by the native CYP1A1_na gene isolated from a human 
liver cDNA library. 
 
Lanes             1         2 
60 kDa–
 
Figure 3.65. Western blot that shows the amounts of CYP1A1 protein being 
expressed by equal number of cells (1X 106) from different yeast strains. Lane 
1: protein from cells which contain the plasmid pSYE263/CYP1A1_na (lane 1); 
lane 2: protein from cells which contain the plasmid pSYE263/CYP1A1_yc 
(lane 2). The expected size of CYP1A1 protein is 58.2 kDa. The blot was probed 
by a human CYP1A1 specific monoclonal antibody (Santa Cruz Biotechnology, 





3.15 Cloning of CYP1B1_yc gene in the episomal 
plasmid pSY263 for expression of human 
CYP1B1 enzyme 
 
3.15.1 Cloning of CYP1B1_yc gene in the episomal plasmid 
pSY263 
 
Like CYP1A1, CYP1B1 is considered a target for finding novel anticancer agents. It has 
been suggested that CYP1B1 inhibitors can have a role in the prevention of hormone 
dependent cancers related to the breast and prostate (Mohd et al., 2016; a publication from 
our group). The human CYP1B1 gene was cloned for expression in yeast. Some 
interesting chemical scaffolds have been identified by our group using CYP1B1 
microsomal enzyme produced in yeast (Horley et al., 2017; another publication from our 
group). This is the twelfth enzyme in the list of enzymes that was cloned for the work 
described in this thesis.  
The human CYP1B1_yc gene, with yeast biased codons, was cloned in the yeast 
expression vector pSYE263 using methodologies similar to cloning of the CYP3A4_yc 
gene in the same pSYE263 vector (this Chapter, Section 3.4.1). The resultant plasmid 
was named pSYE263/h_CYP1B1_yc.  
A 1563 bp BamHI-XhoI CYP1B1_yc gene fragment (Figure 3.66) was isolated from the 
plasmid pUC57/BamHI-XhoI/h_CYP1B1_yc for DNA ligase mediated ligation to the 
5711 bp BamHI-XhoI fragment of vector pSYE263, to create the episomal, 2µ-plasmid 







Lanes     1      2      3      4      5      6
 
Figure 3.66. An agarose gel that shows the expected DNA fragments when the 
plasmid pSYE263/BamHI-Xhol/h_CYP1B1_yc was digested with BamHI and 
Xhol (lanes 2 to 6). The 1563 bp gene insert fragment was isolated from the 
gel and ligated with pSYE263 vector digested with BamHI, Xhol to obtain the 
plasmid pSYE263/h_CYP1B1_yc. Lane 1, DNA ladder showing DNA fragments 
with defined base pairs. 
 
 
Figure 3.67. The map of the plasmid pSYE263/h_CYP1B1_yc, with restriction 
sites that occur in the plasmid only once. The BamHI and XhoI sites of pSYE263 
were used for cloning the synthetic h_CYP1B1_yc gene with yeast biased 










































After ligation and transformation of the ligation mixture in E. coli DH5α competent cells, 
individual bacterial transformants were grown for preparation of plasmid DNA using the 
alkaline lysis method (Chapter 2, Section 2.4.1.8). 
The authenticity of the resultant plasmid DNA, pSYE263/h_CYP1B1_yc was confirmed 
by digestion with restriction enzymes BamHI, XbaI. It was verified that the newly 




Lanes   1       2        3       4      5
 
Figure 3.68. An agarose gel that shows the expected DNA fragments when the 
plasmid pSYE263/BamHI-Xhol/h_CYP1B1_yc was digested with BamHI and 
XbaI restriction enzymes (lanes 2 to 5). Lane 1, DNA ladder. 
 
3.15.2 Comparison of CYP1B1 enzyme activities expressed 
by ‘synthesised’ CYP1B1_yc and ‘native’ CYP1B1_na 
genes, both encoded by the episomal plasmid 
pSY263, using a fluorescence-based assay 
 
The results shown in Figure 3.69 (below) indicate that the ‘synthesised’ CYP1B1_yc gene 
produces a lot more CYP1B1 active enzyme than the ‘native’ CYP1B1_na gene in YY7 
(containing only the modified human CPR, ∆hRDM, gene) derived yeast strains. In the 
case of CYP1B1, the yeast biased codons do provide a far more stable mRNA than the 
mRNA transcribed by the ‘native’ gene. This should also be reflected in the different 





Figure 3.69. (A) The graphs show the rate at which the activity of the CYP1B1 
enzyme, expressed in yeast strain YY7 from the ‘synthesised’ CYP1B1_yc gene 
and the ‘native’ CYP1B1_na gene (co-expressed with only ∆hRDM gene), 
increases over 30 min. Rate was measured in terms of relative fluorescence 
units (RFUs) using 7-ethoxy resorufin (7-ER) as substrate. 7-ER is de-ethylated 
by CYP1A1 to form resorufin. (B) Depicts the comparison of fluorescence 
emitted by the three yeast strains at 30 min of reaction of enzyme with 














(A) Comparison of CYP1B1 enzyme activities obtained from 'native' 
CPY1B1_na gene and that obtained from 'synthetic' CYP1B1_yc





















(B) Comparison of CYP1B1 enzyme activities obtained from 'native' 
CPY1B1_na gene and that obtained from 'synthetic' CYP1B1_yc






Indeed, Western blotting (Figure 3.70) provided confirmation that the mRNA derived 
from CYP1B1 coding sequence, with yeast biased codons, did translate more protein 
relative than what was produced by the ‘native’ mRNA. For this experiment, equal 
number of cells (1X 106), expressing the two variants, ‘synthesised’ and ‘native’, of the 
CYP1B1 gene were taken for lysis of cells. Densitometric quantification (results not 
shown) suggests that at least 15 times more protein is produced by CYP1B1_yc gene than 
by the native CYP1B1_na gene isolated from a human liver cDNA library. 
 
Lanes       1                2 
60 kDa–
 
Figure 3.70. Western blot that shows the amounts of CYP1B1 protein being 
expressed by equal number of cells (1X 106) from different yeast strains. Lane 
1: protein from cells which contain the plasmid pSYE263/CYP1B1_na (lane 1); 
lane 2: protein from cells which contain the plasmid pSYE263/CYP1B1_yc 
(lane 2). The expected size of CYP1B1 protein is 60.8 kDa. The blot was probed 
by a human CYP1B1 specific monoclonal antibody (Santa Cruz Biotechnology, 





3.16 Cloning of CYP4F3A_yc gene in the episomal 
plasmid pSY263 for expression of human 
CYP4F3A enzyme 
 
3.16.1 Cloning of CYP4F3A_yc gene in the episomal plasmid 
pSY263 
 
CYP4F3A is involved in the inactivation leukotriene B4 which is responsible for 
inflammatory responses within the human body that may lead to cancer and many other 
diseases (Kalsotra et al., 2004). It catalyses the omega(ω)-hydroxylation of leukotriene 
B4 to its 20-hydroxy derivative. CYP4F3A belongs to the CYP4 family. Like the other 
twelve main CYPs, members of this family are also responsible for the bio-activation of 
various types of medicines that lead to their elimination from the human body. However, 
they are also involved in the solubilisation of endogenous fatty acids (such as eicosanoids 
derived from arachidonic acid) which exist within the human body (Kalsotra et al., 2004). 
Probably because of its difficulty in expression in a recombinant organism, it is not widely 
available commercially.  
The human CYP4F3A_yc gene, with yeast biased codons, was cloned in the yeast 
expression vector pSYE263 using methodologies similar to cloning of the CYP3A4_yc 
gene in the same vector (this Chapter, Section 3.4.1). The resultant plasmid was named 
pSYE263/h_CYP4F3A_yc.  
A 1575 bp BamHI-XhoI CYP4F3A_yc gene fragment (Figure 3.71) was isolated from the 
plasmid pUC57/BamHI-XhoI/h_CYP4F3A_yc for DNA ligase mediated ligation to the 
5699 bp BamHI-XhoI fragment of vector pSYE263, to create the episomal, 2µ-plasmid 





Lanes     1     2                      3
 
Figure 3.71. An agarose gel that shows the expected DNA fragments when the 
plasmid pUC57/BamHI-Xhol/h_CYP4F3A_yc was digested with BamHI-Xhol 
(lanes 2, 3). The 1575 bp insert fragment was isolated from the gel and ligated 





Figure 3.72. The map of the plasmid pSYE263/h_CYP4F3A_yc, with restriction 
sites that occur in the plasmid only once. The BamHI and XhoI sites of pSYE263 
were used for cloning the synthetic h_CYP4F3A_yc gene with yeast biased 















































The authenticity of the resultant plasmid, pSYE263/h_CYP4F3A_yc (Figure 3.72) was 
confirmed by two separate enzyme digests, with (a) BamHI, XhoI and (b) BamHI-XbaI 
(Figure 3.73).  
 
 





(B) Lanes  1      2      3        4            5
 
Figure 3.73. Agarose gels that show the expected DNA fragments when the 
plasmid pSYE263/h_CYP4F3A_yc was digested with restriction enzymes (A) 
BamHI, XhoI and (B) BamHI, XbaI. Lane 1, DNA ladder; lanes 2 to 5, 







3.16.2 Comparison of CYP4F3A enzyme activities 
expressed by ‘synthesised’ CYP4F3A_yc from an 
episomal plasmid pSY263, in the presence/absence 
of cytochrome b5, using a fluorescence-based assay 
 
The results shown in Figure 3.74 (above) indicate that the ‘synthesised’ CYP4F3A_yc 
gene produces a lot more CYP4F3A active enzyme in the presence of cytochrome b5 (in 
the strain YAB79) than in its absence (YY7). The ‘native’ CYP4F3A_na gene had not 
been cloned earlier from a human liver cDNA library. That cytochrome b5 (a) augments 
CYP4F3A enzyme activity and/ or (b) increases the levels of CYP4F3A protein has not 
been reported before (Ammed et al., 2016). The possibility of the latter happening can be 
confirmed by Western blotting.  
Indeed, Western blotting (Figure 3.75) has confirmed that cytochrome b5 helps in 
increasing CYP4F3A protein levels. For this experiment, equal number of cells (1X 106), 
expressing CYP4F3A, in the absence or presence of cytochrome b5, was taken for lysis 
of cells and extraction of total cellular protein. Densitometric quantification (results not 
shown) suggested that at least 5 times more protein is produced in the presence of 








Figure 3.74. (A) The graphs show the rate at which the activity of the CYP4F3A 
enzyme, expressed in yeast strain YY7 and YAB79 from the ‘synthesised’ 
CYP4F3A_yc gene [co-expressed only with ∆hRDM gene (YY7) or co-expressed 
with ∆hRDM and cytochrome b5 genes (YAB79)), increases over 40 min. Rate 
was measured in terms of relative fluorescence units (RFUs) using 3-cyano-7-
ethoxycoumarin (CEC) as the substrate. CEC is de-ethylated by CYP4F3A to 
form 3-cyano7-hdroxycoumarin (CHC). (B) Depicts the comparison of 
fluorescence emitted by the three yeast strains at 40 min of reaction of enzyme 












(A) Comparison of CYP4F3A enzyme activities obtained from 
'native' CYP4F3A_na gene and that obtained from 'synthetic' 




















(B) Comparison of CYP4F3A enzyme activities obtained from 
'native' CYP4F3A_na gene and that obtained from 'synthetic' 






Western blot was performed with cells form the same strains used for the experiments 
described in Figure 3.74. The blot shows that at least 5 times more CYP4F3A protein is 
produced in the presence of cytochrome b5 than in its absence.  
 
Lanes      1           2 
60 kDa–
 
Figure 3.75. Western blot that shows the amounts of CYP4F3A protein which 
is expressed by equal number of cells (1X 106) from two different yeast 
strains. The amount of total cellular protein obtained from these cells was 
loaded on wells of an SDS polyacrylamide gel. Cells which contain 
pSYE263/CYP4F3A_yc + cytochrome b5 (lane 1) and only pSYE263/ 
CYP4F3A_yc but no cytochrome b5 (lane 2). The expected size of CYP4F3A 
protein is 59.9 kDa. The blot was probed by a human CYP4F3A specific 
monoclonal antibody (Santa Cruz Biotechnology, Cat no: sc-374421). 
 
 
3.17 Cloning of CYP17A1_yc gene in the episomal 
plasmid pSY263 for expression of human 
CYP17A1 enzyme 
 
3.17.1 Cloning of CYP17A1_yc gene in the episomal plasmid 
pSY263 
 
CYP17A1 plays a key part in the biosynthesis of steroids. Through its ability to control 
levels of mineralocorticoids, it greatly influences the synthesis of (a) glucocorticoids 
associated with stress and immune responses and (b) androgens and estrogens which 
partake in the development and overall homeostasis of reproductive tissues. Hence, it has 
been reported that because of CYP17A1’s multifunctional roles, understanding of its 
228 
 
biochemistry is key to the treatment of prostate cancer, blood pressure, problems related 
to fertility and other diseases (Mark et al., 2015; Yoshimoto et al., 2015).  
The human CYP17A1_yc gene, with yeast biased codons, was cloned in the yeast 
expression vector pSYE263 using methodologies similar to cloning of the CYP3A4_yc 
gene in the same vector (this Chapter, Section 3.4.1). The resultant plasmid was named 
pSYE263/h_ CYP17A1_yc.  
A 1539 bp BamHI-XhoI CYP17A1_yc gene fragment (Figure 3.76) was isolated from the 
plasmid pUC57/BamHI-XhoI/h_CYP17A1_yc for DNA ligase mediated ligation to the 
5699 bp BamHI-XhoI fragment of vector pSYE263, to create the episomal, 2µ-plasmid 
pSYE263/h_CYP17A1_yc (Figure 3.77) for expression of human CYP17A1 enzyme.  
 
1539 bp–
Lanes     1        2        3       4
 
Figure 3.76. An agarose gel that shows the expected DNA fragments when the 
plasmid pUC57/BamHI-Xhol/h_CYP17A1_yc was digested with BamHI, XhoI 
(lanes, 2, 3, 4). The 1539 bp insert fragment was isolated from the gel and 






Figure 3.77. The map of the plasmid pSYE263/h_CYP17A1_yc, with restriction 
sites that occur in the plasmid only once. The BamHI and XhoI sites of pSYE263 
were used for cloning the synthetic h_CYP17A1_yc gene with yeast biased 
codons, in the episomal 2µ-plasmid pSYE263. 
 
After ligation and transformation of the ligation mixture in E. coli DH5α competent cells, 
individual bacterial transformants were grown for preparation of plasmid DNA. 
The authenticity of the resultant plasmid DNA, pSYE263/h_CYP17A1_yc was 
confirmed by digestion with restriction enzymes BamHI, XhoI. It was verified that the 
newly constructed plasmid contained the correct size fragments (e.g. 1539 bp BamHI, 




Lanes     1       2        3      4        5
 
Figure 3.78. An agarose gel that shows the expected DNA fragments when the 
plasmid pSYE263/BamHI-Xhol/h_CYP17A1_yc was digested with the enzymes 












































3.17.2 Comparison of CYP17A1 enzyme activities 
expressed by ‘synthesised’ CYP17A1_yc from an 
episomal plasmid pSY263, in the presence/absence 
of cytochrome b5, using a fluorescence-based assay 
 
The results shown in Figure 3.79 (below) indicate that the ‘synthesised’ CYP17A1_yc 
gene produces a lot more CYP17A1 active enzyme in the presence of cytochrome b5 (in 
the strain YAB79) than in its absence (YY7). The ‘native’ CYP17A1_na gene had not 
been cloned earlier from a human liver cDNA library. That cytochrome b5 (a) augments 
CYP17A1 enzyme activity and/ or (b) increases the levels of CYP17A1 protein has not 
been reported before (Duggal et al., 2016; Estradal et al., 2103). The possibility of the 
latter happening can be confirmed by Western blotting.  
Indeed, Western blotting (Figure 3.80) has confirmed that cytochrome b5 helps in 
increasing CYP17A1 protein levels. For this experiment, equal number of cells (1X 106), 
expressing CYP17A1, in the absence or presence of cytochrome b5, was taken for lysis 




Figure 3.79. The graphs show the rate at which the activity of the CYP17A1 
enzyme, expressed in yeast strain YY7 and YAB79 from the ‘synthesised’ 
CYP17A1_yc gene [co-expressed with only ∆hRDM gene (YY7) or co-expressed 
with ∆hRDM and cytochrome b5 genes (YAB79)), increases over 30 min. Rate 
was measured in terms of relative fluorescence units (RFUs), using 
dibenzylfluorescein (DBF) as substrate. DBF is dealkylated by CYP17A1 to 
form the fluorescent product flourscein. The empty plasmid (pSYE263 
containing no CYP17A1 gene), when expressed in yeast, showed no (basal) 
activity. (B) Depicts the comparison of fluorescence emitted by the different 
yeast strains at 30 min of reaction of enzyme with substrate. The data 










(A) Activity of CYP17A1 enzyme obtained from ‘synthesised’ 
CYP17A1_yc gene encoded by the episomal plasmid pSY263 
























(B) Activity of CYP17A1 enzyme obtained from ‘synthesised’ 
CYP17A1_yc gene encoded by the episomal plasmid pSY263 









Densitometric quantification (results not shown) of the Western blot (Figure 3.80) 
suggests that at least 10 times more CYP17A1 protein is produced in the presence of 
cytochrome b5 than in its absence.  
 
Lanes                1                        2 
60 kDa–
 
Figure 3.80. Western blot that shows the amounts of CYP17A1 protein being 
expressed by equal number of cells (1X 106) from two different yeast strains. 
Lane 1: protein from cells which only contain the plasmid 
pSYE263/CYP17A1_yc but no cytochrome b5 (lane 1); lane 2: protein from 
cells which contain the plasmid pSYE263/CYP17A1_yc and also cytochrome b5 
(lane 2). The expected size of CYP17A1 protein is 57.4 kDa. The blot was 
probed by a human CYP17A1 specific monoclonal antibody (Santa Cruz 






3.18 Cloning of CYP19A1_yc gene in the episomal 
plasmid pSY263 for expression of human 
CYP19A1 enzyme 
 
3.18.1 Cloning of CYP19A1_yc gene in the episomal plasmid 
pSY263 
 
CYP19A1, also known as aromatase, plays different roles at the crossroads of multiple 
signalling pathways. It has been claimed that maintenance of its levels is vital for human 
health. Unfortunately, aromatase concentrations in humans fluctuate dramatically 
because of environmental chemicals such as chemical additives in food and personal care 
products which disrupt the endocrine system. Variety of medications and hormone 
replacement therapy also affect aromatase levels. Aromatase converts androgens to 
estrogens. It has been reported that alterations of aromatase concentrations can lead to 
breast, gastric, ovarian, pituitary and prostate cancers, besides many other ailments such 
as Alzheimer's disease and schizophrenia. It is also thought to be involved in polycystic 
ovary syndrome, endometriosis and osteoporosis (Petrunak et al., 2014). 
The human CYP19A1_yc gene, with yeast biased codons, was cloned in the yeast 
expression vector pSYE263 using methodologies similar to cloning of the CYP3A4_yc 
gene in the same vector (this Chapter, Section 3.4.1). The resultant plasmid was named 
pSYE263/h_CYP19A1_yc.  
A 1524 bp BamHI-XhoI CYP19A1_yc gene fragment (Figure 3.81) was isolated from the 
plasmid pUC57/BamHI-XhoI/h_CYP19A1_yc for DNA ligase mediated ligation to the 
5699 bp BamHI-XhoI fragment of vector pSYE263, to create the episomal, 2µ-plasmid 





Lanes    1                      2                     3
 
Figure 3.81. An agarose gel that shows the expected DNA fragments when the 
plasmid pUC57/BamHI-Xhol/h_CYP19A1_yc was digested with BamHI, XhoI 
(lanes 2, 3). The 1524 bp gene insert fragment was isolated from the gel and 
was ligated to the pSYE263 vector that had been digested with BamHI, XhoI to 
obtain the plasmid pSYE263/h_CYP19A1_yc.  
 
 
Figure 3.82. The map of the plasmid pSYE263/h_CYP19A1_yc, with restriction 
sites that occur in the plasmid only once. The BamHI and XhoI sites of pSYE263 
were used for cloning the synthetic h_CYP19A1_yc gene with yeast biased 
codons, in the episomal 2µ-plasmid pSYE263. 
After ligation and transformation of the ligation mixture in E. coli DH5α competent cells, 









































The authenticity of the resultant plasmid DNA, pSYE263/h_CYP19A1_yc was 
confirmed by digestion with restriction enzymes BamHI, XhoI. It was verified that the 
newly constructed plasmid contained the correct size fragments (e.g. 1524 bp BamHI, 




Lanes        1           2         3           4          5
 
Figure 3.83. An agarose gel that shows the expected DNA fragments when the 
plasmid pSYE263/BamHI-Xhol/h_CYP19A1_yc was digested with the enzymes 
BamHI and Xhol (lanes 2 to 5). Lane 1, DNA ladder.  
 
 
3.18.2 Comparison of CYP19A1 enzyme activities 
expressed by ‘synthesised’ CYP19A1_yc from an 
episomal plasmid pSY263, in the presence/absence 
of cytochrome b5, using a fluorescence-based assay 
 
The results shown in Figure 3.84 (below) indicate that the ‘synthesised’ CYP19A1_yc 
gene produces as much CYP19A1 active enzyme in the presence of cytochrome b5 (in 
the strain YAB79) than in its absence (YY7). The ‘native’ CYP19A1_na gene had not 
been cloned earlier from a human liver cDNA library. In the case of CYP19A1 it would 
seem that cytochrome b5 may not have any effect on CYP19A1 enzyme activity and/ or 
levels of CYP19A1 protein. There have been contradictions in the literature regarding the 
use of cytochrome b5 in the heterologous expression of CYP19A1 (Hiroshi Yamazaki, 




Figure 3.84. The graphs show the rate at which the activity of the CYP19A1 
enzyme, expressed in yeast strain YY7 and YAB79 from the ‘synthesised’ 
CYP19A1_yc gene [co-expressed with only ∆hRDM gene (YY7) or co-expressed 
with ∆hRDM and cytochrome b5 genes (YAB79)), increases over 30 min. Rate 
was measured in terms of relative fluorescence units (RFUs), using 
dibenzylfluorescein (DBF) as substrate. DBF is dealkylated by CYP19A1 to 
form the fluorescent product flourscein. The empty plasmid (pSYE263 
containing no CYP19A1 gene), when expressed in yeast, showed no (basal) 
activity. (B) Depicts the comparison of fluorescence emitted by the different 
yeast strains at 30 min of reaction of enzyme with substrate. The data 












(A) Activity of CYP19A1 enzyme obtained from ‘synthesised’ 
CYP19A1_yc encoded by the episomal plasmid pSY263 (expressed 





















(B) Activity of CYP19A1 enzyme obtained from ‘synthesised’ 
CYP19A1_yc encoded by the episomal plasmid pSY263 (expressed 









Western blotting (Figure 3.85) confirms that cytochrome b5 may not have much of a role 
to play in CYP19A1 protein levels during expression in yeast. Densitometric 
quantification (results not shown) of the Western blot (Figure 3.85) also suggest that is 
so. For this experiment, once again equal number of cells (1X 106), expressing CYP19A1, 
in the absence or presence of cytochrome b5, was taken for lysis of cells and extraction 
of total cellular proteins.  
 
Lanes       1                2 
60 kDa–
 
Figure 3.85. Western blot that shows the amounts of CYP19A1 protein being 
expressed by equal number of cells (1X 106) from two different yeast strains. 
Lane 1: protein from cells which only contain the plasmid 
pSYE263/CYP19A1_yc but no cytochrome b5 (lane 1); lane 2: protein from 
cells which contain the plasmid pSYE263/CYP19A1_yc and also cytochrome b5 
(lane 2). The expected size of CYP19A1 protein is 52.9 kDa. The blot was 
probed by a human CYP19A1 specific monoclonal antibody (Santa Cruz 






3.19 Cloning of CYP2J2_yc gene in the episomal 
plasmid pSY263 for expression of human 
CYP2J2 enzyme 
 
3.19.1 Cloning of CYP2J2_yc gene in the episomal plasmid 
pSY263 
 
Like CYP4F3A, CYP17A1 and CYP19A1, CYP2J2 is also an extra-hepatic cytochrome 
P450 enzyme. It plays a pivotal role in the metabolism of both endogenous 
(polyunsaturated fatty acids; PUFAs) and exogenous (i.e. xenobiotics) molecules to the 
human body. In recent years, CYP2J2 has been studied for elucidation of its biological 
function in cardiac diseases. It has also been noted that CYP2J2 levels are quite high in 
various cancers. Hence, CYP2J2 modulation has been thought to be a new avenue for 
treatment of cancer and malfunction of the heart (Ma et al., 2013).  
The human CYP2J2_yc gene, with yeast biased codons, was cloned in the yeast 
expression vector pSYE263 using methodologies similar to cloning of the CYP3A4_yc 
gene in the same vector (this Chapter, Section 3.4.1). The resultant plasmid was named 
pSYE263/h_CYP2J2_yc.  
A 1521 bp BamHI-XhoI CYP2J2_yc gene fragment (Figure 3.86) was isolated from the 
plasmid pUC57/BamHI-XhoI/h_CYP2J2_yc for DNA ligase mediated ligation to the 
5699 bp BamHI-XhoI fragment of vector pSYE263, to create the episomal, 2µ-plasmid 






Lanes        1                    2
 
Figure 3.86. An agarose gel that shows the expected DNA fragments when the 
plasmid pUC57/BamHI-Xhol/h_CYP2J2_yc was digested with BamHI, XhoI 
(lanes 2, 3). The 1524 bp gene insert fragment was isolated from the gel and 
was ligated to the pSYE263 vector that had been digested with BamHI, XhoI to 
obtain the plasmid pSYE263/h_CYP2J2_yc.  
 
 
Figure 3.87. The map of the plasmid pSYE263/h_CYP2J2_yc, with restriction 
sites that occur in the plasmid only once. The BamHI and XhoI sites of pSYE263 
were used for cloning the synthetic h_CYP2J2_yc gene with yeast biased 






































After ligation and transformation of the ligation mixture in E. coli DH5α competent cells, 
individual bacterial transformants were grown for preparation of plasmid DNA. 
The authenticity of the resultant plasmid DNA, pSYE263/h_CYP2J2_yc was confirmed 
by two separate enzyme digests, with (a) BamHI, XhoI and (b) BamHI-XbaI. It was 





(A) Lanes     1    2       3        4          5
5699 bp–
1533 bp–
(B) Lanes     1    2       3       4         5
 
Figure 3.88. Agarose gels that show the expected DNA fragments when the 
plasmid pSYE263/h_CYP2J2_yc was digested with restriction enzymes (A) 
BamHI, XhoI and (B) BamHI, XbaI. Lane 1, DNA ladder; lanes 2 to 5, 







3.19.2 Comparison of CYP2J2 enzyme activities expressed 
by ‘synthesised’ CYP2J2_yc from an episomal 
plasmid pSY263, in the presence/absence of 
cytochrome b5, using a fluorescence-based assay 
 
The results shown in Figure 3.84 (below) indicate that the ‘synthesised’ CYP2J2_yc gene 
produces as much CYP2J2 active enzyme in the presence of cytochrome b5 (in the strain 
YAB79) than in its absence (YY7). The ‘native’ CYP2J2_na gene, cloned from a human 
liver cDNA library, was not available. It seems that cytochrome b5 may not have any 
noticeable effect on CYP2J2 enzyme activity (Figure 3.89). However, cytochrome b5 
does have an influence on the levels of CYP2J2 protein (Figure 3.90). These results would 
suggest that cytochrome b5 provides stability to the CYP2J2 protein expressed but it may 
be deleterious to enzyme activity indicating that cytochrome b5 may have an adverse 
effect on the active site conformation of CY2J2.  
Published literature indicates that, until now, only an N-terminal truncated CYP2J2 gene 
with C-terminal 6X His-tag has been expressed in bacterial cells but not in yeast (Park et 
al., 2014). However, it has been noted that there is variability in CYP2J2 enzymatic 
activity which depends on its redox partners CPR and cytochrome b5. The amounts of 
CPR and cytochrome b5 co-expressed have dramatic effects on CYPJ2 activity 






Figure 3.89. The graphs show the rate at which the activity of the CYP2J2 
enzyme, expressed in yeast strain YY7 and YAB79 from the ‘synthesised’ 
CYP2J2_yc gene [co-expressed with only ∆hRDM gene (YY7) or co-expressed 
with ∆hRDM and cytochrome b5 genes (YAB79)), increases over 30 min. Rate 
was measured in terms of relative fluorescence units (RFUs), using 7-
benzyloxymethyloxy-3-cyanocoumarin (BOMCC) as substrate. BOMCC is 
dealkylated by CYP2J2 to form the fluorescent product 7-hydroxy-3-
cyanocoumarin (HCC). The empty plasmid (pSYE263 containing no CYP2J2 
gene), when expressed in yeast, showed basal activity. (B) Depicts the 
comparison of fluorescence emitted by the different yeast strains at 30 min of 
reaction of enzyme with substrate. The data represent mean ± S.D. of three 












(A) Activity of CYP2J2 enzyme obtained from ‘synthesised’ 
CYP2J2_yc encoded by the episomal plasmid pSY263 (expressed 






















(B) Activity of CYP2J2 enzyme obtained from ‘synthesised’ 
CYP2J2_yc encoded by the episomal plasmid pSY263 (expressed 









Western blotting (Figure 3.90) suggests that cytochrome b5 must have a role to play in 
CYP2J2 protein levels during expression in yeast. Densitometric quantification (results 
not shown) of the Western blot (Figure 3.85) suggest that there is 3.5-fold increase in 
CYP2J2 levels having used total cellular proteins from equal number of cells (1X 106) 
for the blot. Cells which express CYP2J2, in the absence or presence of cytochrome b5, 
were taken for lysis of cells and extraction of total cellular proteins.  
 
Lanes             1               2 
60 kDa–
 
Figure 3.90. Western blot that shows the amounts of CYP2J2 protein being 
expressed by equal number of cells (1X 106) from two different yeast strains. 
Lane 1: protein from cells which only contain the plasmid pSYE263/CYP2J2 _yc 
but no cytochrome b5 (lane 1); lane 2: protein from cells which contain the 
plasmid pSYE263/CYP2J2 _yc and also cytochrome b5 (lane 2). The expected 
size of CYP2J2 protein is 57.9 kDa. The blot was probed by a human CYP2j2 





3.20 Cloning of CYP3A5_yc gene in the episomal 
plasmid pSY263 for expression of human 
CYP3A5 enzyme 
 
3.20.1 Cloning of CYP3A5_yc gene in the episomal 
plasmid pSY263 
 
CYP3A5 is another one of the CYP enzymes, which is used for Drug Metabolism studies. 
It is very similar in its primary sequence to CYP3A4 (Huang et al., 2004; Zanger et al., 
2013). At first, the plasmid pUC57/h_CYP35_yc was digested with the restriction 
enzymes BamHI and XbaI. The 1521 bp insert fragment containing the human 
CYP3A5_yc gene was isolated from an agarose gel and the 2700 bp pUC57 vector 
fragment was ignored (Figure 3.91). The CYP3A5_yc gene insert was then cloned in 
pSYE263, which had been digested also with BamHI and XbaI restriction enzymes to 
obtain the plasmid pSYE263/h_CYP3A5_yc (Figure 3.92).  
 
1521 bp–
Lanes           1          2                            3
 
Figure 3.91. An agarose gel that shows the expected DNA fragments when the 
plasmid pUC57/BamHI-Xhol/h_CYP3A5_yc was digested with BamHI, XhoI 
(lanes 2, 3). The 1521 bp gene insert fragment was isolated from the gel and 
was ligated to the pSYE263 vector that had been digested with BamHI, XhoI to 





Figure 3.92. The map of the plasmid pSYE263/h_CYP3A5_yc, with restriction 
sites that occur in the plasmid only once. The BamHI and XhoI sites of pSYE263 
were used for cloning the synthetic h_CYP3A5_yc gene with yeast biased 
codons, in the episomal 2µ-plasmid pSYE263. 
 
After ligation and transformation of the ligation mixture in E. coli DH5α competent cells, 
individual bacterial transformants were grown for preparation of plasmid DNA. 
The authenticity of the resultant plasmid DNA, pSYE263/h_CYP3A5_yc was confirmed 

















































Figure 3.93. An agarose gel that shows the expected DNA fragments when the 
plasmid pSYE263/h_CYP3A5_yc was digested with restriction enzymes BamHI 
and XhoI Lane 1, DNA ladder; lanes 2 to 4, pSYE263/h_CYP3A5_yc digested 
with BamHI-XbaI (A).  
 
3.20.2 Comparison of CYP3A5 enzyme activities expressed 
by ‘synthesised’ CYP3A5_yc from an episomal 
plasmid pSY263, in the presence/absence of 
cytochrome b5, using a fluorescence-based assay 
 
The results shown in Figure 3.94 (below) indicate that the ‘synthesised’ CYP3A5_yc gene 
produces much more CYP3A5 active enzyme in the presence of cytochrome b5 (in the 
strain YAB79) than in its absence (YY7). The ‘native’ CYP3A5_na gene, cloned from a 
human liver cDNA library, was not available. It is clear that cytochrome b5 does have a 
noticeable effect on CYP3A5 enzyme activity indicating cytochrome b5 influences the 
levels of CYP3A5 protein. Published literature indicates that CYP3A5 makes a 
substantial contribution to the total metabolic intrinsic clearance of some drugs, and this 
depends on the presence of at least one wild-type CYP3A5 allele within the cells and the 






Figure 3.94. The graphs show the rate at which the activity of the CYP3A5 
enzyme, expressed in yeast strain YY7 and YAB79 from the ‘synthesised’ 
CYP3A5_yc gene [co-expressed with only ∆hRDM gene (YY7) or co-expressed 
with ∆hRDM and cytochrome b5 genes (YAB79)), increases over 30 min. Rate 
was measured in terms of relative fluorescence units (RFUs), using 
dibenzylfluorescein (DBF) as substrate. DBF is de-alkylated by CYP3A5 to 
form the fluorescent product flourscein. The empty plasmid (pSYE263 
containing no CYP3A5 gene), when expressed in yeast, showed no (i.e. basal) 
activity. (B) Depicts the comparison of fluorescence emitted by the different 
yeast strains at 30 min of reaction of enzyme with substrate. The data 












(A) Activity of CYP3A5 enzyme obtained from ‘synthesised’ 
CYP3A5_yc encoded by the episomal plasmid pSY263 


















(B) Activity of CYP3A5 enzyme obtained from ‘synthesised’ 
CYP3A5_yc encoded by the episomal plasmid pSY263 (expressed 







Western blotting (Figure 3.95) suggests that cytochrome b5 has a role to play in CYP3A5 
protein levels during expression in yeast. Densitometric quantification (results not shown) 
of the Western blot (Figure 3.95) suggest that there is ~5-fold increase in CYP3A5 levels, 
in the presence of cytochrome b5, having used proteins from equal number of cells (1X 
106) for the blot. Cells which express CYP3A5, in the absence or presence of cytochrome 
b5, were taken for lysis of cells and extraction of total cellular proteins for the Western 
blot.  
 
Lanes              1                           2
60 kDa–
 
Figure 3.95. Western blot that shows the amounts of CYP3A5 protein being 
expressed by equal number of cells (1X 106) from two different yeast strains. 
Lane 1: protein from cells which only contain the plasmid pSYE263/CYP3A5 
_yc but no cytochrome b5 (lane 1); lane 2: protein from cells which contain the 
plasmid pSYE263/CYP3A5 _yc and cytochrome b5 (lane 2). The expected size 
of CYP3A5 protein is 57.1 kDa. The blot was probed by a human CYP3A5 






3.21 Conclusions  
 
Codon usage is a phenomenon defined by 61 codons which code for 20 amino acids (Gray 
1999). So far from this Chapter it is clear that, using yeast biased codons, there is up-
regulation of the production of CYP450 proteins when they are expressed in baker’s 
yeast. It is not new that fine-tuning of codons for a gene that is expressed in a foreign 
organism has had a great impact on its expression as a protein. In the past, advances in 
biotechnology have paved the way for the replacement of rare codons with more 
frequently occurring ones thereby matching the host organism’s codon usage bias (Sharp 
and Li, 1987). However, the major setback has been the observation that usage of host-
specific codons may often have no influence on translation efficiency (Tuller et al., 2010).  
In this chapter with the use of yeast biased codons, I have been able to show that: 
1. Co-expression of cytochrome b5 has no influence on the activities or levels of 
expression of CYP2C18 and CYP19A1. Both proteins were co-expressed either 
(a) with ∆hRDM alone or (b) with ∆hRDM and cytochrome b5. To the best of our 
knowledge, this has not been published before although observations contrary to 
ours have been published, i.e. that cytochrome b5 is essential for CYP2C18 
activity (Zhang et al., 2015). 
2. Co-expression of cytochrome b5 with CYP1A2 enhances levels of protein 
expression which was confirmed by Western blotting. This has also not been 
observed before. In fact, it has been mentioned that cytochrome b5 may have a 
deleterious effect on the expression of CYP1A2 (Zhang et al., 2015).  
3. CYPs (2C19, 2C9, 2C8, 3A4, 2A6 and 2B6) have been successfully cloned and 
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expressed in the baker’s yeast strain YAB79 that co-expresses ∆hRDM and 
cytochrome b5 genes. 
4. CYPs (2J2, 17A1 2E1, and 4F3A1) have been cloned and expressed in baker’s 
yeast strain YAB79. All these CYPs have shown that cytochrome b5 is essential 
for their expression.  
5. CYPs (2D6 together with its three SNPs, and 1A1, 1B1) have been successfully 
cloned and expressed in the baker’s yeast strain YY7 that contains only ∆hRDM. 
In summary, the expression of human CYP genes, chemically synthesised using yeast 
biased codons (i.e. CYP_yc genes), have been compared with the expression of CYP 
cDNAs (CYP_na genes) that had been isolated earlier from a human liver cDNA library. 
It was found that, in general, expression levels of CYP_yc genes were much higher than 
the native CYP_na genes. For expression of both sets of genes, an episomal plasmid 
(usually referred to as a ‘multi-copy’ plasmid) was used.  
The effect of the findings described in this Chapter will be further discussed and utilised 
in the Chapters that follow. At this stage, one should point out that plasmids derived from 
an episomal vector are not stable. When expressing genes, encoded by an episomal 
plasmid, in complete medium which is conducive to high expression, the plasmid is lost. 
This is because in the absence of selection pressure, an extra-chromosomal plasmid is 
quickly ‘aborted’ by the cells. Hence, integrating gene expression cassettes into 
chromosomal loci could be an alternative that would allow growth of cells and expression 
of genes in non-selective complete medium. Integration would lead to incorporation of a 
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gene expression cassette into the genome of yeast and would allow propagation in 


















Chapter 4 Improved production of human 
cytochrome P450 (CYP) enzymes, 
within yeast cells, from a 





The baker’s yeast, Saccharomyces cerevisiae, has been the source of wellbeing of humans 
over a couple centuries from the time it was known that it could be used for baking bread. 
It also has been used as an immuno-stimulant (Sarlin and Philip 2011).  
In the past three decades, baker’s yeast, a unicellular eukaryotic microorganism, has 
widely been exploited by scientists throughout the world for recombinant protein 
production in both academic labs and commercial projects. Over centuries, this organism 
has been used for making beer. Elucidation of the genetics behind the beer making process 
has contributed to the successful use of yeast for the production of recombinant proteins. 
Kim et al. (2015) recently reported that a protein isolated from baker’s yeast shows 
potential against leukemic cells (Source: Fundacao de Amparo, Sao Paulo, 2017). The 
human insulin which is sold worldwide by Novo Nordisk is produced from baker’s yeast 
using recombinant DNA technology (Raskin, 1991).  
The main characteristic of baker’s yeast is its capacity to ferment glucose. It can use the 
sugar as a sole carbon source for its growth. Ethanol is formed as the only product of 
fermentation of glucose. For energy conversion, yeast uses two pathways, namely 
glycolysis and aerobic respiration. The two phases are linked by the use of ethanol as a 
carbon source in the later phase of growth. In this Chapter, I describe a yeast expression 
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system that is powered by the promoter of one of the two yeast alcohol dehydrogenase 
(ADH) genes, coding for an enzyme that allows conversion of alcohol into acetaldehyde 
within yeast cells.  
In the 1980s, the two yeast ADH genes were identified and were later cloned (Williamson 
et al., 1980, 1981). The DNA sequences (Russell et al., 1983) revealed the identity of the 
primary amino acid sequences of the two proteins, Adh1 and Adh2, coded for by the two 
ADH genes. Both proteins consist of 347 amino acid residues. Only 22 residues are 
different in the two proteins. It has been shown that they have no difference in their ability 
to use ethanol as a substrate for its biocatalysis to acetaldehyde (Ganzhorn et al., 1987). 
In this study, a 573 bp promoter fragment of the yeast ADH2 gene was isolated from the 
genomic DNA of the wild type yeast strain S288C (see Chapter 2, Section 2.4.1.3). It was 
used for construction of plasmids that would allow expression of heterologous human 
CYP proteins, in yeast. The expression of foreign genes in baker’s yeast is usually 
regulated by constitutive native yeast promoters while inducible promoters have been 
used to induce high levels of expression of proteins that could potentially be toxic to 
yeast.  
In the past, the inducible copper metallothionein (CUP1) and galactosidase (GAL1 or 
GAL10) promoters (Ramanos et al., 1992) have been utilised for syntheses of a wide range 
of foreign, mainly human, gene products in baker’s yeast. The difficulty with these 
promoters is that they are not commercially economic. The processes for expression of 
proteins using these promoters are lengthy, requiring many days. Moreover, the processes 
are prone to contamination due to the requirement for addition of copper (Cu2+) ions (for 
CUP1 promoter) or galactose (for GAL1/GAL10 promoter) which are factors that are 
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essential for induction of expression of foreign genes which have been cloned 
downstream of the two inducible promoters. 
It has previously been reported that the yeast ADH2 promoter (ADH2p) is repressed in 
the presence of glucose and induced in the presence of ethanol (Price et al., 1990). The 
repression of the mechanism was explained by Di Mauro et al. (2000). In that study, it 
was explained that as glucose is depleted, the level of the alcohol dehydrogenase regulator 
(ADR1), a transcription factor, increases. The ADR1 protein then binds to the ADH2 
promoter initiating transcription. Therefore, the most important advantage of the ADH2 
promoter is that no additional inducer is required before or after expression. This has been 
seen further, during this study, in the case of recombinant yeast cells that were grown 
over a period of 96 h. During growth of yeast strains that contained one copy, two and 
three copies of integrated CYP gene expression cassettes, only 2% glucose was required 
every 24 h to supplement growth and for concomitant increase in production of proteins. 
Over a period of 12 h, glucose is gradually converted into ethanol. During this time 
period, cells grow vigorously. After complete conversion of glucose to ethanol, the ADH2 
promoter is fully induced by ethanol for production of proteins. During a 96 h time period, 
CYP activity gradually increases, in parallel with increase in volume of yeast cells (i.e. 
cell numbers), measured through monitoring of optical density of cells at 600 nm (OD600).  
As has been discussed earlier, the presence of a CYP450 reductase (CPR) is essential for 
CYP enzymatic activity. CPR abstracts electrons from NADPH to the active site of a CYP 
to allow it to function in the catalysis of a chemical reaction. This implies that, without 
co-expression of a CPR within host cells, a CYP would be completely inactive. 
Heterologous expression of certain human CYPs in a host organism, besides requiring a 
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CPR, also requires co-expression of cytochrome b5 which is the substrate for cytochrome 
b5 reductase (CBR). Like CPR, CBR also participates in the transfer of electrons to the 
active site of a CYP (Elahian et al., 2014). It is known from the literature that certain 
CYPs require the participation of both the CPR and CBR for optimal activity. However, 
it is not yet clear which specific human CYPs require both CPR and CBR. Cytochrome 
b5 needs to be co-expressed with CPR and a CYP for CYPs that require CBR. This is 
because cytochrome b5 is limiting in eukaryotic host organisms (e.g. in insect or yeast 
cells) that are widely used for recombinant expression of human CYP proteins.  
During the studies conducted for this thesis, the role that cytochrome b5 plays in the 
enzyme activities of the CYP3A proteins, CYP3A4 and CYP3A5, was clarified. It 
became quite clear that cytochrome b5 is essential for the activity of these two enzymes. 
It has been reported previously that CYP3A4 catalysed reactions cannot progress without 
the mediation of cytochrome b5 (Yamazaki et al., 1999, 2002).  
This study has also confirmed that co-expression of cytochrome b5 may not be at all 
necessary, as has been reported earlier, for some of the CYP2C enzymes, i.e. CYP2C19, 
CYP2C9, CYP2C18 and CYP2C8. The observations reported in this study show for the 
first time that the CYP2C18 enzyme shows no deficit in its activity, when expressed in 
the absence of cytochrome b5 (see Chapter 3, section 3.8.2). This is in contrast to what 
has been published before (Yamazaki et al., 1999, 2002).  
This study has also tried to establish which CYP enzyme selectively requires the presence 
of cytochrome b5. It provides evidence, corroborating earlier claims, that CYP2D6 indeed 
does not require cytochrome b5 for mediation of its enzyme activity (Yamazaki et al. 
2002). However, the activity of CYP1A2 and CYP2E1, quite unexpectedly, is 
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dramatically enhanced by cytochrome b5 which has never been reported before. Yamzaki 
et al. (1996) reported in a study that cytochrome b5 stimulation of ferric (Fe3+) CYP450 
does not seem to enhance the activity of recombinant human CYPs, CYP1A2 and 
CYP2E1 (see Chapter 3).  
It has been described in Chapter 3 that CYP2D6 enzyme activity decreases 10-12-fold in 
the presence of cytochrome b5. Enzyme assays using recombinant human CYP2D6-
bound microsomes, isolated from whole yeast cells, show that the microsomal enzyme 
may have been damaged by the presence of cytochrome b5 (unpublished results from this 
lab). In parallel, it was seen that cytochrome b5 greatly enhances CYP1A2 activity within 
yeast cells and also in recombinant human CYP1A2-bound microsomes that are isolated 
from yeast cells (see Chapter 5). This was a surprise since it contrasts with the report by 
Yamazaki et al. (2002) which claims that cytochrome b5 has no stimulatory effect on the 
activity of CYP1A2. The stimulatory effect of cytochrome b5 in the bio-activation of 
human CYP1A2 and CYP2E1 has also been studied by Duarte et al (2005) who reported 
that cytochrome b5 may have a marginal stimulatory effect on CYP1A2 but can 
profoundly increase the activity of CYP2E1. 
One can conclude broadly from the published literature that cytochrome b5 can stimulate 
reactions mediated by some CYP enzymes and that not all enzymes require the co-
expression of this co-factor. However, it is not clear which CYP enzymes require the 
presence of cytochrome b5. It has been shown in Chapter 3, also for the first time, that 
cytochrome b5 may be an integral requirement for the 17, 20-lyase activity of the 
steroidogenic enzyme CYP17A1.  
257 
 
In Chapter 3, the introduction of CYP gene bearing episomal 2-micron (2µ)-based 
plasmids into baker’s yeast, through a process known as ‘transformation’, was described. 
The results have shown that CYP genes, chemically synthesized using yeast-biased 
codons, produce higher enzyme activities compared to the enzymes produced from native 
genes isolated from a liver cDNA library. An episomal plasmid can be maintained in 
selective minimal media which lack the nutrition for vigorous growth of yeast cells. 
Production of a heterologous protein in yeast using a minimal selective medium often 
becomes a futile exercise since very little protein, in our case, CYP enzyme is obtained 
because of poor cell growth. Instead, complete full medium which does not select for the 
presence of the plasmid bearing the heterologous (in our case CYP) gene, is used for short 
term expression over a period of 24 to 48 h. However, in full medium, there is always 
huge loss of plasmid from the cell population in a few generations of growth, implying 
that cells continue to grow in the absence of a plasmid that bears the heterologous (CYP) 
gene.  
To avoid plasmid loss and allow growth of yeast cells in complete full medium, we have 
established a generic technology that allows chromosomal integration of CYP expression 
cassettes bearing CYP genes, synthesized using yeast bias codons, to create highly stable 
yeast strains that can continuously express CYP genes of interest over many generations 
merely by continuous feeding the cells with the nutrients in the full media. Since the 
promoter used for gene transcription is ADH2, the duration of growth of yeast cells could 
be as long as the cells can divide within a defined enclosed space (i.e. a fermentor). It 
should be noted that aged cells are incapable of vigorous cell division. For stoppage of 
cell growth, because of aging, could take more than a fortnight, perhaps much longer, 
depending on the conditions used for fermentation. Moreover, in order to prevent cells to 
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become fully saturated with ethanol whereby they cannot grow any further, cells can be 
grown under fed-batch fermentation conditions, where ethanol produced is drained away 
and glucose is continuously drip-fed.  
In this Chapter, ADH2 promoter driven expression of CYPs has been monitored within 
live cells using substrates which make fluorescent products upon reaction with active 
CYP enzymes. Based on CYP activities, levels of expression of CYPs have thus been 
compared rapidly.  
 
 
 A typical cellular assay that allows 
monitoring of CYP activities to permit 
comparison of CYP expression levels 
between different recombinant yeast 
strains 
 
Yeast strains harbouring CYP genes, stored at -80°C, freezer were streaked out on 
minimum media agar plates containing different selection markers. The plates were 
grown for 3 days, at 30°C, in a static incubator. A scoopful of cells which grew on plates 
was taken for inoculation in full YDP broth, which is a complex rich medium for routine 
yeast growth. It contains 1% bacto-yeast extract, 2% bacto-peptone, 2% glucose, as 
described in Chapter 2. It cannot select for the presence of extra-chromosomal plasmids 
within cells.  
5 ml of YPD broth was transferred into 6-well sterile plastic plates. Then, the inoculum 
(i.e. scoopful of cells) from freshly grown agar plates, containing different yeast strains, 
was added to the different wells of a 6-well plate containing 1 ml of YPD broth. 2% 
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adenine was added was added to supplement the adenine present in YPD because adenine 
is rapidly used-up by the cells’ biomass.  
The 6-well plates were transferred to a shaking incubator set at 30°C for overnight growth 
of cells. After 12 h, glucose is used up and full induction of the ADH2 promoter occurs. 
This allows expression of the CYP enzyme. The optical density at 600 nm (i.e. OD600) 
was measured from each of the incubated cultures. Cells usually attained an OD600/ml of 
around 25. The cells were transferred into 2 ml Eppendorf tubes and were harvested. The 
cell pellets were washed three times with 500 µl TE buffer (50 mM Tris-HCl, 1 mM 
EDTA, pH 7.4) by spinning down the cells at 13,000 rpm, each time for 1 min. Cells were 
finally re-suspended in 450 µl of TE buffer to measure the kinetics of CYP enzyme 
activities. 
 
 Assay for CYP enzymes activities  
 
50 µl of cell suspensions were transferred into a sterile 96-well microtiter plate to which 
50 µl of a substrate mixture (depending on the substrate for a specific CYP) was added. 
The parameters for the fluorescence plate reader (Synergy HT BioTek) were set using the 
appropriate extinction/emission filters and appropriate gain sensitivity setting to obtain 
the best kinetic output from the plate reader. The plate was incubated at 30°C for 30 sec 
before the fluorescence emissions were measured using specific fluorogenic substrates 





Table 4.1. Fluorogenic substrates used for monitoring cellular CYP enzyme 
activities.  
 
CYPs Non-Fluorescent Substrates 
Fluorescent Product 
Formed 
3A4, 2C9,  3A5, 2C8 DBF Fluoroscein 
2D6,2E1 EOMCC 7-HCC 
4F3A CEC CHC 
1A2, 2C19, CEC CHC 
1A1, 1B1 EROD Resorufin 
2C9 7-MFC HFC 
 
 Outline of Chapter 4  
 
This chapter describes the expression of a copy of synthetic CYP gene (chemically 
synthesized with yeast-biased codons), from a single yeast ‘chromosomal’ locus. The aim 
was to find out which chromosomal locus gives the best expression of human CYP 
proteins. Expression of genes from chromosomal loci allows growth of yeast cells in 
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cheap, ‘non-selective’ growth media, continuously over 5 to 7 days, or longer, in shake-
flasks. As described above, it could be far longer in appropriate fermentors. In contrast, 
expression from extra-chromosomal, episomal plasmids demand growth of yeast cells in 
‘selective’ growth media, which are expensive, where cell numbers are relatively low, 
and cell growth is restricted to 24 – 48 h.  
It has been speculated that, heterologous (i.e. foreign) gene expression from yeast depends 
on the yeast proteins that reside in the neighbourhood of the human protein that is being 
expressed from a particular yeast chromosome (Branco and Pombo, 2006; Romanos et 
al., 1992). Hence, CYP gene expression cassettes (consisting of a promoter, a gene of 
interest and a transcription terminator) were integrated into different chromosomal loci, 
using homologous recombination, a technology which also facilitates gene therapy in 
human cells. The results obtained clearly show that there is differential expression of a 
human CYP enzyme when expressed from the neighbourhood of the yeast ADE2, HIS3 
and URA3 gene locations. Indeed, the best human CYP expression occurs from a 
particular locus of chromosome XV, where the yeast HIS3 gene resides. 
Integrative plasmids that encode the CYP_yc genes were constructed so that a copy of a 
CYP_yc gene could be integrated into 2 or 3 different yeast chromosomal loci. Expression 
of a CYP enzyme activity from a yeast strain that contained an integrated copy of a 
CYP_yc gene were then compared with the strain that harboured an episomal plasmid 





 Construction of yeast integrative plasmids that 
would allow integration of CYP gene expression 
cassettes into the yeast genome 
 
4.5.1 Construction of the yeast integrative plasmid 
YIpAdeADH2S to allow integration at the ADE2 
locus of the yeast genome  
 
The yeast integrative plasmid YIpAdeADH2S (Y= yeast; I= integrative; p= plasmid; 
Ade= ADE2 selection marker; ADH2= ADH2 promoter; S= SUC2 terminator sequence) 
was created via the following steps (1) to (3).   
(1) Isolation of vector fragment.  
The plasmid YIpAdeGAL1S (Figure 4.1) contains the GAL1 promoter (GAL1), 
which had been isolated from the GAL1/GAL10 gene of baker’s yeast, S. 
cerevisiae, by PCR using genomic DNA as a template. The promoter can drive 
expression of genes which are cloned downstream at its 3’-end. ‘S’ signifies the 
SUC2 terminator, a transcription termination signal isolated from the SUC2 gene 
of S. cerevisiae by PCR, using genomic DNA as a template. The plasmid 
YIpAdeGAL1S was digested with the restriction enzymes BamHI and SalI to 
obtain the 5798 bp ‘YIpAde’ fragment (Figure 4.2). It was isolated and used as 
the vector for ligation, as in step (3). Restriction enzyme digestion with BamHI, 
SalI eliminates the GAL1 promoter and allows, in its place, introduction of the 
ADH2 promoter.  
(2) Isolation of insert fragment.  
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The plasmid pBluKS(+)/ADH2p (Figure 4.3) was digested with BamHI, SalI. The 
573 bp ADH2 promoter (ADH2p) insert fragment was isolated (Figure 4.2). The 
ADH2p fragment had originally been isolated from the genome of S. cerevisiae 
by PCR.  
(3) The vector and insert fragments, from (1) and (2), were ligated to obtain the 
plasmid YIpAdeADH2S (Figure 4.4). 
 
 
Figure 4.1. Map of YIpAdeGAL1S that contains the GAL1 promoter and which 
allows integration pf the plasmid and its derivatives into the ADE2 locus of the 
yeast genome. The restriction sites shown are the ones that occur only once in 

















































Lanes 1             2           3                4
 
Figure. 4.2. The agarose gel shows the 5798 bp vector fragment obtained after 
digestion of the plasmid YIAdeGAL1S with the restriction enzymes BamHI and 
SaII (lanes 2, 3). Lane 4, The 593 bp ADH2p insert fragment obtained after 
digestion of plasmid pBluKS(+)/ADH2p (Figure 4.3) with BamHI, SaII. The 
fragments were isolated from the agarose gel for further ligation. Lane 1, 2-log 
DNA ladder.  
 
 
Figure 4.3. The map of the plasmid pBluKS(+)/ADH2p from which the ADH2 
promoter fragment was isolated. It shows restriction sites that occur in the 








































Figure 4.4. The map of the plasmid YIpAdeADH2S. It contains the ADH2 
promoter (ADH2p) and the SUC2 terminator (S). The plasmid and its 
derivatives would allow integration into the ADE2 locus of the yeast genome. 
The map shows restriction sites that would cut the plasmid only once.  
 
The 5798 bp YIAde vector fragment and the 593 bp ADH2p insert were ligated with the 
help of the enzyme, DNA ligase. After ligation and transformation in the E. coli strain 
DH5α, 3 individual colonies were grown for preparation of plasmid DNA using the 
alkaline lysis method (Chapter 2; Section2.4.1.8).  The resultant plasmid, 
YIAdeADH2MS (Figure 4.4), was confirmed by multiple restriction enzyme digestions. 
The agarose gel that shows digestion of the plasmid with restrictions enzymes, BamHI, 
SalI are shown in Figure 4.5. The expected fragments were observed confirming the 















































Figure 4.5. An agarose gel that shows the expected fragments (5798 bp and 
593 bp) of different clones of the plasmid YIpAdeADH2S, after digestion with 
restriction enzymes BamHI and SaII (lanes 2, 3). Lane 1, 2-log DNA ladder.  
 
The plasmid YIpADE2ADH2S can now be used for cloning of any gene downstream of 
the ADH2 promoter. The gene expression cassettes in the resultant plasmids can then be 
integrated into the ADE2 locus on chromosome XV (564476to 566191bps) of the yeast 
S. cerevisiae.   
 
4.5.2 Construction of the yeast integrative plasmid, 
YIpTrpADH2S, that allows integration of a CYP gene 
expression cassette at the TRP1 locus of the yeast 
genome  
 
The yeast integrative plasmid YIpTrpADH2S (the letters in the name of the plasmid has 
the same meaning as that of the plasmid described in Section 4.4.1, excepting that ‘Trp’ 
stands for the functional TRP1 gene, was created via the following steps:  
(1) Isolation of vector fragment.  
The plasmid YIpTrpGAL1S (Figure 4.6) contains the GAL1 promoter (GAL1). 
The plasmid was digested with BamHI and SalI to obtain the 4544 bp ‘YIpTrp’ 
fragment which was isolated and used for ligation, as in step (3). Restriction 
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enzyme digestion with BamHI, SalI eliminated the GAL1 promoter to allow its 
replacement by the ADH2 promoter.  
(2) Isolation of insert fragment.  
The 593 bp ADH2 promoter (ADH2p) insert fragment was isolated from the 
plasmid pBluKS(+)/ADH2p (Figure 4.3), as in Section 4.4.1.  
(3) The vector and insert fragments, from (1) and (2), were ligated to obtain the 
plasmid YIpTrpADH2S (Figure 4.7). 
 
 
Figure 4.6. Map of YIpTrpGAL1S that contains the GAL1 promoter and which 
allows integration of the plasmid and its derivatives into the TRP1 locus of the 
yeast genome. The restriction sites shown are the ones that occur only once in 









































Figure 4.7. The map of the plasmid YIpTrpADH2S. It contains the ADH2 
promoter (ADH2p) and the SUC2 terminator (S). The plasmid and its 
derivatives would allow integration into the TRP1 locus of the yeast genome. 
The map shows restriction sites that would cut the plasmid only once.  
 
The resultant plasmid, YITrpADH2MS (Figure 4.7), was confirmed by two sets of 








Lanes 1              2       3     4      5      6      7
 
Figure 4.8. An agarose gel that shows the expected fragments of different 
clones of the plasmid YIpTrpADH2S after digestion with (a) restriction 
enzymes BamHI and SaII (4544, 593 bp; lanes 3, 5, 6) and (b) restriction 







































The results obtained from the agarose gel (Figure 4.8) confirm the integrity of the newly 
created plasmid.  
The YIpTrpADH2S plasmid can now be used for cloning any gene downstream of the 
ADH2 promoter.  The gene expression cassettes in the resultant plasmids can then be 
integrated into the TRP1 locus on chromosome IV (461842 to 462516bps) of the yeast S. 
cerevisiae.   
 
4.5.3 Construction of the yeast integrative plasmid, 
YIpHisADH2S, that allows integration of a CYP gene 
expression cassette at the HIS3 locus of the yeast 
genome 
 
The yeast integrative plasmid YIpHisADH2S (the letters in the name of the plasmid has 
the same meaning as that of the plasmid described in Section 4.4.1, excepting that ‘His’ 
stands for the functional HIS3 gene) was created via the following steps:  
(1) Isolation of vector fragment.  
The plasmid YIpHisGAL1S (Figure 4.9) contains the GAL1 promoter (GAL1). 
The plasmid was digested with BamHI and SalI to obtain the 4726 bp ‘YIpHis’ 
fragment (Figure 4.10) which was isolated and used for ligation, as in step (3). 
Restriction enzyme digestion with BamHI, SalI eliminated the GAL1 promoter 
to allow its replacement by the ADH2 promoter.  
(2) Isolation of insert fragment.  
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The 593 bp ADH2 promoter (ADH2p) insert fragment was isolated from the 
plasmid pBluKS(+)/ADH2p (Figure 4.3), as in Section 4.4.1.  
(3) The vector and insert fragments, from (1) and (2), were ligated to obtain the 
plasmid YIpHisADH2S (Figure 4.11).  
 
 
Figure 4.9. Map of YIpHisGAL1S that contains the GAL1 promoter, and which 
allows integration of the plasmid and its derivatives into the HIS3 locus of the 
yeast genome. The restriction sites shown are the ones that occur only once in 
the plasmid. 
 
The plasmid YIpHisGAL1S was digested with BamHI, SalI to obtain the 4726 bp vector 












































Lanes 1            2                     3
 
Figure 4.10. The plasmid YIpHisGAL1S (lanes 2, 3) was digested with the 
restriction enzymes BamHI and SaII. The 4726 bp YIpHis vector fragments, 
which did not contain the GAL1 promoter fragment (~700bp), were isolated 
from the agarose gel. Lane1, 2-log DNA ladder. 
 
After ligation of the 4726 bp YIpHis vector fragment to the 593 bp ADH2 promoter 
fragment, the plasmid YIpHisADH2S was obtained (Figure 4.11).  
 
Figure 4.11. The map of the plasmid YIpHisADH2S. It contains the ADH2 
promoter (ADH2p) and the SUC2 terminator (S). The plasmid and its 
derivatives would allow integration into the HIS3 locus of the yeast genome. 








































The veracity of the plasmid was confirmed by digestion with restriction enzymes, BamHI 
and SalI (Figure 4.12).  




Figure 4.12. An agarose gel that shows the expected fragments (4726 bp and 
593 bp) of different clones of the plasmid YIpHisADH2S, after digestion with 
restriction enzymes BamHI and SaII (lanes 2, 3, 4). Lane 1, 2-log DNA ladder; 
lane 5, an uncut plasmid.  
 
The YIHisADH2MS plasmid can be used for cloning any gene downstream of the ADH2 
promoter. The gene expression cassettes in the resultant plasmids can then be integrated 
into the HIS3 locus on chromosome XV (721946 to 722608bps) of the yeast S. cerevisiae.   





4.5.4 Construction of the yeast integrative plasmid, 
YIpUraADH2S, that allows integration of a CYP gene 
expression cassette at the URA3 locus of the yeast 
genome 
 
The yeast integrative plasmid YIpUraADH2S (the letters in the name of the plasmid has 
the same meaning as that of the plasmid described in Section 4.2.1, excepting that ‘Ura’ 
stands for the functional URA3 gene) was created via the following steps: 
(1) Isolation of vector fragment.  
The plasmid YIpUraGAL1S (Figure 4.13) contains the GAL1 promoter (GAL1). 
The plasmid was digested with BamHI and SalI to obtain the 4654 bp ‘YIpUra’ 
fragment (Figure 4.14) which was isolated and used for ligation, as in step (3). 
Restriction enzyme digestion with BamHI, SalI eliminated the GAL1 promoter 
to allow its replacement by the ADH2 promoter.  
(2) Isolation of insert fragment.  
The 593 bp ADH2 promoter (ADH2p) insert fragment was isolated from the 
plasmid pBluKS(+)/ADH2p (Figure 4.3), as in Section 4.4.1.  
(3) The vector and insert fragments, from (1) and (2), were ligated to obtain the 





Figure 4.13. Map of YIpUraGAL1S that contains the GAL1 promoter and which 
allows integration pf the plasmid and its derivatives into the URA3 locus of the 
yeast genome. The restriction sites shown are the ones that occur only once in 
the plasmid. 
 




Figure 4.14. The plasmid YIpUraGAL1S (lanes 2, 3) was digested with the 
restriction enzymes BamHI and SaII. The 4654 bp YIpUra vector fragments, 
which did not contain the GAL1 promoter fragment (~700bp), were isolated 
from the agarose gel. Lane 1, 2-log DNA ladder.  
 
The 4654 bp YIpUra vector fragment was ligated to the 593 bp ADH2 promoter fragment 










































Figure 4.15. The plasmid map of YIpUraADH2S. It contains the ADH2 promoter 
(ADH2p) and the SUC2 terminator (S). The plasmid and its derivatives would 
allow integration into the URA3 locus of the yeast genome. The map shows 
restriction sites that would cut the plasmid only once. 
 




Figure 4.16. An agarose gel that shows the expected DNA fragments (4654, 593 
bp) when clones of the plasmid YIUraADH2MS (lanes 3-6) was digested with 
the restriction enzymes BamHI, Sall. Lane 1, 2-log DNA ladder; lane 2, an uncut 
plasmid.  
 
The plasmid YIUraADH2S can be used for cloning any gene downstream of the ADH2 
promoter.  The gene expression cassettes in the resultant plasmids can then be integrated 








































 Construction of yeast strains that bear 
expression cassettes of the human CYP3A4 
gene, chemically synthesized using yeast biased 
codons, and comparison of CYP3A4 enzyme 
activities produced by the strains  
 
4.6.1 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP3A4 
enzyme from the ADE2 chromosomal locus of a 
yeast strain 
 
The yeast integrative plasmid YIpAdeADH2S/CYP3A4_yc (CYP3A4_yc = gene 
synthesized using yeast-biased codons which code for the human CYP3A4 protein) was 
created via the following steps:  
(1) After digestion of the vector YIpAdeADH2S (Figure 4.4) with restriction 
enzymes BamHI, SpeI, a 6383 bp fragment was isolated. The enzyme digestion 
eliminates ~20 bp in the multi-cloning site which cannot be seen on the agarose 
gel (Figure 4.17).  
(2) A 1524 bp BamHI-XbaI CYP3A4_yc gene fragment (i.e. the human CYP3A4 
gene was synthesized with yeast-biased codons based on its protein sequence, 
NCBI Accession Number NP_059488) was isolated from a pUC57 based plasmid 
into which the chemically synthesised gene had been cloned at the outset. The 
made-to-order gene construct was obtained from Genewiz.  
(3) The 6383 bp vector and the 1524 bp insert were ligated to obtain the plasmid 









Figure 4.17. An agarose gel shows the digestion of the plasmid YIpAdeADH2S 
with the restriction enzymes BamHI and Spel (lane 2). Lane 1, 2-log DNA 
ladder (3 defined fragments have been labelled on the left); lane 3, uncut 
plasmid. The 6383 bp vector fragment was isolated from lane 2 of the agarose 
gel for further ligation.  
 
The BamHI-SpeI cut 6383 bp vector fragment was ligated with the 1524 bp BamHI-XbaI 
CYP34_yc gene fragment to obtain the plasmid YIpAdeADH2S/CYP3A4_yc.  
 
 
Figure 4.18. Map of plasmid YIpAdeADH2S/CYP3A4_yc that allows integration 
of a human CYP3A4 gene expression cassette at the ADE2 locus of the yeast 
genome. The human CYP3A4 gene was synthesized using yeast-biased codons 
and was named h_CYP3A4_yc. The map shows restriction sites that cut the 


































For integration into yeast cells, via homologous recombination, the plasmid was 
linearized at the EcoRV site (indicated by an arrow in Figure 4.18). In order to facilitate 
homologous recombination, the restriction sites HpaI or AflII (Figure 4.18) could also 
have been used for linearization. 
The newly constructed plasmid was further analysed using a SalI restriction enzyme 
digest (Figure 4.19).  
 




Figure 4.19. The agarose gel that shows the expected DNA fragments (6383, 
1524 bp) of YIpAdeADH2pS/CYP3A4_yc when plasmids isolated from three 
bacterial clones were digested with Sall (lanes 2-4). Lane 1, 2-log DNA ladder; 
lane 5, uncut plasmid.  
 
The YIAdeADH2S/CYP3A4_yc plasmid can be used for expression of human CYP3A4 
gene, synthesized using yeast-biased codons, driven by the ADH2 promoter. Upstream of 
the CYP3A4 gene is a 6A consensus sequence. It has been found, in this laboratory, that 
the 5’-end 6A consensus sequence provides higher expression of foreign genes in yeast. 
To allow this to happen, without loss of plasmid, the CYP3A4_yc gene expression cassette 
must be integrated into the yeast genome. YIAdeADH2S/CYP3A4_yc (Figure 4.18) 
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allows integration into the ADE2 locus on chromosome XV of yeast cells. The yeast strain 
that was used for integration of YIAdeADH2S/CYP3A4_yc was YAB79.  
The strain YAB79 contained (a) a modified less toxic version of the human reductase, 
ΔhRDM gene under the control of the ADH2 promoter, and (b) the human cytochrome b5 
gene under the control of the constitutive GAPDH promoter. Cells from the YAB79 strain 
containing an integrated copy of the plasmid YIAdeADH2S/CYP3A4_yc at its ADE2 
locus were named YAB79::3A4_yc(ADE2). Expression from this strain was compared 
with the levels of expression obtained from the strain YAB79::3A4_yc(263) that 
expressed human CYP3A4 from the episomal plasmid, pSYE263/CYP3A4_yc (Chapter 
3, Section 3.4.2).  
 
4.6.2 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP3A4 
enzyme from the URA3 chromosomal locus of a 
yeast strain 
 
The yeast integrative plasmid YIUraADH2pS/CYP3A4_yc was created via the following 
steps: 
(1) After digestion of the vector YIpUraADH2S (Figure 4.15) with restriction 
enzymes BamHI, SpeI, a 5239 bp fragment was isolated. The enzyme digestion 
eliminates ~20 bp in the multi-cloning site which cannot be seen on the agarose 
gel (Figure 4.20).  
(2) The 1524 bp BamHI-XbaI CYP3A4_yc gene fragment was isolated from a pUC57 
based plasmid, as in Section 4.4.1.  
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(3) The 5239 bp vector and the 1524 bp insert were ligated to obtain the plasmid 





Lanes  1              2               3
 
Figure 4.20. An agarose gel showing the digestion of the plasmid YIpUraADH2S 
with the restriction enzymes BamHI and Spel (lane 3). Lane 1, 2-log DNA 
ladder, showing 3 defined DNA fragments; lane 2, uncut plasmid. The 5239 bp 
vector fragment was isolated from lane 2 of the agarose gel for further ligation.  
 
 
Figure 4.21. Map of plasmid YIpUraADH2S/CYP3A4_yc that allows integration 
of a human CYP3A4 gene expression cassette at the URA3 locus of the yeast 
genome. The human CYP3A4 gene, synthesized using yeast-biased codons, is 
referred to as h_CYP3A4_yc. The map shows restriction sites that cut the 


































For integration into the yeast strain YAB79, via homologous recombination, the plasmid 
YIpUraADH2S/CYP3A4_yc was linearized at the EcoRV site (indicated by an arrow in 
Figure 4.21). In order to facilitate homologous recombination, the restriction site NcoI 
(Figure 4.21) could also have been used for linearization. 
The veracity of the plasmid was confirmed by digestion with the restriction enzymes 
BamHI, XbaI (Figure 4.22) and it showed expected sizes of fragments.  
 





Figure 4.22. The agarose gel that shows the expected DNA fragments (5239, 
1524 bp) of YIpUraADH2pS/CYP3A4_yc when plasmids isolated from three 
bacterial clones were digested with Sall (lanes 2, 3, 5). Lane 1, 2-log DNA 
ladder; lane 4, uncut plasmid. 
 
The YIpUraADH2S/CYP3A4_yc plasmid can be used for expression of CYP3A4_yc 
gene driven by the ADH2 promoter.  To allow this, the CYP3A4_yc gene expression 
cassette must be integrated into the URA3 locus on chromosome V of the yeast genome.    
The resultant strain YAB79::3A4_yc(URA3) was used to analyse levels of expression of 
human CYP3A4 enzyme and compared with the levels of expression obtained from the 
strain YAB79::3A4_yc(263) expressing CYP3A4 from the episomal plasmid, 




4.6.3 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP3A4 
enzyme from the HIS3 chromosomal locus of a yeast 
strain  
 
The yeast integrative plasmid YIpHisADH2S/CYP3A4_yc was created via the following 
steps:  
(1) After digestion of the vector YIpHisADH2S (Figure 4.11) with restriction 
enzymes BamHI, SpeI, a 5311 bp fragment was isolated. The enzyme digestion 
eliminates a small ~20 bp in the multi-cloning site which cannot be seen on the 
agarose gel (Figure 4.23).  
(2) The 1524 bp BamHI-XbaI CYP3A4_yc gene fragment was once again isolated 
from a pUC57 based plasmid, as in Section 4.4.1.  
(3) The 5311 bp vector and the 1524 bp insert were ligated to obtain the plasmid 











Figure 4.23. An agarose gel showing the digestion of the plasmid YIpHisADH2S 
with the enzymes BamHI and Spel (lane 2) and the plasmid pUC57/CYP3A4_yc 
with the enzymes BamHI and Xbal (lane 3). Lane 1, 2-log DNA ladder. The 5311 
bp vector and the 1524 bp insert fragments were isolated from lanes 2 and 3 




Figure 4.24. Map of plasmid YIpHisADH2S/CYP3A4_yc that allows integration 
of a human CYP3A4 gene expression cassette at the HIS3 locus of the yeast 
genome. The human CYP3A4_yc gene was synthesized using yeast-biased 
codons. The map shows restriction sites that cut the plasmid only once.  
 
For integration into the yeast strain YAB79, via homologous recombination, the plasmid 
YIpHisADH2S/CYP3A4_yc was linearized at the NheI site (indicated by an arrow in 
Figure 4.24). In order to facilitate efficient homologous recombination, alternatively the 

































In order to confirm that the plasmid YIpHisADH2S/CYP3A4_yc was constructed 
correctly, plasmid DNA obtained from bacterial clones via alkaline lysis (see Chapter 2, 
Section 2.4.1.8) was digested with the restriction enzyme PvuII (Figure 4.25). The 
plasmid showed expected sizes of fragments.  
 






Figure 4.25. The agarose gel that shows the expected DNA fragments (4008, 
2821 bp) of YIpHisADH2pS/CYP3A4_yc when plasmid DNA isolated from three 
bacterial clones were digested with the restriction enzyme PvuIl (lanes 2, 3, 
4). Lane 1, 2-log DNA ladder.  
 
The plasmid YIpHisADH2pS/CYP3A4_yc can be used for expression of the CYP3A4_yc 
gene driven by the ADH2 promoter. To allow this, the CYP3A4_yc gene expression 
cassette must be integrated into the HIS3 locus on chromosome XV.    
The resultant strain YAB79::3A4_yc(HIS3) was used to analyse levels of expression of 
human CYP3A4 enzyme and compared with the levels of expression obtained from the 
strain YAB79::3A4_yc(263) which expresses CYP3A4 from the episomal plasmid, 





4.6.4 Construction of yeast strains that contain a copy of 
the CYP3A4_yc gene expression cassette integrated 
into three different chromosomal loci of the yeast 
strain YAB79  
 
Three yeast strains were generated that contained a single copy of the CYP3A4_yc gene 
expression cassette. They were obtained by individually integrating the plasmids that bear 
the CYP3A4_yc expression cassette, in the yeast strain YAB79.  
The strain YAB79 contains a modified version of the human P450 reductase, hRD, which 
is referred to as ΔhRDM. The modified gene was cloned downstream of the ADH2 
promoter and its gene expression cassette was integrated at the LEU2 chromosomal locus 
of the strain BC300 which was originally derived from the commercially available strain 
W303-1A (ATCC # 208352). After integration of the ΔhRDM gene expression cassette, 
the resultant strain was named YY7. Cytochrome b5 is the substrate of the cytochrome 
b5 reductase which is an alternate source of electrons for activation of cytochrome P450 
(CYP) enzymes. A human cytochrome b5 gene was cloned downstream of the 
constitutive GAPDH promoter that would allow constant expression of cytochrome b5 
throughout the growth of cells from time zero (t= 0). The human cytochrome b5 gene 
expression cassette was integrated at the TRP1 chromosomal locus of YY7 to obtain the 





















































































Figure 4.26. Construction of the yeast strain YAB79 from BC300. (a) Plasmid 
YIpLeuADH2S/∆hRDM was integrated at the LEU2 locus of strain BC300 to 
create the strain YY7. (b) Plasmid YIpTrpGAPS/cyto-b5 was integrated at the 
TRP1 locus of the strain YY7 to create the strain YAB79.  
 
The CYP3A4_yc gene encoding plasmids used for integration in the strain YAB79 were:  
(1) YIpAdeADH2S/CYP3A4_yc,  
(2) YIpUraADH2S/CYP3A4_yc, and  
(3) YIpHisADH2S/CYP3A4_yc.  
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After integration, the strains were named:  
(a) YAB79::3A4_yc(ADE2),  
(b) YAB79::3A4_yc(URA3), and  
(c) YAB79::3A4_yc(HIS3).  
 
4.6.5 Comparison of activities of enzyme expressed in 
yeast cells from (a) chromosomal integrants and (b) 
an episomal plasmid bearing CYP3A4_yc gene  
 
The activities of CYP3A4 enzyme expressed from different chromosomal loci, ADE2, 
HIS3 and URA3, were compared. The enzyme expressed from a strain containing 
CYP3A4 gene-bearing episomal plasmid [YAB79::3A4_yc(2µ)] was used as a positive 
control whereas any enzyme activity from cells containing an empty integrated plasmid 






Figure 4.27. The graph shows the activities of CYP3A4 enzyme expressed from 
a single copy of the CYP3A4_yc gene expression cassette, integrated at the 
URA3, ADE2 or HIS3 chromosomal locus, in the yeast strain YAB79. Activities 
are compared with the CYP3A4 enzyme expressed from an episomal plasmid. 
The graphs represent the average of results obtained from three independent 
experiments.  
 
It appears from Figure 4.27 that the CYP3A4 enzyme expressed from the HIS3 locus has 
the best activity, better than that produced from the URA3 or the ADE2 locus of the strain 
YAB79. The kinetic analysis of the CYP3A4 enzyme, co-expressed with cytochrome b5 
and cytochrome P450 reductase (CPR; ∆hRDM), and expressed from different strains 
were performed, using DBF as a substrate. The intact yeast cells bearing the CYP3A4_yc 
gene integrated in chromosomal loci (ADE2, HIS3 and URA3), an episomal plasmid 
bearing the CYP3A4_yc gene and the control empty plasmid yeast strain were grown as 
described in Section 4.1.1 and the kinetics of the enzymes produced were compared, as 
described in Section 4.1.2, to measure the formation of the product, fluorescein. The 
procedures were carried out in three independent experiments.  
The activities obtained at 30 min (in Figure 4.27) were re-plotted as bars to show clearly 












Comparison of activities of CYP3A4 enzyme expressed from 
different chromosomal loci and from an episomal plasmid in 










Figure 4.28. The bar plot shows the activities of CYP3A4 enzyme expressed 
from a single copy of the CYP3A4_yc gene expression cassette integrated at the 
ADE2, HIS3 or URA3 locus of the yeast strain YAB79 and compared with that 
obtained from an episomal 2-micron (2µ) plasmid. The bars mirror the 
readout, obtained at 30 min, shown in Figure 4.27. The data represent mean ± 
S.D. of three independent experiments.  
 
Figure 4.28 shows that the CYP3A4 enzyme expressed from the HIS3 locus has better 
activity than the one from the URA3 locus while the enzyme produced from the URA3 
locus was better than that from the ADE2 locus. The latter activity was better than that 
obtained from the episomal plasmid. Further corroboration of these results is revealed in 
Chapter 5 of this study.  
The graphs in Figures 4.27 and 4.28 would suggest that the amounts of CYP3A4 
expressed depend on the genetic locus and the chromosome in which the CYP3A4_yc 
gene expression cassette is integrated. The results also show that the amounts of CYP3A4 
expressed in cells containing a single copy of CYP3A4_yc gene is higher than in cells 


















Comparison of activities of CYP3A4 enzyme expressed 
from different chromosomal loci and from an episomal 









gene, borne on an episomal plasmid should, in theory, provide multiple copies per cell 
and, therefore, should have yielded more CYP3A4 than in cells which contain a single 
copy of the gene. Our results suggest that CYP3A4 expression occurs more stably from 
a chromosomal locus than from an extra-chromosomal 2µ-plasmid. 
 
 
 Construction of yeast strains bearing 
expression cassettes of the human CYP1A2 
gene, chemically synthesized using yeast biased 
codons, and comparison of CYP1A2 enzyme 
activities produced by the strains 
 
4.7.1 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP1A2 
enzyme from the HIS3 chromosomal locus of a yeast 
strain 
 
The yeast integrative plasmid YIpHisADH2S/CYP1A2_yc (CYP1A2_yc = gene coding 
for human CYP1A2, synthesized using yeast-biased codons) was created via the 
following steps:  
(1) After digestion of the vector YIpHisADH2S (Figure 4.11) with restriction 
enzymes BamHI, XbaI, a 5305 bp fragment was isolated (Figure 4.29). This 
eliminated ~20 bp in the multi-cloning site.  
(2) A 1575 bp BamHI-XbaI CYP1A2_yc gene fragment was isolated from a pUC57 
based plasmid into which the chemically synthesised gene had been cloned. The 
tailor-made gene construct was obtained from Genewiz. CYP1A2_yc gene was 
synthesized with yeast-biased codons using the human CYP1A2 protein as a 
template (Accession Number of protein sequence, NM_000761).  
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(3) The 5305 bp vector and the 1575 bp insert were ligated to obtain the plasmid 
YIpHisADH2S/CYP1A2_yc (Figure 4.29).  
 
5305 bp-
Lanes           1                                   2 
 
Figure 4.29. An agarose gel showing the digestion of the plasmid YIpHisADH2S 
with the restriction enzymes BamHI and Xbal (lane 1). Lane 2, uncut plasmid.  
 
The 5305 bp vector fragment was isolated from lane 1 of the agarose gel (Figure 4.29) 
for ligation with the 1575 bp CYP1A2_yc gene fragment to obtain the plasmid 






Figure 4.30. Map of plasmid YIpHisADH2S/CYP1A2_yc that allows integration 
of a human CYP1A2 gene expression cassette at the HIS3 locus of the yeast 
genome. The human CYP1A2 gene was synthesized using yeast-biased codons 
and was named h_CYP1A2_yc. The map shows restriction sites that cut the 
plasmid only once. 
 
For integration into yeast cells, via homologous recombination, the plasmid 
YIpHisADH2S/CYP1A2_yc was linearized at the NdeI site (indicated by an arrow in 
Figure 4.30). In order to facilitate homologous recombination, the restriction sites NheI 
or BalI (Figure 4.30) could also have been used for linearization. 
The newly constructed plasmid YIpHisADH2S/CYP1A2_yc was further analysed via 
digestion with XhoI and BamI + SacI restriction enzymes (Figure 4.31). The agarose gels 








































Lanes    1         2              3                 4     (A) (B) 
 
Figure 4.31. Agarose gels (A, B) that show the expected DNA fragments of 
YIpHisADH2S/CYP1A2_yc when plasmids isolated from four (A) or three (B) 
bacterial clones were digested with XhoI (lanes 2-5; A) and BamHI-SacI (lanes 
2-4; B). Lane 1 (A & B), 2-log DNA ladder.  
 
The YIpHisADH2S/CYP1A2_yc plasmid can be used for expression of the CYP1A2_yc 
gene driven by the ADH2 promoter. To allow this, the CYP1A2_yc gene expression 
cassette was integrated into the HIS3 locus on chromosome XV.  
 
4.7.2 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP1A2 
enzyme from the URA3 chromosomal locus of a 
yeast strain 
 
The yeast integrative plasmid YIpUraADH2S/CYP1A2_yc was created via the following 
steps:  
(1) After digestion of the vector YIpUraADH2S (Figure 4.15) with restriction 
enzymes BamHI, XbaI, a 5233 bp fragment was isolated. The enzyme digestion 
eliminates 12 bp in the multi-cloning site which cannot be seen on the agarose gel 
(Figure 4.32).  
(2) The 1575 bp BamHI-XbaI CYP1A2_yc gene fragment was isolated from a pUC57 
based plasmid, as in Section 4.5.1.  
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(3) The 5233 bp vector and the 1575 bp insert were ligated to obtain the plasmid 
YIpUraADH2S/CYP1A2_yc (Figure 4.33).  
 
Lanes 1 2           3      
5233 bp-
 
Figure 4.32. An agarose gel showing the digestion of the plasmid YIpUraADH2S 




Figure 4.33. Map of plasmid YIpUraADH2S/CYP1A2_yc that allows integration 
of a human CYP1A2 gene expression cassette at the URA3 locus of the yeast 
genome. The human CYP1A2 gene was synthesized using yeast-biased codons 
and was named h_CYP1A2_yc. The map shows restriction sites that cut the 































For integration into yeast cells, via homologous recombination, the plasmid 
YIpUraADH2S/CYP1A2_yc was linearized at the PstI site (indicated by an arrow in 
Figure 4.33).  
The newly constructed plasmid YIpUraADH2S/CYP1A2_yc was further analysed via 
digestion with XhoI and BamI + SacI restriction enzymes (Figure 4.34). The agarose gels 
showed the expected sizes of DNA fragments.  
 
(B) Lanes      1 2               3                4                5
4890 bp-
1924 bp-





Figure 4.34. Agarose gels (A, B) that show the expected DNA fragments of 
YIpUraADH2S/CYP1A2_yc when plasmids isolated from four bacterial clones 
were digested with PvuII (lanes 2-5; A) and BamHI-SacI (lanes 2-5; B). Lane 1 
(A & B), 2-log DNA ladder. 
 
The plasmid YIpUraADH2S/CYP1A2_yc can be used for expression of the CYP1A2_yc 
gene driven by the ADH2 promoter. To allow this, the CYP1A2_yc gene expression 




4.7.3 Construction of yeast strains that contain a copy of 
the CYP1A2_yc gene expression cassette integrated 
into two different chromosomal loci of the yeast 
strains YY7 and YAB79  
 
Four yeast strains were generated that contained a single copy of the CYP1A2_yc gene 
expression cassette. They were obtained by individually integrating the plasmids that bear 
the CYP1A2_yc expression cassette, in the yeast strains YY7 and YAB79.  
The genesis of the strain YAB79 (BC300::∆hRDM/LEU2+, b5/TRP1+; Figure 4.26) has 
been explained in Section 4.4.4. It expresses ΔhRDM, a modified version of the human 
CYP450 reductase, hRD, the gene being expressed from the ADH2 promoter. It also co-
expresses human cytochrome b5 from the GAPDH promoter. The strain YY7 
(BC300::∆hRDM/LEU2+) expresses only ΔhRDM but not cytochrome b5.  
The CYP1A2_yc gene encoding plasmids used for integration in the strains YY7 and 
YAB79 (see Section 4.4.4) were:  
(1) YIpUraADH2S/CYP1A2_yc, and  
(2) YIpHisADH2S/CYP1A2_yc. 
After integration, the four strains were named: 
(a) YY7::1A2_yc(URA3), YAB79::1A2_yc(URA3), and  




4.7.4 Comparison of activities of CYP1A2 enzyme 
expressed in yeast cells from (a) chromosomal 
integrants of CYP1A2_yc gene expression cassettes 
and (b) an episomal plasmid bearing CYP1A2_yc 
gene 
 
The activities of CYP1A2 enzyme expressed from two different chromosomal loci, URA3 
and HIS3 were compared. The enzyme expressed from a strain containing CYP1A2 gene-
bearing episomal plasmid [YAB79::1A2_yc(2µ)] was used as a positive control whereas 
any enzyme activity from cells containing an empty integrated plasmid (URA3 or HIS3) 
was used as a negative control (Figure 4.35). The comparative kinectic analysis of 
CY1A2_yc co-expressed with and without cytochrome b5 with cytochrome P450 
reductase (CPR) using CEC as a substrate. The intact yeast cells bearing the CYP1A2 
integrated in chromosomal loci (HIS3 and URA3), the episomal CYP3A4_yc and the 
control empty plasmid yeast strain were grown as described in section 4.1.1 and the 
comparative enzyme kinetic assays were measure as described in section 4.1.2 to measure 





Figure 4.35. The graph shows the activity of CYP1A2 enzyme expressed from a 
single copy of the CYP1A2_yc gene expression cassette, integrated at the HIS3 
chromosomal locus, in the yeast strain YY7 which lacks cytochrome b5. 
Activity is compared with the CYP1A2 enzyme expressed in YY7 from an 
episomal plasmid. The graphs represent the average of results obtained from 





Figure 4.36. The bar plot shows the activity of CYP1A2 enzyme expressed from 
a single copy of the CYP1A2_yc gene expression cassette integrated at the HIS3 
locus of the yeast strain YY7, which lacks cytochrome b5, and compared with 
that obtained from an epiosmal 2-micron (2µ) plasmid. The data represent 











Comparison of activity of human CYP1A2 enzyme expressed from the 
HIS3 locus with a strain that expresses the enzyme from an episomal 
















Comparison of activity of human CYP1A2 enzyme expressed from 
the HIS3 locus with a strain that expresses the enzyme from an 






These results once again show that the amounts of a human CYP, in this case CYP1A2, 
expressed in cells which contain a single copy of a CYP_yc gene, integrated at a particular 
chromosomal locus, is higher than in cells which express CYP1A2 enzyme from an 
episomal 2µ-plasmid. As mentioned before, the CYP1A2_yc gene, borne on an episomal 
plasmid should, in theory, provide multiple copies per cell and, therefore, should have 
yielded more CYP1A2 than in cells which contain a single copy of the gene. This 
definitely suggests that a human CYP expression, in yeast, occurs more stably from a 
chromosomal locus than from an extra-chromosomal multi-copy plasmid.  
 
4.7.5 Comparison of activities of CYP1A2 enzyme 
expressed in YY7 and YAB79 
 
The levels of expression of CYP1A2_yc gene, in YY7 (which does not contain the 
cytochrome b5 gene) and in YAB79 which expresses the human cytochrome b5 protein 
were then compared. The results, in Figure 4.37, show that the presence of cytochrome 





Figure 4.37. The graph (A) shows the activity of CYP1A2 enzyme expressed 
from a single copy of the CYP1A2_yc gene expression cassette, integrated at 
the HIS3 chromosomal locus, in the yeast strain YY7 which lacks cytochrome 
b5. Activity is compared with the CYP1A2 enzyme expressed in the strain 
YAB79 which expresses cytochrome b5. The graphs represent the average of 
results obtained from three independent experiments. The bar plot (B) 


















(A) Activity of CYP1A2 expressed in the strains YY7 and 
YAB79, in the absence and presence of cytochrome b5, 


















(B) Activity of CYP1A2 expressed in the strains YY7 
and YAB79, in the absence and presence of 





4.7.6 Comparison of activities of CYP1A2 enzyme 
expressed in the yeast strain YAB79, from two 
different loci, HIS3 and URA3 
 
Activities of human CYP1A2 enzyme expressed from two different chromosomal loci, 
HIS3 and URA3, were then compared. The results are depicted in Figure 4.38 and show 
that chromosomal location of the CYP1A2_yc gene at the HIS3 locus has huge effect 





Figure 4.38. The graph (A) compares the CYP1A2 enzyme activity produced by 
a copy of the CYP1A2_yc gene expression cassette, integrated at the HIS3 and 
URA3 chromosomal loci, in the yeast strain YAB79 which co-expresses 
cytochrome b5. The graphs represent the average of results obtained from 
three independent experiments. The bar plot (B) mirrors the graphs in (A). 
The data represent mean ± S.D. of three independent experiments. 
 
The amounts of CYP1A2 expressed from an integrated copy of the CYP1A2_yc 
expression cassette at the URA3 locus were then compared with the amounts produced 

















(A) Comparison of CYP1A2 enzyme activities 
expressed in YAB79 cells from HIS3 and URA3 















(B) Comparison of CYP1A2 enzyme activities 
expressed in YAB79 cells from HIS3 and URA3 





4.7.7 Comparison of activities of CYP1A2 enzyme 
expressed from (a) the URA3 chromosomal locus 




Figure 4.39. The graph (A) compares the CYP1A2 enzyme activity produced by 
a copy of the CYP1A2_yc gene expression cassette, integrated at the URA3 
chromosomal locus [YAB79::1A2(HIS3)] and the strain YAB79::1A2(2µ) 
expressing CYP1A2 from an episomal plasmid. The graphs represent the 
average of results obtained from three independent experiments. The bar plot 
(B) mirrors the graphs in (A). The data represent mean ± S.D. of three 
independent experiments. 
 















(A) Comparison of activity of human CYP1A2 enzyme expressed 
from the URA3 locus with a strain that expresses the enzyme from 





















(B) Comparison of activity of human CYP1A2 enzyme expressed 
from the URA3 locus with a strain that expresses the enzyme from 






Although the CYP1A2 amounts were far more when expressed from the HIS3 locus [i.e. 
from the cells in the strain YAB79::1A2(HIS3)] than from the URA3 locus [i.e. from the 
cells in the strain YAB79::1A2(URA3)], yet the amounts produced by the latter strain 
were ~4-fold more than that produced by the strain [YAB79::1A2(2µ)] expressing 
CYP1A2 from the episomal, multi-copy plasmid pSYE263/CYP1A2_yc (Chapter 3, 
Figure 3.35). This would indicate that chromosomal integration provides a much more 
stable environment for expression of the CYP1A2 enzyme than when it is expressed from 
an episomal plasmid.  
 
 
 Construction of yeast strains, bearing 
expression cassettes of the human CYP2D6 
variant genes, chemically synthesized using 
yeast biased codons, and comparison of 
CYP2D6 enzyme activities produced by 
different strains 
 
4.8.1 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP2D6(1) 
enzyme from the URA3 chromosomal locus of a 
yeast strain 
 
The yeast integrative plasmid YIpUraADH2S/CYP2D6(1)_yc [CYP2D6(1)_yc = gene 
coding for CYP2D6(1) (Val374) protein (NCBI Accession Number, NM_000106) and 
synthesized using yeast-biased codons] was created via the following steps:  
(1) After digestion of the vector YIpUraADH2S (Figure 4.15) with restriction 
enzymes BamHI, XbaI, a 5233 bp fragment was isolated. This eliminated 12 bp 
in the multi-cloning site.  
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(2) A 1524 bp BamHI-XbaI CYP2D6(1)_yc gene fragment was isolated from a 
pUC57 based plasmid into which the chemically synthesised gene had been 
cloned (obtained from Genewiz). CYP2D6(1)_yc gene was synthesized with 
yeast-biased codons using the human CYP2D6(1) protein as a template 
(Accession Number of protein sequence, NM_000106; Figure 4.40).  
(3) The 5233 bp vector and the 1524 bp insert were ligated to obtain the plasmid 
YIpUraADH2S/CYP2D6(1)_yc (Figure 4.41).  
 
 
   1  MGLEALVPLA VIVAIFLLLV DLMHRRQRWA ARYPPGPLPL PGLGNLLHVD FQNTPYCFDQ 
  61  LRRRFGDVFS LQLAWTPVVV LNGLAAVREA LVTHGEDTAD RPPVPITQIL GFGPRSQGVF 
 121  LARYGPAWRE QRRFSVSTLR NLGLGKKSLE QWVTEEAACL CAAFANHSGR PFRPNGLLDK 
 181  AVSNVIASLT CGRRFEYDDP RFLRLLDLAQ EGLKEESGFL REVLNAVPVL LHIPALAGKV 
 241  LRFQKAFLTQ LDELLTEHRM TWDPAQPPRD LTEAFLAEME KAKGNPESSF NDENLRIVVA 
 301  DLFSAGMVTT STTLAWGLLL MILHPDVQRR VQQEIDDVIG QVRRPEMGDQ AHMPYTTAVI 
 361  HEVQRFGDIV PLGVTHMTSR DIEVQGFRIP KGTTLITNLS SVLKDEAVWE KPFRFHPEHF 
 421  LDAQGHFVKP EAFLPFSAGR RACLGEPLAR MELFLFFTSL LQHFSFSVPT GQPRPSHHGV 
 481  FAFLVSPSPY ELCAVPR 
Figure 4.40. The protein sequence of CYP2D6(1), NM_000106, as published in 
the NCBI database (https://www.ncbi.nlm.nih.gov/). The residue Valine at 







Figure 4.41. Map of plasmid YIpUraADH2S/CYP2D6(1)_yc that allows 
integration of a human CYP2D6(1) gene expression cassette at the URA3 locus 
of the yeast genome. The human h_CYP2D6(1) gene was synthesized using 
yeast-biased codons and was named CYP2D6(1)_yc. The map shows 
restriction sites that cut the plasmid only once.  
 
For integration into yeast cells, via homologous recombination, the plasmid 
YIpUraADH2S/CYP2D6(1)_yc was linearized at the StuI site (as indicated by an arrow 
in Figure 4.41). Alternatively, the EcoRV site could have been used for linearization.  
The newly constructed plasmid YIpUraADH2S/CYP2D6(1)_yc was further analysed via 
digestion with XhoI and BamI + XhoI restriction enzymes (Figure 4.42). The agarose gels 





































(B)   Lanes  1      2      3      4      5      6       7
 
Figure 4.42. Agarose gels (A, B) that show the expected DNA fragments of 
YIpUraADH2S/CYP2D6(1)_yc when plasmids isolated from five (A) and six (B) 
bacterial clones were digested with XhoI (lanes 2-6; A) and BamHI-XhoI (lanes 
2-7; B). Lane 1 (A & B), 2-log DNA ladder. 
 
The YIpUraADH2S/CYP2D6(1)_yc plasmid can be used for expression of the 
CYP2D6(1)_yc gene driven by the ADH2 promoter. In order to allow this, the 
CYP2D6(1)_yc gene expression cassette was integrated into the URA3 locus on yeast 






4.8.2 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP2D6(1) 
enzyme from the HIS3 chromosomal locus of a yeast 
strain 
 
The yeast integrative plasmid YIpHisADH2S/CYP2D6(1)_yc was created via the 
following steps:  
(1) After digestion of the vector YIpHisADH2S (Figure 4.11) with restriction 
enzymes BamHI, XbaI, a 5305 bp fragment was isolated. This eliminated 12 bp 
in the multi-cloning site.  
(2) A 1524 bp BamHI-XbaI CYP2D6(1)_yc gene fragment (NCBI Accession 
Number, NM_000106) was isolated from a pUC57 based plasmid into which the 
chemically synthesised gene had been cloned (as in Section 4.6.1).  
(3) The 5305 bp vector and the 1524 bp insert were ligated to obtain the plasmid 







Figure 4.43. Map of plasmid YIpHisADH2S/CYP2D6(1)_yc that allows 
integration of a human CYP2D6(1) gene expression cassette at the HIS3 locus 
of the yeast genome. The human h_CYP2D6(1) gene was synthesized using 
yeast-biased codons and was named CYP2D6(1)_yc. The map shows 
restriction sites that cut the plasmid only once. 
 
For integration into yeast cells, via homologous recombination, the plasmid 
YIpHisADH2S/ CYP2D6(1)_yc was linearized at the NheI site (indicated by an arrow in 
Figure 4.43). In order to facilitate homologous recombination, the restriction sites BalI or 
BsaBI (Figure 4.43) could also have been used for linearization. 
The newly constructed plasmid YIpHisADH2S/CYP2D6(1)_yc was further analysed via 
digestion with XhoI and PvuII restriction enzymes (Figure 4.44). The agarose gels showed 


































(A) Lanes              1                  2                    3
4008 bp-
2815 bp-
(B) Lanes     1             2             3             4            5
 
Figure 4.44. Agarose gels (A, B) that show the expected DNA fragments of 
YIpHisADH2S/CYP2D6(1)_yc when plasmids isolated from two (A) or four (B) 
bacterial clones were digested with XhoI (lanes 2-3; A) and PvuII (lanes 2-5; 
B). Lane 1 (A & B), 2-log DNA ladder [not visible in (B)].  
 
The YIpHisADH2S/CYP2D6(1)_yc plasmid can be used for expression of the 
CYP2D6(1)_yc gene driven by the ADH2 promoter.  In order to allow this, the 
CYP2D6(1)_yc gene expression cassette would have to be integrated into the HIS3 locus 
on chromosome XV. 
 
4.8.3 Construction of yeast strains that contain a copy of 
the CYP2D6(1)_yc gene expression cassette 
integrated into two different chromosomal loci of 
the yeast strain YY7 
 
Two yeast strains were generated that contained a single copy of the CYPD6(1)_yc gene 
expression cassette. They were obtained by individually integrating the plasmids that bear 
the CYPD6(1)_yc expression cassette in the yeast strain YY7 (BC300::∆hRDM/LEU2+) 
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that can express ΔhRDM from the LEU2 locus. YY7 cells do not contain the human 
cytochrome b5 gene.  
The CYPD6_yc gene encoding plasmids used for integration in the strain YY7 were:  
(1) YIpUraADH2S/CYP2D6(1)_yc, and  
(2) YIpHisADH2S/CYP2D6(1)_yc. 
After integration, the strains were named: 
(a) YY7::2D6(1)_yc(URA3) and  
(b) YY7::2D6(1)_yc(HIS3). 
 
YAB79 (BC300::∆hRDM/LEU2+, b5/TRP1+; Figure 26) has been explained in Section 
4.4.4. It expresses ΔhRDM, a modified version of the human CYP450 reductase, hRD, 
the gene being expressed from the ADH2 promoter. It also co-expresses human 
cytochrome b5 from the GAPDH promoter 
The CYPD6_yc gene encoding plasmids used for integration in the strain YAB79 were:  
After integration, the strains were named: 
(a) YAB79::2D6(1)_yc(URA3) and  
(b) YAB79::2D6 (1)_yc(HIS3). 
The amounts of enzyme expressed from these strains were then compared in fluorescence 
assays using an appropriate fluorogenic substrate. Comparative kinetic analysis of 
CY2D6_yc co-expressed with and without cytochrome b5 in the presence of the modified 
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cytochrome P450 reductase (∆hRDM), using EOMCC as a substrate, was performed 
(Figure 4.45). The intact yeast cells bearing the CYP2D6(1)_yc gene integrated in the 
chromosomal loci of HIS3 and URA3 genes, an episomal plasmid encoding the 
CYP2D6(1)_yc gene and the control empty plasmid contacting yeast strain were grown 
as described in Section 4.1.1 and the comparative enzyme kinetic assays were performed 
as described in Section 4.1.2. Formation of product, 7-HCC, was measured. These 






4.8.4 Comparison of activities of CYP2D6(1) enzyme 
expressed from (a) the CYP2D6(1)_yc gene 
chromosomally integrated at the HIS3 or URA3 
locus, and (b) an episomal plasmid bearing the 


































(A) Comparison of CYP2D6(1) enzyme 
















(B) Comparison of CYP2D6(1) enzyme 







Figure 4.45. The graph (A) compares the CYP2D6(1) enzyme activities 
produced in the strains YY7::2D6(1)(HIS3) and YY7::2D6(1)(URA3), 
expressing a copy of the CYP2D6(1)_yc gene expression cassette, integrated at 
the HIS3 and URA3 chromosomal loci, and the strain YY7:: 2D6(1)(2µ) 
expressing CYPD6(1)_yc from an episomal, 2-micron (2u) plasmid. The graphs 
represent the average of results obtained from three independent 
experiments. The bar plot (B) mirrors the graphs in (A). The graph (C) 
compares the CYP2D6(1) enzyme activities produced in the strains 
YAB79::2D6(1)(HIS3) and YY7::2D6(1)(HIS3), expressing a copy of the 
CYP2D6(1)_yc gene expression cassette, integrated at the HIS3 and URA3 
chromosomal loci in the presence/absence of cytochrome b5, and similarly 
the strain YY7:: 2D6(1)(2µ) and YAB79::2D6(1)(2µ) expressing CYPD6(1)_yc 
from an episomal, 2-micron (2u) plasmid in the presence/absence of 
cytochrome b5. The graphs represent the average of results obtained from 
three independent experiments. The bar plot (D) mirrors the graphs in (C).  











(C) Comparison of CYP2D6(1) enzyme activities co-
















(D) Comparison of CYP2D6(1) enzyme activities co-










The graphs in Figure 45 (A) show the expression of a single copy of the CYP2D6 (1)_yc 
gene expression cassette from the HIS3 locus is superior to that from the URA3 locus. 
The CYP2D6 (1) enzyme expressed from the HIS3 locus has a better activity than from 
the URA3 locus implying that levels of CYP2D6 (1) expressed from the HIS3 locus is 
more than that from the URA3 locus. It should also be noted that both integrated copies 
produce higher amounts of CYP2D6 (1) enzyme than that from an episomal plasmid. 
Also the graphs in Figure 45 (C) show the expression of both the episomal plasmid (2µ) 
and single copy (HIS3) when co-expressed in the presence of cytochrome b5. The results 
show that b5 does not enhance the activity of CYP2D6 but, in contrary, tends to block the 
binding site of CYP2D6, making CYP2D6 activities collapse drastically compared to the 
enzyme expressed in the absence of cytochrome b5. 
 
4.8.5 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP2D6(2) 
enzyme from the HIS3 chromosomal locus of a yeast 
strain 
 
The yeast integrative plasmid YIpHisADH2S/CYP2D6(2)_yc was created via the 
following steps:  
(1) The vector YIpHisADH2S (Figure 4.11) was digested with restriction enzymes 
BamHI, XbaI, and a 5305 bp fragment was isolated.  
(2) A 1524 bp BamHI-XbaI CYP2D6(2)_yc gene fragment (coding for the Met374 
wild-type variant) was isolated from a pUC57 based plasmid into which the 
chemically synthesised gene, using yeast-biased codons, had been cloned. The 
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gene was synthesized on the basis of the protein sequence published in the NCBI 
database (Accession Number, M20403; Figure 4.46).  
(3) The 5305 bp vector and the 1524 bp insert were ligated to obtain the plasmid 
YIpHisADH2S/ CYP2D6(2)_yc (Figure 4.48).  
 
   1  MGLEALVPLA VIVAIFLLLV DLMHRRQRWA ARYPPGPLPL PGLGNLLHVD FQNTPYCFDQ 
  61  LRRRFGDVFS LQLAWTPVVV LNGLAAVREA LVTHGEDTAD RPPVPITQIL GFGPRSQGVF 
 121  LARYGPAWRE QRRFSVSTLR NLGLGKKSLE QWVTEEAACL CAAFANHSGR PFRPNGLLDK 
 181  AVSNVIASLT CGRRFEYDDP RFLRLLDLAQ EGLKEESGFL REVLNAVPVL LHIPALAGKV 
 241  LRFQKAFLTQ LDELLTEHRM TWDPAQPPRD LTEAFLAEME KAKGNPESSF NDENLRIVVA 
 301  DLFSAGMVTT STTLAWGLLL MILHPDVQRR VQQEIDDVIG QVRRPEMGDQ AHMPYTTAVI 
 361  HEVQRFGDIV PLGMTHMTSR DIEVQGFRIP KGTTLITNLS SVLKDEAVWE KPFRFHPEHF 
 421  LDAQGHFVKP EAFLPFSAGR RACLGEPLAR MELFLFFTSL LQHFSFSVPT GQPRPSHHGV 
 481  FAFLVSPSPY ELCAVPR 
Figure 4.46. The protein sequence of CYP2D6(2), M20403, as published in the 
NCBI database (https://www.ncbi.nlm.nih.gov/). 
 
                         10        20        30        40        50 
                          *         *         *         *         * 
2D6-1.PRT        MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVD 
2D6-2.PRT        MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVD 
 
                         60        70        80        90       100 
                          *         *         *         *         * 
2D6-1.PRT        FQNTPYCFDQLRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTAD 
2D6-2.PRT        FQNTPYCFDQLRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTAD 
 
                        110       120       130       140       150 
                          *         *         *         *         * 
2D6-1.PRT        RPPVPITQILGFGPRSQGVFLARYGPAWREQRRFSVSTLRNLGLGKKSLE 
2D6-2.PRT        RPPVPITQILGFGPRSQGVFLARYGPAWREQRRFSVSTLRNLGLGKKSLE 
 
                        160       170       180       190       200 
                          *         *         *         *         * 
2D6-1.PRT        QWVTEEAACLCAAFANHSGRPFRPNGLLDKAVSNVIASLTCGRRFEYDDP 
2D6-2.PRT        QWVTEEAACLCAAFANHSGRPFRPNGLLDKAVSNVIASLTCGRRFEYDDP 
 
                        210       220       230       240       250 
                          *         *         *         *         * 
2D6-1.PRT        RFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKVLRFQKAFLTQ 
2D6-2.PRT        RFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKVLRFQKAFLTQ 
 
                        260       270       280       290       300 
                          *         *         *         *         * 
2D6-1.PRT        LDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA 
2D6-2.PRT        LDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA 
 
                        310       320       330       340       350 
                          *         *         *         *         * 
2D6-1.PRT        DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQ 
2D6-2.PRT        DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQ 
 
                        360       370       380       390       400 
                          *         *         *         *         * 
2D6-1.PRT        AHMPYTTAVIHEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLS 
2D6-2.PRT        AHMPYTTAVIHEVQRFGDIVPLGMTHMTSRDIEVQGFRIPKGTTLITNLS 
 
                        410       420       430       440       450 
                          *         *         *         *         * 
2D6-1.PRT        SVLKDEAVWEKPFRFHPEHFLDAQGHFVKPEAFLPFSAGRRACLGEPLAR 
2D6-2.PRT        SVLKDEAVWEKPFRFHPEHFLDAQGHFVKPEAFLPFSAGRRACLGEPLAR 
 
                        460       470       480       490 
                          *         *         *         * 
2D6-1.PRT        MELFLFFTSLLQHFSFSVPTGQPRPSHHGVFAFLVSPSPYELCAVPR 
2D6-2.PRT        MELFLFFTSLLQHFSFSVPTGQPRPSHHGVFAFLVSPSPYELCAVPR 
Figure 4.47. Alignment of CYP2D6(1) and CYP2D6(2) protein sequences. The 




The protein sequences of CYP2D6(1) and CYP2D6(2) differ in one amino acid residue 
at position 374 (Figure 4.47).  
It has been suggested that the variant CYP2D6(1) (Vall374) produces much higher activity 
than CYP2D6(2) (Met374) in insect cells (Yu et al., 2002). In fact, the leading 
manufacturer of recombinant human CYP enzymes (Corning-Gentest) distributes only 
CYP2D6(1) enzyme produced in insect cells.  
 
 
Figure 4.48. Map of plasmid YIpHisADH2S/CYP2D6(2)_yc that allows 
integration of a human CYP2D6(2) gene expression cassette at the HIS3 locus 
of the yeast genome. The human CYP2D6(2) gene was synthesized using yeast-
biased codons and was named hCYP2D6(2)_yc. The map shows restriction 
sites that cut the plasmid only once. 
 
For integration into yeast cells, via homologous recombination, the plasmid 
































Figure 4.48). In order to facilitate homologous recombination, the restriction sites BalI or 
BsaBI (Figure 4.48) could also have been used for linearization. 
The newly constructed plasmid YIpHisADH2S/CYP2D6(2)_yc was further analysed via 
digestion with XhoI and BamHI-XbaI restriction enzymes (Figure 4.49). The agarose gels 
show the expected fragments.  
4714 bp-
2106 bp-
(A) Lanes      1           2             3              4 
4714 bp-
2106 bp-
(B) Lanes       1         2          3        4
 
Figure 4.49. Agarose gels (A, B) that show the expected DNA fragments of 
YIpHisADH2S/CYP2D6(2)_yc when plasmids isolated from three bacterial 
clones (A and B) were digested with XhoI (lanes 2-4; A & B) and BamHI-XbaI 
(lanes 2-4; A & B). Lane 1 (A & B), 2-log DNA ladder [not clearly visible in (B)]. 
 
The plasmid YIpHisADH2S/CYPD6(2)_yc can be used for expression of the 
CYP2D6(2)_yc  gene driven by the ADH2 promoter.  In order to allow this, the 
CYP2D6(2)_yc gene expression cassette must be integrated into the HIS3 locus on 




4.8.6 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP2D6(2) 
enzyme from the URA3 chromosomal locus of a 
yeast strain 
 
The yeast integrative plasmid YIpUraADH2S/CYP2D6(2)_yc was created via the 
following steps:  
(1) The vector YIpUraADH2S (Figure 4.15) was digested with restriction enzymes 
BamHI, XbaI, and a 5233 bp fragment was isolated.  
(2) A 1524 bp BamHI-XbaI CYP2D6(2)_yc gene fragment was isolated from the 
pUC57 based plasmid, as in Section 4.6.5.  
(3) The 5233 bp vector and the 1524 bp insert were ligated to obtain the plasmid 







Figure 4.50. Map of plasmid YIpUraADH2S/CYP2D6(2)_yc that allows 
integration of a human CYP2D6(2) gene expression cassette at the URA3 locus 
of the yeast genome. The human CYP2D6(2) gene was synthesized using yeast-
biased codons and was named hCYP2D6(2)_yc. The map shows restriction 
sites that cut the plasmid only once. 
 
For integration into yeast cells, via homologous recombination, the plasmid 
YIpUraADH2S/CYP2D6(2)_yc was linearized at the EcoRV site (as indicated by an 
arrow in Figure 4.40). Alternatively, the NcoI site could have been used for linearization.  
The newly constructed plasmid YIpUraADH2S/CYP2D6(2)_yc was further analysed via 
digestion with BamI + XbaI restriction enzymes (Figure 4.51). The agarose gel showed 

































Lanes          1         2         3         4       5           6 
 
Figure 4.51. Agarose gel that shows the expected DNA fragments of 
YIpUraADH2S/CYP2D6(2)_yc when plasmids isolated from five bacterial 
clones were digested with BamHI-XbaI (lanes 2-6). Lane 1, 2-log DNA ladder. 
 
The YIpUraADH2S/CYPD6(2)_yc plasmid was used for expression of the 
CYP2D6(2)_yc gene driven by the ADH2 promoter. In order to allow this, the 
CYP2D6(2)_yc gene expression cassette was integrated into the URA3 locus on 
chromosome V. 
 
4.8.7 Construction of yeast strains that contain a copy of 
the CYP2D6(2)_yc gene expression cassette 
integrated into two different chromosomal loci of 
the yeast strain YY7 and YAB79 
 
Two yeast strains were generated that contained a single copy of the CYP2D6(2)_yc gene 
expression cassette. They were obtained by individually integrating the plasmids that bear 
the CYP2D6(2)_yc expression cassette in the yeast strain YY7 (BC300::∆hRDM/LEU2+) 
that can express ΔhRDM from the LEU2 locus. YY7 cells do not contain the human 
cytochrome b5 gene.  
The CYP2D6(2)_yc gene encoding plasmids used for integration in the strain YY7 were:  
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(1) YIpUraADH2S/CYP2D6(2)_yc, and  
(2) YIpHisADH2S/CYP2D6(2)_yc. 
After integration, the strains were named: 
(a) YY7::2D6(2)_yc(URA3) and  
(b) YY7::2D6(2)_yc(HIS3). 
 
The amounts of enzyme expressed from these strains were then compared in fluorescence 
assays using an appropriate fluorogenic substrate. The comparative kinectic analysis of 
CY2D6(2)_yc co-expressed  without cytochrome b5 with cytochrome P450 reductase 
(CPR) using EOMCC as a substrate. The intact yeast cells bearing the CYP2D6(2) 
integrated in chromosomal loci (HIS3 and URA3), the episomal CYP2D6(2)_yc and the 
control empty plasmid yeast strain were grown as described in section 4.1.1 and the 
comparative enzyme kinetic assays were measure as described in section 4.1.2 to measure  
product, 7-HCC formation. These procedures were carried out in three different 
experiments.  
YAB79 (BC300::∆hRDM/LEU2+, b5/TRP1+; Figure 26) has been explained in Section 
4.4.4. It expresses ΔhRDM, a modified version of the human CYP450 reductase, hRD, 
the gene being expressed from the ADH2 promoter. It also co-expresses human 
cytochrome b5 from the GAPDH promoter 
The CYPD6(2)_yc gene encoding plasmids used for integration in the strain YAB79 were:  
After integration, the strains were named: 
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(a) YAB79::2D6(2)_yc(URA3) and  
(b) YAB79::2D6 (2)_yc(HIS3). 
The amounts of enzyme expressed from these strains were then compared in fluorescence 
assays using an appropriate fluorogenic substrate. Comparative kinetic analysis of 
CY2D6(2)_yc co-expressed with and without cytochrome b5 in the presence of the 
modified cytochrome P450 reductase (∆hRDM), using EOMCC as a substrate, was 
performed (Figure 4.45). The intact yeast cells bearing the CYP2D6(2)_yc gene integrated 
in the chromosomal loci of HIS3 and URA3 genes, an episomal plasmid encoding the 
CYP2D6(2)_yc gene and the control empty plasmid contacting yeast strain were grown 
as described in Section 4.1.1 and the comparative enzyme kinetic assays were performed 
as described in Section 4.1.2. Formation of product, 7-HCC, was measured. These 







4.8.8 Comparison of activities of CYP2D6(2) enzyme 
expressed from (a) the CYP2D6(2)_yc gene 
chromosomally integrated at the HIS3 or URA3 
locus, and (b) an episomal plasmid bearing the 
CYP2D6(2)_yc gene, in the yeast strain YY7; 

















(A) Comparison of CYP2D6(2) enzyme activities 

















(B) Comparison of CYP2D6(2) enzyme activities 



















(C) Comparison of CYP2D6(1&2) enzyme 










Figure 4.52. The graph (A) compares the CYP2D6(2) enzyme activities 
produced in the strains YY7::2D6(2)(HIS3) and YY7::2D6(2)(URA3), 













(D) Comparison of CYP2D6(1&2) enzyme 
















(E) Comparison of CYP2D6(2) enzyme activities 




















(F) Comparison of CYP2D6(2) enzyme activities 









the HIS3 and URA3 chromosomal loci, and the strain YY7::2D6(2)(2µ) 
expressing CYPD6(2)_yc from an episomal, 2-micron (2u) plasmid. The graphs 
represent the average of results obtained from three independent 
experiments. The bar plot (B) mirrors the graphs in (A). The data represent 
mean ± S.D. of three independent experiments. The graph (C) compares the 
activities of the CYP2D6(1) and CYP2D6(2) enzymes. The bar plot (D) 
represents units emitted at 30 min of reaction with the substrate, EOMCC. The 
graph (E) compares the CYP2D6(2) enzyme activities produced in the strains 
YAB79::2D6(2)(HIS3) and YY7::2D6(2)(HIS3), expressing a copy of the 
CYP2D6(2)_yc gene expression cassette, integrated at the HIS3  chromosomal 
loci in the presence/absence of cytochrome b5, and similarly the strain YY7:: 
2D6(2)(2µ) and YAB79::2D6(2)(2µ) expressing CYPD6(2)_yc from an 
episomal, 2-micron (2u) plasmid in the presence/absence of cytochrome b5. 
The graphs represent the average of results obtained from three independent 
experiments. The bar plot (F) mirrors the graphs in (E).  The data represent 
mean ± S.D. of three independent experiments. 
 
 
Figure 4.52 shows that the expression of a single copy of the CYP2D6(2)_yc gene from 
the HIS3 locus is superior to that from the URA3 locus. The CYP2D6(2) enzyme 
expressed from the HIS3 locus has a better activity than from the URA3 locus which may 
reflect that the enzyme produced from the HIS3 locus is more than that produced from 
the URA3 locus. However, once again, both integrated copies of the gene produce higher 
amounts than that obtained from an episomal plasmid.  
Also the graphs in Figure 4.52 (E) show the expression of both the episomal plasmid (2µ) 
and single copy (HIS3) when co-expressed in the presence of cytochrome b5. The results 
show that b5 does not enhance the activity of CYP2D6(2) but, in contrary, tends to block 
the binding site of CYP2D6(2), making CYP2D6(2) activities collapse drastically 





 Construction of yeast strains, bearing 
expression cassettes of the human CYP2C19 
gene, chemically synthesized using yeast biased 
codons, and comparison of CYP2C19 enzyme 
activities produced by different strains 
 
4.9.1 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP2C19 
enzyme from the HIS3 chromosomal locus of a yeast 
strain 
 
The yeast integrative plasmid YIpHisADH2S/CYP2C19_yc was created via the 
following steps:  
(1) After digestion of the plasmid YIpHisADH2S (Figure 4.11) with restriction 
enzymes BamHI, XbaI, the 5305 bp vector fragment was isolated.  
(2) A 1485 bp BamHI-XbaI CYP2C19_yc gene fragment was isolated from a pUC57 
plasmid. The gene was synthesized (Genewiz), using yeast-biased codons, based 
on the sequence of the human CYP2C19 protein with NCBI Accession Number, 
NP_000760. The gene was isolated from the pUC57 based plasmid into which the 
chemically synthesised gene had been cloned.  
(3) The 5305 bp vector and the 1485 bp insert were ligated to create the plasmid 





Figure 4.53. Map of plasmid YIpHisADH2S/CYP2C19_yc that allows integration 
of a human CYP2C19 gene expression cassette at the HIS3 locus of the yeast 
genome. The human CYP2C19 gene was synthesized using yeast-biased 
codons and was named h_CYP2C19_yc. The map shows restriction sites that 
cut the plasmid only once. 
 
For integration into yeast cells, via homologous recombination, the plasmid 
YIpHisADH2S/CYP2C19_yc was linearized at the NheI site (indicated by the arrow in 
Figure 4.53). In order to facilitate homologous recombination, the restriction sites BalI, 
BsaBI or BclI (Figure 4.53) could also have been used for linearization. 
The newly constructed plasmid YIpHisADH2S/CYP2C19_yc was further analysed via 
digestion with BamHI-XbaI (double-digest) and PstI restriction enzymes (Figure 4.54). 



































(A) Lanes    1      2      3       4     5




Figure 4.54. Agarose gels (A, B) that show the expected DNA fragments of 
YIpHisADH2S/CYP2C19_yc when plasmids isolated from four bacterial clones 
were digested with BamHI-XbaI (lanes 2-5) and PstI (lanes 2-5). Lane 1 (A & 
B), 2-log DNA ladder.  
 
The YIpHisADH2S/CYP2C19_yc plasmid can be used for expression of the 
CYP2C19_yc gene driven by the ADH2 promoter. In order to allow this, the CYP2C19_yc 





4.9.2 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP2C19 
enzyme from the URA3 chromosomal locus of a 
yeast strain 
 
The yeast integrative plasmid YIpUraADH2S/CYP2C19_yc [CYP2C19_yc = gene 
coding for CYP2C19 protein (as in Section 4.7.1; Accession Number NP_000760) and 
synthesized using yeast-biased codons] was created via the following steps:  
(1) After digestion of the vector YIpUraADH2S (Figure 4.15) with restriction 
enzymes BamHI, XbaI, a 5233 bp fragment was isolated. This eliminated 12 bp 
in the multi-cloning site.  
(2) A 1485 bp BamHI-XbaI CYP2C19_yc gene fragment was isolated from a pUC57 
based plasmid (as in Section 4.7.1).  
(3) The 5233 bp vector and the 1485 bp insert were ligated to obtain the plasmid 






Figure 4.55. Map of plasmid YIpUraADH2S/CYP2C19_yc that allows 
integration of a human CYP2C19 gene expression cassette at the URA3 locus 
of the yeast genome. The human CYP2C19 gene was synthesized using yeast-
biased codons and was named h_CYP2C19. The map shows restriction sites 
that cut the plasmid only once. 
 
For integration into yeast cells, via homologous recombination, the plasmid 
YIpUraADH2S/CYP2C19_yc was linearized at the StuI site (as indicated by the arrow in 
Figure 4.55). Alternatively, the EcoRV site could also have been used for linearization.  
The newly constructed plasmid YIpUraADH2S/ CYP2C19 was further analysed via 
digestion with BamHI-XbaI (double-digest) and NcoI restriction enzymes (Figure 4.56). 
































(A) Lanes    1      2      3      4     5
4088 bp-
2636 bp-
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Figure 4.56. Agarose gels (A, B) that show the expected DNA fragments of 
YIpUraADH2S/CYP2C19_yc when plasmids isolated from four bacterial clones 
were digested with BamHI-XbaI (lanes 2-5) and NcoI (lanes 2-5). Lane 1 (A & 
B), 2-log DNA ladder.  
 
The plasmid YIpUraADH2S/CYP2C19_yc can be used for expression of the 
CYP2C19_yc gene driven by the ADH2 promoter. In order to allow this, the CYP2C19_yc 








4.9.3 Construction of yeast strains that contain a copy of 
the CYP2C19_yc gene expression cassette integrated 
into two different chromosomal loci of the yeast 
strain YAB79 
 
Two yeast strains were generated that contained a single copy of the CYP2C19_yc gene 
expression cassette. They were obtained by individually integrating the plasmids that bear 
the CYP2C19_yc expression cassette in the yeast strain YAB79 
(BC300::∆hRDM/LEU2+, b5/TRP1+; Figure 4.26) that express ΔhRDM from the LEU2 
locus and cytochrome b5 from the TRP1 locus.  
The CYP2C19_yc gene encoding plasmids used for integration in the strain YAB79 were:  
(1) YIpUraADH2S/CYP2C19_yc, and  
(2) YIpHisADH2S/ CYP2C19_yc. 
After integration, the strains were named: 
(a) YAB79::2C19_yc(URA3) and  
(b) YAB79::2C19_yc(HIS3). 
 
The amounts of enzyme expressed from these strains were then compared in fluorescence 
assays using an appropriate fluorogenic substrate. The kinetic analysis of CY2C19 
enzyme co-expressed with cytochrome b5 and cytochrome P450 reductase ∆hRDM, 
using CEC as a substrate, is shown in Figure 4.57. The intact yeast cells bearing the 
CYP2C19_yc gene integrated in chromosomal loci HIS3 and URA3, the episomal plasmid 
encoding the CYP2C19_yc gene and the control empty plasmid containing yeast strain 
were grown as described in section 4.1.1 and the comparative enzyme kinetic assays were 
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measure as described in section 4.1.2 to measure  product, CHC formation. These 




4.9.4 Comparison of activities of CYP2C19 enzyme 
expressed from (a) the CYP2C19_yc gene 
chromosomally integrated at the HIS3 or URA3 
locus, and (b) an episomal plasmid bearing the 
CYP2C19_yc gene, in the yeast strain YAB79 
 
 
Figure 4.57. The graph (A) compares the CYP2C19 enzyme activities produced 
in the strains YAB79::2C19(HIS3) and YAB79::2C19(URA3), expressing a copy 
of the CYP2C19_yc gene expression cassette, integrated at the HIS3 and URA3 
chromosomal loci, and the strain YAB79::2C19(2µ) expressing CYP2C19_yc 
from an episomal, 2-micron (2u) plasmid. The graphs represent the average 
of results obtained from three independent experiments. The bar plot (B) 














(A) Comparison of 2C19 enzyme activities using 

















(B) Comparison of 2C19 enzyme activities using 







Figure 4.57 shows that the expression of a single copy of the CYPC19_yc gene from the 
HIS3 locus is superior to that from the URA3 locus. The CYP2C19 enzyme expressed 
from the HIS3 locus has a better activity than from the URA3 locus which may reflect 
that the enzyme produced from the HIS3 locus is more than that produced from the URA3 
locus. However, once again, both integrated copies of the gene produce higher amounts 
than that obtained from an episomal plasmid. 
 
 
 Construction of yeast strains, bearing 
expression cassettes of the human CYP2C9 
gene, chemically synthesized using yeast biased 
codons, and comparison of CYP2C9 enzyme 
activities produced by different strains 
 
4.10.1 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP2C9 
enzyme from the URA3 chromosomal locus of a 
yeast strain 
 
The yeast integrative plasmid YIpUraADH2S/CYP2C9_yc [CYP2C9_yc = gene coding 
for CYP2C9 protein (Accession Number AAI25055) and synthesized using yeast-biased 
codons] was created via the following steps:  
(1) The plasmid YIpUraADH2S (Figure 4.15) digested with the restriction enzymes 
BamHI, XbaI, and a 5233 bp vector fragment was isolated.  
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(2) A 1485 bp BamHI-XbaI CYP2C9_yc gene fragment was isolated from a pUC57 
based plasmid into which the human CYP2C9 gene, chemically synthesized using 
yeast-biased codons (Genewiz), was cloned.  
(3) The 5233 bp vector and the 1485 bp insert were ligated to obtain the plasmid 
YIpUraADH2S/CYP2C9_yc (Figure 4.58).  
 
 
Figure 4.58. Map of plasmid YIpUraADH2S/CYP2C9_yc that allows integration 
of a human CYP2C9 gene expression cassette at the URA3 locus of the yeast 
genome. The human CYP2C9 gene was synthesized using yeast-biased codons 
and was named h_CYP2C9. The map shows restriction sites that cut the 
plasmid only once. 
 
For integration into yeast cells, via homologous recombination, the plasmid 
YIpUraADH2S/CYP2C9_yc was linearized at the StuI site (as indicated by the arrow in 



































The newly constructed plasmid YIpUraADH2S/CYP2C9 was further analysed via double 
digestion with BamHI, XbaI and digestion with only PvuII restriction enzymes (Figure 




(A) Lanes  1   2   3   4   5   6  7  
4008 bp-
2782 bp-
(B) Lanes1    2     3   4    5    6    7  
 
Figure 4.59. Agarose gels (A, B) that show the expected DNA fragments of 
YIpUraADH2S/CYP2C9_yc when plasmids isolated from seven bacterial clones 
were digested with BamHI-XbaI (lanes 2-7) and PvuII (lanes 2-7). Lane 1 (A & 
B), 2-log DNA ladder.  
 
The plasmid YIpUraADH2S/CYP2C9_yc was used for expression of the CYP2C9_yc 
gene driven by the ADH2 promoter.  In order to allow this, the expression cassette for 
CYP2C9_yc gene, coding for the human CYP2C9 protein, was integrated at the URA3 






4.10.2 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP2C9 
enzyme from the HIS3 chromosomal locus of a yeast 
strain 
 
The yeast integrative plasmid YIpHisADH2S/CYP2C9_yc was created via the following 
steps:  
(1) After digestion of the plasmid YIpHisADH2S (Figure 4.11) with restriction 
enzymes BamHI, XbaI, the 5305 bp vector fragment was isolated.  
(2) A 1485 bp BamHI-XbaI CYP2C9_yc gene fragment was isolated. The gene was 
synthesized (Genewiz) as in Section 4.8.1, using yeast-biased codons based, based 
on the human protein sequence (NCBI Accession Number AAI25055).  
(3) The 5305 bp vector and the 1485 bp insert were ligated to create the plasmid 






Figure 4.60. Map of plasmid YIpHisADH2S/CYP2C9_yc that allows integration 
of a human CYP2C9 gene expression cassette at the HIS3 locus of the yeast 
genome. The human CYP2C9 gene was synthesized using yeast-biased codons 
and was named h_CYP2C9. The map shows restriction sites that cut the 
plasmid only once. 
 
For integration into yeast cells, via homologous recombination, the plasmid 
YIpHisADH2S/CYP2C9_yc was linearized at the NheI site (indicated by the arrow in 
Figure 4.60). In order to facilitate homologous recombination, the restriction sites BalI, 
BsaBI or BclI (Figure 4.60) could also have been used for linearization. 
The newly constructed plasmid YIpHisADH2S/CYP2C9_yc was further analysed via 
double digestion with BamHI, XbaI and digestion with PvuII (Figure 4.61). The agarose 
gels show the expected sizes of DNA fragments. The plasmid was used for expression of 
the CYP2C9_yc gene driven by the ADH2 promoter.  To allow this, the CYP2C9_yc gene 





































(A) Lanes   1   2   3   4   5    6   7
4008 bp-
2782 bp-
(B) Lanes  1    2    3    4    5    6    7
 
Figure 4.61. Agarose gels (A, B) that show the expected DNA fragments of 
YIpHisADH2S/CYP2C9_yc when plasmids isolated from seven bacterial clones 
were digested with BamHI-XbaI (lanes 2-7) and PvuII (lanes 2-7). Lane 1 (A & 
B), 2-log DNA ladder. 
 
4.10.3 Construction of yeast strains that contain a copy of 
the CYP2C9_yc gene expression cassette integrated 
into two different chromosomal loci of the yeast 
strain YAB79 
 
Two yeast strains, containing a single copy of the CYP2C9_yc gene expression cassette, 
were obtained by individually integrating the plasmids that bear the CYP2C9_yc 
expression cassette in the yeast strain YAB79 (BC300::∆hRDM/LEU2+, b5/TRP1+; 
Figure 4.26) that expresses ΔhRDM from the LEU2 locus and cytochrome b5 from the 
TRP1 locus.  
The two CYP2C9_yc gene encoding plasmids that were used for integration in the YAB79 
strain were:  




After integration, the strains were named: 
(a) YAB79::2C9_yc(URA3) and  
(b) YAB79::2C9_yc(HIS3). 
The amounts of enzyme expressed from these strains were then compared in fluorescence 
assays using an appropriate fluorogenic substrate. Comparative kinetic analysis of 
CY2C9 enzyme co-expressed with cytochrome b5 and cytochrome P450 reductase 
∆hRDM, using 7-MFC as a substrate, is shown in Figure 4.62. The intact yeast cells 
bearing the CYP2C9_yc gene integrated in the chromosomal loci HIS3 and URA3, the 
episomal plasmid bearing CYP2C9_yc gene and the control empty plasmid containing 
yeast strain were grown as described in Section 4.1.1. Comparative enzyme kinetic assays 
were performed as described in Section 4.1.2 to measure the formation of the product, 






4.10.4 Comparison of activities of CYP2C9 enzyme 
expressed from (a) the CYP2C9_yc gene 
chromosomally integrated at the HIS3 or URA3 
locus, and (b) an episomal plasmid bearing the 
CYP2C9_yc gene, in the yeast strain YAB79 
 
 
Figure 4.62. The graph (A) compares the CYP2C9 enzyme activities produced 
in the strains YAB79::2C9(HIS3) and YAB79::2C9(URA3), expressing a copy of 
the CYP2C9_yc gene expression cassette, integrated at the HIS3 and URA3 
chromosomal loci, and the strain YAB79::2C9(2µ) expressing CYP2C9 from an 
episomal, 2-micron (2u) plasmid. The graphs represent the average of results 
obtained from three independent experiments. The bar plot (B) mirrors the 














(A) Comparison of CYP2C9 enzyme activities using 

















(B) Comparison of CYP2C9 enzyme activities using 







Figure 4.62 shows that the expression of a single copy of the CYP2C9_yc gene from the 
HIS3 locus is slightly superior to that from the URA3 locus, i.e. slightly more CYP2C9 
enzyme is expressed from the HIS3 locus than from the URA3 locus The episomal 
plasmid distinctly provides much less enzyme, per unit number of cells, than the cells 
which have integrated copies of the CYP2C9_yc gene. 
 
 
 Construction of yeast strains, bearing 
expression cassettes of the human CYP4F3A 
gene, chemically synthesized using yeast biased 
codons, and comparison of CYP4F3A enzyme 
activities produced by different strains 
 
4.11.1 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP4F3A 
enzyme from the HIS3 chromosomal locus of a yeast 
strain 
 
The yeast integrative plasmid YIpHisADH2S/CYP4F3A_yc was created via the 
following steps:  
(1) After digestion of the plasmid YIpHisADH2S (Figure 4.11) with restriction 
enzymes BamHI, XbaI, the 5305 bp vector fragment was isolated.  
(2) Isolation of a 1587 bp BamHI-XbaI CYP4F3A_yc gene fragment. The gene was 
synthesized (Genewiz) using yeast-biased codons based on the protein template 
with NCBI Accession Number, NP_000887. The gene was isolated from a pUC57 
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based plasmid into which the chemically synthesised gene had originally been 
cloned.  
(3) The 5305 bp vector and the 1587 bp insert were ligated to create the plasmid 
YIpHisADH2S/CYP4F3A_yc (Figure 4.62).  
 
 
Figure 4.62. Map of plasmid YIpHisADH2S/CYP4F3A_yc that allows integration 
of a human CYP4F3A gene expression cassette at the HIS3 locus of the yeast 
genome. The human CYP4F3A gene was synthesized using yeast-biased codons 
and was named h_CYP4F3A_yc. The map shows restriction sites that cut the 
plasmid only once. 
 
For integration into yeast cells, via homologous recombination, the plasmid 
YIpHisADH2S/CYP4F3A_yc was linearized at the NdeI site (indicated by the arrow in 
Figure 4.62). In order to facilitate homologous recombination, the restriction sites BsaBI 




























The newly constructed plasmid YIpHisADH2S/CYP4F3A_yc was further analysed via 
double digestion with BamHI-XbaI restriction enzymes and a single digest with NgoMIV 




(A) Lanes   1      2               3         4           5
6537 bp-
355 bp-
(B) Lanes     1       2       3        4 
 
Figure 4.63. Agarose gels (A, B) that show the expected DNA fragments of 
YIpHisADH2S/CYP4F3A_yc when plasmids isolated from four (A) and three 
(B) bacterial clones were digested with BamHI-XbaI (lanes 2-5; A) and NgoMIV 
(lanes 2-4; B). Lane 1 (A & B), 2-log DNA ladder.  
 
The YIpHisADH2S/CYP4F3A_yc plasmid can be used for expression of the 
CYP4F3A_yc gene driven by the ADH2 promoter. In order to allow this, the CYP4F3A_yc 





4.11.2 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP4F3A 
enzyme from the URA3 chromosomal locus of a 
yeast strain 
 
The yeast integrative plasmid YIpUraADH2S/CYP4F3A_yc [CYP4F3A_yc = gene 
coding for CYP4F3A protein (as in Section 4.9.1; Accession Number NP_000887) and 
synthesized using yeast-biased codons] was created via the following steps:  
(1) After digestion of the vector YIpUraADH2S (Figure 4.15) with restriction 
enzymes BamHI, XbaI, a 5233 bp fragment was isolated. This eliminated 12 bp 
in the multi-cloning site.  
(2) A 1587 bp BamHI-XbaI CYP4F3A_yc gene fragment was isolated, as in Section 
4.9.1.  
(3) The 5233 bp vector and the 1587 bp insert were ligated to obtain the plasmid 





Figure 4.64. Map of plasmid YIpUraADH2S/CYP4F3A_yc that allows 
integration of a human CYP4F3A gene expression cassette at the URA3 locus of 
the yeast genome. The human CYP4F3A gene was synthesized using yeast-
biased codons and was named h_CYP4F3A_yc. The map shows restriction sites 
that cut the plasmid only once. 
 
For integration into yeast cells, via homologous recombination, the plasmid 
YIpUraADH2S/CYP4F3A_yc was linearized at the StuI site (as indicated by the arrow 
in Figure 4.64). Alternatively, the EcoRV or even PstI site could have been used for 
linearization.  
The newly constructed plasmid YIpUraADH2S/CYP4F3A_yc was further analysed via 
a single digest with NgoMIV (Figure 4.65). The agarose gel shows the expected sizes of 




































Lanes          1                2             3               4                 5
 
Figure 4.65. Agarose gel that shows the expected DNA fragments of 
YIpUraADH2S/CYP4F3A_yc when plasmids isolated from four bacterial clones 
were digested with NgoMIV (lanes 2-5). Lane 1, 2-log DNA ladder. 
 
The plasmid YIpUraADH2S/CYP4F3A_yc was used for expression of the CYP4F3A_yc 
gene driven by the ADH2 promoter.  In order to allow this, the CYP4F3A_yc gene 
expression cassette was integrated into the URA3 locus on chromosome V.  
 
4.11.3 Construction of yeast strains that contain a copy of 
the CYP4F3A_yc gene expression cassette 
integrated into two different chromosomal loci of 
the yeast strain YAB79 
 
Two yeast strains, containing a single copy of the CYP4F3A_yc gene expression cassette, 
were obtained by individually integrating the plasmids that bear the CYP4F3A_yc 
expression cassette in the yeast strain YAB79 (BC300::∆hRDM/LEU2+, b5/TRP1+; 
Figure 4.26) that expresses ΔhRDM from the LEU2 locus and cytochrome b5 from the 
TRP1 locus.  
The two CYP4F3A_yc gene encoding plasmids that were used for integration in the 
YAB79 strain were:  




After integration, the strains were named: 
(a) YAB79::4F3A_yc(URA3) and  
(b) YAB79::4F3A_yc(HIS3). 
The amounts of enzyme expressed from these strains were then compared in fluorescence 
assays using an appropriate fluorogenic substrate. Comparative kinetic analysis of 
CY4F3A enzyme co-expressed with cytochrome b5 and cytochrome P450 reductase 
∆hRDM, using CEC as a substrate, is shown in Figure 4.66. The intact yeast cells bearing 
the CYP4F3A_yc gene integrated in the chromosomal loci HIS3 and URA3, the episomal 
plasmid bearing the CYP4F3A_yc gene and the control empty plasmid yeast strain were 
grown as described in Section 4.1.1. Comparative enzyme kinetic assays were performed, 
as described in Section 4.1.2, to measure the formation of the product, CHC. These 





4.11.4 Comparison of activities of CYP4F3A enzyme 
expressed from (a) the CYP4F3A_yc gene 
chromosomally integrated at the HIS3 or URA3 
locus, and (b) an episomal plasmid bearing the 
CYP4F3A_yc gene, in the yeast strain YAB79 
 
 
Figure 4.66. The graph (A) compares the CYP4F3A enzyme activities produced 
in the strains YAB79::4F3A(HIS3) and YAB79:: 4F3A(URA3), expressing a copy 
of the CYP4F3A_yc gene expression cassette the HIS3 and URA3 chromosomal 
loci, and the strain YAB79:: 4F3A(2µ) expressing CYP4F3A from an episomal, 
2-micron (2u) plasmid. The graphs represent the average of results obtained 
from three independent experiments. The bar plot (B) mirrors the graphs in 



















Figure 4.66 clearly shows that the expression of a single copy of the CYP4F3A_yc gene 
in the yeast strain YAB79 from the HIS3 chromosomal locus is far superior to expression 
from the URA3 locus. Moreover, expression from the chromosomal URA3 locus is > 3-
fold better than the expression of CYP4F3A enzyme from an episomal, 2µ-plasmid which 
is an extra-chromosomal entity. Further corroboration of these results is provided in 
Chapter 5.  
 
 
 Construction of yeast strains, bearing 
expression cassettes of the human CYP1A1 
gene, chemically synthesized using yeast biased 
codons, and comparison of CYP1A1 enzyme 
activities produced by different strains 
 
4.12.1 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP1A1 
enzyme from the HIS3 chromosomal locus of a yeast 
strain 
 
The yeast integrative plasmid YIpHisADH2S/CYP1A1_yc was created via the following 
steps:  
(1) After digestion of the plasmid YIpHisADH2S (Figure 4.11) with restriction 
enzymes BamHI, XbaI, the 5305 bp vector fragment was isolated.  
(2) Isolation of a 1563 bp BamHI-XbaI CYP1A1_yc gene fragment. The gene was 
synthesized (Genewiz) using yeast-biased codons based on the protein template 
with NCBI Accession Number, NM_000499. The gene was isolated from a 
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pUC57 based plasmid into which the chemically synthesised gene had originally 
been cloned.  
(3) The 5305 bp vector and the 1563 bp insert were ligated to create the plasmid 
YIpHisADH2S/CYP1A1_yc (Figure 4.67).  
 
 
Figure 4.67. Map of plasmid YIpHisADH2S/CYP1A1_yc that allows integration 
of a human CYP1A1 gene expression cassette at the HIS3 locus of the yeast 
genome. The human CYP1A1 gene was synthesized using yeast-biased codons 
and was named h_CYP1A1_yc. The map shows restriction sites that cut the 
plasmid only once. 
 
For integration into yeast cells, via homologous recombination, the plasmid 
YIpHisADH2S/CYP1A1_yc was linearized at the NdeI site (indicated by the arrow in 
Figure 4.67). In order to facilitate homologous recombination, the restriction sites BsaBI 
or NheI (Figure 4.67) could also have been used for linearization. 
The newly constructed plasmid YIpHisADH2S/CYP1A1_yc was further analysed via 
double digestion with BamHI-XbaI restriction enzymes and a single digestion with XhoI 




































(B) Lanes    1       2       3       4         5 
 
Figure 4.68. Agarose gels (A, B) that show the expected DNA fragments of 
YIpHisADH2S/CYP1A1_yc when plasmids isolated from four bacterial clones 
were digested with BamHI-XbaI (lanes 2-5; A) and XhoI (lanes 2-5; B). Lane 1 
(A & B), 2-log DNA ladder.  
 
The YIpHisADH2S/CYP1A1_yc plasmid can be used for expression of the CYP1A1_yc 
gene driven by the ADH2 promoter. In order to allow this, the CYP1A1_yc gene 
expression cassette was integrated into the HIS3 locus on chromosome XV. 
 
4.12.2 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP1A1 
enzyme from the URA3 chromosomal locus of a 
yeast strain 
 
The yeast integrative plasmid YIpUraADH2S/CYP1A1_yc [CYP1A1_yc = gene coding 
for CYP1A1 protein (as in Section 4.10.1; Accession Number NM_000499) and 
synthesized using yeast-biased codons] was created via the following steps:  
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(1) After digestion of the vector YIpUraADH2S (Figure 4.15) with restriction 
enzymes BamHI, XbaI, a 5233 bp fragment was isolated. This eliminated 12 bp 
in the multi-cloning site.  
(2) A 1563 bp BamHI-XbaI CYP1A1_yc gene fragment was isolated, as in Section 
4.10.1.  
(3) The 5233 bp vector and the 1587 bp insert were ligated to obtain the plasmid 
YIpUraADH2S/CYP1A1_yc (Figure 4.69).  
 
 
Figure 4.69. Map of plasmid YIpUraADH2S/CYP1A1_yc that allows integration 
of a human CYP1A1 gene expression cassette at the URA3 locus of the yeast 
genome. The human CYP1A1 gene was synthesized using yeast-biased codons 
and was named h_CYP1A1_yc. The map shows restriction sites that cut the 
plasmid only once. 
 
For integration into yeast cells, via homologous recombination, the plasmid 
YIpUraADH2S/CYP1A1_yc was linearized at the EcoRV site (as indicated by the arrow 
































The newly constructed plasmid YIpUraADH2S/CYP1A1_yc was further analysed via a 
digestions with PvuII and NgoMIV (Figure 4.70). The agarose gels show the expected 




(A) Lanes    1       2       3       4
6441 bp-
355 bp-
(B) Lanes   1     2      3     4      5
 
Figure 4.70. Agarose gels (A, B) that show the expected DNA fragments of 
YIpUraADH2S/CYP1A1_yc when plasmids isolated from four bacterial clones 
were digested with PvuII (lanes 1-4; A) and NgoMIV (lanes 2-5; B). Lane 1 (B), 
2-log DNA ladder.  
 
The plasmid YIpUraADH2S/CYP1A1_yc was used for expression of the CYP1A1_yc 
gene driven by the ADH2 promoter. In order to allow this, the CYP1A1_yc gene 
expression cassette was integrated into the URA3 locus on chromosome V.  
 
4.12.3 Construction of yeast strains that contain a copy of 
the CYP1A1_yc gene expression cassette integrated 
into two different chromosomal loci of the yeast 
strain YY7 
 
Two yeast strains, containing a single copy of the CYP1A1_yc gene expression cassette, 
were obtained by individually integrating the plasmids that bear the CYP1A1_yc 
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expression cassette in the yeast strain YY7 (BC300::∆hRDM/LEU2+; Figure 4.26) that 
expresses ΔhRDM from the LEU2 locus.  
The two CYP1A1_yc gene encoding plasmids that were used for integration in the YAB79 
strain were:  
(1) YIpUraADH2S/CYP1A1_yc, and  
(2) YIpHisADH2S/CYP1A1_yc. 
After integration, the strains were named: 
(a) YY7::1A1_yc(URA3) and  
(b) YY7::1A1_yc(HIS3). 
The amounts of enzyme expressed from these strains were then compared in fluorescence 
assays using an appropriate fluorogenic substrate. Comparative kinetic analysis of 
CY1A1 enzyme co-expressed without cytochrome b5 but in the presence of cytochrome 
P450 reductase ∆hRDM, using 7-ER as a substrate is shown in Figure 4.71. The intact 
yeast cells bearing the CYP1A1_yc gene integrated in the chromosomal loci HIS3 and 
URA3, the episomal plasmid bearing the CYP1A1_yc gene and the control empty plasmid 
containing yeast strain were grown as described earlier. Comparative enzyme kinetic 
assays were performed to measure the formation of the product, resorufin, from 7-ER. 






4.12.4 Comparison of activities of CYP1A1 enzyme 
expressed from (a) the CYP1A1_yc gene 
chromosomally integrated at the HIS3 or URA3 
locus, and (b) an episomal plasmid bearing the 
CYP1A1_yc gene, in the yeast strain YY7 
 
 
Figure 4.71. The graph (A) compares the CYP1A1 enzyme activities produced 
in the strains YY7::1A1(HIS3) and YY7::1A1(URA3), expressing a copy of the 
CYP1A1_yc gene expression cassette, integrated at the HIS3 and URA3 
chromosomal loci, and the strain YY7::1A1(2µ) expressing CYP1A1 from an 
episomal, 2-micron (2u) plasmid. The graphs represent the average of results 
obtained from three independent experiments. The bar plot (B) mirrors the 
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Figure 4.71 shows the expression of a single copy of the CYP1A1_yc gene in the baker’s 
yeast strain YY7 from the HIS3 and URA3 chromosomal loci. It could be inferred that 
CYP1A1 enzyme is expressed at higher levels from the HIS3 locus than from the URA3 
locus while the enzyme levels produced from the URA3 locus was higher than that 
obtained from a strain that expressed CYP1A1_yc from an episomal plasmid. Further 
corroboration of these results is provided in Chapter 5 of this study. 
The results suggest that the amounts of CYP1A1 expressed depend on the genetic locus 
and the chromosome in which the CYP1A1_yc gene expression cassette is integrated. 
 
 
 Construction of yeast strains, bearing 
expression cassettes of the human CYP1B1 
gene, chemically synthesized using yeast 
biased codons, and comparison of CYP1B1 
enzyme activities produced by different 
strains 
 
4.13.1 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP1B1 
enzyme from the HIS3 chromosomal locus of a yeast 
strain 
 
The yeast integrative plasmid YIpHisADH2S/CYP1B1_yc was created via the following 
steps:  
(1) After digestion of the plasmid YIpHisADH2S (Figure 4.11) with restriction 
enzymes BamHI, XbaI, the 5305 bp vector fragment was isolated.  
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(2) Isolation of a 1656 bp BamHI-XbaI CYP1B1_yc gene fragment. The gene was 
synthesized (Genewiz) using yeast-biased codons based on the protein template 
with NCBI Accession Number, NM_000104. The gene was isolated from a 
pUC57 based plasmid into which the chemically synthesised gene had originally 
been cloned.  
(3) The 5305 bp vector and the 1656 bp insert were ligated to create the plasmid 
YIpHisADH2S/CYP1B1_yc (Figure 4.72).  
 
 
Figure 4.72. Map of plasmid YIpHisADH2S/CYP1B1_yc that allows integration 
of a human CYP1B1 gene expression cassette at the HIS3 locus of the yeast 
genome. The human CYP1B1 gene was synthesized using yeast-biased codons 
and was named h_CYP1B1_yc. The map shows restriction sites that cut the 
plasmid only once. 
 
For integration into yeast cells, via homologous recombination, the plasmid 
YIpHisADH2S/CYP1B1_yc was linearized at the NheI site (indicated by the arrow in 
Figure 4.72). In order to facilitate homologous recombination, the restriction sites BsaBI 

























The newly constructed plasmid YIpHisADH2S/CYP1B1_yc was further analysed via 
double digestion with BamHI-XbaI restriction enzymes and a single digestion with XhoI 
(Figure 4.73). The agarose gels show the expected sizes of DNA fragments.  





(B) Lanes   1     2      3      4
 
Figure 4.73. Agarose gels (A, B) that show the expected DNA fragments of 
YIpHisADH2S/CYP1B1_yc when plasmids isolated from two (A) and three (B) 
bacterial clones were digested with BamHI-XbaI (lanes 2-3; A) and XhoI (lanes 
2-4; B). Lane 1 (A & B), 2-log DNA ladder.  
 
The YIpHisADH2S/CYP1B1_yc plasmid can be used for expression of the CYP1B1_yc 
gene driven by the ADH2 promoter. In order to allow this, the CYP1B1_yc gene 





4.13.2 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP1B1 
enzyme from the URA3 chromosomal locus of a 
yeast strain 
 
The yeast integrative plasmid YIpUraADH2S/CYP1B1_yc [CYP1B1_yc = gene coding 
for CYP1B1 protein (as in Section 4.11.1; Accession Number NM_000104) and 
synthesized using yeast-biased codons] was created via the following steps:  
(1) After digestion of the vector YIpUraADH2S (Figure 4.15) with restriction 
enzymes BamHI, XbaI, a 5233 bp fragment was isolated. This eliminated 12 bp 
in the multi-cloning site.  
(2) A 1656 bp BamHI-XbaI CYP1B1_yc gene fragment was isolated, as in Section 
4.11.1.  
(3) The 5233 bp vector and the 1656 bp insert were ligated to obtain the plasmid 






Figure 4.74. Map of plasmid YIpUraADH2S/CYP1B1_yc that allows integration 
of a human CYP1B1 gene expression cassette at the URA3 locus of the yeast 
genome. The human CYP1B1 gene was synthesized using yeast-biased codons 
and was named h_CYP1B1_yc. The map shows restriction sites that cut the 
plasmid only once. 
 
For integration into yeast cells, via homologous recombination, the plasmid 
YIpUraADH2S/CYP1B1_yc was linearized at the StuI site (as indicated by the arrow in 
Figure 4.74). Alternatively, the EcoRV site could also be used for linearization.  
The newly constructed plasmid YIpUraADH2S/CYP1B1_yc was further analysed via a 
double digestion with the restriction enzyme BamHI-XbaI (Figure 4.75). The agarose gel 






























Lanes   1    2               3                4        
 
Figure 4.75. Agarose gel shows the expected DNA fragments of 
YIpUraADH2S/CYP1B1_yc when plasmids isolated from three bacterial clones 
were digested with BamHI-XbaI (lanes 2-3). Lane 1, 2-log DNA ladder.  
 
The plasmid YIpUraADH2S/CYP1B1_yc was used for expression of the CYP1B1_yc 
gene driven by the ADH2 promoter. In order to allow this, the CYP1B1_yc gene 
expression cassette was integrated into the URA3 locus on chromosome V.  
 
4.13.3 Construction of yeast strains that contain a copy of 
the CYP1B1_yc gene expression cassette integrated 
into two different chromosomal loci of the yeast 
strain YY7 
 
Two yeast strains, containing a single copy of the CYP1B1_yc gene expression cassette, 
were obtained by individually integrating the plasmids that bear the CYP1B1_yc 
expression cassette in the yeast strain YY7 (BC300::∆hRDM/LEU2+; Figure 4.26) that 
expresses ΔhRDM from the LEU2 locus.  
The two CYP1B1_yc gene encoding plasmids that were used for integration in the YAB79 
strain were:  




After integration, the strains were named: 
(a) YY7::1B1_yc(URA3) and  
(b) YY7::1B1_yc(HIS3). 
 
The amounts of enzyme expressed from these strains were then compared in fluorescence 
assays using an appropriate fluorogenic substrate. The comparative kinetic analysis of 
CYP1B1 enzyme gene co-expressed with cytochrome P450 reductase ∆hRDM, in the 
absence of cytochrome b5, using 7-ER as a substrate is shown in Figure 4.76. The intact 
yeast cells bearing the CYP1B1_yc gene integrated at the chromosomal loci, HIS3 or 
URA3, the episomal plasmid bearing the CYP1B1_yc gene and the control empty plasmid 
containing yeast strain were grown as described in Section 4.1.1. Comparative kinetic 
assays were performed, as described in Section 4.1.2 to measure formation of the product, 





4.13.4 Comparison of activities of CYP1B1 enzyme 
expressed from (a) the CYP1B1_yc gene 
chromosomally integrated at the HIS3 or URA3 
locus, and (b) an episomal plasmid bearing the 
CYP1B1_yc gene, in the yeast strain YY7 
 
 
Figure 4.76. The graph (A) compares the CYP1B1 enzyme activities produced 
in the strains YY7::1A1(HIS3), YY7::1A1(URA3) and YY7::1A1(HIS3,URA3) 
with the strain YY7::1A1(2µ) expressing CYP1B1 from an episomal, 2-micron 
(2u) plasmid. The first two integrated strains contain a copy of the CYP1B1_yc 
gene expression cassette, integrated at the HIS3 and URA3 chromosomal loci, 
whereas the third integrated strain contains two copies of CYP1B1_yc. The 
graphs represent the average of results obtained from three independent 
experiments. The bar plot (B) mirrors the graphs in (A). The data represent 














(A) Comparison of CYP1B1 enzyme activities 
















(B) Comparison of CYP1B1 enzyme activities 







The results show that the cytochrome P450 enzyme CYP1B1 is expressed at a much 
higher level from the HIS3 locus than from the URA3 locus, within live yeast cells. The 
CYP1B1_yc gene expressed from both chromosomal loci expresses more CYP1B1 
enzyme than when it is expressed from an episomal plasmid. Further confirmation of 
these results is revealed in Chapter 5 of this study. 
Figure 4.76 suggests that the amounts of CYP1B1 expressed depends on the genetic locus 
and the chromosome in which the CYP1B1_yc gene expression cassette is integrated.  
 
 
 Construction of yeast strains, bearing 
expression cassettes of the human CYP3A5 
gene, chemically synthesized using yeast biased 
codons, and comparison of CYP3A5 enzyme 
activities produced by different strains 
 
4.14.1 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP3A5 
enzyme from the HIS3 chromosomal locus of a yeast 
strain 
 
The yeast integrative plasmid YIpHisADH2S/CYP3A5_yc was created via the following 
steps:  
(1) After digestion of the plasmid YIpHisADH2S (Figure 4.11) with restriction 
enzymes BamHI, XbaI, the 5305 bp vector fragment was isolated.  
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(2) Isolation of a 1533 bp BamHI-XbaI CYP3A5_yc gene fragment. The gene was 
synthesized (Genewiz) using yeast-biased codons based on the protein template 
with NCBI Accession Number, NP_000768. The gene was isolated from a pUC57 
based plasmid into which the chemically synthesised gene had originally been 
cloned.  
(3) The 5305 bp vector and the 1533 bp insert were ligated to create the plasmid 
YIpHisADH2S/CYP3A5_yc (Figure 4.77).  
 
 
Figure 4.77. Map of plasmid YIpHisADH2S/CYP3A5_yc that allows integration 
of a human CYP3A5 gene expression cassette at the HIS3 locus of the yeast 
genome. The human CYP3A5 gene was synthesized using yeast-biased codons 
and was named h_CYP3A5_yc. The map shows restriction sites that cut the 
plasmid only once. 
 
For integration into yeast cells, via homologous recombination, the plasmid 































Figure 4.77). In order to facilitate homologous recombination, the restriction sites BsaBI, 
NdeI, BalI or BclI (Figure 4.77) could also have been used for linearization. 
The newly constructed plasmid YIpHisADH2S/CYP3A5_yc was further analysed via 
double digestion with BamHI-XbaI restriction enzymes and a single digestion with XhoI 




(A) Lanes  1     2     3     4    5   
5305 bp-
1533 bp-
(B) Lanes  1    2      3     4     5
 
Figure 4.78. Agarose gels (A, B) that show the expected DNA fragments of 
YIpHisADH2S/CYP3A5_yc when plasmids isolated from four (A, B) bacterial 
clones were digested with PvuII (lanes 2-5; A) and BamHI-XbaI (lanes 2-5; B). 
Lane 1 (A & B), 2-log DNA ladder.  
 
The YIpHisADH2S/CYP3A5_yc plasmid can be used for expression of the CYP3A5_yc 
gene driven by the ADH2 promoter. In order to allow this, the CYP3A5_yc gene 




4.14.2 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP3A5 
enzyme from the URA3 chromosomal locus of a 
yeast strain 
 
The yeast integrative plasmid YIpUraADH2S/CYP3A5_yc [CYP3A5_yc = gene coding 
for CYP3A5 protein (as in Section 4.12.1; Accession Number NP_000768) and 
synthesized using yeast-biased codons] was created via the following steps:  
(1) After digestion of the vector YIpUraADH2S (Figure 4.15) with restriction 
enzymes BamHI, XbaI, a 5233 bp fragment was isolated. This eliminated 12 bp 
in the multi-cloning site.  
(2) A 1533 bp BamHI-XbaI CYP3A5_yc gene fragment was isolated, as in Section 
4.12.1.  
(3) The 5233 bp vector and the 1656 bp insert were ligated to obtain the plasmid 





Figure 4.79. Map of plasmid YIpUraADH2S/CYP3A5_yc that allows integration 
of a human CYP3A5 gene expression cassette at the URA3 locus of the yeast 
genome. The human CYP3A5 gene was synthesized using yeast-biased codons 
and was named h_CYP3A5_yc. The map shows restriction sites that cut the 
plasmid only once. 
 
For integration into yeast cells, via homologous recombination, the plasmid 
YIpUraADH2S/CYP3A5_yc was linearized at the StuI site (as indicated by the arrow in 
Figure 4.79). Alternatively, the EcoRV or NcoI site could also have been used for 
linearization.  
The newly constructed plasmid YIpUraADH2S/CYP3A5_yc was further analysed via a 
digestions with BamHI-XbaI and PvuII (Figure 4.80). The agarose gels show the expected 



































(A) Lanes   1    2    3    4    5
4648 bp-
2118 bp-
(B) Lanes  1   2     3    4     5
 
Figure 4.80. Agarose gels (A, B) that show the expected DNA fragments of 
YIpUraADH2S/CYP3A5_yc when plasmids isolated from four (A, B) bacterial 
clones were digested with BamHI-XbaI (lanes 2-5; A) and PvuII (lanes 2-5; B). 
Lane 1 (A & B), 2-log DNA ladder.  
 
The plasmid YIpUraADH2S/CYP3A5_yc was used for expression of the CYP3A5_yc 
gene driven by the ADH2 promoter. In order to allow this, the CYP3A5_yc gene 
expression cassette was integrated into the URA3 locus on chromosome V.  
 
4.14.3 Construction of yeast strains that contain a copy of 
the CYP3A5_yc gene expression cassette integrated 
into two different chromosomal loci of the yeast 
strain YAB79 
 
Two yeast strains, containing a single copy of the CYP3A5_yc gene expression cassette, 
were obtained by individually integrating the plasmids that bear the CYP3A5_yc 
expression cassette in the yeast strain YAB79 (BC300::∆hRDM/LEU2+, b5/TRP1; 
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Figure 4.26) that expresses ΔhRDM from the LEU2 locus and cytochrome b5 from the 
TRP1 locus.  
The two CYP3A5_yc gene encoding plasmids that were used for integration in the YAB79 
strain were:  
(1) YIpUraADH2S/CYP3A5_yc, and  
(2) YIpHisADH2S/CYP3A5_yc. 
After integration, the strains were named: 
(a) YAB79::3A5_yc(URA3) and  
(b) YAB79::3A5_yc(HIS3). 
The amounts of enzyme expressed from these strains were then compared in fluorescence 
assays using an appropriate fluorogenic substrate. The comparative kinetic analysis of 
CYP3A5 enzyme co-expressed with cytochrome b5 and cytochrome P450 reductase 
∆hRDM, using DBF as a substrate, is shown in Figure 4.81. The intact yeast cells bearing 
the CYP3A5_yc gene integrated in the chromosomal loci HIS3 and URA3, the episomal 
plasmid bearing the CYP3A5_yc gene and the control empty plasmid containing yeast 
strain were grown as described in Section 4.1.1. The comparative enzyme kinetic assays 
were performed as described in Section 4.1.2 to measure formation of the product, 





4.14.4 Comparison of activities of CYP3A5enzyme 
expressed from (a) the CYP3A5_yc gene 
chromosomally integrated at the HIS3 or URA3 
locus, and (b) an episomal plasmid bearing the 
CYP3A5_yc gene, in the yeast strain YAB79 
 
 
Figure 4.81. The graph (A) compares the CYP3A5 enzyme activities produced 
in the strains YAB79::3A5(HIS3), YAB79::3A5(URA3) with the strain 
YAB70::3A5(2µ) expressing CYP3A5 from an episomal, 2-micron (2u) 
plasmid. The graphs represent the average of results obtained from three 
independent experiments. The bar plot (B) mirrors the graphs in (A). The data 










































Figure 4.81 shows that the HIS3 locus provides the best expression of a single copy of 
the CYP3A5_yc gene in the yeast strain YAB79. It is better than when it is expressed from 
the URA3 locus. The results also show that expression from a chromosomal locus is better 
than that from an episomal, 2-micron (2µ) plasmid. Further corroboration of these results 
is revealed in Chapter 5 of this study.  
Figure 4.81 suggests that the amounts of CYP3A5 expressed depend on the genetic locus 
and the chromosome in which the CYP3A5_yc gene expression cassette is integrated. 
 
 
 Construction of yeast strains, bearing 
expression cassettes of the human CYP2C8 
gene, chemically synthesized using yeast biased 
codons, and comparison of CYP2C8 enzyme 
activities produced by different strains 
 
4.15.1 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP2C8 
enzyme from the HIS3 chromosomal locus of a yeast 
strain 
 
The yeast integrative plasmid YIpHisADH2S/CYP2C8_yc was created via the following 
steps:  
(1) After digestion of the plasmid YIpHisADH2S (Figure 4.11) with restriction 
enzymes BamHI, XbaI, the 5305 bp vector fragment was isolated.  
(2) Isolation of a 1497 bp BamHI-XbaI CYP2C8_yc gene fragment. The gene was 
synthesized (Genewiz) using yeast-biased codons based on the protein template 
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with NCBI Accession Number, NM_000770. The gene was isolated from a 
pUC57 based plasmid into which the chemically synthesised gene had originally 
been cloned.  
(3) The 5305 bp vector and the 1497 bp insert were ligated to create the plasmid 
YIpHisADH2S/CYP2C8_yc (Figure 4.82).  
 
 
Figure 4.82. Map of plasmid YIpHisADH2S/CYP2C8_yc that allows integration 
of a human CYP2C8 gene expression cassette at the HIS3 locus of the yeast 
genome. The human CYP2C8 gene was synthesized using yeast-biased codons 
and was named h_CYP2C8_yc. The map shows restriction sites that cut the 
plasmid only once. 
 
For integration into yeast cells, via homologous recombination, the plasmid 
YIpHisADH2S/CYP2C8_yc was linearized at the NheI site (indicated by the arrow in 
Figure 4.82). In order to facilitate homologous recombination, the restriction sites BsaBI, 
































The newly constructed plasmid YIpHisADH2S/CYP2C8_yc was further analysed via 
digestion with PvuII and XhoI restriction enzymes (Figure 4.83). The agarose gels show 




(A) Lanes  1      2      3      4     5
4720 bp-
2080 bp-
(B) Lanes     1     2      3      4      5
 
Figure 4.83. Agarose gels (A, B) that show the expected DNA fragments of 
YIpHisADH2S/CYP2C8_yc when plasmids isolated from four (A, B) bacterial 
clones were digested with PvuII (lanes 2-5; A) and XhoI (lanes 2-5; B). Lane 1 
(A & B), 2-log DNA ladder.  
 
The YIpHisADH2S/CYP2C8_yc plasmid can be used for expression of the CYP2C8_yc 
gene driven by the ADH2 promoter. In order to allow this, the CYP2C8_yc gene 







4.15.2 Construction of a yeast strain that contains a copy of 
the CYP2C8_yc gene expression cassette integrated 
into HIS3 chromosomal loci of the yeast strain 
YAB79 
 
A yeast strain, containing a single copy of the CYP2C8_yc gene expression cassette, was 
obtained by integrating the plasmid that bears the CYP2C8_yc expression cassette in the 
yeast strain YAB79 (BC300::∆hRDM/LEU2+, b5/TRP1; Figure 4.26) that expresses 
ΔhRDM from the LEU2 locus and cytochrome b5 from the TRP1 locus.  
The CYP2C8_yc gene encoding plasmid that was used for integration in the YAB79 strain 
was YIpHisADH2S/CYP2C8_yc.  
After integration, the strain was named YAB79::2C8_yc(HIS3).  
The amount of enzyme expressed from this strain was then compared with that from the 
strains that bears an episomal plasmid. Fluorescence assays, using an appropriate 
fluorogenic substrate, were used for this comparison.  The comparative kinetic analysis 
of CYP2C8 enzyme, co-expressed with cytochrome b5 and cytochrome P450 reductase 
∆hRDM, was performed using DBF as a substrate. The intact yeast cells bearing the 
CYP2C8_yc gene integrated in the HIS3 chromosomal locus, the episomal plasmid 
bearing the CYP2C8_yc gene and the empty plasmid containing control yeast strain were 
grown as described in Section 4.1.1. Comparative enzyme kinetic assays were performed, 
as described in Section 4.1.2, to measure formation of the product, fluoroscein. These 




4.15.3 Comparison of activities of CYP2C8 enzyme 
expressed from (a) the CYP2C8_yc gene 
chromosomally integrated at the HIS3 locus and (b) 
an episomal plasmid bearing the CYP2C8_yc gene, in 
the yeast strain YAB79 
 
 
Figure 4.84. The graph (A) compares the CYP2C8 enzyme activities produced 
in the strain YAB79::2C8(HIS3) with the strain YAB70::2C8(2µ) that expresses 
CYP2C8 from an episomal, 2-micron (2u) plasmid. The graphs represent the 
average of results obtained from three independent experiments. The bar plot 
(B) mirrors the graphs in (A). The data represent mean ± S.D. of three 
















(A) Comparison of CYP2C8 enzyme activities 
















(B) Comparison of CYP2C8 enzyme activities 






Figure 4.84 shows that the expression levels of human CYP2C8 enzyme are better when 
expressed from a chromosomal locus than when it is expressed from an episomal, 2-
micron (2µ) plasmid.  
 
 
 Construction of yeast strains, bearing 
expression cassettes of the human CYP2E1 
gene, chemically synthesized using yeast biased 
codons, and comparison of CYP2E1 enzyme 
activities produced by different strains 
 
4.16.1 Construction of a yeast integrative plasmid that 
would allow stable expression of human CYP2E1 
enzyme from the HIS3 chromosomal locus of a yeast 
strain 
 
The yeast integrative plasmid YIpHisADH2S/CYP2E1 _yc was created via the following 
steps:  
(1) After digestion of the plasmid YIpHisADH2S (Figure 4.11) with restriction 
enzymes BamHI, XbaI, the 5305 bp vector fragment was isolated.  
(2) Isolation of a 1506 bp BamHI-XbaI CYP2E1_yc gene fragment. The gene was 
synthesized (Genewiz) using yeast-biased codons based on the protein template 
with NCBI Accession Number, NM_000773. The gene was isolated from a 
pUC57 based plasmid into which the chemically synthesised gene had originally 
been cloned.  
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(3) The 5305 bp vector and the 1506 bp insert were ligated to create the plasmid 
YIpHisADH2S/CYP2E1_yc (Figure 4.85).   
 
 
Figure 4.85. Map of plasmid YIpHisADH2S/CYP2E1_yc that allows integration 
of a human CYP2E1 gene expression cassette at the HIS3 locus of the yeast 
genome. The human CYP2E1 gene was synthesized using yeast-biased codons 
and was named h_CYP2E1_yc. The map shows restriction sites that cut the 
plasmid only once. 
 
For integration into yeast cells, via homologous recombination, the plasmid 
YIpHisADH2S/CYP2E1_yc was linearized at the NheI site (indicated by the arrow in 
Figure 4.82). In order to facilitate homologous recombination, the restriction sites BsaBI, 
NdeI, BalI or BclI (Figure 4.85) could also have been used for linearization. 
The newly constructed plasmid YIpHisADH2S/CYP2E1_yc was further analysed via 
digestion with the restriction enzyme XhoI (Figure 4.86). The agarose gel shows the 





































Lanes    1     2      3     4     5     6     7
 
Figure 4.86. Agarose gel that shows the expected DNA fragments of 
YIpHisADH2S/CYP2E1_yc when plasmids isolated from six  bacterial clones 
were digested with XhoI (lanes 2-7). Lane 1, 2-log DNA ladder.  
 
The YIpHisADH2S/CYP2E1_yc plasmid can be used for expression of the CYP2E1_yc 
gene driven by the ADH2 promoter. In order to allow this, the CYP2E1_yc gene 
expression cassette was integrated into the HIS3 locus on chromosome XV.  
 
4.16.2 Construction of a yeast strain that contains a copy of 
the CYP2E1_yc gene expression cassette integrated 
into HIS3 chromosomal loci of the yeast strain 
YAB79 
 
A yeast strain, containing a single copy of the CYP2E1_yc gene expression cassette, was 
obtained by integrating the plasmid that bears the CYP2E1_yc expression cassette in the 
yeast strain YAB79 (BC300::∆hRDM/LEU2+, b5/TRP1; Figure 4.26) that expresses 
ΔhRDM from the LEU2 locus and cytochrome b5 from the TRP1 locus.  
The CYP2E1_yc gene encoding plasmid that was used for integration in the YAB79 strain 
was YIpHisADH2S/CYP2E1_yc.  
After integration, the strain was named YAB79::2E1_yc(HIS3).  
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The amount of enzyme expressed from this strain was then compared with that from the 
strains that bears an episomal plasmid. Fluorescence assays, using an appropriate 
fluorogenic substrate, were used for this comparison. The comparative kinetic analysis of 
CYP2E1 enzyme co-expressed with cytochrome b5 and cytochrome P450 reductase 
∆hRDM, was performed using EOMCC as a substrate. The intact yeast cells bearing the 
CYP2E1_yc gene integrated in the HIS3 chromosomal locus, the episomal plasmid 
bearing the CYP2E1_yc gene and the empty plasmid containing control yeast strain were 
grown as described in Section 4.1.1. Comparative enzyme kinetic assays were performed 
as described in Section 4.1.2 to measure formation of product, 7-HCC. These procedures 





4.16.3 Comparison of activities of CYP2E1 enzyme 
expressed from (a) the CYP2E1_yc gene 
chromosomally integrated at the HIS3 locus and (b) 
an episomal plasmid bearing the CYP2E1_yc gene, in 
the yeast strain YAB79 
 
 
Figure 4.87. The graph (A) compares the CYP2E1 enzyme activities produced 
in the strain YAB79::2E1(HIS3) with the strain YAB70::2E1(2µ) that expresses 
CYP2E1 from an episomal, 2-micron (2u) plasmid. The graphs represent the 
average of results obtained from three independent experiments. The bar plot 

















(A) Comparison of CYP2E1 enzyme activities 

















(B) Comparison of CYP2E1 enzyme activities 





Figure 4.87 suggests that the expression level of human CYP2E1 enzyme is slightly better 
when expressed from an integrated locus than expression from an episomal, 2-micron 




In this Chapter (i.e. Chapter 4), I have cloned and expressed genes that code for the CYPs 
1A2, 1A1, 1B1, 3A4, 2C9, 2C19, 4F3A, 3A4, 2E1, 2C8, 2D6(1), and 2D6(2). Integration 
into chromosomal loci has shown greater enzyme activity than from an episomal plasmid. 
This may correlate with (a) higher expression levels and (b) higher activity of the enzymes 
for all the CYPs that have been expressed. This has been tested further in Chapter 5 where 
results corroborate that both assumptions are probably correct.  
The insect cell-baculovirus expression system is extensively used for the expression of 
recombinant proteins. The two leading manufacturers of recombinant human CYP 
enzymes produce them using the baculovirus expression system. In general, a baculovirus 
which has a stably integrated copy of a foreign gene is used to infect insect cells. 
However, in this system of expression, production of recombinant proteins is generally 
low compared to that obtained in bacterial cells (Rosano and Ceccarelli, 2014). 
Nonetheless, the human CYP enzymes produced in this system are considered more 
authentic (i.e. more akin to enzymes produced in human cells) than that produced form 
bacterial cells since insect cells are eukaryotic.  
Yeast is also a eukaryotic organism. It can provide comparable levels of expression of 
foreign proteins as bacterial cells. The advantage of expressing human CYPs in 
eukaryotic yeast is that it possesses ER membranes. Human CYPs, which all contain an 
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N-terminal membrane-binding domain, are naturally bound to the ER membranes. Yeast 
can provide a natural internal environment in which human CYP enzymes could be bound 
to its ER membranes. Binding to the ER provides active CYP proteins. Soluble CYPs are 
totally inactive. However, until now, expression of human CYPs in yeast has not been a 
great success. Usually, expression has been seen at low levels (Zimmermann et al.,2011).  
In Chapter 3, we had found that synthesising the human CYP genes with yeast biased 
codons provides higher levels of CYPs compared to the native genes. In this Chapter we 
find that integrating a CYP gene, synthesized with yeast biased codons, at a particular 
chromosomal locus yields higher levels of CYPs than expression from the same gene 
borne on an extra-chromosomal plasmid. The use of the inducible ADH2 promoter further 
helps in the expression of human CYP proteins. Usually, inducible promoters switch on 
gene transcription very quickly in the presence of the inducer. In the case of the inducible 
yeast GAL (GAL1/10) promoters, galactose is the inducer whereas for the yeast 
metallothionein promoter, CUP1, it is the divalent Cu2+ cation. During the use of the 
GAL1/10 and the CUP1 promoters, the cells have to quickly adapt to the production of 
foreign proteins, after the inducer has been added, which could be very stressful for the 
cells. During production of foreign proteins with the ADH2 promoter, cells however can 
slowly adapt to the protein that is being produced. As glucose is being utilized by yeast 
cells for growth, the ethanol that is made gradually induces the promoter, thereby 
allowing time for the cells to gently adjust to the foreign protein that is being expressed.  
We believe that this unique conglomeration of features facilitates high yields of CYPs 
that have been obtained until now, in this thesis. Integration of CYP genes on to the 
chromosome also allows yeast cells to be grown in complete medium to obtain large 
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volumes of cells compared to cells grown in synthetic SD minimal medium; cells 
containing an episomal plasmid must be grown in SD medium for maintenance of the 
plasmid.  
Using the technology for targeting genes into chromosomal loci, the importance of CBR 
(cytochrome b5 reductase) was clarified to some extent. CYP2D6 expression level was 
compared when co-expressed with and without CBR’s substrate cytochrome b5. Our 
results show that for both the CYP2D6(1) and CYP2D6(2) variants, CBR does not aid 
production of these CYP variants; in fact, it is deleterious (Figure 4.45). In contrast, CBR 
has a role to play in the expression of CYP1A2 since cytochrome b5 definitely augments 
CYP1A2 expression levels (i.e. activity) (Figure 4.37). This has never been reported 
before (Duarte et al., 2005). Besides, it was clearly seen that cytochrome b5 has an effect 
on the levels/activities of CYP3A4, CYP3A5, CYP2C8, CYP2C9, CYP2C19, CYP2E1, 
and CYP4F31A enzymes. CYP3A4 is involved in the metabolism, in the liver, of more 
than 50% of all approved drugs.  
The CYP3A4 and CYP3A5 enzymes isolated from insect cells using baculoviruses 
(Corning-Gentest’s Supersomes) have been used to test which of these enzymes 
metabolise vinorelbine, an alkaloid used in the treatment of breast and non-small lung 
cancers. It was concluded that vinorebine clearance is closely associated with CYP3A4 
activities but not with that of CYP3A5 (Ariel et al., 2013). It would be reasonable to 
assume that due to the high levels of human CYP enzyme expression in yeast, it will be 
of great advantage to use these CYP enzymes expressed within yeast for routine drug 
metabolism studies. The recombinant yeast cells would also be robust and cost effective 
means of conducting such studies.  
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Expression of integrated copies of CYP1A1 and CYP1B1 genes have shown that the levels 
of CYP enzymes produced is much higher when compared to expression from strains 
containing episomal plasmids that encode these genes. Whole yeast cells, expressing 
these two enzymes, have been used for the biotransformation of 5,7-dihydroxyflavone 
(chrysin) to 5,6,7-trihydroxyflavone (baicalein) via regio-selective C6-hydroxylation 
with greater than 90% yield (see Chapter 6, Section 6.3; Ibidapo WIlliams et al., 2017, 
published online; in press). Baicalein is known for its fascinating anticancer properties 
in various cancer types including pancreatic, gastric, colorectal cancer, multiple 
myeloma, head and neck, and breast cancers (Roy at al., 2007).  
Cells expressing CYP2C9 and CYP3A4 have also been used, during the course of the 
present study, on nano-electrodes to develop biosensors for the two anticoagulants 
warfarin and rivaroxaban (yet unpublished observations). The approach is expected to be 
useful in diagnostics. Our results indicate that all major clinically important CYP450 
enzymes could be integrated as potential biosensors to accurately test the levels of 
medicines (as CYP450 substrates) in patients’ blood. This platform can be developed 
further to create point-of care or at home monitoring devices to detect all CYP enzyme-
metabolised medicines. This would provide useful information on drug dosages which 
patients themselves can adjust if and when required. . 
In conclusion, the results presented in this Chapter are likely to open up new avenues 
towards further research in the use of whole yeast cells which highly express human 




Chapter 5 Isolation of Sacchrosomes (i.e. CYP 
enzymes bound to yeast microsomal 
membranes), from yeast strains 
expressing two integrated copies of a 
CYP, and comparison of their activities 
with commercially available 
microsomal enzymes isolated from 




Chapter 4 described the development of yeast strains which contained one 
chromosomally integrated copy of a human CYP gene expression cassette. These strains 
allowed expression from the yeast cells’ different chromosomal locations at which the 
ADE2, HIS3 or URA3 genes were situated. It was observed that a strain containing an 
integrated copy of a single CYP gene unexpectedly produces much higher levels of the 
CYP protein than a strain containing an episomal, 2-micron (2µ) plasmid which ought to 
produce multiple copies of the gene product (Falcon et al., 2005). After a pre-culture in a 
selective medium, which selects for the URA3 gene present in both episomal and 
integrative plasmids, the two strains were grown in non-selective full medium for 18 h 
(i.e. a time period in which an episomal plasmid undergoes minimal plasmid loss). 
Fluorogenic (i.e. non-fluorescent) substrates which, upon reaction with CYP enzymes, 
produce fluorescent products were used for these comparative studies. It was inferred that 
greater the amount of fluorescence (i.e. the fluorescent product) detected from the cells 
of a specific strain, higher the level of CYP enzyme that is produced within these cells.  
Integration of a CYP gene expression cassette in a chromosomal locus overcomes the 
problem of instability (i.e. plasmid loss) when cells are grown in full YPD medium which 
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is normally encountered by cells harbouring an episomal plasmid. Although a highly 
nutritious full medium allows healthy growth of cells, they are unable to enforce the 
continuous presence of an extra-chromosomal plasmid (i.e. an episomal plasmid) within 
the cells during cell division. Gradual loss of an episomal plasmid starts at around ten 
generations of growth in YPD, each generation lasting ~90 min (Lopez et al, 1996); a 
‘generation’ in yeast’s cell division is defined as the time taken to double the number of 
cells.  
A gradual loss of an episomal plasmid bearing a heterologous human gene (i.e. in this 
case, the human CYP gene), in YPD medium, would lead to steady decline in protein 
production and, hence, decrease in CYP activity. Complete loss of CYP activity can be 
seen within 3-5 days of growth. However, once integrated at a chromosomal locus, a CYP 
gene expression cassette can never be lost when grown in YPD medium. Only when yeast 
cells become extremely stressed, they may undergo apoptosis, which is a form of 
programmed cell death. Apoptosis could occur because (a) the conditions of cell culture 
produce a toxic chemical entity and/ or (b) the cells produce large amounts of protein, 
which is inherently toxic to the cell.  
The consequence of growth of yeast cells in YPD medium is in stark contrast to growth 
in selective minimal SD medium. Growth of cells in SD medium prevents plasmid loss 
by selecting for the presence of an extra-chromosomal plasmid through its auxotrophic 
marker, as long as essential nutrients within the medium are present. This implies that 
yeast cells that lack the URA3 gene, but contain an episomal plasmid (such as pSYE263; 
Figure 5.1) which bears the URA3 gene besides encoding an expression cassette for a 
heterologous CYP gene or any other gene of choice, can be selected in SD minimal 
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medium lacking uracil. This implies that only those yeast cells that contain the URA3 
bearing episomal plasmid will grow on such medium. Unfortunately, however, SD 
medium, which is deprived of most of the essential nutrients present in YPD medium, 
allows only miniscule levels of cell growth compared to growth of cells in YPD. Less 




Figure 5.1. An episomal, 2-micron (2u) based plasmid, pSYE263. It contains 
the functional URA3 gene that allows selection of the plasmid in yeast cells 
that contain a mutant, dysfunctional ura3 gene, when cells are grown in 
minimal SD medium that lacks uracil. The restriction sites that occur only 









































The complete stability of yeast strains that contain an integrated copy of a CYP gene 
expression cassette can provide an exciting and beneficial avenue towards industrial scale 
use of these strains. In this Chapter, attempts have been made to improve on the levels of 
CYP proteins that were already obtained from such integrated strains. It was logical to 
think that a second copy of a CYP gene expression cassette would further improve CYP 
levels obtained in yeast cells than what was already observed in the one-copy strains, 
described in Chapter 4. However, there were also serious doubts about the feasibility of 
introduction of a second copy. It could be that overexpression of CYPs could lead to 
toxicity whereby cells would have to adapt spontaneously to produce decreased levels of 
CYPs to avoid toxic levels of the protein. CYPs are redox proteins, overproduction of 
which could be potentially toxic. Side by side, overproduction of a potentially toxic 
protein could lead to the possibility of seeing less cell growth.  
To explore further, it was decided to introduce a second copy of a CYP gene to the existing 
one-copy CYP gene containing yeast strains. Jensen et al (2014) have integrated, via 
homologous recombination, three genes coding for different fluorescent proteins. This 
was attempted to show that multiple genes can be integrated into a yeast strain and be 
functionally expressed. All three gene expression cassettes, under the control of the 
constitutive GAPDH promoter, were integrated on the same chromosome (i.e. 
chromosome X) of the genome of a yeast S. cerevisiae strain. Fluorescence at different 
emission/absorption wavelength was monitored to show only that the three proteins were 
merely expressed. It was seen that expression occurred at very low levels.  
As was plainly seen in Chapter 4, there were different levels of CYP enzyme expression 
from the HIS3 and the URA3 chromosomal loci of yeast cells. Integration of a CYP gene 
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expression cassette at the HIS3 chromosomal locus produces more CYP proteins than 
from the URA3 locus. HIS3 belongs to yeast chromosome XV and the URA3 gene is an 
integral part of chromosome V. It can be speculated that, during expression with an 
inducible promoter (i.e. ADH2p), proteins neighbouring the HIS3 and URA3 genes in 
chromosomes XV and V, where the heterologous CYP genes are embedded, may have a 
differential effect on CYP gene transcription, mediated by the ADH2p. These adjacent 
proteins, when in trans, may be acting differentially to produce different amounts of a 
CYP enzyme. In order to avoid the possibility of these proteins, which act in trans to 
enhance gene expression, being limiting it was decided to integrate two copies of a CYP 
gene expression cassette at two separate chromosomal loci, that is, at the HIS3 and the 
URA3 loci of yeast cells. This would allow stable expression of a CYP gene of choice, 
without any loss of plasmid in full YPD medium and would avoid the limitations of 
factors that may be aiding gene transcription.  
Metabolic engineering of the yeast Saccharomyces cerevisiae, with the aim of producing 
important chemicals relevant for the sustenance of human beings, has made huge progress 
in recent years. This has paved the way for advancing the genetic tools needed for the 
expression of heterologous proteins in yeast (Krivoruchko et al., 2011). Work in this 
Chapter has used methods related to chromosomal integration, which allows permanent 
attachment of a heterologous gene of interest at a chromosomal locus so that the 
corresponding protein could be expressed consistently in full YPD medium without loss 
of the gene from the cells. As described earlier, in the absence of selection pressure in 
YPD medium, which allows vigorous growth, an episomal plasmid is lost from the cells. 
An episomal plasmid can be maintained only in minimal SD medium, which, in contrast 
to YPD medium, unfortunately permits only poor growth of cells.  
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Most importantly, the microorganism yeast S. cerevisiae provides a robust system that 
possesses highly active machinery for homologous recombination. This yeast contains a 
conglomeration of enzymes that constitutes a platform for reliable integration of 
linearized DNA, which contains specific gene expression cassettes, into the yeast 
genome. The linearized DNA is flanked by DNA pieces which are homologous (i.e. 
identical) to regions in the yeast chromosome that encode auxotrophic markers. Mutations 
within genes encoding enzymes in biosynthetic pathways that lead to the synthesis of the 
basic metabolic building blocks, such as an amino acid or a nucleotide, are referred to as 
auxotrophic markers. They are used as selection markers during the process of 
transformation of an episomal plasmid or a linearized DNA. Transformation of an 
episomal plasmid leads to extra-chromosomal propagation of the plasmid whereas the 
linearized DNA through transformation (i.e. the process of introduction into cells) 
becomes permanently embedded on a particular site, where an auxotrophic marker lies, 
on the chromosome.  
Various methods for integration of a linearized plasmid have been described in the 
literature. They include ‘DNA assembly’ (Shao and Zhao, 2009) and ‘reiterative 
recombination’ (Wingler and Cornish, 2011). These methods were adapted to create a 
protocol that facilitates integration of linearized pieces of DNA, encoding different gene 
expression cassettes, into a single locus on a particular chromosome of the yeast genome. 
In order to circumvent the problem of genes on a single chromosome influencing the 
expression of each other at the transcriptional level (as mentioned above), it was decided 
that we introduce the second and, in some cases, the third copy of the CYP genes into 
different chromosomal locations. This would allow later on (as in Chapters 6 and 7), 
independent of transcriptional interference, investigations on the effects of the expression 
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of more than one CYP protein on each CYP’s active site geometry. This is often referred 
to as ‘neighbouring effect’ or ‘crowding effect’ that occurs through the simultaneous 
expression of proteins belonging to the same family (Bryant et al., 2014).  
In summary, in this Chapter (i.e. Chapter 5), the hypothesis that integration of 2 or 3 
copies of CYP genes on different chromosomal loci will provide higher levels of protein, 
visualized through monitoring of their activities via fluorescence assays, than one 
integrated copy has been explored by performing experiments with different CYP genes.  
 
5.2 Outline of this Chapter 
 
This Chapter is a continuation of Chapter 4. Here, two (in one case, three) copies of 
human CYP genes (chemically synthesized with yeast biased codons) have been 
integrated at two (or three) different chromosomal loci, via homologous recombination. 
The aim was to express human CYP enzymes within baker’s yeast cells, at high levels 
and with enhanced activity. The ultimate goal was to create robust recombinant yeast 
strains that would allow isolation of microsomal [i.e. endoplasmic reticular (ER) 
membrane bound] enzymes from these cells, in high yields and with activities which were 
better than what has been published before. CYPs are totally inactive when shorn off the 
microsomal (ER) membranes. To be able to isolate these fragile microsomal enzymes in 
enhanced yields and activities, a new process was developed.  
In order to achieve the goal, a number of yeast strains were created and they were 
individually screened for CYP enzyme activity, via fluorescence assays using fluorogenic 
substrates. The enzyme activities for a particular CYP, from different clones of the same 
strain, were then compared. It was inferred that enzyme activities correlate with the 
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amounts of CYPs within the cells. This was verified by isolating microsomal human CYP 
enzymes (i.e. bound to ER membranes) from the best and worst CYP producing clones 
that were identified through the initial screening process. The activities of baker’s yeast 
derived microsomal enzymes (Sacchrosomes) were then compared, head-to-head, with 
the three commercially available enzymes, which are, produced either from insect or 
bacterial cells and which are sold worldwide. Global market size of recombinant human 
CYPs is considered to be at least $250 million. The results obtained show that the human 
CYP enzymes, produced from baker’s yeast, are 2-3 times more active than the 
commercially available enzymes. The results also suggest that, without embarking on 
production of these enzymes in a cheaper environment, the human CYP enzymes could 
easily be produced in the UK and sold at half the price quoted by the current 
manufacturers. Yet these cheap, highly active enzymes, if marketed, could still provide a 
profitable margin. Because of their cheapness, they could be made widely available for 
early pre-clinical research which is not possible right now because recombinant human 








5.3.1 Fluorescence-based assays for determining CYP 
enzyme activities in whole cells and isolated 
microsomes 
 
Only a few chemical molecules have been found to be useful as selective probes (i.e. as 
inhibitors and substrates) of each human CYP enzyme. Analysis of CYP enzyme 
inhibition and identification of metabolites that are formed, upon reaction of a CYP 
enzyme with its substrate, involves the use of techniques such as high-pressure liquid 
chromatography (HPLC) and liquid chromatography in tandem with mass spectrometry 
(LC-MS). These methodologies are slow and massively labour intensive. Alternatively, 
for rapid screening of libraries of chemical compounds for their potential to inhibit CYP 
enzymes, fluorogenic substrates are used. These substrates do not fluoresce on their own 
but form fluorescent products upon reacting with specific CYP enzymes.  
Several substrates have been used to analyse metabolite formation for different CYP 
enzymes. For example, non-fluorescent or low-fluorescent P450 substrates have been 
used that produce highly fluorescent metabolites in aqueous solutions. Historically, the 
very early substrates had limited aqueous solubility and poor metabolite formation; it 
gave a high background and low signal to noise ratio, which was not appropriate for 
screening of CYP enzyme inhibitors. Later on, O-alkyl derivatives of resorufin, 
fluorescein, 7-hydroxycoumarins and other molecules were discovered to study CYP-
mediated fluorescent metabolite formation (Burke at al., 1985 & Stresser et al., 2000).  
Some non-fluorescent probes (substrates) are selective and have been reported to be 
useful for measuring individual CYP enzyme activities (Chauret at al., 1999, 2001). 
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However, it was also realised that non-selective substrates would not be good enough for 
measuring CYP450 activities in human liver microsomes in vitro because there are 12-
15 of the CYP enzymes which are co-expressed in the human liver. However, this 
limitation of the substrates being non-selective can be overlooked in the case of 
recombinant membrane-bound CYP enzymes, which are individually expressed within 
cell factories. Hence, for recombinant microsomal CYP enzymes, non-selective 
substrates can be used for testing individual CYP activities.  
In this study, a battery of fluorescence-based assays have been described for rapid 
measurement of different CYP enzyme activities expressed within intact yeast cells and 
in microsomes isolated from these cells which express individual CYP enzymes. The 
cultured yeast cells were washed with 1X TE buffer, as was described in Materials and 
Methods (Chapter 2) before directly incubating them with a fluorogenic substrate (i.e. a 
non-fluorescent substrate which can produce a fluorescent product upon reaction with a 
CYP enzyme). The metabolites (i.e. products) formed were quantified fluorometrically 
by measuring the fluorescence emitted by the product, on a plate reader.  
These assays also:  
(a) gave the possibility of clonally selecting sub-sets of cells that express high CYP 
activities and also  
(b) provided the chance of analysing the inhibitory effects of new chemical 
compounds individually on each CYP enzyme.  
The standard curves of the products formed by reaction of substrate with individual 
microsomal enzymes were obtained. The activities of isolated CYP microsomes were 
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then measured using fluorescence substrates, after incubation of enzyme with substrate 
for a few minutes. It was found the results obtained from intact cells and isolated 
microsomes were similar.  
In this study some of the non-fluorescent (fluorogenic) substrates, listed below (Table 
5.1), have been used to establish the amount of fluorescent metabolites that were formed 
during CYP-mediated metabolism of substrates. 
 
Table 5.1. The non-fluorescent substrates and the fluorescent products formed in 
CYP enzyme assays.  
 
CYP Substrate Metabolite Formed 
1A2 CEC  (3-cyano-7-ethoxycoumarin) 
CHC  
(3-cyano-7-hydroxycoumarin) 
2A6 Coumarin  Hydroxycoumarin 
2B6 EFC  (7-ethoxy-trifluoromethylcoumarin) 
HFC 
(7-hydroxytrifluoromethylcoumarin) 


























DBF (dibenzylfluorescein), BFC (7-
benzoyloxy-4-trifluoromethyl 








5.3.2 Relative stability of a yeast strain containing an 
integrated copy of CYP1A2 gene compared to a 
strain that bears an episomal plasmid that encodes 
CYP1A2 gene 
 
Before embarking on the creation of yeast strains that contain 2 copies of a CYP gene, the 
stability of prototypic strain that contains only a copy of a specific CYP gene was tested. 
To the strain YAB79, containing a modified human P450 reductase [∆hRDM (Chapter 4) 
and cytochrome b5, was introduced one copy of the CYP1A2 gene by integration in 
YAB79’s HIS3 chromosomal locus. The resultant strain named YAB79::1A2(HIS3) was 
used for this experiment. The cells pertaining to the strain YAB79::1A2(HIS3) were 
subjected to a long period of growth in which cells were repeatedly inoculated into fresh 
YPD full medium, after every 24 h of growth. YPD medium contains 2% glucose as 
carbon source for growth of cells. After every 24 h, the cell culture was spun down and 
fresh medium was added.  
Glucose is known to affect a variety of processes in yeast S. cerevisiae. This includes 
induction of genes needed for glucose transport, protein synthesis and repression of genes 
required for cell growth on carbon sources other than glucose (Carlson, M. 1999). 
Another important role of glucose is in the transcription of certain yeast genes, although 
the mechanism via which glucose regulates gene expression has not been fully 
understood. In 1997, Joseph et al demonstrated that the genes that are regulated by the 
change from fermentative growth on glucose to oxidative growth pertain to a diauxic 
shift. Yeast cells enter diauxic shift when glucose becomes limiting. It involves switching 
cells’ metabolism from glycolysis to aerobic utilization of ethanol and is characterized by 
decreased growth rate. This would mean that if ethanol was used as a carbon source, it 
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would result in the repression of certain genes involved in yeast cell growth. Joseph et 
al’s study portrayed the findings via cell growth curves. It showed that, when glucose is 
exhausted, there is a shift in the expression of genes. Besides this, the authors observed 
that when yeast cells became stressed the metabolic activity of the cells was depressed. 
This was monitored via expression of the green fluorescent protein (GFP) during yeast 
cell growth. The fluorescence produced in stressed cells was inversely proportional to the 
fluorescence emanated by cells that were not stressed.  
With the above information at hand, YAB79 cells were transformed (i.e. a process of 
introduction of DNA into live yeast cells) with an  
(a) Episomal (pSYE263/h_CYP1A2_yc; Figure 5.2) and  
(b) Integrating plasmid (YIpHisADH2S/CYP1A2_yc; Figure 5.3).  
The resultant strains obtained after transformation were named  
(i) YAB79::1A2(2µ), and  
(ii) YAB79::1A2(HIS3).  
The episomal plasmid allows extra-chromosomal replication of plasmid during cell 
division, whereas the integrating plasmid targets the plasmid to a yeast chromosome.  
The two yeast strains YAB79::1A2(2µ) and YAB79::1A2(HIS3) were grown in YPD 
medium and their growth was monitored over 4 days. The cultures were started with an 
initial inoculum of equal number of cells. Both cell cultures were grown in exactly the 
same way, with fresh YPD medium being provided at identical time points of growth. 





Figure 5.2. Episomal plasmid that contains a human CYP1A2 gene expression 
cassette. It was used to create the yeast strain YAB79::1A2(2µ). The restriction 
sites shown occur in the plasmid only once.  
 
The CYP1A2 gene, in the plasmid pSYE263/h_CYP1A2_yc, was synthesized using yeast 
biased codons. It is driven by the ADH2 promoter which is upstream (5’-end) of the gene. 
The transcription terminator is from the yeast CYC1 gene. The CYP1A2 gene expression 
cassette consists of the CYP1A2 gene sandwiched between the ADH2 promoter and the 
CYC1 terminator. The URA3 gene is the dominant gene in yeast’s biosynthetic pathway 
that leads to the synthesis of the nucleoside, uracil. It is the selection marker on the 
episomal plasmid. This allows selection (maintenance) of the plasmid when transformed 
into the cells of a yeast strain which lacks a functional URA3 gene (represented by the 
term ‘ura3’, in lowering casing). This implies that the episomal plasmid can continue to 







































SD medium that lacks uracil. The episomal plasmid is comprised of an essential part 
(1472 bp; ‘2u’ in Figure 5.2) of the endogenous 2-micron (2u) sequence (6318 bp) of 
yeast that allows autonomous replication of the plasmid when yeast cells divide. The 1472 
bp ‘2u’ sequence in the plasmid, shown in Figure 5.2, includes the sequences that code 
for the Rep 1 and Rep 2 proteins that are involved in plasmid partitioning and stability 
during yeast cell division (Velmurugan et., 2000; Rizvi et al., 2017). It should be 
emphasised that there is no selection pressure in full YPD medium which contains all 
essential nutrients, including uracil. Cells from the strain YY7 when transformed with 
episomal plasmid were named YAB79::1A2(2µ).  
 
 
Figure 5.3. The plasmid that has been used for integration at the HIS3 locus of 
the yeast strain YAB79 that lacks a functional HIS3 gene (‘his3’). The plasmid 
contains a functional copy of the HIS3 gene and was used to create the strain 
YAB79::1A2(HIS3). The restriction sites shown on the map occur in the 



































For integration, the plasmid, in Figure 5.3, must be linearized at a restriction site within 
the HIS3 gene that is encoded by the plasmid. The HIS3 gene is a dominant gene in the 
yeast cells’ pathway to making the amino acid histidine biosynthetically. The restriction 
site for linearization is chosen such that it occurs only once in the plasmid. This is to 
enable efficient homologous recombination of a linearized DNA fragment to occur on the 
chromosomal locus of yeast cells where the non-functional his3 gene resides. Plasmid 
integration into the chosen his3 chromosomal locus of the strain is confirmed by plating 
cells, after yeast transformation, in SD minimal medium that lacks histidine. Cells that 
grow in this medium must once again contain a functional HIS3 gene. After thus 
confirming integration, the cells containing an integrated copy of the CYP1A2 gene 




Figure 5.4. Comparison of the growth of YAB79 derivatives, harbouring (a) a 
CYP1A2 gene expression cassette-bearing episomal 2µ-plasmid [YAB79::1A2 
(2µ)] and (b) and an identical expression cassette that had been integrated 
into the HIS3 locus of the yeast chromosome [YAB79::1A2 (HIS3)]. The optical 
densities were measured at 600 nm (cell count) and 1X 107 cells were taken 
for measurement in each case.The data represent mean ± S.D. of three 




















Comparison of OD600 readings of YAB79 cells containing  
an (a) episomal copy and (b) integrated copy of the 






The bar plots in Figure 4 show the optical density, measured at 600 nanometres (i.e. 
OD600), of cells from strains that express (a) CYP1A2 gene from an episomal plasmid 
[strain YAB79::1A2(2µ)] and (b) an integrated copy [strain YAB79::1A2(HIS3)]. After 
Day 1, YAB79::1A2(2µ) cells (blue coloured bar in the Figure) compared well with 
YAB79::1A2(HIS3) cells. From Day 2, however, YAB79::1A2(HIS3) cells grew far 
quicker than YAB79::1A2(2µ), the cells that contain the episomal plasmid. At completion 
of Day 3, cells of both strains doubled their cell numbers, the amount of nutrients in the 
cell culture medium playing an important role. At completion of Day 4, YAB79::1A2(2µ) 
cells did not show any further increase in cell number while the integrated strain 
YAB79::1A2(HIS3) almost doubled the number of cells that were obtained after Day 3.  
We then asked the question why the density of cells of the strain YAB79::1A2(2µ), 
bearing an episomal plasmid, lags behind the cells of strain YAB79::1A2(HIS3) that 
contains an integrated copy of CYP1A2 gene, after 4 days of growth. It could be assumed 
that the majority of YAB79::1A2(2µ) cells would have lost the plasmid after 4 days of 
growth because they were gown in the non-selective YPD medium. It would seem that 
cells were stressed after loss of plasmid and, therefore, lagged in growth. This could 
perhaps be explained by the fact that the YAB79 strain was originally derived from a 
basic strain that was circle-zero, that is, it lacked the endogenous 2µ plasmid which all 
wild yeast cells contain. The endogenous 2µ plasmid sustains cell growth. Circle-zero 
cells grow much slower than circle-plus cells (Chen et al., 2005). The episomal plasmid, 
which has been used for these studies, contains part of the endogenous 2µ plasmid and, 
hence, episomal plasmids are often referred to as 2µ plasmids. In the context of growth, 
an episomal plasmid is likely to compensate for the absence of the endogenous 2µ 
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plasmid. Therefore, it would be expected that, after loss of the CYP1A2 gene-bearing 
episomal plasmid, during growth in non-selective YPD medium, the yeast cells would 
grow slower.  
The observation that cells, containing an integrated copy of a human gene, grew so well 
over 4 days (i.e. up to an OD600 of around 100) has relevance to industrial scale production 
of recombinant CYP proteins in yeast. It would seem that another advantage of the 
YAB79 cells used is their robustness because of their ability to withstand high ethanol 
concentrations. Usually, most laboratory yeast strains die or grow very sluggishly in cell 
culture medium that contains ethanol. It should be highlighted that in each new 
consecutive cycle of growth in YPD medium, the cells were exposed to increasing 
concentrations of ethanol. Hence, cells containing integrated copies of genes would be 
extremely important as part of a generic manufacturing process whereby proteins such as 
CYP enzymes and other recombinant proteins are produced. Having cells growing to such 
high density, without any loss of genetic information from within the cells, would 
definitely allow consistent and reproducible production of high levels of CYP proteins. 
Having obtained these results, it was thought that it would be interesting to find out if the 
integrated strain YAB79::1A2 (HIS3) produces more or less CYP enzyme activity than 
the episomal strain YAB79::1A2(2µ), per unit number of cells.  
Figures 5.5 and 5.6 show that the yeast strain YAB79::1A2(2µ), containing the CYP1A2 
gene-bearing episomal plasmid, had a dramatic decrease in CYP1A2 enzyme activity, per 
1X 107 cells, compared to cells that contained an integrated copy of the CYP1A2 gene, 
that is, YAB79::1A2(HIS3). Since the cells were not subjected to any selection pressure 
in YPD medium, as explained above, YAB79::1A2 (2µ) cells had lost the ability to 
408 
 
sustain the CYP1A2 gene bearing plasmid. As a result of the instability of the episomal 
plasmid in YPD, CYP1A2 enzyme activity decreased drastically compared to 
[YAB79::1A2 (HIS3)] cells that contained an integrated copy of the CYP1A2 gene.  
 
 
Figure 5.5. Comparison of the kinetics of CYP1A2 enzyme activities obtained 
from YAB79::1A2(2µ) and YAB79::1A2(HIS3) cells. Activities were monitored 
in 1X 107 cells that were grown for 1 to 3 days, using CEC as a substrate (Table 














Comparison of CYP1A2 enzyme activities within yeast cells that 
harbour (a) an episomal plasmid encoding the gene [1A2(2µ)] and (b) 
an integrated copy  of the CYP1A2 gene [1A2(HIS3)],  measured after 










Figure 5.6. Comparison of CYP1A2 enzyme activities obtained from 
YAB79::1A2(2µ) and YAB79::1A2(HIS3) cells. Activities were determined at 9 
min, using 1X 107 cells, in an end-point enzymatic assay. CEC was used as the 
fluorogenic substrate (Table 1). The Figure mirrors the results shown in 
Figure 5.5.  
 
The results in Figures 5.5 and 5.6 depict the strength of CYP1A2 activities displayed by 
strains that express an integrated copy of the gene. The episomal plasmid strain 
YAB79::1A2 (2µ) has the highest activity on Day 2 while there was a sharp decrease in 
the activity of episomal on Day 3. The strain YAB79::1A2 (HIS3), containing the 
integrated copy of CYP1A2 gene, show gradual increase in activity from Days 1 to 3. 
Activity increased only ~30% from Days 1 to 2 but there was ~98 % increase from Days 
2 to 3. However, it was most surprising that the strain expressing CYP1A2 from an 
episomal would produce much less CYP enzyme than the strain that contains a single 
copy of the CYP1A2 gene even on Day 1. Episomal plasmids, containing the 2-micron 


















Comparison of CYP1A2 enzyme activities within yeast cells that 
harbour (a) an episomal plasmid [1A2(2µ)] encoding the CYP1A2 gene 
and (b) an integrated copy of the CYP1A2 gene [1A2(HIS3)],  
measured via an end-point assay using 10 µM CEC as  substrate, af
1A2(2µ), Day 1 1A2(HIS3), Day1 1A2(2µ), Day 2
1A2(HIS3), Day 2 1A2(2µ), Day 3 1A2(HIS3), Day 3
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gene per cell (Broach et al., 1991; Futcher and Cox, 1993; Falcon et al., 2005). However, 
during the expression of toxic human proteins in yeast, the copy number of a 2µ-plasmid 
could be less than one (Kingsman et al., 1985). CYP-CPR complexes constitute redox 
enzymes. Overexpression of such complexes could potentially be very harmful for living 
cells. In human cells, CYP expression is highly regulated. When expressed, their levels 
are very low and that is one of the reasons that the availability of recombinant CYP 
enzymes is so crucial for drug discovery. Moreover, overexpression of CPR in humans is 
known to cause neurodegenerative disease (Yao et al., 2013). Hence, overexpression of 
CPR in human cells is toxic.  
It was, therefore, very exciting to observe that the yeast strain YAB79::1A2(HIS3), 
containing ‘one’ integrated copy of the CYP1A2 gene, not only grows to a much higher 
optical density (Figure 5.4) but also that, per defined number of cells (e.g. 1X 107), the 
strain expresses a lot more enzyme than the strain YAB79::1A2(2µ) which contains a 
CYP1A2 gene bearing episomal, 2µ-plasmid which ought to produce multiple copies of 
CYP1A2 gene. This would indicate that integration of CYP gene expression cassettes into 
yeast’s chromosomes may provide an excellent method for stable production of human 
CYP enzymes at high levels.  
 
5.3.3 Comparison of CYP1A2 enzyme activity produced 
from a yeast strain that expresses 2 copies of the 
CYP1A2 gene and strains that express 1 copy of the 
gene 
 
A second copy of the CYP1A2 gene expression cassette was introduced into the URA3 
locus of the strain YAB79::1A2(HIS3) to obtain the new strain 
YAB79::1A2(HIS3,URA3) [1A2(HIS3,URA3) in Figure 5.7] which contains 2 copies of 
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the CYP1A2 gene. Activity produced in this 2-copy CYP1A2 strain was then compared 
with the ones produced by the strains that express only one copy of CYP1A2 gene from 
two different chromosomal loci, HIS3 and URA3 [strains 1A2(HIS3) and 1A2URA3) in 
Figure 5.7]. The results are depicted Figures 5.7 and 5.8. Equal numbers of cells (1X 107) 
were used for determination of CYP1A2 enzyme activity expressed by each strain.  
 
 
Figure 5.7. Comparison of the kinetics of CYP1A2 enzyme activities obtained 
from the yeast strain YAB79::1A2(HIS3,URA3), that contains 2 copies of 
CYP1A2 gene, and strains [YAB79::1A2(HIS3) & YAB79::1A2(URA3)] that 
contain one copy of the gene at the HIS3 and URA3 loci. The strain 
YAB79::1A2(2µ), that contained the episomal plasmid, was used as a control. 
Activities were determined using 1X 107 cells from cultures that were grown 
for 3 days. CEC was used as a substrate. The depicted results were an average 













Comparison of CYP1A2 enzyme activities within yeast cells that harbour (a) two 
integrated copies and (b) an integrated copy  of the CYP1A2 gene,  measured 









Figure 5.8. Comparison of CYP1A2 enzyme activities obtained from the 2-copy 
[YAB79::1A2(HIS3,URA3)] yeast strain and 1-copy CYP1A2 expressing strains 
[YAB79::1A2(HIS3) and YAB79::1A2(URA3)]. YAB79::1A2(2µ) cells were used 
as control. Activities were determined at 15 min, using 1X 107 cells, in an end-
point enzymatic assay, using CEC as a substrate.  
 
The graph in Figure 5.7 and the bar plot in Figure 5.8 depict the expression of CYP1A2 
in the strain YAB79 which contains the modified human P450 reductase ∆hRDM at the 
LEU2 locus and cytochrome b5 at the TRP1 locus. It is observed that the strain expressing 
2 copies of the CYP1A2 gene, simultaneously from the HIS3 and URA3 loci, is by far the 
best in producing the CYP1A2 enzyme, compared to the strains that express one copy of 
the CYP1A2 gene. Both the HIS3 and URA3 loci were chosen for integration since it had 
been found, from the experiments described in Chapter 4, that these loci produced the 
highest amount of CYP enzymes. As seen before, expression of the enzyme from an 

















Comparison of CYP1A2 enzyme activities within yeast cells that harbour (a) 
two integrated copies and (b) an integrated copy of the CYP1A2 gene,  
measured after 72 h of growth, in baffled flasks, using 10 µM CEC as a 







5.3.4 Comparison of amounts of CYP1A2 microsomal 
enzyme isolated from yeast strains containing 
CYP1A2 gene which is (a) chromosomally 
integrated at two different loci and (b) encoded 
by an episomal plasmid 
 
Until now, the amounts produced within whole cells were inferred from the CYP enzyme 
activities that had been measured within whole cells. Although indicative, this was not a 
precise way of quantifying the amounts produced. Hence, microsomal enzymes were 
isolated from the 2-copy strain YAB79::1A2(HIS3,URA3) [referred to as 
1A2(HIS3,URA3) in Figure 5.9] and the episomal strain, YAB79::1A2(2µ) [1A2(2µ), in 
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Figure 5.9. (A), (B): CYP450 contents, in the strains YAB79::1A2(HIS3,URA3) 
(A) and YAB79::1A2(2µ) (B) were determined by Fe2+ versus Fe3+ CO 
difference spectrophotometry using 1.0 µg of microsomal protein. (C) The 
amount of CYP450 (in nanomoles), obtained from the 2 strains (400 ml of YPD 
culture grown in baffled flasks), and represented as bar plots. The data 
represent mean ± S.D. of three independent experiments. (D) Western blots 
used 10 µg of total protein from the strains YAB79::1A2 (HIS3, URA3) (lane 1), 
YAB79::1A2 (HIS3) (lane 2) and YAB79::1A2 (2µ) (lane 3) to probe with a 




The microsomal CYP1A2 enzymes isolated from the two strains were measured via 
carbon monoxide (CO) difference spectroscopy (see Chapter 2, Section 2.8.3.1) which 
involves binding of CO to CYP450 enzymes [Figure 5.9 (A) and (B)]. Figure 5.9 (C) 
shows that 400 ml of cells cultured from the integrated strain YAB79::1A2(HIS3,URA3) 
produced 69 nM (i.e. 69 nanomoles) of microsomal CYP1A2 enzyme compared to only 
6 nM of enzyme from 400 ml of cells from the strain YAB79::1A2(2µ). The Western blot 
in Figure 5.9 (D) shows a clear difference in the amounts of CYP1A2 produced within 
the cells from the strains  
(a) YAB79::1A2(HIS3,URA3), harbouring 2 copies of CYP1A2 gene,  
(b) YAB79::1A2(HIS3), harbouring 1 copy of CYP1A2 gene, and  
(c) YAB79::1A2(2µ), harbouring an episomal plasmid that encodes the CYP1A2 
gene.  
All Western blot protein bands, in this Chapter, were visualized using the software 
Quantity One (Chem Doc; Bio-Rad). The strain YAB79::1A2(HIS3,URA3) expressing 2 
copies of the CYP1A2 gene produced the highest amount of CYP1A2 protein.  
 
5.3.5 Comparison of human CYP3A4 enzyme activities, 
expressed within cells, from yeast strains that 
contain 1-3 integrated copies of CYP3A4 gene 
 
With the aim of finding a yeast strain that would produce high amounts of human 
CYP3A4 enzyme, attempts were made to express the enzyme from different yeast strains 
that contain different copy numbers of a human CYP3A4 gene expression cassette. The 
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human CYP3A4 gene was chemically synthesised using yeast biased codons. Different 
yeast strains were created for comparative analysis of human CYP3A4 enzyme 
expression.  
YAB79 cells (containing ∆hRDM and cytochrome b5 genes) were transformed with an 
(1) Episomal (pSYE263/h_CYP3A4_yc; Figure 3.6) to create a control strain,  
(2) Integrating plasmid (YIpAdeADH2S/CYP1A2_yc; Figure 4.18, Chapter 4),  
(3) Integrating plasmid (YIpHisADH2S/CYP1A2_yc; Figure 4.24, Chapter 4), 
(4) Integrating plasmid (YIpUraADH2S/CYP1A2_yc; Figure 4.21, Chapter 4), 
The resultant strains obtained after transformation were named  
(i) YAB79::3A4(2µ), a control strain, where the plasmid replicates extra-
chromosomally during cell division occurring during yeast cell growth [referred 
to as 3A4(2µ) in Figure 5.10],  
(ii) YAB79::3A4(ADE2) [referred to as 3A4(ADE2) in Figure 5.10], 
(iii) YAB79::3A4(HIS3) [referred to as 3A4(HIS3) in Figure 5.10], 
(iv) YAB79::3A4(URA3) [referred to as 3A4(URA3) in Figure 5.10].  
The strains YAB79::3A4(ADE2) and YAB79::3A4(HIS3) were used to introduce a 
second copy of the human CYP3A4 gene. The resultant strains obtained after 
transformation were named  
(v) YAB79::3A4(ADE2,HIS3) [referred to as 3A4(ADE2,HIS3) in Figure 5.10], 
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(vi) YAB79::3A4(ADE2,URA3) [referred to as 3A4(ADE2,URA3) in Figure 5.10], 
(vii) YAB79::3A4(HIS3,URA3) [referred to as 3A4(HIS3,URA3) in Figure 5.10], 
To the yeast strain YAB79::3A4(HIS3,URA3) was introduced a third copy of the 
CYP3A4 gene to create the strain  
(viii) YAB79::3A4(ADE2,HIS3,URA3) [referred to as 3A4(ADE2,HIS3,URA3) in 
Figure 5.10].  
The strain YAB79:: – (ADE2,HIS3,URA3) was generated to act as a negative control. It 
was created by stepwise integration of an empty plasmid that does not contain any 
CYP3A4 gene. In Figure 5.10, it is referred to simply as “– (ADE2,HIS3,URA3)”.  
All integrating plasmids, listed above, allow integration of a plasmid into yeast’s 
chromosomes.  
The yeast strains were grown in YPD medium for 72 h, replenished with new medium 
every 24 h. The CYP3A4 activities, within cells, were monitored in (1X 107) cells 
harvested after 72 h. Each culture was started with an inoculum of equal number of cells. 
All cell cultures were grown exactly in the same way, with fresh YPD medium being 
provided at identical time points of growth. The results in Figure 5.10 show comparative 








Figure 5.10. The graph (A) shows the comparison of CYP3A4 enzyme activities 
within cells of different yeast strains, derived from YAB79. They contain the 
CYP3A4 gene in 1 copy, 2 & 3 integrated copies, and CYP3A4 gene encoded by 
an episomal plasmid. A strain which contained 3 empty plasmids on the ADE2, 
HIS3 and URA3 loci acted as a negative control. The graphs represent the 
average of results obtained from three independent experiments. The bar plot 
(B) mirrors the graphs in (A). The data represent mean ± S.D. of three 














(A) Comparison of CYP3A4 enzyme activities within yeast cells that 
harbour integrated copies of the CYP3A4 gene,  measured after 72h of 























(B) Comparison of CYP3A4 enzyme activities within yeast cells that harbour 
integrated copies of the CYP3A4 gene,  measured after 72h of growth, in baffled 












The results in Figure 5.10 clearly show that the yeast cells from the strain 
YAB79::3A4(ADE2,HIS3,URA3) [referred to as 3A4(ADE2,HIS3,URA3), containing 3 
copies of the human CYP3A4 gene, produce the highest activity of CYP3A4 enzyme 
implying. Hence, it could be deduced that the 3-copy strain, per 1X 107 cells, produces 
the highest amount of the CYP3A4 enzyme. However, the 2-copy strain, expressing 
CYP3A4 simultaneously from the HIS3 and URA3 chromosomal loci, was a close second. 
Since the 3-copy strain did not grow as well as the 2-copy strain, probably because of 
latent toxicity due to overexpression, the latter [i.e. the strain YAB79::3A4(HIS3,URA3), 
referred to as 3A4(HIS3,URA3)], was used further for isolation of microsomal CYP3A4 
enzyme.  
 
5.3.6 Comparison of amounts of CYP3A4 microsomal 
enzyme isolated from yeast strains containing 
CYP3A4 gene which is (a) chromosomally 
integrated at two different loci and (b) encoded 
by an episomal plasmid 
 
In order to evaluate the true expression levels of CYP3A4 enzyme in the strain 
YAB79::3A4(HIS3,URA3), referred to as 3A4(HIS3,URA3) in Figure 5.11, microsomal 
CYP3A4 enzyme was isolated. The correctly folded CYP protein, which provides the 
activity, was determined at 450 nm via CO difference spectroscopy (see Chapter 2, 
Section 2.8.3.1). Results shown in panels (A) and (B) of Figure 5.11 clearly show that the 
amount of enzyme produced by this integrated strain is much more than the enzyme 
obtained from the episomal plasmid containing strain YAB79::3A4(2µ), referred to as 
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3A4(2µ) in Figure 5.11. Both strains were grown in 400 ml of YPD cell culture, under 
























Figure 5.11. (A), (B): P450 contents, in the strains YAB79::3A4(HIS3,URA3) 
[3A4(HIS3,URA3); (A)] and YAB79:: 3A4(2µ) [3A4(2µ); (B)] were determined 
by CO difference spectroscopy using 1.0 µg of microsomal protein. (C) The 
amount of CYP450 (in nanomoles), obtained from the 2 strains (400 ml of YPD 
culture grown in baffled flasks), and represented as bar plots. The data 
represent mean ± S.D. of three independent experiments. (D) Western blots 
where 10 µg of total protein from the strains YAB79::3A4(HIS3,URA3) (lane 
1), YAB79::3A4(HIS3) (lane 2) and YAB79::3A4(2µ) (lane 3) were probed with 
a CYP3A4 specific antibody (Santa Cruz Biotechnology, Cat no:sc-27639). 
 
Panel C (Figure 5.11) shows that the strain containing 2 integrated copies of the CYP3A4 
gene produced 48 nanomoles of CYP3A4 enzyme while the episomal produced only 15 
nanomoles from 400 ml of cell culture. Panel D depicts a Western blot of CYP3A4 
proteins obtained from different strains. It visually confirms that the strains that express 
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1-2 integrated copies of CYP3A4 gene produce more protein than the strain that expresses 
CYP3A4 from an episomal plasmid.  
5.3.7 Comparison of human CYP3A5 enzyme activities, 
expressed within yeast cells, from strains that 
contain 1 copy and 2 integrated copies of CYP3A5 
gene 
 
With the aim of identifying a yeast strain that would produce high amounts of human 
CYP3A5 enzyme, four new strains were created from the strain YAB79 that contains 
∆hRDM and cytochrome b5 genes at the LEU2 and TRP1 loci, respectively.  
YAB79 cells were transformed with an 
(1) Episomal (pSYE263/h_CYP3A5_yc; Figure 3.92, Chapter 3) to create a control 
strain,  
(2) Integrating plasmid (YIpHisADH2S/CYP3A5_yc; Figure 4.77, Chapter 4), 
(3) Integrating plasmid (YIpUraADH2S/CYP3A5_yc; Figure 4.79, Chapter 4). 
The resultant strains obtained after transformation were named  
(i) YAB79::3A5(2µ), the control strain, [referred to as 3A5(2µ) in Figure 5.12],  
(ii) YAB79::3A5(HIS3) [referred to as 3A5(HIS3) in Figure 5.12], and 
(iii) YAB79::3A5(URA3) [referred to as 3A5(URA3) in Figure 5.12]. 
The strain YAB79::3A5(HIS3) was used to introduce a second copy of the human 
CYP3A5 gene at the URA3 locus. The resultant strain obtained after transformation was 
named YAB79::3A5(HIS3,URA3), referred to as 3A5(HIS3,URA3) in Figure 5.12.  
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The yeast strains were grown in YPD medium for 72 h, replenished with new medium 
every 24 h. The CYP3A5 activities, within cells, were monitored in (1X 107) cells 
harvested after 72 h of growth. Each culture was started with an inoculum of equal 
number of cells. All cell cultures were grown exactly in the same way, with fresh YPD 
medium being provided at identical time points of growth. The results in Figure 5.12 
show comparative CYP3A5 enzyme activities obtained from four different strains. 
 
 
Figure 5.12. The graph (A) shows the comparison of CYP3A5 enzyme activities 
within cells of different yeast strains, derived from YAB79. They contain the 
CYP3A5 gene in 1 integrated copy, 2 integrated copies, and the CYP3A5 gene 












(A) Comparison of CYP3A5 enzyme activities within yeast cells that 
harbour integrated copies of the CYP3A5 gene,  measured after 72h of 

















(B) Comparison of CYP3A5 enzyme activities within yeast cells that 
harbour integrated copies of the CYP3A5 gene,  measured after 72h of 







results obtained from three independent experiments. The bar plot (B) 
mirrors the graphs in (A). The data represent mean ± S.D. of three 
independent experiments.  
 
Figure 5.12 depicts the expression of human CYP3A5 in baker’s yeast. The results show 
that the 2-copy integrated strain YAB79::3A5(HIS3,URA3), referred to as 
3A5(HIS3,URA3), has the highest activity. This strain was used to prepare CYP3A5 
microsomal enzyme.  
 
5.3.8 Comparison of amounts of CYP3A5 microsomal 
enzyme isolated from yeast strains containing 
CYP3A5 gene which is (a) chromosomally 
integrated at two different loci and (b) encoded 
by an episomal plasmid 
 
In order to evaluate the true expression levels of CYP3A5 enzyme in the strain 
YAB79::3A5(HIS3,URA3), referred to as 3A5(HIS3,URA3) in Figure 5.13, microsomal 
CYP3A4 enzyme was isolated. Both strains were grown in 400 ml of YPD cell culture, 
under exactly the same conditions. The correctly folded CYP protein, which provides the 
activity, was determined at 450 nm via CO difference spectroscopy (see Chapter 2, 
Section 2.8.3.1). Results shown in panels (A) and (B) of Figure 5.13 clearly show that the 
amount of enzyme produced by this integrated strain is more than the enzyme obtained 
from the episomal plasmid containing strain YAB79::3A5(2µ), referred to as 3A5(2µ) in 
Figure 5.13. Comparison of the graphs in panels (A) and (B) reveals that the amounts of 
cytochrome b5 expressed is much less in YAB79::3A5(HIS3,URA3) cells than in the 
strain YAB79::3A5(2µ). This may imply that the overall CYP3A5 microsomal enzyme 
activity from YAB79::3A5(HIS3,URA3) may be lower than the enzyme obtained from 
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YAB79::3A5(2µ), if cytochrome b5 had a role in the overall activity of CYP3A5. 
However, it has been shown later in this Chapter, after isolation of the microsomal 
enzyme, cytochrome b5 levels may not be too relevant for CYP3A5 activity. This is in 

























Figure 5.13. (A), (B): P450 contents, in the strains YAB79::3A5(HIS3,URA3) 
[3A5(HIS3,URA3); (A)] and YAB79::3A5(2µ) [3A5(2µ); (B)] were determined 
by CO difference spectroscopy using 1.0 µg of microsomal protein. (C) The 
amount of CYP450 (in nanomoles), obtained from the 2 strains (from 400 ml 
of YPD culture grown in baffled flasks), and represented as bar plots. The data 
represent mean ± S.D. of three independent experiments. (D) Western blots 
where 10 µg of total protein from the strains YAB79::3A5(HIS3,URA3) (lane 
1), YAB79::3A5(HIS3) (lane 2) and YAB79::3A5(2µ) (lane 3) were probed with 
a CYP3A5 specific antibody (Santa Cruz Biotechnology, Cat no:sc-53616). 
 
Panel C (Figure 5.13) shows that the strain containing 2 integrated copies of the CYP3A5 
gene produced 245 nanomoles of CYP3A5 enzyme while the episomal produced only 15 
nanomoles from 400 ml of cell culture. Panel D depicts a Western blot of CYP3A5 
proteins obtained from different strains. One can plainly see that the strains which express 
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1-2 integrated copies of human CYP3A5 gene produce more protein than the strain that 
expresses CYP3A5 from an episomal plasmid.   
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5.3.9 Comparison of human CYP2D6(1) (Val374) enzyme 
activities, expressed within yeast cells, from strains 
that contain 1 copy and 2 integrated copies of 
CYP2D6 gene 
 
To find a yeast strain that would produce high amounts of human CYP2D6(1) enzyme 
[CYP2D6(Val374); see Chapter 4, Section 4.6.1], four new strains were created from the 
strain YY7 that contains only ∆hRDM at the LEU2 locus.  
YY7 cells were transformed with an 
(1) Episomal (pSYE263/h_CYP2D6(1)_yc; Figure 3.38, Chapter 3) to create a 
control strain,  
(2) Integrating plasmid (YIpHisADH2S/CYP2D6(1)_yc; Figure 4.43, Chapter4), 
(3) Integrating plasmid (YIpUraADH2S/CYP2D6(1)_yc; Figure 4.41, Chapter 4). 
The resultant strains obtained after transformation were named  
(i) YY7::2D6-1(2µ), the control strain, [referred to as 2D6-1(2µ) in Figure 5.14],  
(ii) YY7::2D6-1(HIS3) [referred to as 2D6-1(HIS3) in Figure 5.14], and 
(iii) YY7::2D6-1(URA3) [referred to as 2D6-1(URA3) in Figure 5.14]. 
A second copy of the human CYP2D6(1) gene was introduced at the URA3 locus, via 
transformation, into the strain YY7::2D6-1(HIS3). The resultant strain was named 
YY7::2D6-1(HIS3,URA3), referred to as 2D6-1(HIS3,URA3) in Figure 5.14.  
The yeast strains were grown in YPD medium for 72 h, replenished every 24 h with new 
medium. The CYP2D6-1 [i.e. CYP2D6(Val374)] enzyme activities, within cells, were 
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monitored in (1X 107) cells harvested after 72 h of growth. Each culture was grown 
identically in YPD medium with an initial inoculum of equal number of cells. Fresh YPD 
medium was provided at each 24 h cycle of growth. The results in Figure 5.14 show the 
CYP2D6(1) (Val374) enzyme activities obtained in four different strains.  
 
Figure 5.14. The graph (A) shows the comparison of CYP2D6(1) enzyme 
activities within cells of different yeast strains, derived from YY7. They 
contain the CYP2D6(1) gene in 1 integrated copy (two strains), 2 integrated 
copies (one strain), and the CYP2D6(1) gene encoded by an episomal plasmid. 















(A) Comparison of CYP2D6(1) enzyme activities within yeast cells that 
harbour integrated copies of the CYP2D6(1) gene,  measured after 72 h of 





















(B) Comparison of CYP2D6(1) enzyme activities within yeast cells that 
harbour integrated copies of the CYP2D6(1) gene,  measured after 72 h of 







independent experiments. The bar plot (B) mirrors the graphs in (A). The data 
represent mean ± S.D. of three independent experiments.  
 
Figure 5.14 depicts the expression of human CYP2D6(1) enzyme in baker’s yeast. The 
results show that the 2-copy integrated strain YY7::2D6-1(HIS3,URA3), referred to as 
2D6-1(HIS3,URA3), has the highest activity amongst the four strains. This particular 
strain was used to prepare CYP2D6(1) (Val374) microsomal enzyme.  
 
5.3.10 Comparison of amounts of CYP2D6(1) (Val374) 
microsomal enzyme isolated from yeast strains 
containing CYP2D6(1) gene which is (a) 
chromosomally integrated at two different loci 
and (b) encoded by an episomal plasmid 
 
In order to evaluate the true expression levels of CYP2D6(1) enzyme in the strain 
YY7::2D6-1(HIS3,URA3), referred to as 2D6-1(HIS3,URA3) in Figure 5.15, 
microsomal CYP2D6(1) enzyme was isolated. Both strains were grown in 400 ml of YPD 
cell culture, under identical conditions. The correctly folded CYP protein, which provides 
the activity, was determined at 450 nm via CO difference spectroscopy (see Chapter 2, 
Section 2.8.3.1). Results shown in panels (A) and (B) of Figure 15 clearly show that the 
amount of enzyme produced by this integrated strain is more than the enzyme obtained 
from the episomal plasmid containing strain YY7::2D6-1(2µ), referred to as 2D6(2µ) in 
Figure 5.15.  
Panel C (Figure 5.15) shows that the strain containing 2 integrated copies of the 
CYP2D6(1) gene produced 59 nanomoles of CYP2D6(1) (Val374) enzyme while the 
episomal produced only 15 nanomoles from 400 ml cell cultures. Panel D depicts a 
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Western blot of CYP2D6(1) proteins obtained from two different strains. One can plainly 
see that the strain which expresses 2 integrated copies of human CYP2D6(1) gene produce 


























Figure 5.15. (A), (B): P450 contents, in the strains YY7::2D6-1(HIS3,URA3) 
[2D6-1(HIS3,URA3); (A)] and YY7::2D6-1(2µ) [2D6-1(2µ); (B)] were 
determined via CO difference spectroscopy using 1.0 µg of microsomal 
protein. (C) The amount of CYP450 (in nanomoles), obtained from the two 
strains (from 400 ml of YPD culture grown in baffled flasks), and represented 
as bar plots. The data represent mean ± S.D. of three independent 
experiments. (D) Western blots where 10 µg of total protein from the strains 
YY7::2D6-1(HIS3,URA3) (lane 1), and YY7::2D6-1(2µ) (lane 2) were probed 






5.3.11 Comparison of human CYP2D6(2) (Met374) enzyme 
activities, expressed within yeast cells, from strains 
that contain 1 and 2 integrated copies of CYP2D6(2) 
gene 
 
To find a yeast strain that would produce high amounts of human CYP2D6(2) enzyme 
[CYP2D6(Met374); see Chapter 4, Section4.6.5], four new strains were created from the 
strain YY7 that contains only ∆hRDM at the LEU2 locus.  
YY7 cells were transformed with an 
(1) Episomal (pSYE263/h_CYP2D6(2)_yc; Figure 3.38 , Chapter 3) to create a 
control strain,  
(2) Integrating plasmid (YIpHisADH2S/CYP2D6(2)_yc; Figure 4.48, Chapter 4), 
(3) Integrating plasmid (YIpUraADH2S/CYP2D6(2)_yc; Figure 4.50, Chapter 4). 
The resultant strains obtained after transformation were named  
(i) YY7::2D6-2(2µ), the control strain, [referred to as 2D6-2(2µ) in Figure 5.16],  
(ii) YY7::2D6-2(HIS3) [referred to as 2D6-2(HIS3) in Figure 5.16], and 
(iii) YY7::2D6-2(URA3) [referred to as 2D6-2(URA3) in Figure 5.16]. 
A second copy of the human CYP2D6(2) gene was introduced at the URA3 locus, via 
transformation, into the strain YY7::2D6-2(HIS3). The resultant strain was named 
YY7::2D6-2(HIS3,URA3), referred to as 2D6-2(HIS3,URA3) in Figure 5.16.  
The yeast strains were grown in YPD medium for 72 h, replenished every 24 h with new 
medium. The CYP2D6-2 [i.e. CYP2D6(Met374)] enzyme activities, within cells, were 
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monitored in (1X 107) cells harvested after 72 h of growth. Each culture was grown 
identically in YPD medium with an initial inoculum of equal number of cells. Fresh YPD 
medium was provided at each 24 h cycle of growth. The results in Figure 5.16 show the 
CYP2D6(2) (Met374) enzyme activities obtained from four different yeast strains. The 
CYP2D6 activity of YY7::2D6-1(HIS3,URA3) (Val374) was included for the sake of 
comparison, in panels (A) and (B) of Figure 5.16. The results show that the amounts 
produced by the strain YY7::2D6-1(HIS3,URA3) that produces the Val374 variant are 
marginally more than the amounts from the strain YY7::2D6-2(HIS3,URA3) that 





Figure 5.16. The graph (A) shows the comparison of CYP2D6(2) enzyme 
activities within cells of different yeast strains, derived from YY7. They 
contain the CYP2D6(2) gene in 1 integrated copy (two strains), 2 integrated 
copies (one strain), and the CYP2D6(2) gene encoded by an episomal plasmid. 
The graphs (A) represent the average of results obtained from three 
independent experiments. The bar plot (B) mirrors the graphs in (A). The data 
represent mean ± S.D. of three independent experiments.  
 
Figure 5.16 depicts the expression of human CYP2D6(2) enzyme in baker’s yeast. The 
results show again that the 2-copy integrated strain YY7::2D6-2(HIS3,URA3), referred 
to as 2D6-2(HIS3,URA3), has the highest activity amongst the four 2D6-2 strains. This 
















(A) Comparison of CYP2D6(2) enzyme activities within yeast cells that 
harbour integrated copies of the CYP2D6(2) gene,  measured after 72 h 




















(B) Comparison of CYP2D6(2) enzyme activities within yeast cells that 
harbour integrated copies of the CYP2D6(2) gene,  measured after 72 h 









5.3.12 Comparison of amounts of CYP2D6(2) (Met374) 
microsomal enzyme isolated from strains 
containing CYP2D6(2) gene which is (a) 
chromosomally integrated at two different loci 
and (b) encoded by an episomal plasmid 
 
With the aim of evaluating the true expression levels of CYP2D6(2) enzyme in the strain 
YY7::2D6-2(HIS3,URA3), referred to as 2D6-2(HIS3,URA3) in Figure 5.17, 
microsomal CYP2D6(2) enzyme was isolated. As in other instances, both strains were 
grown in 400 ml of YPD cell culture, under exactly the same conditions as before. The 
correctly folded CYP protein, which provides the activity, was determined at 450 nm via 
CO difference spectroscopy (see Chapter 2, Section 2.8.3.1). Results shown in panels (A) 
and (B) of Figure 5.17 clearly show that the amount of enzyme produced by this 
integrated strain is more than the enzyme obtained from the episomal plasmid containing 
strain YY7::2D6-2(2µ), referred to as 2D6(2µ) in Figure 5.17.  
Panel C (Figure 5.17) shows that the strain containing 2 integrated copies of the 
CYP2D6(2) gene produced 52 nanomoles of CYP2D6(1) (Met374) enzyme while the 
episomal produced only 9 nanomoles from 400 ml cell cultures. Panel D depicts a 
Western blot of CYP2D6(2) proteins obtained from three different strains. One can 
plainly see that the two strains which expresses 1 integrated copy and 2 integrated copies 
of human CYP2D6(2) gene produce more CYP protein than the strain that expresses 




























Figure 5.17. (A), (B): P450 contents, in the strains YY7::2D6-2(HIS3,URA3) 
[2D6-2(HIS3,URA3); (A)] and YY7::2D6-2(2µ) [2D6-1(2µ); (B)] were 
determined via CO difference spectroscopy using 1.0 µg of microsomal 
protein. (C) The amount of CYP450 (in nanomoles), obtained from the two 
strains (from 400 ml of YPD culture grown in baffled flasks), and represented 
as bar plots. The data represent mean ± S.D. of three independent 
experiments. (D) Western blots where 10 µg of total protein from the strains 
YY7::2D6-2(HIS3,URA3) (lane 1), YY7::2D6-2(HIS3) (lane 2),and YY7::2D6-
1(2µ) (lane 3) were probed with a CYP2D6 specific antibody (Santa Cruz 






5.3.13 Comparison of human CYP2C19 enzyme activities, 
expressed within yeast cells, from strains that 
contain 1 and 2 integrated copies of CYP2C19 gene 
 
With the aim of identifying a yeast strain that would produce high amounts of human 
CYP2C19 enzyme, four new strains were created from the strain YAB79 that contains 
∆hRDM and cytochrome b5 genes at the LEU2 and TRP1 loci, respectively.  
YAB79 cells were transformed with an 
(1) Episomal (pSYE263/h_CYP2C19_yc; Figure 3.17, Chapter 3) to create a control 
strain,  
(2) Integrating plasmid (YIpHisADH2S/CYP2C19_yc; Figure 4.53, Chapter 4), 
(3) Integrating plasmid (YIpUraADH2S/CYP2C19_yc; Figure 4.55, Chapter 4). 
The resultant strains obtained after transformation were named  
(i) YAB79::2C19(2µ), the control strain, [referred to as 2C19(2µ) in Figure 5.18],  
(ii) YAB79::2C19(HIS3) [referred to as 2C19(HIS3) in Figure 5.18], and 
(iii) YAB79::2C19(URA3) [referred to as 2C19(URA3) in Figure 5.18].  
The strain YAB79::2C19(HIS3) was used to introduce a second copy of the human 
CYP2C19 gene at the URA3 locus. The resultant strain obtained after transformation was 
named YAB79::2C19(HIS3,URA3), referred to as 2C19(HIS3,URA3) in Figure 5.18.  
The yeast strains were grown in YPD medium for 72 h, replenished with new medium 
every 24 h. The CYP2C19 activities, within cells, were monitored in (1X 107) cells 
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harvested after 72 h of growth. Each culture was started with an inoculum of equal 
number of cells. All cell cultures were grown identically, with fresh YPD medium being 
provided at the same time points of growth. The results in Figure 5.18 show comparative 
CYP2C19 enzyme activities obtained from four different strains.  
 
 
Figure 5.18. The graph (A) shows the comparison of CYP2C19 enzyme 
activities within cells of different yeast strains, derived from YAB79. They 
contain the CYP2C19 gene in 1 integrated copy, 2 integrated copies, and the 
CYP2C19 gene encoded by an episomal plasmid. The graphs (A) represent the 
average of results obtained from three independent experiments. The bar plot 
(B) mirrors the graphs in (A). The data represent mean ± S.D. of three 











(A) Comparison of CYP2C19 enzyme activities within yeast 
cells that harbour integrated copies of the CYP2C19 gene,  
















(B) Comparison of CYP2C19 enzyme activities within yeast 
cells that harbour integrated copies of the CYP2C19 gene,  








Figure 18 depicts the expression of human CYP2C19 in baker’s yeast. The results show 
that the 2-copy integrated strain YAB79::2C19(HIS3,URA3), referred to as 
2C19(HIS3,URA3), has the highest activity. This strain was used to prepare CYP2C19 
microsomal enzyme.  
 
5.3.14 Comparison of amounts of CYP2C19 microsomal 
enzyme isolated from yeast strains containing 
CYP2C19 gene which is (a) chromosomally 
integrated at two different loci and (b) encoded 
by an episomal plasmid 
 
In order to evaluate the true expression levels of CYP2C19 enzyme in the strain 
YAB79::2C19(HIS3,URA3), referred to as 2C19(HIS3,URA3) in Figure 5.18, 
microsomal CYP2C19 enzyme was isolated. Both strains were grown in 400 ml of YPD 
cell culture, under exactly the same conditions. The correctly folded CYP protein, which 
provides the activity, was determined at 450 nm via CO difference spectroscopy (see 
Chapter 2, Section 2.8.3.1). Results shown in panels (A) and (B) of Figure 5.19 clearly 
show that the amount of enzyme produced by this integrated strain is more than the 
enzyme obtained from the episomal plasmid containing strain YAB79::2C19(2µ), 
referred to as 2C19(2µ) in Figure 5.19. Comparison of the graphs in panels (A) and (B) 
reveals that the amounts of cytochrome b5 expressed is much less in 
YAB79::2C19(HIS3,URA3) cells than in the strain YAB79::2C19(2µ). As has been 
shown later in this Chapter, after isolation of the microsomal enzyme, cytochrome b5 
































Figure 5.19. (A), (B): P450 contents, in the strains YAB79::2C19(HIS3,URA3) 
[2C19(HIS3,URA3); (A)] and YAB79::2C19(2µ) [2C19(2µ); (B)] were 
determined by CO difference spectroscopy using 1.0 µg of microsomal protein. 
(C) The amount of CYP450 (in nanomoles), obtained from the 2 strains (from 
400 ml of YPD culture grown in baffled flasks), and represented as bar plots. 
The data represent mean ± S.D. of three independent experiments. (D) 
Western blots where 10 µg of total protein from the strains 
YAB79::2C19(HIS3,URA3) (lane 1), YAB79::2C19(HIS3) (lane 2) and 
YAB79::2C19(2µ) (lane 3) were probed with a CYP2C19 specific antibody 
(Santa Cruz Bitechnology, Cat no:sc25581). 
 
Panel C (Figure 19) shows that the strain containing 2 integrated copies of the CYP2C19 
gene produced 68 nanomoles of CYP2C19 enzyme while the episomal produced only 15 
nanomoles from 400 ml of cell culture. Panel D depicts a Western blot of CYP2C19 
proteins obtained from different strains. One can again see clearly that the strains which 
express 1-2 integrated copies of human CYP2C19 gene produce more protein than the 
strain that expresses CYP2C19 from an episomal plasmid. 
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5.3.15 Comparison of human CYP2C9 enzyme activities, 
expressed within yeast cells, from strains that 
contain 1 and 2 integrated copies of CYP2C9 gene 
 
With the aim of identifying a yeast strain that would produce high amounts of human 
CYP2C9 enzyme, four new strains were created from the strain YAB79 that contains 
∆hRDM and cytochrome b5 genes at the LEU2 and TRP1 loci, respectively.  
YAB79 cells were transformed with an 
(1) Episomal (pSYE263/h_CYP2C9_yc; Figure 3.12, Chapter 3) to create a control 
strain,  
(2) Integrating plasmid (YIpHisADH2S/CYP2C9_yc; Figure 4.60, Chapter 4), 
(3) Integrating plasmid (YIpUraADH2S/CYP2C9_yc; Figure 4.58, Chapter 4). 
The resultant strains obtained after transformation were named  
(i) YAB79::2C9(2µ), the control strain, [referred to as 2C9(2µ) in Figure 5.20],  
(ii) YAB79::2C9(HIS3) [referred to as 2C9(HIS3) in Figure 5.20], and 
(iii) YAB79::2C9(URA3) [referred to as 2C9(URA3) in Figure 5.20]. 
The strain YAB79::2C9(HIS3) was used to introduce a second copy of the human 
CYP2C9 gene at the URA3 locus. The resultant strain obtained after transformation was 
named YAB79::2C9(HIS3,URA3), referred to as 2C9(HIS3,URA3) in Figure 5.20.  
The yeast strains were grown in YPD medium for 72 h, replenished with new medium 
every 24 h. The CYP2C9 activities, within cells, were monitored in (1X 107) cells 
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harvested after 72 h of growth. Each culture was started with an inoculum of equal 
number of cells. All cell cultures were grown identically, with fresh YPD medium being 
provided at the same time points of growth. The results in Figure 5.20 show comparative 
CYP2C9 enzyme activities obtained from four different strains.  
 
 
Figure 5.20. The graph (A) shows the comparison of CYP2C9 enzyme activities 
within cells of different yeast strains, derived from YAB79. They contain the 
CYP2C9 gene in 1 integrated copy, 2 integrated copies, and the CYP2C9 gene 
encoded by an episomal plasmid. The graphs (A) represent the average of 
results obtained from three independent experiments. The bar plot (B) 
mirrors the graphs in (A). The data represent mean ± S.D. of three 













(A) Comparison of CYP2C9 enzyme activities within yeast cells 
that harbour integrated copies of the CYP2C9 gene,  measured 




















(B) Comparison of CYP2C9 enzyme activities within yeast cells 
that harbour integrated copies of the CYP2C9 gene,  measured 









Figure 20 depicts the expression of human CYP2C9 enzyme in baker’s yeast. The results 
show that the 2-copy integrated strain YAB79::2C9(HIS3,URA3), referred to as 
2C19(HIS3,URA3), has slightly more activity than the 1-copy strains. The 2-copy strain 
was used to prepare CYP2C9 microsomal enzyme.  
 
5.3.16 Comparison of amounts of CYP2C9 microsomal 
enzyme isolated from yeast strains containing 
CYP2C9 gene which is (a) chromosomally 
integrated at two different loci and (b) encoded 
by an episomal plasmid 
 
In order to evaluate the true expression levels of CYP2C9 enzyme in the strain 
YAB79::2C9(HIS3,URA3), referred to as 2C9(HIS3,URA3) in Figure 5.20, microsomal 
CYP2C9 enzyme was isolated. Both strains were grown in 400 ml of YPD cell culture, 
under exactly the same conditions. The correctly folded CYP protein, which provides the 
activity, was determined at 450 nm via CO difference spectroscopy (see Chapter 2, 
Section 2.8.3.1). Results shown in panels (A) and (B) of Figure 5.21 clearly show that the 
amount of enzyme produced by this integrated strain is more than the enzyme obtained 
from the episomal plasmid containing strain YAB79::2C9(2µ), referred to as 2C9(2µ) in 
Figure 5.21.  
Panel C (Figure 5.21) shows that the strain containing 2 integrated copies of the CYP2C9 
gene produced 206 nanomoles of CYP2C9 enzyme while the episomal produced only 10 
nanomoles from 400 ml of cell culture. Panel D depicts a Western blot of CYP2C9 
proteins obtained from different strains. One can see that the strains which express 1-2 
441 
 
integrated copies of human CYP2C9 gene produce more protein than the strain that 
expresses CYP2C9 from an episomal plasmid. 
 


























Figure 5.21. (A), (B): P450 contents, in the strains YAB79::2C9(HIS3,URA3) 
[2C9(HIS3,URA3); (A)] and YAB79::2C9(2µ) [2C9(2µ); (B)] were determined 
by CO difference spectroscopy using 1.0 µg of microsomal protein. (C) The 
amount of CYP450 (in nanomoles), obtained from the 2 strains (from 400 ml 
of YPD culture grown in baffled flasks), and represented as bar plots. The data 
represent mean ± S.D. of three independent experiments. (D) Western blots 
where 10 µg of total protein from the strains YAB79::2C9(HIS3,URA3) (lane 1), 
YAB79::2C9(HIS3) (lane 2) and YAB79::2C9(2µ) (lane 3) were probed with a 








5.3.17 Comparison of human CYP1B1 enzyme activities, 
expressed within yeast cells, from strains that 
contain 1 and 2 integrated copies of CYP1B1 gene 
 
The aim was again to identify a yeast strain that would produce high amounts of human 
CYP1B1 enzyme. Four new strains were created from the strain YY7 that contains only 
∆hRDM at the LEU2 locus.  
YY7 cells were transformed with an 
(1) Episomal (pSYE263/h_CYP1B1_yc; Figure 3.67, Chapter 3) to create a control 
strain,  
(2) Integrating plasmid (YIpHisADH2S/CYP1B1_yc; Figure 4.72, Chapter4), 
(3) Integrating plasmid (YIpUraADH2S/CYP1B1_yc; Figure 4.74, Chapter 4). 
The resultant strains obtained after transformation were named  
(i) YY7::1B1(2µ), the control strain, [referred to as 1B1(2µ) in Figure 5.22],  
(ii) YY7::1B1(HIS3) [referred to as 1B1(HIS3) in Figure 5.22], and 
(iii) YY7::1B1(URA3) [referred to as 1B1(URA3) in Figure 5.22]. 
The strain YY7::1B1(HIS3) was used to introduce a second copy of the human CYP1B1 
gene at the URA3 locus. The resultant strain obtained after transformation was named 
YY7::1B1(HIS3,URA3), referred to as 1B1(HIS3,URA3) in Figure 5.22.  
The yeast strains were grown in YPD medium for 72 h, replenished with new medium 
every 24 h. The CYP1B1 activities, within cells, were monitored in (1X 107) cells 
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harvested after 72 h of growth. Each culture was started with an inoculum of equal 
number of cells. All cell cultures were grown identically, with fresh YPD medium being 
provided at the same time points of growth. The results in Figure 5.22 show comparative 
CYP1B1 enzyme activities obtained from four different strains.  
 
 
Figure 5.22. The graph (A) shows the comparison of CYP1B1 enzyme activities 
within cells of different yeast strains, derived from YY7. They contain the 
CYP1B1 gene in 1 integrated copy, 2 integrated copies, and the CYP1B1 gene 
encoded by an episomal plasmid. The graphs (A) represent the average of 
results obtained from three independent experiments. The bar plot (B) 
mirrors the graphs in (A). The data represent mean ± S.D. of three 












(A) Comparison of CYP1B1 enzyme activities within yeast cells that 
harbour integrated copies of the CYP1B1 gene,  measured after 72 h of 






















(B) Comparison of CYP1B1 enzyme activities within yeast cells that 
harbour integrated copies of the CYP1B1 gene,  measured after 72 h of 







Figure 5.22 depicts the expression of human CYP1B1 enzyme in baker’s yeast. The 
results show that the 2-copy integrated strain YY7::1B1(HIS3,URA3), referred to as 
1B1(HIS3,URA3), has slightly more activity than the 1-copy strain which expresses 
enzyme from the HIS3 locus. The 2-copy strain was used to prepare CYP1B1 microsomal 
enzyme.  
 
5.3.16 Comparison of amounts of CYP1B1 microsomal 
enzyme isolated from yeast strains containing 
CYP1B1 gene which is (a) chromosomally 
integrated at two different loci and (b) encoded 
by an episomal plasmid 
 
In order to evaluate the true expression levels of CYP1B1 enzyme in the strain 
YY7::1B1(HIS3,URA3), referred to as 1B1(HIS3,URA3) in Figure 5.22, microsomal 
CYP1B1 enzyme was isolated. Both strains were grown in 400 ml of YPD cell culture, 
under exactly the same conditions. The correctly folded CYP protein, which provides the 
activity, was determined at 450 nm via CO difference spectroscopy (see Chapter 2, 
Section 2.8.3.1). Results shown in panels (A) and (B) of Figure 23 clearly show that the 
amount of enzyme produced by this integrated strain is more than the enzyme obtained 
from the episomal plasmid containing strain YY7::1B1(2µ), referred to as 1B1(2µ) in 
Figure 5.23.  
Panel C (Figure 5.23) shows that the strain containing 2 integrated copies of the CYP1B1 
gene produced 105 nanomoles of CYP1B1 enzyme while the episomal produced 10 
nanomoles from 400 ml of cell culture. Panel D depicts a Western blot of CYP1B1 
proteins obtained from different strains. One can see that the strains which express 1-2 
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integrated copies of human CYP1B1 gene clearly produce more protein than the strain 
























Figure 5.23. (A), (B): P450 contents, in the strains YY7::1B1(HIS3,URA3) 
[1B1(HIS3,URA3); (A)] and YY7::1B1(2µ) [1B1(2µ); (B)] were determined by 
CO difference spectroscopy using 1.0 µg of microsomal protein. (C) The 
amount of CYP450 (in nanomoles), obtained from the 2 strains (from 400 ml 
of YPD culture grown in baffled flasks), and represented as bar plots. The data 
represent mean ± S.D. of three independent experiments. (D) Western blots 
where 10 µg of total protein from the strains YY7::1B1(HIS3,URA3) (lane 1), 
YY7::1B1(HIS3) (lane 2) and YY7::1B1(2µ) (lane 3) were probed with a 






5.3.17 Comparison of human CYP1A1 enzyme activities, 
expressed within yeast cells, from strains that 
contain 1 and 2 integrated copies of CYP1A1 gene 
 
The aim was again to identify a yeast strain that would produce high amounts of human 
CYP1A1 enzyme. Four new strains were created from the strain YY7 that contains only 
∆hRDM at the LEU2 locus.  
YY7 cells were transformed with an 
(1) Episomal (pSYE263/h_CYP1A1_yc; Figure 3.62, Chapter 3.62) to create a 
control strain,  
(2) Integrating plasmid (YIpHisADH2S/CYP1A1_yc; Figure 4.67, Chapter4), 
(3) Integrating plasmid (YIpUraADH2S/CYP1A1_yc; Figure 4.69, Chapter 4). 
The resultant strains obtained after transformation were named  
(i) YY7::1A1(2µ), the control strain, [referred to as 1A1(2µ) in Figure 5.24],  
(ii) YY7::1A1(HIS3) [referred to as 1A1(HIS3) in Figure 5.24], and 
(iii) YY7::1A1(URA3) [referred to as 1A1(URA3) in Figure 5.24]. 
The strain YY7::1A1(HIS3) was used to introduce a second copy of the human CYP1A1 
gene at the URA3 locus. The resultant strain obtained after transformation was named 
YY7::1A1(HIS3,URA3), referred to as 1A1(HIS3,URA3) in Figure 5.24.  
The yeast strains were grown in YPD medium for 72 h, replenished with new medium 
every 24 h. The CYP1A1 activities, within cells, were monitored in (1X 107) cells 
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harvested after 72 h of growth. Each culture was started with an inoculum of equal 
number of cells. All cell cultures were grown identically, with fresh YPD medium being 
provided at the same time points of growth. The results in Figure 5.24 show comparative 
CYP1A1 enzyme activities obtained from four different strains.  
 
 
Figure 5.24. The graph (A) shows the comparison of CYP1A1 enzyme activities 
within cells of different yeast strains, derived from YY7. They contain the 
CYP1A1 gene in 1 integrated copy, 2 integrated copies, and the CYP1A1 gene 
encoded by an episomal plasmid. The graphs (A) represent the average of 
results obtained from three independent experiments. The bar plot (B) 
mirrors the graphs in (A). The data represent mean ± S.D. of three 












(A) Comparison of CYP1A1 enzyme activities within yeast cells that 
harbour integrated copies of the CYP1A1 gene,  measured after 72 h of 


















(B) Comparison of CYP1A1 enzyme activities within yeast cells that 
harbour integrated copies of the CYP1A1 gene,  measured after 72 h of 








Figure 5.24 depicts the expression of human CYP1A1 enzyme in baker’s yeast. The 
results show that the 2-copy integrated strain YY7::1A1(HIS3,URA3), referred to as 
1A1(HIS3,URA3), has by far better activity than the 1-copy strains which express 
enzyme from the HIS3 and URA3 loci. The 2-copy strain was further used to prepare 
CYP1A1 microsomal enzyme.  
 
5.3.18 Comparison of amounts of CYP1A1 microsomal 
enzyme isolated from yeast strains containing 
CYP1A1 gene which is (a) chromosomally 
integrated at two different loci and (b) encoded 
by an episomal plasmid 
 
In order to evaluate the true expression levels of CYP1A1 enzyme in the strain 
YY7::1A1(HIS3,URA3), referred to as 1A1(HIS3,URA3) in Figure 5.24, microsomal 
CYP1A1 enzyme was isolated. Both strains were grown in 400 ml of YPD cell culture, 
under exactly the same conditions. The correctly folded CYP protein, which provides the 
activity, was determined at 450 nm via CO difference spectroscopy (see Chapter 2, 
Section 2.8.3.1). Results shown in panels (A) and (B) of Figure 5.25 clearly show that the 
amount of enzyme produced by this integrated strain is more than the enzyme obtained 
from the episomal plasmid containing strain YY7::1A1(2µ), referred to as 1A1(2µ) in 
Figure 5.25.  
Panel C (Figure 5.25) shows that the strain containing 2 integrated copies of the CYP1A1 
gene produced 105 nanomoles of CYP1A1 enzyme while the episomal produced 10 
nanomoles from 400 ml of cell culture. Panel D depicts a Western blot of CYP1A1 
proteins obtained from different strains. One can see that the strains which express 1-2 
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integrated copies of human CYP1A1 gene clearly produce more protein than the strain 
that expresses CYP1A1 from an episomal plasmid. 
























Figure 5.25. (A), (B): P450 contents, in the strains YY7::1A1(HIS3,URA3) 
[1A1(HIS3,URA3); (A)] and YY7:: 1A1(2µ) [1A1(2µ); (B)] were determined by 
CO difference spectroscopy using 1.0 µg of microsomal protein. (C) The 
amount of CYP450 (in nanomoles), obtained from the 2 strains (from 400 ml 
of YPD culture grown in baffled flasks), and represented as bar plots. The data 
represent mean ± S.D. of three independent experiments. (D) Western blots 
where 10 µg of total protein from the strains YY7::1A1(HIS3,URA3) (lane 1), 
YY7::1A1(HIS3) (lane 2) and YY7:: 1A1(2µ) (lane 3) were probed with a 






5.3.19 Comparison of human CYP4F3A enzyme activities, 
expressed within yeast cells, from strains that 
contain 1 and 2 integrated copies of CYP4F3A gene 
 
The aim was again to identify a yeast strain that would produce high amounts of human 
CYP4F3A enzyme. Four new strains were created from the strain YAB79 that contains 
∆hRDM and cytochrome b5 at the LEU2 and TRP1 loci, respectively.  
YAB79 cells were transformed with an 
(4) Episomal (pSYE263/h_CYP4F3A_yc; Figure 3.72, Chapter3) to create a control 
strain,  
(5) Integrating plasmid (YIpHisADH2S/CYP4F3A_yc; Figure 4.62, Chapter 4), 
(6) Integrating plasmid (YIpUraADH2S/CYP4F3A_yc; Figure 4.64, Chapter 4). 
The resultant strains obtained after transformation were named  
(iv) YAB79::4F3A(2µ), the control strain, [referred to as 4F3A(2µ) in Figure 26],  
(v) YAB79::4F3A(HIS3) [referred to as 4F3A(HIS3) in Figure 5.26], and 
(vi) YAB79::4F3A(URA3) [referred to as 4F3A(URA3) in Figure 5.26]. 
The strain YY7::4F3A(HIS3) was used to introduce a second copy of the human 
CYP4F3A gene at the URA3 locus. The resultant strain obtained after transformation was 
named YY7::4F3A(HIS3,URA3), referred to as 4F3A(HIS3,URA3) in Figure 5.26.  
The yeast strains were grown in YPD medium for 72 h, replenished with new medium 
every 24 h. The CYP4F3A activities, within cells, were monitored in (1X 107) cells 
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harvested after 72 h of growth. Each culture was started with an inoculum of equal 
number of cells. All cell cultures were grown identically, with fresh YPD medium being 
provided at the same time points of growth. The results in Figure 5.26 show comparative 
CYP4F3A enzyme activities obtained from four different strains.  
 
 
Figure 5.26. The graph (A) shows the comparison of CYP4F3A enzyme 
activities within cells of different yeast strains, derived from YAB79. They 
contain the CYP4F3A gene in 1 integrated copy, 2 integrated copies, and the 
CYP4F3A gene encoded by an episomal plasmid. The graphs (A) represent the 
average of results obtained from three independent experiments. The bar plot 
(B) mirrors the graphs in (A). The data represent mean ± S.D. of three 












(A) Comparison of CYP4F3A enzyme activities within yeast cells 
that harbour integrated copies of the CYP4F3A gene,  measured 


















(B) Comparison of CYP4F3A enzyme activities within yeast cells 
that harbour integrated copies of the CYP4F3A1 gene,  measured 







Figure 5.26 depicts the expression of human CYP4F3A enzyme in baker’s yeast. The 
results show that the 2-copy integrated strain YAB79::4F3A(HIS3,URA3), referred to as 
4F3A(HIS3,URA3), has by far the best activity compared to the other integrated strains. 
The strain [YAB79::4F3A(2µ)] containing the episomal plasmid hardly has any activity. 
The 2-copy strain was further used to prepare CYP4F3A microsomal enzyme from yeast 
cells.  
 
5.3.20 Comparison of amounts of CYP4F3A microsomal 
enzyme isolated from yeast strains containing 
CYP4F3A gene which is (a) chromosomally 
integrated at two different loci and (b) encoded 
by an episomal plasmid 
 
In order to evaluate the true expression levels of CYP4F3A enzyme in the strain 
YAB79::4F3A(HIS3,URA3), referred to as 4F3A(HIS3,URA3) in Figure 5.26, 
microsomal CYP4F3A enzyme was isolated. Both strains were grown in 400 ml of YPD 
cell culture, under exactly the same conditions. The correctly folded CYP protein, which 
provides the activity, was determined at 450 nm via CO difference spectroscopy (see 
Chapter 2, Section 2.8.3.1). Results shown in panels (A) and (B) of Figure 5.27 clearly 
show that the amount of enzyme produced by this integrated strain is more than the 
enzyme obtained from the episomal plasmid containing strain YAB79::4F3A(2µ), 
referred to as 4F3A(2µ) in Figure 5.27.  
Panel C (Figure 5.27) shows that the strain containing 2 integrated copies of the CYP4F3A 
gene produced 56 nanomoles of CYP4F3A enzyme while the episomal produced 5 
nanomoles from 400 ml of cell culture. Panel D depicts a Western blot of CYP4F3A 
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proteins obtained from different strains. One can see that the strains which express 1-2 
integrated copies of human CYP4F3A gene clearly produce more protein than the strain 
























Figure 5.27. (A), (B): P450 contents, in the strains YAB79::4F3A(HIS3,URA3) 
[4F3A(HIS3,URA3); (A)] and YAB79::4F3A(2µ) [4F3A(2µ); (B)] were 
determined by CO difference spectroscopy using 1.0 µg of microsomal protein. 
(C) The amount of CYP450 (in nanomoles), obtained from the 2 strains (from 
400 ml of YPD culture grown in baffled flasks), and represented as bar plots. 
The data represent mean ± S.D. of three independent experiments. (D) 
Western blots where 10 µg of total protein from the strains 
YAB79::4F3A(HIS3,URA3) (lane 1), YAB79::4F3A(HIS3) (lane 2) and 
YAB79::4F3A(2µ) (lane 3) were probed with a CYP4F3A specific antibody 






5.3.21 Comparison of enzyme activity of CYP1A2 
Sacchrosomes with commercially available CYP1A2 
microsomes isolated from insect and bacterial cells  
 
 
Figure 5.28. 1 picomole of CYP1A2 microsomes isolated from yeast 
(Sacchrosomes), insect cells [Baculosomes (Invitogen); Supersomes 
(Corning)], and bacterial cells [Bactosome (Cypex)]. Substrate concentration 
used was 4 µM CEC (3-Cyano-7-ethoxycoumarin) for each assay. The data 
represent mean ± S.D. of three independent experiments. 
 
Results show that CYP1A2 Sacchrosomes are ~40% better in activity than the best 
























































5.3.22 Comparison of enzyme activity of CYP2C9 
Sacchrosomes with those of commercially available 
CYP2C9 microsomes from insect and bacterial cells  
 
 
Figure 5.29. 1 picomole of CYP2C9 microsomes isolated from yeast 
(Sacchrosome), insect cells [Baculosome (Invitogen); Supersome (Corning)], 
and bacterial cells [Bactosome (Cypex)]. Substrate concentration used was 10 
µM 7-MFC (7-Methoxy-4-trifluoromethylcoumarin) for each assay. The data 
represent mean ± S.D. of three independent experiments. 
 
Results show that CYP2C9 Sacchrosomes are 6-fold better in activity than the best 







































5.3.23 Comparison of enzyme activity of CYP2C19 
Sacchrosomes with those of commercially available 





Figure 5.30. 1 picomole of CYP2C19 microsomes isolated from yeast 
(Sacchrosomes), insect cells [Baculosomes (Invitogen); Supersomes 
(Corning)], and bacterial cells [Bactosomes (Cypex)]. Substrate concentration 
used was 4 µM CEC (3-Cyano-7-ethoxycoumarin) for each assay. The data 
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Results show that CYP2C19 Sacchrosomes are 25-fold better in activity than the other 
three commercially available enzymes available from Corning, Cypex and Invitrogen.  
5.3.24 Comparison of enzyme activity of CYP2D6 
Sacchrosomes with those of commercially available 




Figure 5.31. 1 picomole of CYP2D6-2 microsomes isolated from yeast 
(Sacchrosomes), insect cells [Baculosomes (Invitogen); Supersomes 
(Corning)], and bacterial cells [Bactosomes (Cypex)]. Substrate concentration 
used was 4 µM EOMCC (7-Ethyloxymethyloxy-3- cyanocoumarin) for each 







































Results show that CYP2D6-2 Sacchrosomes are at least 2-fold better in activity than the 
other three commercially available enzymes available from Corning, Cypex and 
Invitrogen.  
5.3.25 Comparison of enzyme activity of CYP3A4 
Sacchrosomes with those of commercially available 




Figure 5.32. 1 picomole of CYP3A4 microsomes isolated from yeast 
(Sacchrosomes), insect cells [Baculosomes (Invitogen); Supersomes 








































used was 10 µM BOMCC (3-cyano-7-(benzyloxymethoxy)-coumarin) for each 
assay. The data represent mean ± S.D. of three independent experiments. 
 
Results show that CYP3A4 Sacchrosomes are ~2-fold better in activity than the enzyme 
(Supersome) available from Corning.  
5.3.26 Comparison of enzyme activity of CYP2E1 
Sacchrosomes with one of the commercially 




Figure 5.33. 1 picomole of CYP2E1 microsomes isolated from yeast 
(Sacchrosomes), insect cells [Baculosomes (Invitogen); Supersomes 



































used was 10 µM EOMCC (7-Ethyloxymethyloxy-3- cyanocoumarin) for each 
assay. The data represent mean ± S.D. of three independent experiments. 
 
Results show that CYP2E1 Sacchrosomes are at least ~20-fold better in activity than the 
enzyme (Supersome) available from Corning.  
 
5.3.27 Comparison of enzyme activity of CYP4F3A 
Sacchrosomes with the only commercial CYP4F3A 










































Figure 5.34. 1 picomole of CYP4F3A microsomes isolated from yeast 
(Sacchrosomes), insect cells [Baculosomes (Invitogen); Supersomes 
(Corning)], and bacterial cells [Bactosomes (Cypex)]. Substrate concentration 
used was 4 µM CEC (3-Cyano-7-Ethoxycoumarin)  for each assay. The data 
represent mean ± S.D. of three independent experiments. 
 
Results show that CYP4F3A Sacchrosomes are ~200-fold better in activity than the 
enzyme (Supersome) available from Corning-Gentest.  
 
5.3.28 Epilogue: CYP microsomal enzymes  
 
In general, recombinant DNA technology has been very helpful in the discovery of new 
CYP genes. The use of purified CYP microsomal enzymes (i.e. enzymes bound to 
endoplasmic reticular membranes), from recombinant systems, and the identification of 
selective CYP substrates with their inhibitors has been a work in progress over the past 
few decades.  
Microsomal CYP enzymes have been used to delineate the role human CYP enzymes 
play in the solubilisation of prospective new medicines for excretion from the human 
body, a process known as drug metabolism. To be able to achieve these goals, the 
pharmaceutical industry constantly uses these recombinant CYP enzymes to examine 
drug metabolism in vitro. Before studies in animals begin, recombinant CYP enzymes, 
derived from insect and bacterial cells, currently provide an ethical and cost effective 
means to investigate drug metabolism (Rodrigues, 1999). They are used to define, in vitro, 
the CYP-mediated metabolites that are formed within the human body (Masimiremba at 
al., 1999). Gonzalez and Korzekwa (1995) have explained that it was vital to express 
human CYP enzymes in heterologous expression systems. In their review of the topic, 
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they also have claimed that the activities of recombinant human CYP enzymes were 
comparable to that present in human liver microsomes where multiple CYPs exist at the 
same time.  
In contrast to pools of human liver microsomes which have huge batch to batch variations 
in CYP activities, recombinant CYP enzymes can be manufactured reproducibly in large 
amounts to (a) meet the demands of screening large chemical libraries of compounds for 
inhibition of CYPs, and (b) obtain metabolic products, from prospective medicines in 
development, for further characterization.  
In this Chapter, results have been presented that show the creation of stable yeast strains 
that allow production of large amounts of CYP enzymes from yeast.  These enzymes have 
been named Sacchrosomes, that is, microsomes isolated from the yeast Saccharomyces 
cerevisiae. These enzymes have been shown to have activities that surpass the activities 













In this chapter, the role of chromosomal copy number of CYP genes in the expression of 
CYP enzymes in bakers’ yeast has been established. The CYP isoforms that are involved 
in the metabolism of most pharmaceuticals are CYP1A2, CYP2C9, CYP2C19, CYP2D6 
and CYP3A4 (Baranczewski, 2006 and Schroer, 2010). They were produced in high 
levels and activities in yeast, amongst many other CYP isozymes, using two copies of 
their genes integrated at two different chromosomal loci, HIS3 and URA3.  
Inhibition studies with these enzymes are essential for establishing the propensity for 
drug-drug interactions of prospective medicines (Schroer, 2010 and Tracy, 2016). These 
inhibition studies are usually performed at a late stage of the process of drug discovery 
because recombinant CYP enzymes are very expensive. It would be immensely 
advantageous if these enzymes were to be available at the early stage of drug discovery. 
It would allow elimination of possible drug-drug interactions early on in the drug 
discovery process and would significantly reduce the risks involved in the discovery of 
new drugs. It would also lead to diminishing the huge expenditures that pharmaceutical 
companies face during the process of approval of a new chemical entity (NCE) by drug 
regulatory authorities. Recombinant CYP enzymes which are reproducibly high in their 
activity and which could be cheaply available, as described in this Chapter, would be a 
boon to drug discovery. 
Selleck et al (2008) has revealed certain bacterial cell lines for the production of CYP 
enzymes. It is widely accepted that bacterial cells are easy to grow and can make large 
amounts of recombinant proteins which may or may not be active. But contrary to this 
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report, as shown in this Chapter, baker’s yeast has also proved to be quite exceptional in 
the production of CYP enzymes, especially using CYP genes synthesised using yeast 
biased-codons. Selleck et al (2008) also reported a strategy whereby expression of 
recombinant CYPs can be enhanced in bacterial (E. coli) cells through modification of 
the 5’-end of the CYP genes so that strong secondary sequences at the N-terminus, around 
the initiation codon of human CYP proteins, are deleted. It was also observed that for 
expression of active human CYPs in bacterial cells, co-expression of a CYP and a 
cytochrome P450 reductase (CPR) was essential. Co-expression enhanced the enzymatic 
activity of CYP3A4 30-fold compared to parent bacterial strain that did not contain CPR. 
In the previous Chapter of this study (Chapter 4), it was shown that co-expression of 
cytochrome b5 may enhance enzyme activity of a certain isozyme, CYP1A2, which was 
not known to require cytochrome b5 for its activity. For CYP2D6, CYP1B1 and CYP1A1 
enzyme activity, when expressed in baker’s yeast, it was confirmed that cytochrome b5 
is not required. The data for CYP1B1 and CYP1A1, in the presence of cytochrome b5, 
has not been shown but is similar to the data shown in Chapter 4 (Figure 4.45).  
The enzymes CYP2C19, CYP2C9, CYP2C8, CYP3A4, CYP3A5, CYP2E1 and 
CYP4F3A studied in this report have shown higher levels of activity and protein when 
co-expressed with cytochrome b5 (results not shown).  
Table 5.2 compares the essential features of the yeast recombinant system, presented 





Table 5.2. Comparison of expression of human CYP genes, chemically 
synthesised using yeast biased codons and integrated at chromosomal loci 








Enzyme Yield Strengths & Weaknesses 








> 200 nmol/L 
from cells 
grown in 400 ml 
cultures grown 
in 2L baffled 
shake flasks. 
Yields are likely 




Ease of growth and 
purification; process similar 
to that in mammalian cells 
due to the ability to localize 
CYP proteins on ER 
membranes. Unlike bacterial 
expression, no requirement 
of any modification in the 
CYP genetic sequence. 
Chromosomal integration of 
CYP genes creates stable cell 
lines. Provides highly active 
CYPs for in vitro studies. 
Cost effective for large-scale 
production. 
Bacterial (E. coli) 
cells (using CYP 










Loss of plasmid stability 
when grown for a longer 
period of time. CYP proteins 
produced not the same as 
wild type.  
Insect cells > 3 months 
100 nmol/L 
from cells 
grown in large 
fermentors 
Lower expression levels. 
Production much more 
expensive than yeast and 
bacterial cells.  
Mammalian cells 6 months 
100 pmol/mg 
from cells 
grown in large 
bags 
Longer time for synthesis of 
CYP proteins; low 
expression levels and 
expensive.  
 
In general, all CYP enzymes studied have been expressed from CYP genes that have been 
chemically synthesised using yeast biased codons. Optimal reproducible yields were 
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obtained only when the CYP gene expression cassettes are permanently integrated into 
specific locations on yeast’s chromosomes.  
Several recent studies have shown the importance of codon bias such as the existence of 
a ‘ramp’ of rare, slowly translated codons at the 5’ end of a protein-coding sequence, 
which help in the efficiency of of protein synthesis (Tuller et al., 2015). Pechmann and 
Frydman (2013) established that codon bias influences protein folding during expression. 
In another study, Ingolia (2014) has revealed that codon bias plays a vital role in 
translation of ribosome profiling data and this helps in translation efficiency. 
Human liver microsomes (HLMs) are preferred in pharmaceutical industry for CYP 
inhibition studies. HLMs are derived mostly from human livers obtained from individuals 
who are alcoholics and drug addicts. These degenerate livers are the major source of 
HLMs and hepatocytes which are used to obtain vast amount of data that is later evaluated 
by the FDA for their final decision regarding approval of an NCE. It would definitely be 
worthwhile if alternative systems were available which could be used instead of HLMs.  
The invention of CYP microsomal enzymes, using cDNAs optimized for expression in 
bakers’ yeast can greatly facilitate CYP inhibition studies ethically and in a much more 
cost effective manner. Three companies that manufacture CYP microsomal enzymes are 
Cypex (Bactosomes, isolated from bacteria), Invitrogen, a Thermo-Fisher subsidiary 
(Baculosomes, from insect cells) and Corning (Supersomes from insect cells). The IC50 
values of inhibition of microsomal enzymes (Sacchrosomes and Supersomes/ 
Baculosomes), for the five major CYPs by FDA-approved CYP inhibitory compounds, 
have been compared with inhibition of CYP enzymes residing in HLMs. The comparative 





Table 5.3. Comparison of IC50 values of CYP inhibitory compounds for inhibition of 
CYP enzymes expressed in yeast with that published in the literature. 
 
CYP Inhibitor Fluorogenic Substrate 




















1A2 Furafylline CEC 3.6 µM ± 0.001 0.5 µM ± 
0.21,2 
5.26 µM a 
2D6 Quinidine EOMCC 0.69 µM ± 
0.002 
0.01 µM ± 
0.021,2 
0.47 µM b 
2C19 Ticlopidine CEC 0.26 µM ± 0001 0.01 µM ± 
0.021,2 
0.23 µM c 
3A4 Ketoconazole DBF 0.24 µM ± 0.03 0.02 µM ± 
0.021,2 
0.18 µM d 
2C9 Sulphaphenazole DBF 0.9 µM ± 0.002 0.24 µM ± 
0.151,2 
0.5 µM d 
 
 IC50 values published in Corning and Invitrogen websites. 
aLin et al, 2007; bGhosal et al, 2003; dGuidance for Industry, 2012; cStresser et al, 2004 
(IC50 values in HLMs).  
 
These CYP enzyme inhibition studies (Table 5.3) were performed to gauge the validity 
of the yeast-produced enzymes. The closer the IC50 values are, using isolated microsomal 
CYP enzymes, to the values obtained using HLMs would imply that the recombinant 
enzymes have similar 3-D structures at their active sites to the native enzyme. The IC50 
value for CYP inhibition by a compound denotes the concentration of compound that 
allows 50% inhibition of activity of an enzyme. Different IC50 values, using different 
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enzymes form different recombinant sources, would signify that active sites structures of 
the enzymes are likely to be dissimilar to the native enzyme. Failing to portray the true 
CYP inhibitory capacity of a compound in pre-clinical studies can lead to major safety 
concerns in clinical development and have, in the past, led to the removal of several drugs 
from the market (Diaz, 2016).  
The results in Table 5.3 reveal that the active sites of the CYP-Sacchrosomes are probably 
quite similar to the native enzymes in HLMs. It would indicate that most Sacchrosomes 
possess active sites that are probably identical to the native enzymes produced in human 
liver cells. Hence, we would like to propose that Sacchrosomes could reliably be used, 













Chapter 6  Biotransformation using recombinant 




6.1.1 Whole yeast cells for biotransformation 
 
The endogenous enzymes existing within baker’s yeast has been described as being ideal 
for chemists in their search for stereo-selective biocatalysts which could lead to the 
syntheses of novel and important chemical compounds (Servi, 1990). Yeast is an 
organism which is non-pathogenic, inexpensive and simple to culture in the laboratory. 
Moreover, its growth can be optimised for large-scale production of cells. Stocks of yeast 
strains can be stored indefinitely at 4°C as agar stabs or at -80°C as glycerol stocks (Faber 
et al., 2004).  
There are three major advantages of using whole native baker’s yeast cells for 
biocatalysis. 
(1)  The cellular abundance of all required cofactors of important enzymes that could 
be envisaged to participate in biotransformation and the presence of metabolic 
pathways for their regeneration.  
(2) The ability of yeast cells to grow vigorously in glucose, which is inexpensive and 
which is used by yeast as an energy source and as well as a substrate of enzymes 
essential for growth.  
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(3) The compounds which are recovered from yeast cell culture after biocatalysis can 
be used without the necessity of protracted purification from toxic metabolites 
which occur in organisms other than yeast (Mata-Gomez et al., 2014).  
 
6.1.2 Recombinant CYP-expressing yeast cells for 
possible biotransformation reactions 
 
Recombinant CYP450-expressing baker’s yeast cells have the potential of being used for 
redox biocatalysis, provided the cells efficiently express heterologous CYP enzymes. 
Efficiency of expression relates to how much of CYP enzymes are made within the cells 
and how active they are. In theory, yeast cells should provide a comfortable environment 
for the proteins that are expressed within the cells making them more stable. The caveat, 
however, is that the overproduction of heterologous proteins usually induces proteolysis 
of the proteins that are being expressed (Prelich, 2012).  
In order to avoid degradation of foreign proteins expressed in yeast, basic yeast strains 
can be selected for resistance to proteolysis of specific proteins. In fact, that’s how 
BC300, derived from the commercially available ATCC strain W303-1A (ATCC 
#208352), was selected for production of heterologous membrane proteins over many 
years. BC300 is the strain that has been used for all the work described in this thesis. 
BC300 was identified many years before the work described in this thesis began.  
This Chapter focusses on the use of recombinant CYP-expressing whole yeast cells for 
biotransformation. In nature, important metabolites are often produced via inefficient 
natural biological processes, resulting in their scarcity. The complexities of the structures 
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of naturally occurring molecules make it very difficult for them to be synthesised easily. 
Around a couple of decades ago, it was first thought that natural yeast cells themselves 
could be used for biotransformation processes. It was surmised that endogenous yeast 
enzymes, similar to those involved in the synthetic pathways of certain metabolites, 
would be helpful in converting a natural product A to another natural product B, “B” not 
being amenable to easy isolation (Kebamo et al, 2015).  
 
6.1.3 Syntheses of secondary metabolites via bioorganic 
reactions 
 
Some secondary metabolites, such as morphine, taxol, artemisinin, coenzyme Q10, 
docosahexaenoic acid (DHA), and carotenoids, which exist in plants, mammals, 
microalgae, and other microorganisms (Facchini et al., 2012) are regarded as high-value 
metabolites (Chang and Keasling, 2006). Vast majority of these metabolites play 
important roles in coping with or reacting to environmental changes by the human 
organism. The metabolites provide protection against biotic and abiotic stresses, 
radiation, and may at times act as regulatory molecules for human health (Marienhagen 
and Bott, 2013). All these metabolites are, in one way or the other, involved in human 
health and treatment of diseases. For example, morphine is used for pain control 
(Chappell, 2008), taxol and vincristine for cancer treatment (Chappell, 2008 and Ye and 
Bhatia, 2012), and carotenoids and DHA as part of heart disease treatment ( Marta-Gomez 
et al., 2014).  
Up to 30-40% of the FDA approved drugs have been derived from natural metabolites. 
More than 48% of drugs used in cancer research stem from naturally occurring 
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metabolites (Li and Vederas, 2009; Newman and Cragg, 2012). These metabolites are 
present in very low quantity in natural sources. Ye and Bhatia (2012) state that less than 
0.2% of the total dry weight yield of the Pacific yew trees consists of taxol. The content 
of vincristine in Cantharanthus roseus is only 0.0003% (Kuboyama et al., 2004). It is 
obvious that these low quantities in the natural sources place barriers to the industrial use 
of these very important metabolites (Chang and Keasling, 2006).  
The approaches to organic chemical synthesis of high-value, scarcely-occurring natural 
products have been hindered by low yields in multi-step synthetic protocols which can be 
also be tedious or impossible to achieve for production of large amounts of a particular 
chemical (Nicolaou et al., 1994; Kuboyama et al., 2004). For years, baker’s yeast has 
been used in the production of different types of food and beverages. It is also well 
recognised that baker’s yeast is safe for human consumption.  
 
6.1.4 Using yeast to perform CYP450-mediated 
bioorganic reactions 
 
 Since the genome of baker’s yeast Saccharomyces cerevisiae has been sequenced 
completely (Goffeau, 2000), the revelation of the genome’s DNA sequence can now play 
a key role in research related to yeast molecular biology. For production of high-value 
metabolites, baker’s yeast has genetically been engineered so that it could be used as a 
cell factory for exploration of new methods that would allow synthesis of important 
chemicals of value (Shao and Zhao, 2009). Creation of these new methodologies involved 
expression of heterologous proteins in yeast (Dai et al., 2012; Zhou et al., 2012).  
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During the study conducted for this thesis, it was observed that biosynthesis of human 
CYP proteins in yeast can be stabilized when expressed from genes that had been 
chemically synthesised using yeast biased codons. Upregulation of levels of active CYP 
enzymes was seen compared to enzymes that were produced from native genes that had 
been isolated from a human liver cDNA library (Chapters 3 to 5). Due to yeast cells’ 
robustness and similar intracellular architecture to human cells, baker’s yeast as a 
recombinant organism provides a physical and physiological environment for the 
functional expression of any protein that is present in humans or animals. Specifically for 
the human CYPs which are naturally bound to the endoplasmic reticular (ER) 
membranes, yeast provides the same ER membranes which have similar structure to the 
ER membranes present in human cells. Therefore, human CYP proteins can be anchored 
to the ER membranes of yeast, to possibly provide similar activity to that present in 
human cells (Eckart and Bussineau, 1996; Pompon et al., 1996).  
In recent years, the discovery of genes, coding for membrane-bound proteins, involved in 
nature in the synthesis of high-value metabolites together with advances in synthetic 
biology has enabled successful construction of yeast strains that allow for the production 







6.1.5 Yeast as a cell factory for the syntheses of steroids, – 
involvement of CYP450-mediated bioorganic 
reactions 
 
Steroids are molecules bound by four carbon rings. They are mostly synthesised in plants, 
animals and fungi via CYP450-mediated chemical reactions (de Souza at al., 2011). 
Steroids vary from dietary lipids to cholesterol to sex hormones such as estradiol and 
testosterone, and the pharmaceutical drug hydrocortisone (Heftmann, 1974). Xu and Nes 
(1998) revealed that an erg6-mutant yeast strain besides predominantly producing 
ergosterol as a major metabolite also produces trace amounts of cholesterol. Presence of 
either of the two yeast genes ERG5 or ERG6 is essential for ergosterol synthesis. ERG5 
codes for a yeast CYP450, whereas ERG6 is a sterol 24-C-methyltransferase. However, 
for medium level cholesterol production, both the ERG5 and ERG6 genes, which are 
responsible for introducing changes in the side-chain of sterols, had to be disrupted. 
Overproduction of cholesterol in yeast was only achieved by engineering the 
overexpression of heterologous Danio rerio genes that code for the enzymes 
dehydrocholesterol-7-reductase (DHCR7) and dehdrocholesterol-24-reductase 
(DHCR24) in yeast strains which lacked ERG5 and ERG6 genes (de Souza et al., 2011).  
Hydrocortisone is an anti-inflammatory drug which is widely used as an ointment and is 
prescribed for oral and intravenous administration (Menkin, 1954). Yeast was used as a 
cell factory to synthesise hydrocortisone after the introduction of 13 genes, most of them 
coding for CYP genes that exist in plants and humans into the baker’s yeast, S. cerevisiae. 
The newly introduced 13 genes were critical for the efficient synthesis of hydrocortisone 




6.1.6 Flavonoids as substrates for CYP450-mediated 
bioorganic reactions 
 
The flavonoid class of compounds are natural products formed from phenyl-propanoid 
structural motifs. Flavonids are considered as nutritional compounds (Siddiqui et al., 
2012; Zhou et al., 2014). Yeast naturally does not produce flavonoids but it does produce 
the amino acids, tyrosine and phenylalanine, which are flavonoid precursors. By devising 
suitable systems for expression of heterologous proteins, yeast can be manipulated to 
express certain flavonoids. For example, the flavonoid naringenin has been produced 
from yeast by assembling, in yeast, four plant CYP450 genes which convert p-coumaric 
acid to naringenin. The four CYP450 genes cinnamate-hydroxylase (C4H) (from 
Arabidopsis thaliana), 4-coumarate-CoA-ligase (4CL) (from Petroselinum cripum), 
chalcone isomerase (CHI) and chalcone synthase (CHS) (from a Petunia hybrid) were 
introduced into baker’s yeast S. cerevisiae resulting in a yeast strain that produced the 
naturally occurring flavonoid, naringenin (Yan et al., 2005).  
Naringenin can be a valuable precursor for the CYP450-mediated synthesis of a variety 
of other flavonoids/isoflavonoids such as genistein (an isoflavone), apigenin (a flavone), 













6.1.7 Alkaloids as substrates for CYP450-mediated 
bioorganic reactions 
 
Plant alkaloids belong to a class of natural products which is highly diverse in their 
chemical structure. They are classified based on their heterocyclic ring system. It is 
estimated that, in plants, there are 12,000 different alkaloids produced with an assorted 
range of pharmacological properties. The alkaloids are synthesised within plants with the 
help of plant CYP450 enzymes. Usually, in each plant species there are 400-500 CYP 
genes whereas in humans there are only 57 CYPs.  
 
6.1.8 Role of human CYP450 enzymes in drug metabolism 
 
The human cytochrome P450 (CYP) enzymes play important roles in the metabolism of 
many endobiotics (i.e. molecules endogenous to the human system) and xenobiotics (i.e. 
molecules exogenous to the human system). Human CYP enzymes are also used for 
testing new drug candidates for their ability to interact with these enzymes during the 
preclinical development phase. Both inhibition and induction of CYP enzymes may have 
deleterious effects on the human body.  
The human CYP isoforms that metabolise the majority of xenobiotics, that include 
medicines, belong to CYP1, CYP2, CYP3 sub-family of isoforms. These enzyme sub-
families are broadly related to each other and have overlapping substrate specificities. 
Because of this, they are responsible for the metabolism of the majority (i.e. 70-80%) of 
known (i.e. approved) drugs (Nobert and Russell, 2002; Guengerich et al., 2005).  
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The pharmacokinetic behaviour of a drug is determined by the metabolic product that is 
formed from the drug and the duration of its metabolism (i.e. reaction rate of product 
formation). Variations in CYP activity, manifested after enzyme inhibition or induction 
by pharmaceutical drugs and other xenobiotics, is often the source of drug-drug 
interactions. Drug-drug interactions can have adverse effects on patients and can 
potentially lead to the removal of a drug from the market. The usual mechanism of drug-
drug interaction is through inhibition of CYP enzymes (Kalgutkar et al., 2007; Pelkonen 
et al., 2008). However, if a drug specifically inhibits one CYP but does not inhibit any 
other CYP, it can have a ‘clear’ pharmacodynamic profile and may have the possibility 
to be part of co-therapeutics, especially in the area of antiviral drug therapy.  
 
6.2 Outline of Chapter 
 
This Chapter explores the use of recombinant CYP-expressing whole yeast cells for 
biotransformation reactions. The same yeast cells, which were described earlier in 
Chapter 5 for isolation of microsomal enzymes, have been used. The following 
recombinant yeast cells have been used for biotransformation:  
(a) Cells that express human CYP1A1 or CYPA2 have been used to transform  
(i) Natural product chrysin to another natural product baicalein, and  
(j) Natural product chrysosplenetin to an yet undefined product (results not 
shown); 
(b) Cells that express variants of human CYP2D6 have been used to convert the opiate 
codeine to the more potent opiate, morphine; and  
478 
 
(c) Cells that express human CYP3A4 have been used to study the metabolism of 
compound AZD-2014, an Astra-Zeneca anticancer drug [an mTORC (mammalian 
target of rapamycin complex) inhibitor] currently in multicentre Phase II/Phase 
III clinical trials.  
It has been reported that, until now, whole cell mediated biotransformation reactions 
generally yield, at best, no more than 10-15% of the product (Das-Bradoo et al., 2004; 
Duran et al., 2017). The natural cells (i.e. not recombinant) that were used for 
biotransformation were from a variety of different organisms (Duran et al., 2017). 
Human/ non-human CYP-expressing bacterial cells have also been used with similar 
yields of products.  
Our results, using human CYP-expressing yeast cells clearly show that there is greater 
than 80% product formation. The amounts of product formed were estimated from thin 
layer chromatographs (TLCs) and, in one case, liquid chromatograph/ mass spectrometric 
analysis (LC/MS).  
The high yields of bioorganic reactions, using CYP-expressing yeast cells indicate that, 
in future, organic chemical reactions in pre-clinical drug discovery research could also be 
performed using this type of robust whole yeast cells. In a chemical laboratory, cells 
harbouring human or plant CYPs could routinely be used for small and large-scale 






6.3 Biotransformation of chrysin to baicalein: 
selective C6-hydroxylation of 5,7-
dihydroxyflavone using whole yeast cells stably 
expressing human CYP1A1 enzyme  
 
[Ibidapo S Williams et al; Journal of Agricultural & Food Chemistry (an American 




Naturally occurring polyphenolic compounds are of medicinal importance because of 
their unique antioxidant, anticancer and chemopreventive properties. Baicalein, a 
naturally occurring polyhydroxy flavonoid possessing a diverse range of pharmacological 
activities, has been used in traditional medicines for treatment of various ailments(J.Mu 
et al., 2016). Apart from its isolation from natural sources, its synthesis has been reported 
via multi-step chemical approaches. Here we report a preparative-scale 
biotransformation, using whole yeast cells stably expressing human cytochrome P450 
1A1 (CYP1A1) enzyme, that allows regio-selective C6-hydroxylation of 5,7-
dihydroxyflavone (chrysin) to form 5,6,7-trihydroxyflavone (baicalein), (Zhang et al., 
2014). Molecular modelling reveals why chrysin undergoes such specific hydroxylation 
mediated by CYP1A1. More than 92% reaction completion was obtained using a shake-
flask based process that mimics fed-batch fermentation. Such highly efficient selective 
hydroxylation, using recombinant yeast cells, has not been reported earlier. Similar CYP-
expressing yeast cell-based systems are likely to have wider applications in the syntheses 






Baicalein (5,6,7-trihydroxyflavone) was originally isolated from the roots of Scutellaria 
baicalensis (Chinese skullcap) which is used for treatment of chronic hepatitis, 
inflammatory diseases, tumours, and diarrheal in China, Korea, Taiwan, and Japan 
(Papafragkakis et al., 2016). Its isolation has also been reported from another plant, 
Oroxylum indicum (Indian trumpet flower). ( Roy at al., 2007) Baicalein is known for its 
anticancer properties in various cancer types ( Roy at al., 2007; Ma et al., 2005) including 
pancreatic, gastric and colorectal cancers, multiple myeloma, head and neck cancer, and 
breast cancer(Liu et al ., 2016; Gao et al., 2016). Baicalein is also considered an anti-
inflammatory (Li et al., 2016; Patwardham et al., 2016)that generally protects against 
oxidative stress (Tsai et al., 2016), more specifically in cardiac cells, (Zhao et al., 2016)  
and in cisplatin-induced acute kidney injury. Because of its wide-ranging medicinal 
applications, an industrial scale protocol for its production would be considered as 
important (Sahu, 2015).  
Baicalein has primarily been produced via five approaches: (a) single-step hydrolysis of 
the natural product baicalin, a glycoside, (Zhang et al., 2014) (b) 4-step total synthesis 
from a cinnamic acid derivative(Kim et al., 2012),  (c) 4-step total synthesis from 3,4,5-
trimethoxyphenol, (Chen et al., 2010),    (d) 3-step total synthesis from 2,4,5,6-
tetrahydroxyacetophenone, ,(Vyas et al., 2016) and (e) 6-step synthesis from chrysin, 
(Righi et al., 2010) involving methylation, bromination, acylation, nucleophilic 
replacement of Br with OMe, followed by de-acylation and demethylation as key steps. 
Selective transformation, using efficient biocatalysts, of a low value phytochemical to 
high value phytochemical is an exciting area of bioorganic chemistry. Sordon and 
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coworkers have reported biotransformations of natural flavonoids naringenin, hesperetin, 
chrysin, apigenin, luteolin, quercetin, epicatechin, and biochanin A using the natural 
yeast, Rhodotorula glutinis.  
One such approach produced norwogonin (5,7,8-trihydroxyflavone) from chrysin (5,7-
dihydroxyflavone). Here we report a preparative scale process for biotransformation of 
chrysin to baicalein, via selective C6-hydroxylation using recombinant human 
cytochrome P450-1A1 (CYP1A1) enzyme expressed within baker’s yeast 
(Saccharomyces cerevisiae) cells. This is the first single-step protocol for a high-yield 
conversion of chrysin to baicalein and, therefore, may serve as a simple and cheap 
strategy for production of baicalein in an industrial scale.  
 
6.3.3 Experimental Section 
 
General Experimental Procedures. All chemicals were obtained from Sigma-Aldrich 
and were used as received. H NMR spectra were recorded on Brucker-Avance DPX FT-
NMR 400 MHz instrument. Chemical data for protons are reported in parts per million 
(ppm) downfield from tetramethylsilane and are referenced to the residual proton in the 
NMR solvent (CD3OD, 3.31 ppm). ESI-MS were recorded on Waters QTOF mass 
spectrometer.  
HPLC analysis was performed on Shimadzu LC-6AD system connected with C18 column 
(4.6 x 25 mm, 5 µ). Mobile phase consisted of A: 0.1% formic acid and B: methanol using 




LC-MS analysis was performed on Waters Acquity UPLC. The column used was C18, 
1.7 µ with dimensions of 100 x 2.1 mm (column temp. 30 °C). Binary gradient system 
was used. Mobile phase A consisted of 5% acetonitrile in water with 0.1% formic acid. 
Mobile phase B consisted of acetonitrile with 0.1% formic acid. Gradient details are: 
Time in min (% B concentration): 0.01 (10), 0.25 (10), 9.00 (100), 10.00 (100), 11.00 
(10), 12.00 (10). PDA range: 220 nm to 400 nm; flow rate: 0.3 mL/min. 
Biotransformation experiment. Yeast strains, each of which contain two copies of 
human CYP1A1 or CYP1A2 genes, downstream of the ADH2 promoter, integrated into 
chromosomal loci of the genome of the yeast strain W303-1a (ATCC 208352), were used 
for biotransformation (Section S2 of supporting information). That they expressed 
CYP1A1 and CYP1A2 proteins were confirmed by Western blotting (supporting 
information-S4). The strains, from frozen stocks, were revived in 250 mL Erlenmeyer 
baffled flasks containing 50 mL YPD (Yeast, Peptone, Dextrose) medium with 
composition (gL-1): peptone 20; yeast extract 10; glucose 15.0, pH 6.0. The flasks were 
shaken at 200 rpm, at 28 °C. Three consecutive YPD pre-cultures were grown for high 
biomass production, before addition of the substrate to cells grown in SD (Synthetic 
Defined) medium. Typically, loopful of CYP-containing freshly grown yeast cells was 
inoculated in a 500 ml Erlenmeyer baffled flask separately containing 100 ml YPD 
medium (pre-culture -1) at 28 °C for 24 h. The cells were harvested after 24 h and 
inoculated into a new 500 ml baffled flask containing 100 ml YPD medium (pre-culture 




The harvested cells, ~3.0 ml (OD600, ~90), were inoculated in 200 ml of minimal SD 
medium contained in a 1 L baffled flask. Composition of SD medium (gL-1): dextrose 
1.0; dipotassium phosphate 7.0; monopotassium phosphate 2.0; sodium citrate 0.50; 
magnesium sulphate 0.10; ammonium sulphate 1.0, pH 7.0 ± 0.2 at 28 °C. Initially, 
reaction was carried out with 10 mg of chrysin. Later, the chrysin at different 
concentrations viz. 0.2, 1, 2, 5 and 10 mg/mL were dissolved in DMSO and further 
incubated in 50 mL of SD medium (keeping the DMSO concentration > 0.5%) for 72 h 
at 28°C, 200 rpm. After every 24 h, the medium was replenished with 1.5% w/v of 
glucose. For optimization of incubation time, the SD cell culture media were harvested 
after 24, 48, 72, 96, 120, 144 and 160 h, and were then analysed on TLC and HPLC/ LC-
MS to monitor the yields of biotransformation at each time point. 
The reaction media was extracted with ethyl acetate (3 times). The combined ethyl acetate 
layer was concentrated on vacuo-rotavapor to obtain crude extracts that contained the 
biotransformation product. The crude residue was loaded on a reverse phase (C18) silica 
gel column packed in water. The crude extract was loaded on the column by making a 
slurry with C18 silica gel. The column was then eluted with increasing concentrations of 
methanol in water. The desired product was collected at 50% methanol in water. 
Evaporation of the solvent gave a yellow solid which was characterized as baicalein (1). 
Yellow powder; m.p. 262-265 °C (Lit. 264-265 °C); TLC: Rf = 0.5 (3% Methanol in 
DCM) and 0.8 (40% EtOAc: Hexane with 0.1% acetic acid); 1H NMR (CD3OD, 400 
MHz, δ ppm): 7.91 (dd, J = 4, 8 Hz, 2H), 7.48 (m, 3H), 6.66 (s, 1H), 6.55 (s, 1H); ESI-
MS: m/z 271.10 [M+H]+. The spectral data was identical to that reported in the literature32 




Molecular modeling: The docking of chrysin with CYP1A1 (PDB ID: 4I8V) was 
performed using the protocol as described in our earlier publications.36, 37 
 
6.3.4 Results and Discussion 
 
CYP enzymes are known for their exceptional ability to carry out hydroxylation, 
epoxidation or demethylation reactions in a regio-selective fashion both in plants and 
humans. We have developed an efficient technology for stable expression of human CYP 
enzymes within yeast cells. Using this platform, recombinant baker’s yeast cells can 
continue to express CYPs in shake flasks, over a week or more, with increasing activities, 
under conditions that mimic fed-batch growth (Supporting Information; S1). Microsomal 
CYP enzymes, isolated from these same recombinant yeast cells, have successfully been 
used by us earlier as drug discovery tools for screening synthetic compounds and natural 
product repositories to identify possible cancer chemopreventive agents.37-39  
Selection of CYPs for biotransformation of chrysin. In this work, use of recombinant 
CYP-expressing whole yeast cells has been explored for their ability to be used as 
biocatalysts for biotransformation reactions. For one of our first experiments, we chose 
the flavonoid chrysin as a substrate using two yeast-expressed enzymes of the CYP1 sub-
family (i.e. CYP1A1 and CYP1A2) as biocatalysts.  
Two recombinant yeast strains, each containing two chromosomally integrated copies of 
CYP1A1 and CYP1A2 genes under the control of the ethanol-inducible alcohol 
dehydrogenase 2 (ADH2) promoter, were created to enable stable and reproducible 
biotransformation reactions (plasmid maps shown in Supporting Information, S2). The 
ADH2 promoter is repressed in the presence of glucose. The aim was that recombinant 
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yeast cells, containing stably integrated CYP expression cassettes, would be grown 
initially in complete YPD medium (containing 2% glucose) to obtain large optical 
density, measured at a wavelength of 600 nm (OD600) of ~90, in shake flasks. This would 
occur without any plasmid loss and would be achieved over 3 days through repetitive 
replenishment of glucose, every 24 h, in the non-selective highly nutritious YPD medium. 
Cells grown in YPD [Figure 6.1 (a)] would then be re-suspended in minimal selective SD 
medium (pH 7.0), supplemented with 1.5% of glucose, for the biotransformation reaction. 
It was thought that rich full YPD medium may not be appropriate for biotransformation 
since there is a possibility of substrate binding to its ingredients.  
For initial optimization, reactions were performed in SD with 10 mg of chrysin in baffled 
flasks shaking at 200 rpm for 72 h, at 28 °C [Figure 6.1 (b)]. After every 24 h, the medium 
was replenished with fresh glucose to a final concentration of 1.5%. Glucose is exhausted 
after 12 h of growth of yeast cells when it is converted to ethanol. Hence, the ethanol-
inducible ADH2 promoter is fully induced every 12 h before more glucose is added to the 
















































Figure 6.1. (a) CYP1A1-expressing cells grown in YPD Medium; (b) 
Biotransformation reaction using CYP1A1 in SD medium; (c) Structures of 
chrysin and baicalein showing key chemical shift values  
 
The reaction media at each time point was extracted with ethyl acetate. The extracts were 
analyzed by TLC followed by HPLC/LC-MS. The formation of new product on TLC with 
lower Rf value than the substrate gave us an indication of a hydroxylation reaction 
(Supporting Information, S3). LC-MS analysis of the reaction mixture confirmed the 
product as mono-hydroxy chrysin with mass of m/z 270. The same product formed using 
both the enzymes, CYP1A1 and CYP1A2, expressed within yeast cells. However, 
conversion of substrate to product was better with CYP1A1. Therefore, for subsequent 
scale-up experiments, only CYP1A1-expressing yeast cells were used for 
biotransformation.  
Scale up and optimization of biotransformation reaction. Scale-up was performed as 
above; cells were at first cultivated in non-selective YPD media for 72 h, with fresh 
glucose (2%) being added every 24 h. Cells were re-suspended in selective SD minimal 
medium. 10, 50, 100, 250 and 500 mg of chrysin were used as substrate for separate 
biotransformation reactions. The chrysin-containing cell culture media were replenished 
with glucose every 24 h to a final concentration of 1.5%. The reaction using 100 mg of 
chrysin was observed to be the most efficient. With 250 and 500 mg, incomplete 
biotransformation occurred, probably because the small number of cells, used for growth 
in these specific experiments, was inhibited by the substrate.  
Based on these results, it was decided to optimize the time period for biotransformation. 
For this, we chose 100 mg of substrate with reaction time points of 24, 48, 72, 96, 120, 
144 and 160 h. HPLC analyses of the reaction mixture after 24, 48, 72, 96, 120, 144 and 
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160 h incubations indicated that, at 144 h, there was nearly complete conversion (>92%) 
of chrysin to the product. The HPLC chromatograms of reaction mixtures at 
representative four time intervals are shown in Figure 6.2. In HPLC analysis, the 
concentration of sample injected at each time interval was kept constant. The increase in 
the AUC of baicalein with increase in the time, from 24 h to 144 h, is indicative of the 
fact that the highest amount of baicalein is formed at the 144 h time point.  
 
 
Figure 6.2. HPLC analysis of biotransformation reaction at different time 
intervals. The concentration of sample injected is kept constant at each time 
interval; therefore there is an increased AUC (and peak height) as the time 
increases from 24 to 144 hrs. 
 
The relative percentages (AUC) of chrysin and baicalein at different time intervals are 
depicted in Figure 6.3a. As shown in Figure 6.3a, the percentage conversion of chrysin to 
baicalein increased with time. Similarly, Figure 3b shows increased peak height (mAU) 
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that 144 h is the optimal reaction time for this transformation. Further details of HPLC 






Figure 6.3. (a) Relative percentage of chrysin and baicalein at different time 
intervals during a typical biotransformation reaction (the percentages are 
based on the AUC of the peaks in HPLC analysis at 270 nm). (b) Baicalein (tR = 




































































Biotransformation reaction time (hrs)
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Isolation and characterization of baicalein. Initial isolation attempts using normal 
phase silica gel column chromatography showed significant loss in product yield. 
Therefore, we attempted reverse phase C18 silica gel column chromatography where 
water-methanol was used as the mobile phase. The product was isolated at 50% methanol 
in water and was characterized by spectral analysis and by comparison with reference 
sample.  
The 1H NMR of chrysin contains a typical bunch of three singlets at chemical shift values 
in the range of 6 to 7 ppm. These three singlets at δ 6.24, 6.49 and 6.74 ppm correspond 
to the protons present at C6, C8 and C3 positions. The C6-proton appears with an up-field 
shift in comparison to two other aromatic protons at C3 and C-6, because of the shielding 
effect from two adjacent C5 and C7 hydroxyls. It is obvious that the hydroxylation 
reaction is possible, either on A or C ring. Since there was no change in the chemical shift 
value pattern of C ring (d 7.91, dd, 2H and d 7.48, m, 3H), it would indicate that the C-
ring is intact and no hydroxylation had taken place on this ring. The hydroxylation on A 
ring has two possibilities, either C6- or C8 hydroxylation. Hydroxylation at C6-position 
will form baicalein (5,6,7-trihydroxyflavone) whereas hydroxylation at C8-position will 
form norwogonin (5,7,8-trihydroxyflavone) as a product. It was interesting to see that, in 
the 1H NMR of the obtained product, the up-field singlet (δ 6.24 ppm) disappeared. This 
singlet peak in chrysin corresponds to the proton present at C6-position. This gave us a 
clear indication that hydroxylation occurred at the C6-position, which means that the 
product is 5,6,7-trihydroxyflavone. This is the naturally occurring flavone, commonly 
named as ‘baicalein’. Furthermore, on comparison of the 1H NMR of the obtained product 
with norwogonin,35 the possibility of norwogonin as the product was ruled out. The 
biotransformation of chrysin using natural yeast, Rhodotorula glutinis yielded C-8 
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hydroxylated product norwogonin,(Sordon et al., 2015)   however in this present study, 
C-6 hydroxylated product (baicalein) was formed, which may be possibly because of the 
regio-specificity of the CYP1A1 enzyme. 
Mass analysis of the isolated product showed m/z peak at 271 in ES+ve mode, which 
matched with the predicted product. The final confirmation of the assigned product was 
done by co-TLC and HPLC analysis with the reference standard of baicalein (CAS 
number: 491-67-8)’ purchased from Sigma-Aldrich. TLC images as well as HPLC 
analysis clearly matched the reference standard (TLC images are shown in Supporting 
Information -S3). 






Figure 6.4. LC-MS analysis of reaction mixture at 144 h. (a) LC chromatogram 
of reaction mixture after 144 h of incubation. (B) LC chromatogram of isolated 
product; (c) Mass spectra of peak at tR 4.69 min. 
 
Docking of chrysin with CYP1A1. In order to decipher the rationale for regio-selective 
hydroxylation, chrysin was docked with the substrate binding site of CYP1A1 enzyme 
(PDB ID: 4I8V). The interactions of chrysin with CYP1A1 are depicted in Figure 6.5. It 











the C-6 carbon of A-ring is present in close-proximity with heme protein, suggesting that 
the reactive heme-oxo intermediate should possibly form at this position. Other key 
interactions which help in stabilizing this orientation of chrysin includes: (a) hydrophobic 
π-π interactions of Phe-224 of I-helix with B and C rings; (b) π-π interactions of Phe-319 
with A ring; and (c) polar H-bonding of C-7 hydroxyl group with Ser-122. This observed 
orientation, excludes the possibility of hydroxylation at C-8 and at aromatic CH of B and 
C rings. 
 
Figure 6.5. Molecular docking of chrysin with CYP1A1, showing the predicted 
site of hydroxylation as C6. 
 
Our efforts using yeast whole cells have resulted in the development of a reproducible 
preparative-scale biotransformation process for the conversion of chrysin to baicalein 
(5,6,7-trihydroxyflavone). According to the literature, the medicinal effects of baicalein 
are more profound than that of chrysin. Furthermore, commercially available baicalein is 
at least 60-times more expensive than chrysin. Thus, this protocol described here can be 
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utilized for production of a high value phytochemical from a low value one, using a 
simple, low-cost, one-step biotransformation reaction. 
In conclusion, we have demonstrated the ability of whole yeast cells, that overexpress the 
human CYP1A1 enzyme, to catalyse biotransformation of >92% of the natural flavonoid 
chrysin to baicalein. Optimal aeration, neutral pH and maintenance of glucose 
concentration, throughout the reaction, played very important roles in the 
biotransformation reaction. The example demonstrated in this paper, provides an 
opportunity for further exploring the utility of stable recombinant CYP enzyme-
expressing yeast cells for industrial production of medicinally important polyphenolic 
compounds.  
 
6.3.5 Supporting information (SI) 
 
S1. CYP activities in yeast cell culture continue to increase with time.  
Results in Figure S1.1 show a remarkable increase of cell numbers, over 72 h, of a 100 
ml yeast culture grown in YPD, in a 500 ml baffled shake flask, of the yeast strain [W303-
1a::CYP1A1(HIS3+), CYP1A1(URA3+)] that contains 2 copies of the human CYP1A1 
gene; it is likely that these results will be replicated in a fed-batch fermentor over a longer 
period of time. Similar results were obtained with the yeast strain [W303-





Figure S1.1. Growth, over 72 h, of the CYP1A1 yeast strain W303-
1a::CYP1A1(HIS3+), CYP1A1(URA3+), replenished with fresh medium every 24 
h. Results clearly show the ‘stability’ of growth of recombinant cells, over time, 
that contain integrated copies of the CYP1A1 gene compared to the strain that 
bears a 2-micron based episomal plasmid (labelled ‘EPISOM’). The y-axis 
represents optical density measured at 600 nm (OD600). The values represent 
mean and standard deviations from three independent experiments.  
 
Results Figure S1.2 show a gradual increase of cellular CYP1A1 activity, over time (24 





Figure S1.2.  Activity of the 2-copy CYP1A1 yeast strain; CYP enzyme activity 
was measured every 24 h using the EROD assay.1-3 The y-axis represents 
relative fluorescence units (RFUs). The values represent mean and standard 
deviations from three independent experiments. 
 
Results confirm a gradual increase of cellular CYP1A1 activity in cells cultured over a 
period of time (24 h  72 h). Similar results were obtained with the yeast strain [W303-






Figure S1.3.  Kinetics of CYP1A1 activities, as shown in Figure S 1.2, measured 
via the EROD assay.1-3 The y-axis represents relative fluorescence units 
(RFUs). The values represent mean and standard deviations from three 
independent experiments. 
 
S2. Maps of human CYP1A1 and CYP1A2 gene bearing plasmids that were 
integrated into the chromosomal loci of the HIS3 (chromosome XV) and URA3 
(chromosome V) genes in the yeast strain W303-1a. 
Chromosomal integration was carried out through homologous recombination in the yeast 
strain W303-1a (ATCC 208352), following standard yeast transformation protocols.  
The human CYP1A1 and CYP1A2 gene sequences were isolated from a human liver 
cDNA library (BioCat). The ADH2 promoter (ADH2p) and the SUC2 terminator (SUC2t) 
sequences were isolated from genomic DNA obtained from the strain S228C (ATCC 
204508). Isolation of all genetic sequences was performed via the polymerase chain 
reaction (PCR), using gene specific primers.  
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Figure S2.1 shows the map of the human CYP1A1 gene encoding plasmid that allows 
integration into the strain W303-1aat the chromosomal locus where the HIS3 gene lies. 
The map shows common restriction sites that occur in the plasmid only once.  
 
Figure S2.1. Human CYP1A1 gene encoding HIS3 integrating plasmid.The 
plasmid was linearized at the NdeI restriction site for integration at the HIS3 
chromosomal locus of strain W303-1a to obtain the strain W303-
1a::CYP1A1(HIS3+).  
 
Figure S2.2 shows the map of the human CYP1A1 gene encoding plasmid that allows 
integration into the strain W303-1a at the chromosomal locus where the URA3 gene lies. 































Figure S2.2. Human CYP1A1 gene encoding URA3 integrating plasmid.The 
plasmid was linearized at the EcoRV restriction site for integration at the URA3 
chromosomal locus of strain W303-1a::CYP1A1(HIS3+) to obtain the strain 
W303-1a::CYP1A1(HIS3+), CYP1A1(URA3+) which was used primarily for the 
biotransformation of chrysin to baicalien, and for optimization of the 
biotransformation process.  
 
Figure S2.3 shows the map of the human CYP1A2 gene encoding plasmid that allows 
integration into the strain W303-1a at the chromosomal locus where the HIS3 gene lies. 

































Figure S2.3. Human CYP1A2 gene encoding HIS3 integrating plasmid. The 
plasmid was linearized at the NdeI restriction site for integration at the HIS3 
chromosomal locus of strain W303-1a to obtain the strain W303-
1a::CYP1A2(HIS3+).  
 
Figure S2.4 shows the map of the human CYP1A2 gene encoding plasmid that allows 
integration into the strain W303-1a at the chromosomal locus where the URA3 gene lies. 



































Figure S2.4. Human CYP1A2 gene encoding URA3 integrating plasmid. The 
plasmid was linearized at the PstI restriction site for integration at the URA3 
chromosomal locus of strain W303-1a::CYP1A2(HIS3) to obtain the strain 
W303-1a::CYP1A2(HIS3+), CYP1A2(URA3+) which was used for the initial 








































Spots from left to right: 
A. Isolated baicalein 
B. co-spot (A+C) 
C. Reaction mixture 
 
Mobile Phase: 3% 







Spots from left to right: 
• Chrysin  
• reaction mixture 
• isolated baicalein 
and  
• reference standard of 
baicalein 
Mobile Phase: 40% EtOAc: 









Spots from left to right: 
• Chrysin  
• reaction mixture 
• isolated baicalein 
and  
• reference standard 
of baicalein 
Mobile Phase: 40% 
EtOAc: Hexane (with 
0.1% acetic acid) 
 
Detection wavelength: 365 
nm 
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S4. Western blots of human CYP1A1 and CYP1A2 proteins expressed in baker’s 
yeast.  
1                2           3
 
Figure S4.1.Western blot of CYP1A1 protein. 106 cells from each recombinant 
yeast strain were from a 24 h SD minimal medium culture. They were lysed 
with glass beads in a SDS containing buffer which is routinely used for yeast 
cell lysis; 15 µl from each 100 µl supernatant was loaded in lanes 1 and 2. Lane 
1, cells from strain W303-1a::CYP1A1(HIS3+) which expresses 1 copy of 
CYP1A1 gene; Lane 2, cells from strain W303-1a::CYP1A1(HIS3+), 
CYP1A1(URA3+) which expresses 2 copies of CYP1A1 gene; Lane 3, 1.5 pmole 
of CYP1A1 microsomal enzyme isolated from whole yeast cells.  
 
 
Figure S4.2.Western blot of CYP1A2 protein. Lane 1, 106 cells from the yeast 
strain W303-1a::CYP1A2(HIS3+), CYP1A2(URA3+), from a 24 h SD minimal 
medium culture, were lysed with glass beads in a SDS containing buffer which 
is routinely used for yeast cell lysis; 15 µl from 100 µl supernatant was loaded. 
Lane 2, 1 pmole of CYP1A2 microsomal enzyme obtained from Corning-
Gentest (Catalogue #456203).  
S5.  HPLC additional details 
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Method: HPLC analysis was performed on Shimadzu LC-6AD system connected with 
C18 column (4.6 x 25 mm, 5 µ). Mobile phase consisted of A: 0.1% formic acid and B: 
methanol using isocratic elution (30: 70 – A: B). Flow rate was 1 mL/min. Detection 
wavelength was 270 nm. 














The analysis of HPLC data for biotrasformation reactions monitored at different 









of baicalein to 
chrysin 
A bunch of 
unknown peaks 
at tR = 2-5 min 
Baicalein 





24 77 16 7 90.7 74: 26 
48 77 21 2 148.8 75: 25 
72 70 19 11 204 78: 22 
96 76 21 3 300 90:10 
120 76 22 2 342 92: 8 
144 72 26 2 484 92: 8 
168 81 17 2 414 89:11 
aTotal area percentage = 100 
The concentration of sample injected is kept constant at each time interval; therefore there 
is an increased AUC (and peak height) as the time increases from 24 to 144 hrs. HPLC 







































S7. LCMS analysis of biotransformation reaction. 
Method: LC-MS analysis was performed on Waters Acquity UPLC. The column used 
was C18, 1.7 µ with dimensions of 100 x 2.1 mm (column temp. 30 °C). Binary gradient 
system was used. Mobile phase A consisted of 5% acetonitrile in water with 0.1% formic 
acid. Mobile phase B consisted of acetonitrile with 0.1% formic acid. Gradient details 
are: Time in min (% B concentration): 0.01 (10), 0.25 (10), 9.00 (100), 10.00 (100), 11.00 
(10), 12.00 (10). PDA range: 220 nm to 400 nm; flow rate: 0.3 mL/min. 
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The LCMS data of biotrasformation reaction, at 168 hrs incubation time: The LC 















6.4 Biotransformation of codeine to morphine 
using whole yeast cells expressing human 
CYP2D6 variants, – revelation of CYP2D6 
variant P34S/A122V/S486T being a far 
superior metaboliser of codeine than the wild-
type (Met374) and Val374 variants 
 
(Manuscript in preparation: Ibidapo S Williams et al; will be published as soon as 




CYP2D6 belongs to the cytochrome P450 (CYP) family of enzymes and is known to 
metabolise codeine to morphine within the human body. It has been reported that, in 
general, only up to 15% of codeine undergoes O-demethylation to form morphine within 
humans. Morphine is codeine’s most active metabolite and is 200-fold stronger than 
codeine that induces which act  as an agonist of the pain mediator, the µ-opioid receptor. 
I have established a platform technology that allows stable expression, in baker’s yeast, 
of human CYP genes from yeast’s chromosomal loci (Chapter 5). Three CYP2D6 variant 
genes, 2D6-1 (NCBI Accession No NM_000106; M374V or Val374), 2D6-2 (NCBI 
Accession No M20403; wild type or Met374) and 2D6-C (isolated from a liver cDNA 
library), were cloned in yeast integration vectors for expression within live yeast cells. 
Surprisingly, results show that the variant 2D6-C (P34S/A122V/S486T), which has never 
been reported before, yields >70% of morphine whereas the yields for 2D6-1 and 2D6-2 
were around only 30%. It seems that the variants 2D6-1 and 2D6-2 predominantly form 
norcodeine, which involves N-demethylation of codeine, with >55% yield. All reactions 
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were carried out in baffled shake-flasks under conditions that mimic fed-batch 
fermentation. The specificity of 2D6-C for O-demethylation and of 2D6-1 and 2D6-2 for 
N-demethylation is being explored via molecular modelling. The system described here, 
on further optimisation, could find generic use in high-yield chemical reactions for the 




Codeine is an opioid class of painkiller. The central nervous system and gastro intestinal 
system are the two major areas of the body where codeine exerts its effects. Codeine’s 
binding to the µ-opioid receptor is weak. However, morphine, a metabolite of codeine, 
has a greater than 200-fold affinity for the µ-opioid receptor than codeine. Codeine 
undergoes O-demethylation by CYP2D6 to form the metabolite, morphine. It has been 
reported that only up to 15% of codeine is metabolised to morphine and the remaining 
85% is converted to inactive forms (codeine-6-glucuronide and nor-codeine via N-
demethylation; Figure 6.6) and excreted. Morphine itself can undergo further metabolism 
to nor-morphine (again via N-demethylation; Figure 6.6) and morphine-6-glucuronide. 
Like codeine itself, glucuronides and N-de-methylated derivatives (Figure 6.6) of both 
codeine and morphine have also weak affinity for the µ-opioid receptor. Therefore, they 
cannot act as effective painkillers like morphine (Palo, 2012; Caudle et al., 2017). 
Drug abuse and the use of illegal heroin (Figure 6.6), identified in blood samples, are 
persistent menace in our society right from the past till the present day. To assess the level 
of heroin in the blood system of users is not easy especially because the metabolite 6-
acetylmorphine (6-AM; Figure 6.6) is difficult to assess due to its short half-life which 
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ranges up to a minute (Goldberger at al., 2005). Total codeine-to-morphine ratio is, 
therefore, employed to detect the presence and amount of heroin or codeine consumption 
(Sindrup et al., 1990).  
 
Figure 6.6. Codeine undergoes O-demethylation to form morphine and N-
demethylation to form norcodeine. [C. Meadway et al., 2002].  
 
CYP2D6 and its isoforms are well known metabolisers of codeine to morphine (Sindrup 
et al., 1990). Any individual suffering from extreme low plasma concentrations (i.e. lack) 
of CYP2D6 enzyme is referred to as a poor metabolizer. It has been reported that 
individuals carrying the genotype of the ultra-rapid CYP2D6 metabolisers are said to be 
45-fold higher in their concentration of morphine, the O-de-methylated metabolite of 
codeine, than individuals with poor metabolism (Yu et al., 1997). There is variation in the 
percentage of individuals carrying the ‘high metaboliser’ genotype, from 5-10% in 
Southern European populations to 10-30% in Asian and North/ East African countries 
(Sachse et al., 1997; Bernal et al., 1999; Aklillu et al., 1996).  
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The current system of rating the levels of heroin detected in the blood maybe unfair on 
certain individuals. The current rating (i.e. codeine-to-morphine ratio) is set at value 
above one (1) which is considered to indicate the use of heroin (Pearce et al., 2008). Since 
the levels of CYP2D6 and its isoforms vary from one individual to another, individuals 
who are active CYP2D6 metabolizers will wrongfully be accused of heroin abuse.  
Moreover, individuals with ultra-rapid metabolizer CYP2D6 genotype of codeine are also 
endangered because of the persistent high amounts of morphine concentrations in their 
bodies. This may result in confusion, sleepiness and shallow breathing. Also, new babies 
can suffer the effect of high concentration of morphine through their mothers’ breast milk 
(Antoine , 2012). 
 
6.4.3 Aim of experiments with CYP2D6 variants 
 
The aim was to establish if whole yeast cells, expressing different CYP2D6 variant 
enzymes, could be used to metabolize proficiently a compound “A” to product “B”. The 











10 micromoles (µmoles) of codeine were incubated in baffled shake-flasks that contained 
liquid cultures of three different yeast strains: that expressed (1) CYP2D6-1, (2) 
CYP2D6-2, and (3) CYP2D6-C enzymes. The protocol followed was exactly as the one 
described in Section 6.3 of this Chapter. The product formed was extracted with organic 
solvents, the solvents were evaporated and the residues were analysed using high-
performance liquid chromatography (HPLC; Figure 6.7).  
7
Nor-Morphine Standard Nor-Codeine Standard
Codeine Morphine, using 2D6-1 Codeine Morphine, using 2D6-2 Codeine Morphine, using 2D6-C









Figure 6.7. Panel 1: internal standard, codeine, with retention time 5.1 min. 
Panel 2: internal standard, morphine, with retention time 4.2 min. Panel 3: 
internal standard,nor- morphine, with retention time 4.65 min. Panel 4: 
internal standard, nor-codeine, with retention time 8.16 min Panel 5: 
codeine  biotransformation, using yeast cells expressing 2D6-1, with 
retention time of morphine as 4.2 min. Panel 6: codeine  
biotransformation, using yeast cells expressing 2D6-2, retention time of 
morphine being 4.2 min. Panel 7: codeine  biotransformation, using yeast 
cells expressing 2D6-C, retention time of morphine as 4.2 min. 10 µmoles of 
codeine, dissolved in water, was incubated with whole yeast cells containing 
the CYP2D6 variants for 72 h. The concentration of samples injected were 
kept constant. In chromatogram 7, morphine is seen to be the major peak. In 




The results in Figure 6.7 would imply that the variant 2D6-C predominantly forms 
morphine (chromatogram 5) when compared with the wild type (2D6-2; chromatogram 
5) and 2D6-1, the Val374 variant (chromatogram 3). The Val374 variant of CYP2D6 
enzyme is sold as Supersomes by Corning-Gentest. Supersomes are used worldwide in 
the process of drug discovery by major pharmaceutical companies. The results from the 
chromatograms have been tabulated (see Table 6.1).  
 
Table 6.1. Shows the percentage of morphine formed from the metabolism 
of codeine by the variants of CYP2D6 expressed in baker’s yeast, S. 
cerevisiae. 
Substrates CYP2D6-1 peak area 
(mAu*) 
CYP2D6-2 peak area 
(mAu*) 
CYP2D6-C peak area 
(mAu*) 
Morphine 800 775 440 
Codeine 300 350 110 
Nor-codeine 1600 1325 35 
Nor-morphine 290 200 120 
Total 2990 2650 705 
% Morphine in the total 
products 
26.8 29.3 62.4 
 
Attempts have been made to rationalize the results obtained in Table 6.1 with the help of 
colleagues at the Indian Institute of Integrative Medicine (IIIM). The results are shown in 
Figures 6.8 to 6.10. A manuscript is in preparation incorporating these results.  
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Me and Glu216: 2.26 A
1. Wild type CYP2D6 (2D6-1) (4WNT)
Figure 6.8.  CYP2D6 (1) docking shows N-demethylation as a preferred site of 
metabolism. The interaction justifies the formation of norcodeine when 
10µM of codeine was added to yeast cells bearing CYP2D6 (1) gene (4WNT). 







2. Mutated CYP2D6-2 variant (4WNT) – Mutations – V374M
Distance between N-Me 
and Glu216: 2.6 A
 
Figure 6.9.  CYP2D6 (2) docking shows N-demethylation as a preferred site of 
metabolism. The interaction justifies the formation of norcodeine when 10µM 
of codeine was added to yeast cells bearing CYP2D6 (2) gene (V374). The 







Site for metabolism 
(demethylation) of 
codeine
Distance between O-Me 
and Glu216: 3.59 A
3. Mutated CYP2D6-C variant (4WNT) – Mutations – P34S/A122V/S486T
Figure 6.10.  CYP2D6 (C) docking shows O-demethylation as a preferred site 
of metabolism. The interaction justifies the formation of norcodeine when 
10µM of codeine was added to yeast cells bearing CYP2D6 (C) gene 
(PS4S/A122/S486T). The distance between O-Me and Glu216:3.59A.    
 
Our efforts using yeast whole cells have resulted in the development of a reproducible 
preparative-scale biotransformation process for the conversion of codeine to morphine. 
According to the literature (Wang et al., 2015), Glu216 and Asp301 are important 
residues which are involved in de-methylation reactions. During docking, the interactions 
with these residues were closely observed. In the demethylation of codeine, Glu216 seems 
to play a crucial role.  
Docking results have shown that in case of 2D6-1 (wild type) and 2D6-2 (V374M 
variant), the N-methyl group orients towards Glu216 residue, whereas OMe group is 
orienting away from this residue. However, in the case of 2D6-C (P34S/A122V/S486T) 
variant, the orientation of codeine was precisely reversed in the binding cavity of this 
enzyme resulting in the orientation of OMe towards Glu216, and N-Me away from this 
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residue. These observations validate our experimental results very well. There is nothing 
in the literature which would indicate that anyone has shown this type of studies with 
CYP2D6. 
Figure 6.11 shows the TLCs of codeine to morphine biotransformation using the three 
CYP2D6 variant enzymes being expressed with live yeast cells.  
NC        NM       C       M   2D6-1    2D6-1 NC          NM          C          M        2D6-2      2D6-2
NM         NC          C          M          2D6-C
Codeine Morphine, using 2D6-1 variant Codeine Morphine, using 2D6-2 variant
Codeine Morphine, using 2D6-C variant
Codeine Morphine, using 2D6-C, 2D6-1, 2D6-2: a comparison using TLC
M         NC          C          NM       2D6-C    2D6-1    2D6-2  
Figure 6.11. The TLCs provide qualitative pictures of the codeine to morphine 
biotransformation, using the yeast strains that express the three CYP2D6 variant 
enzymes, 2D6-1, 2D6-2 and 2D6-C. TLCs also show reproducibility of product 
formation. In all experiments, 10 µM (final concentration) of codeine was added to 
each yeast cell culture, bearing different CYP2D6 variants. After cell culture, the 
media were extracted with solvent; equal volumes (5 µl) were spotted on to lanes of 
the TLC plates [Sigma Aldrich (Z193275-1)]. Solvent system used for extraction, 
CHCl3:MeOH:NH3 = 36:1:0.6. C = codeine; M = morphine; NC = norcodeine; NM 





6.4.5 Discussion and future work 
 
Three variants of CYP2D6 enzyme have been studied for their ability to convert codeine 
to morphine. From the results obtained, the CYP2D6-C variant could be classified as a 
rapid metaboliser of codeine. It was observed that more than 60% of codeine was 
converted to morphine. This is quite high compared to 27% and 29% conversion seen 
with 2D6-1 and 2D6-2 variants (Table 6.1). It has been reported in the literature that up 
to 15% conversion of codeine to morphine is normally observed within the human body 
(Berg-Perdersen et al., 2013). It was seen from the TLCs that with the wild type (2D6-1) 
and the Val374 variant (2D6-2) > 60% of the product was nor-codeine, codeine undergoing 
N-de-methylation to form nor-codeine (Berg-Perdersen et al., 2014). A similar trend is 
seen on the HPLCs where the peak for nor-codeine was the highest (Figure 6.7, Panels 3, 
4, retention time of nor-codeine, 8.2 min).  
We believe that the analysis of codeine to morphine biotransformation could be studied 
in such detail because of the stability of CYP2D6 expression in yeast strains which was 
afforded by the platform technology that has been created during work conducted for this 






6.5 Metabolism of compound AZD-2014 using 





Cytochrome P450 (CYP) enzymes oxidise endogenous compounds, pharmaceutical 
drugs and other xenobiotics (Guengerich, 2007). CYP enzymes can exhibit both induction 
and inhibition in different reactions with drugs to enable their elimination after use. As 
discussed before, this often leads to drug-drug interactions (Heaths and Winkers, 2005). 
Dangers caused by drug-drug interactions are very common (Seymour, 1998). In order to 
analyse such interactions before seeking approval of a prospective drug from drug 
regulatory authorities,  
(1) Firstly, one must determine which CYP enzyme is mediating the metabolism of a 
prospective drug, and  
(2) Secondly, one must determine how much of a metabolite is being formed and then 
identify the metabolite(s) formed.  
The reasoning behind this is  
(a) The CYP enzyme that is mediating metabolism may be strongly inhibited by 
another approved drug so that one needs to be extra cautious about administering 
such drugs together, and 
(b) A CYP enzyme mediated metabolite that is formed from a prospective drug is 
toxic for the human body.  
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Hence, drug regulatory authorities demand identification of a metabolite and the CYP 
enzyme responsible for metabolism.  
 
6.5.2 Aim of experiments 
 
We embarked on experiments to find if CYP3A4, which is the metabolizer of most 
approved drugs, also metabolizes a drug which is currently in clinical trials. The drug 
which was chosen was AstraZeneca’s AZD-2014, an mTORC inhibitor. The main aim of 
these experiments was to see whether there could be an improvement in metabolite 
formation of AZD-2014 using whole yeast cells that express human CYP3A4. 
AztraZeneca had reported that they had obtained less than 10% conversion of AZD-2014 
to metabolite(s) using the processes (i.e. recombinant CYP3A4 enzyme and also different 
types of recombinant whole cells expressing CYP3A4) that they had used.  
 
6.5.3 Background to compound AZD-2014 
 
AZD-2014 is a second generation dual inhibitor of mTORC-1 and 2. It is presently in the 
phase II/III clinical trials. This compound is reported to have shown high inhibition 
against mTORC-1 and 2. mTOR is an atypical serine/threonine kinase that is present as 
two complexes, complex 1 (C1) and complex 2 (C2). The first complex (mTORC 1) 
includes the proteins mTOR, Raptor, GβL and DEPTOR (DEP domain-containing 
mTOR-interacting protein) and it is inhibited by rapamycin. The complex is a master 
growth regulator that regulates and senses integrating different nutritional, cellular 
stresses and other metabolic factors. The second complex, mTORC-2, is composed of 
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mTOR, Rictor, GβL, Sin1, PRR5/Protor-1, and DEPTOR. Complex 2 controls cellular 
survival by activating Akt, a Ser/Thr kinase (Eyre et al., 2014). Misregulation of mTOR 
is involved in many diseases including cancer, diabetes, and cardiovascular disease 
(Dowling et al., 2010). Figure 6.9 shows the different biochemical pathways that relate 
to mTORC-1 and 2. It has been published that AZD-2014 inhibits the AKT/ mTOR signal 
transduction pathway without any negative-feedback on mTORC-2 in any type of tumour 
cells (Rastogi et al., 2013).  
 
 
Figure 6.12. Biochemical pathways linked to mTORC-1 and 2 (Eyre et al., 
2014).  
 
It has been reported that CYP3A4 inhibition should be avoided during the use of mTORC 
inhibitors because CYP3A4 is the major CYP enzyme involved in the metabolism of this 
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class of compounds (Dancey et al., 2010; Laplante et al., 2012). We set out to find out if 




The experimental procedure for this study was similar to the one described earlier in 
Section 6.3 of this Chapter. 10 µM (final concentration) of AZD-2014 (structure shown 
in Figure 6.13) was incubated in baffled shake flasks with whole yeast cells expressing 
CYP3A4 for different time periods.  
 
Figure 6.13. Chemical structure of AZ-2014.  
 
The cultures showed accumulation of white crystallised particles at the bottom of the flask 





Figure 6.14. Shows accumulation of fine white crystalline particles at the 
bottom of the flask when AZD-2014 was incubated with CYP3A4-expressing 
yeast cells.  
 
The picture in Figure 6.14 would indicate metabolite formation since the starting material, 
AZD-2014, is amorphous.  









Figure 6.15. The chromatograms show the results from HPLC after compound 
AZD-2014 (supplied by AstraZeneca) was incubated with yeast cells 
expressing CYP3A4 in a YPD culture. The incubation time lasted from 48 h to 
96 h. Chromatogram 1, retention time (RT) of AZD-2014 is ~8.1 min. 
Chromatogram 2, shows that besides AZD-2014, there was a product formed 
at 48 h which had a RT of 8.405 min. Chromatogram 3, after  96 h of incubation, 
two products could be seen, one with RTof 7.122 and the other RT of 8.405, 
and the AZD-2014 peak was greatly diminished. 
 
The identity of the true metabolite of AZD-2014 has not been revealed in this report 
because of the confidentiality agreement with AstraZeneca over the compound.  
However, the main interest of this study was to establish the percentage conversion of the 
AZD-2014 using whole yeast cells expressing the human CYP3A4 enzyme. Hence, TLCs 





Figure 6.16 (1). The first TLC that shows the formation of metabolites from 
AZD-2014 after incubation with CYP3A4-expressing yeast cells over a time 
period of 96 h.  
 
The results in Figure 6.16 (1) would indicate that more that 80% of AZD-2014 was 









0 (pure)    72h           96h
CYP3A4-mediated metabolism of AZD2014 in baker’s yeast - 1
Components of cell culture medium
Comment: The vanillin 
stain shows TWO 
products.  Semi-
quantification of 
starting material and 
the products indicate 
that ~80% of AZD2014 
has been converted by 
CYP3A4 to products X 





Figure 6.16 (2). The second TLC that shows the formation of metabolites from 
AZD-2014 after incubation with CYP3A4-expressing yeast cells over a time 
period of 96 h.  
 
The results in Figure 6.16 (2) would again indicate that more that 80% of AZD-2014 was 
converted to metabolites. This was also confirmed by densitometric quantification 
(results not shown).  
 
  




0 (pure)           72h              96h
Components of cell culture medium
Comment: The vanillin 
stain shows TWO 
products.  Semi-
quantification of 
starting material and 
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that ~80% of AZD2014 
has been converted by 
CYP3A4 to products X 
& Y.  
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12 : 1.0 : 0.2% = CHCl3 : MeOH : conc NH3
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6.5.5 Future work 
 
The results obtained clearly show that large amounts of metabolites could be quickly 
obtained from a potential medicine that is in development. Without the constraints set by 




In conclusion, herein I have demonstrated the ability of whole yeast cells overexpressing 
CYP1A1, CYP2D6 variants, and CYP3A4 enzymes to metabolize (i.e. bio-transform) 
different substrates. The high yields obtained in all biotransformation reactions, 
performed until now, have never been reported before.  
(1) CYP1A1 was able to catalyse the biotransformation of the natural flavonoid 
chrysin to another natural flavonoid baicalein with more than 92% conversion. 
(2) A CYP2D6 variant converted 62% of codeine to morphine; such high conversion 
to morphine has never been reported before.  
(3) CYP3A4 mediated the conversion of more than 80% of AZD-2014 into two 
unknown metabolites; both metabolites play an important part in the clinical trials 
that are currently running.  
These unique examples demonstrated in this study indicate the future opportunities for 
exploring the utility of these stabilized yeast cell based CYP enzymes for industrial 
production of medicinally important compounds and metabolite formation of medicines 
in development.  
536 
 
In summary, the stable CYP-expressing yeast strains ought to open up new exciting 
avenues in the area of (a) biotransformation and (b) drug metabolism, both being crucially 

















Chapter 7 Establishment of a yeast system that 
stably co-expresses two or three 
different human CYP enzymes,– 
applications in CYP inhibition studies, 







Most high-value chemicals are plant products. These chemicals are formed usually from 
low value natural products widely occurring in plants. The transformation from a low 
value to high value chemical is often mediated by cytochrome P450 (CYP) enzymes. This 
process of conversion is referred to as the process of secondary metabolite formation. The 
metabolites are of high value mostly because they have unique medicinal properties but, 
unfortunately, are produced in nature in very low amounts. Usually, such metabolites are 
not amenable to convenient and affordable synthetic approaches since their formation 
always involves regio- and stereo-specific organic chemical reactions which comprise of 
multiple steps. The beauty of nature is that similar reactions are catalysed by CYP 
enzymes with the transformation occurring in a single step (Zhang et al., 2014).  
Earlier in this study, the yeast S. cerevisiae was shown to be an organism which could be 
used to create powerful recombinant cell systems. In this thesis yeast has specifically been 
utilized as a heterologous expression system for the production of human CYP enzymes 
at high levels with enhanced activity. It was thought at the outset of this project that the 
similar intracellular features of baker’s yeast to that of human cells would be a major 
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advantage that would facilitate efficient heterologous expression in yeast of human CYP 
enzymes with active site geometries identical to that present in human cells. Like human 
cells, yeast is a eukaryotic organism. Since it is unicellular, it is amenable to easier genetic 
modifications than human cells which are multi-cellular. It was conjectured that after 
introduction of human CYP genes into yeast, the human enzymes produced in yeast would 
behave just like the enzymes present in human cells. They would also be expected to be 
bound to the yeast endoplasmic reticular (ER) membranes which are structurally similar 
to the human ER membranes (Zimmermann et al., 2011).  
However, it was also realized that there was a major drawback facing the production of 
these heterologous CYP proteins in yeast. It was the instability of the genetic information, 
which is foreign to yeast, being carried within the cells on extra-chromosomal plasmids 
that could prevent proficient protein synthesis and could lead to inconsistent production 
of human CYP enzymes. Although the genome of S. cerevisiae has completely been 
sequenced (Goffeau et al., 1996), yet until now there is still no complete understanding 
on how to optimise the production of foreign (i.e. heterologous) proteins/enzymes in 
yeast.  
Yeast has been thought of as a system where not only foreign proteins could be made in 
bulk but also where important naturally occurring chemicals or their precursors could be 
made in large amounts (Sordon et al., 2016). Therefore, based on the knowledge of the 
yeast genome, there have been concerted attempts to develop biological tools, aimed at 
utilizing this organism, for construction of novel biosynthetic pathways within the yeast 
genome. The main focus of these attempts has been to establish methodologies that would 
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allow stable introduction of genes into the genome of yeast that would allow efficient 
production of proteins and chemicals (Mumberg et al., 1994, 1995). 
The ability of baker’s yeast to be transformed, with large DNA sequences, which can be 
stably maintained, has made it a powerhouse for sequencing the genome of any living 
organism. Baker’s yeast has the capability of taking up efficiently multiple DNA 
fragments simultaneously. Homologous recombination allows this to take place in a 
single step (Larionov et al., 1996). Consequently, multiple fragments can be integrated 
into the yeast genome so that they could be propagated stably during cell division, without 
having to select for any extra-chromosomal plasmid in slow-growing selective medium. 
 
7.1.2 Stability of genetic information, foreign to yeast, 
during propagation of yeast cells 
 
Several techniques have been developed to open up the possibility of rapid assembly of 
genes, embodying large biosynthetic pathways, on the yeast genome. With the 
advancement of rapid gene synthesis, orchestrated by combinations of overlapping 
oligonucleotides, new biosynthetic pathways have been incorporated on to the yeast 
genome to synthesise novel chemicals (Benders et al., 2010). 
An episomal 2-micron (2µ) plasmid should, by definition, provide multiple (at least >10 
but possibly 40-60) copies of plasmids per cell allowing strong expression of plasmid 
encoded genes (Rizvi et al., 2017). During the course of the studies reported in this thesis, 
this assumption turned out not to be true. On comparison of expression of a CYP gene 
from an episomal plasmid contained in a yeast strain with strains that harboured integrated 
copies of the same gene, it was noticed that instead of expressing multiple copies of a 
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gene, an episomal plasmid expressed much less CYP enzyme than a single copy gene, 
integrated at a chromosomal locus. This would indicate that an episomal plasmid does 
not deliver stable CYP expression within cells. It has been suggested that the inherent 
instability of episomal 2µ plasmids can be burdensome for cells and could result in 
cellular toxicity and cell death (Parent et al., 1985).  
Although low copy number plasmids, which are used to construct yeast artificial 
chromosomes (YACs) afford more stable expression relative to episomal 2µ plasmids, 
they suffer from low gene expression. Hence, low copy number plasmids have limited 
use. Gjuracic and Bruschi (2005) have reported that retention of YAC constructs within 
live yeast cells can be problematic because it is difficult to maintain the selection pressure 
on an extra-chromosomal entity, which is the YAC. YACs can be maintained only in 
selective synthetic defined (SD) minimal medium in which yeast cells do not grow as 
well as in non-selective complete YPD medium. In fact, cells in SD medium grow poorly. 
One of the major achievements of the studies described in this report is the enhancement 
of expression levels of heterologous human CYP genes by using DNA constructs which 
permit chromosomal integration. It has been noticed by others that during the 
simultaneous expression of multiple genes that belong to a biosynthetic pathway of a 
natural product, balancing the expression levels of individual genes is quite important in 
order to achieve an optimal flux through a biochemical pathway and also to avoid the 
accumulation of undesired chemical intermediates or by-products that may be formed 
during biosynthesis (Pitera et al., 2007). The two main aspects which are considered 
before chromosomal integration of a gene are copy number of the gene that is introduced 
into the genome and the strength of the inducible or constitutive promoter.  
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The studies described in this report has used human genes, synthesised with yeast biased 
codons, to overcome the problem of epigenetics, that is, to avoid any sudden changes in 
chromosomal structure after introduction of a foreign gene into host cells that would 
ultimately lead to the lowering of gene expression. Manifestation of epigenetic effects 
after introduction of foreign genes into host organisms has been discovered in several 
systems, including that of E. coli, Lactococcus lactis (Thompson and Gasson, 2001), and 
S. cerevisiae (Yamane at al., 1998, Thompson and Gasson, 2001). Most researchers 
observed epigenetic effects that involve silencing of gene transcription (Ottaviani et al., 
2008). Differential transcriptional silencing effects were observed at different 
chromosomal loci of these organisms (Fang et al., 2011).  
 
7.1.3 ‘Reiteration recombination’ method for 
chromosomal integration of genetic information 
into yeast 
 
Recently, the ‘reiterative recombination’ method has combined high efficiency with 
nuclease induced homologous recombination, for integration of multiple gene expression 
cassettes either (a) randomly into different chromosomal loci or (b) targeted repetitively 
to a particular chromosomal locus. The genes, in the expression cassettes that have been 
reported, represent pathways to the syntheses of different chemical entities. Homologous 
recombination of genes, in the ‘reiterative recombination’ method, can occur stepwise 
with repetitive use of a replaceable selection marker. This occurs at a specific 
chromosomal locus. Alternatively, one could use the 22 bp delta (δ) elements of yeast 
retrotransposons (Tys) to integrate multiple genes in different chromosomal loci. There 
are around 50 Tys in yeast and hundreds of δ elements.  
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In one study, a two-gene biosynthetic pathway for production of the chemical 1,2-
propanediol was constructed using δ integration cassettes. The δ elements that were 
chosen are part of the long terminal repeats (LTRs) of the Ty1 and Ty2 retrotransposons 
of the yeast S. cerevisiae. In the S. cerevisiae chromosomes there are dispersed several 
hundred δ elements which exist alone or are associated with Ty elements. A plasmid 
bearing a heterologous (foreign) gene and containing a δ element can, in theory, allow 
tens (possibly hundreds) of integrations at the different chromosomal loci, where a Ty 
element exists, via yeast transformation. Although transformants are selected in minimal 
medium, the resultant strains can be grown in full medium because the plasmids are 
integrated into the yeast genome, and once integrated there is no possibility of plasmid 
loss. In this particular case, strains with only three copies of each gene showed the highest 
level of production of 1,2-propanediol (Lee and Da Silva, 2006).  
 
7.1.4 ‘Cocktail integration’ method for chromosomal 
integration of genetic information into yeast 
 
Cocktail integration is another method of chromosomal integration of genes in yeast 
which has been described by Yamada et al (2010). Their work was related to simultaneous 
integration of three genes, BGL, EG and CBH, involved in the production of cellulose. 
This again involved the method of delta (δ) integration. Simultaneous introduction of the 
first copy of the cocktail of three genes resulted in the production of higher levels of 
cellulose compared to the experiment when each gene was introduced individually using 
a δ element. Introduction of the second copy of the cocktail of genes, at the same time, 
produced higher cellulose levels than the first copy cocktail. However, after the third copy 
of the cocktail of genes was introduced, it was found that there was saturation in the levels 
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of gene expression, that is, there was the same cellulose level as had been seen in cells 
containing the second copy cocktail.  
 
7.1.5 ‘Recyclable integration’ method for chromosomal 
integration of genetic information into yeast 
 
Codruta et al (2011) have studied the production of plant terpenoids in yeast. They were 
able to improve production of specific terpenes in yeast using ‘recyclable’ integration 
cassettes. It was found that there was around 60% augmentation in protein synthesis with 
appropriate choice of chromosomal loci.  
As seen earlier in this report, the yeast URA3 gene has been used as a selection marker 
for selection of plasmids (both episomal and integrative) during yeast transformation and 
for maintenance of only extra-chromosomal plasmids in minimal SD medium during 
propagation (i.e. growth) of yeast cells. The functional URA3 gene can be used for 
repetitive ‘recycling’ (Alani et al., 1987) during consecutive gene integrations. For 
example, after the first integration with a URA3 integrative plasmid, host cells containing 
a non-functional ura3 gene become URA3+. In order to convert the URA3+ cells back to 
ura3-, the cells are transformed with a truncated non-functional ura3 (∆ura3) gene and 
the transformant cells are then grown in the presence of the chemical 5-fluoroorotic acid 
(5-FOA) to select for the presence of only ura3- cells. The Ura3 protein, coded for by the 
functional URA3 gene, converts 5-FOA to the toxic compound 5-fluoro-UMP. Thus, cells 
which contain a functional URA3 gene die and only the cells containing a non-functional 
ura3 survive and multiply in a uracil containing synthetic SD medium. Thus, the URA3 
gene can be used for repetitive counter-selection (i.e. ‘recycled’) in the presence of 5-
544 
 
FOA, for introduction of a new gene or a new copy of the same gene using a series of 
URA3 integration plasmids.  
In order to repetitively ‘recycle’ virtually any desired selection marker (not only URA3), 
the bacteriophage-derived LoxP-Cre recombinase system has been developed (Hoess & 
Abremski, 1985; Sauer, 1987; Guldener et al., 2002). It exploits the site-specific activity 
of the Cre recombinase which efficiently removes markers by flanking them with a 
targeted LoxP sequence. However, the LoxP-Cre system has a major limitation. Namely, 
it requires the co-expression of a recombinase gene which is borne on a plasmid that must 
contain an additional selection marker (Schorsch et al., 2009). Moreover, the repetitive 
(i.e. ‘recyclable’) use of this system can cause major chromosomal rearrangements.  
 
7.1.6 Comparison of expression from episomal plasmid 
and after chromosomal integration: a published 
study 
 
Barun et al (2012) have co-expressed CYP2D6 and CYP3A4 with CPR from both 
episomal and integrative plasmids. The amounts of CYP proteins obtained were 4 to 10 
fold more when the CYP and CPR genes were co-expressed from a multi-copy episomal 
plasmid than when they were co-expressed from a single integrated copy from the same 
chromosome. Moreover, the multi-copy plasmid transformants showed a 50 to 70-fold 
increase in CYP activity compared to the single copy integrated strains. This is in stark 
contrast to our findings. However, it should be pointed out that the amounts and activities 
of CYPs produced by Barun et al (2012) were negligible compared to what has been 




7.1.7 Drug metabolism, a crucial factor in Drug 
Development 
 
Metabolism of drugs mediated by CYP enzymes is an extremely important factor in 
determining the occurrence of drug-drug interactions. These determinations have been 
greatly aided by the availability of microsomal (ER membrane bound) enzymes that have 
been isolated from recombinant organisms, such as insect cells, and which are available 
commercially from Corning and Invitrogen (Thermo Fisher). The enzymes produced by 
Cypex from bacterial cells are bound to the bacterial cells’ periplasmic membranes; 
prokaryotic bacterial cells do not contain ER membranes.  
The CYP microsomal enzymes that are routinely used for drug-drug interaction studies 
are CYP3A4, CYP3A5, CYP2D6, CYP1A2, CYP2C8, CYP2C9 CYP2C19, CYP2A6, 
CYP2B6 and CYP2E1. The intrinsic and extrinsic factors that affect the activities of these 
CYP enzymes are described in Figure 7.1. The enzymes CYP1A1, CYP1B1, CYP2J2 and 
CYP4F3 have been used less often for drug-drug interaction studies in the past. However, 






Figure 7.1 Pie-chart showing the CYP450 isoforms and factors influencing 
variation of their activities. Adapted from Pharmacology and Therapeutics, 





7.2 Prologue to the studies in Chapter 7 
 
7.2.1 Summary of findings until now 
 
In Chapter 3, it was seen that the human CYP genes, chemically synthesized using yeast 
biased codons, gave enhanced expression of CYP enzymes compared to the native CYP 
genes that had been isolated from a human liver cDNA library.  
In Chapter 4, the effects of integration of a single copy of the CYP gene, synthesized using 
yeast biased codons, at different chromosomal loci of yeast were clarified; it was seen 
that the HIS3 locus produces more CYP enzyme than from the URA3 or the ADE2 loci.  
In Chapter 5, it was shown that a second copy of a CYP gene further enhances the levels 
of CYP enzyme when compared with yeast strains that contain only a copy of the gene.  
In Chapter 6, whole yeast cells expressing specific CYP enzymes, at high levels, were 
used for specific biotransformation reactions. The widely available, naturally occurring 
flavonoid chrysin was converted in >90% yields by human CYP1A1 to bicalein, which 
is another natural flavonoid but available only in miniscule amounts in nature. The wild 
type human CYP2D6 (Met374) and the Val374 variant mediated only ~30% conversion of 
codeine to morphine whereas, surprisingly, the variant S34,V122,T486 was found to be a far 
superior metabolizer of codeine. Whole yeast cells expressing human CYP3A4 were used 
to find out if it was the CYP isozyme that was responsible for metabolite formation of 





7.2.2 Drug-drug interactions 
 
There are many drugs that are crucial for therapeutics and treatment of diseases, which 
either inhibit or induce the activity of CYP enzymes. A CYP that is induced by drug (A) 
may also participate in the metabolism of drug (B). In the presence of drug (A), the dosage 
of the drug (B) must be enhanced to achieve a therapeutic effect within a certain time 
frame. In parallel, if a drug (C) were to repress the activity of a CYP at the transcriptional 
level and if the CYP were to be involved in the metabolism of drug (D), the dosage of 
drug (D) would have to be reduced. If the dosages of drugs (B) and (D) were not to be 
altered, severe side effects would occur (Lu et al., 2008). Hence, knowledge of this type 
of drug-drug interaction is crucial for the process of gaining regulatory approval 
(Prueksaritanont et al., 2013).  
 
7.2.3 True inhibition of a CYP enzyme in the presence of 
other CYPs 
 
In order to find the true inhibition of a CYP enzyme by a particular compound in vivo, 
there is another major issue which is often encountered. It can happen when a compound 
(A) is a verified substrate of CYP(1) enzyme, which implies that it is responsible for the 
metabolism of drug (A) allowing its clearance from the body. However, compound (A) 
also potently inhibits, in vitro, another CYP isozyme CYP(2). In this scenario, it is 
unlikely that the metabolite of drug (A), mediated by CYP(1) enzyme, is an inhibitor of 
CYP(2) enzyme and, hence, drug (A) as such cannot be acting as a potent inhibitor of 
CYP(2) in vivo. It is impossible to see such a phenomenon using isolated microsomal 
enzymes. Such problems have been exemplified through studies with the drug 
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metoprolol, a CYP2D6 substrate (Flockhart et al., 2002), and another drug warfarin which 
interacts with multiple CYP enzymes, CYP1A2, CYP2D6, and CYP3A4 (Weinshilboum 
et al., 2003). That’s why the pharmaceutical industry relies more on human liver 
microsomes, which contain a conglomeration of CYPs, rather than on isolated 
microsomes from recombinant cells. 
In Chapter 5, two copies of CYP genes were introduced into the genome of baker’s yeast. 
The results had shown the creation of a potentially marketable asset. After having 
compared the activities of the yeast produced enzymes (Sacchrosomes) with the activities 
of the commercially available CYP enzymes (from insect and bacterial cells), which are 
already available in the market, it was clearly seen that Sacchrosomes are by far the best. 
On the basis of the studies described, we thought it would be possible to create novel 
systems that would allow the true evaluation of potential CYP inhibitors by constructing 
yeast strains that co-express 2 to 3 different human CYP enzymes, within the same cells 
from different chromosomal loci.  
 
7.3 Outline of Chapter 7 
 
In this Chapter (Chapter 7), based on the results obtained previously, integration of two 
or more different CYP genes in different chromosomal loci of baker’s yeast were 
attempted to find the true CYP inhibitory potential of a compound in the presence of other 
CYPs. This was attempted as experiments using isolated microsomal CYP enzymes can 
lead to misleading data, as explained below. The CYP genes that were selected for these 
cellular studies were CYP3A4, CYP2D6, CYP2C19 and CYP1A2. They are the main CYPs 
that are expressed in the liver.  
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The possibility of inhibition of CYP enzyme(s) by potential medicines is a very important 
aspect in drug development. The basic aim of this Chapter was to develop a yeast-based 
cellular system that would improve the status quo by facilitating CYP inhibition studies 
very early on in the development of new medicines. Because of their expense, HLMs are 
used at a much later stage in the pre-clinical/ clinical interface of drug development.  
 
7.4 CYP3A4, CYP2D6, CYP2C19 and CYP1A2 
enzymes 
 
The CYP3A4 protein accounts for 28-40% of total hepatic CYP450 content. It is 
clinically important because it catalyses the metabolism of ~40% of all medicines that 
have been approved until now. The CYP3A5 isozyme, structurally very close to 
CYP3A4, is responsible for the metabolism of another 15% of drugs (Cheng et al., 2009).  
CYP2D6 is expressed in many tissues including the liver, brain, breast, lungs kidney, and 
placenta. The expression of CYP2D6 is reported to be relatively low in the liver compared 
to the levels of CYP3A4. Although it constitutes 2-5% of total hepatic CYP proteins, it is 
involved in the metabolism of ~25% of therapeutically useful drugs such as codeine, 
bufuralol, debrisoquine, propafenone, morphine and others. One important feature of 
CYP2D6 is the presence of at least one basic nitrogen atom at a distance of 5-7 A° 
(angstrom) from the site that allows oxidation of substrates (Beijnen et al, 2013).  
CYP2C19 is a member of the CYP2C subfamily which accounts for over 20-25 % of the 
total CYP proteins in the human liver. CYP2C family members are involved in the 
metabolism of ~20% of the approved drugs in the market. CYP2C19 substrates are neutral 
or very weakly basic with two or three H-bond donors or acceptors at 4-5A° and 5-8A° 
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from the site of metabolism. It metabolises omeprazole, imipramine diazepam and other 
drugs (Beijnen, 2013).  
The CYP1A2 enzyme represents ~10% of the total CYP content in the human liver. It has 
only one H-bond donor site and therefore there are fewer drugs which are substrates of 
CYP1A2. It plays a part in the metabolism of ~4% of the drugs in the market. They 
include tacrine, caffeine, tamoxifene, propafenone and other related drugs. Besides being 
involved in the metabolism of important drugs, CYP1A2 also has a role in the metabolic 
activation of polyaromatic hydrocarbons (PAHs), aromatic and heterocyclic amines 
(Beijnen, 2014).  
 
7.5 Yeast strains constructed for use in Chapter 7 
 
In Chapter 4, plasmids containing a CYP gene were integrated at different chromosomal 
loci, ADE2, HIS3 and URA3, of a defined yeast strain YY7 or YAB79. The resultant yeast 
strains, containing one copy of a CYP gene, were used to compare CYP enzyme activities 
that these strains expressed with strains that harboured an episomal plasmid.  
In this Chapter (Chapter 7), the same CYP gene bearing integrative plasmids were used 
for further integrations that resulted in the incorporation of multiple CYP gene expression 
cassettes on different chromosomal locations. As stated in Chapter 4, the expression of 
all human CYP genes, including that of CYP1A2, CYP3A4, CYP2D6 and CYP2C19 are 
driven by ADH2 promoter. The yeast integrated plasmids that were used to create the new 
yeast strains in this Chapter are listed in Table 7.1.  
Table 7.1. The integrative plasmids that were used for the construction of 
single-copy CYP gene bearing yeast strains that would allow further 
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introduction of a second and third copy of different CYP genes into yeast 
strains. 
 
Locus Plasmids encoding 
CYP1A2_yc gene 
Plasmids encoding 
CYP2C19_yc gene  
Plasmids encoding 
CYP2D6_yc gene  
Plasmids encoding 
CYP3A4_yc gene  
ADE2    YIpAdeADH2S/CYP3A4  
HIS3 YIpHisADH2S/CYP1A2 YIpHisADH2S/CYP2C19  YIpHisADH2S/CYP2D6   
URA3  YIpUraADH2S/CYP2C19  YIpUraADH2S/CYP2D6  YIpUraADH2S/CYP3A4  
 
The yeast strains, that contained a single copy of a CYP gene and which were used as 
starting points for further integrations, were:  
(i) YAB79::1A2(HISS3),  
(ii) YAB79::2D6(HISS3),  
(iii) YAB79::2C19(HISS3), and  
(iv) YAB79::3A4(ADE2).  
The availability of five distinct auxotrophic markers in the strains YY7 and YAB79 was 
taken advantage of for the introduction of further copies of different CYP genes. In YY7 
cells, only one of the auxotrophic markers (LEU2) was occupied by the ∆hRDM gene 
which would easily allow four different CYP genes to be introduced into the yeast strain. 
In the YAB strain, two of the auxotrophic markers (LEU2 and TRP1) had been used up 
by the ∆hRDM and cytochrome b5 genes so that three different CYP genes could be 
introduced. Besides this, different antibiotic resistance genes, which cause resistance of 
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yeast cells to potent antibiotics that kill yeast cells, could be used for incorporating more 
CYP genes into the yeast chromosome.  
Yeast strains that were created after integration of a second and a third CYP gene, for this 
study, were: 
(d) YAB79::1A2(HIS3), 2C19(URA3)  
(e) YAB79::1A2(HIS3), 3A4(URA3) 
(f) YAB79::1A2(HIS3), 2D6(URA3) 
(g) YAB79::2D6(HIS3), 3A4(URA3) 
(h) YAB79::2C19(HIS3), 2D6(URA3),  
(i) YAB79::2C19(HIS3), 3A4(URA3), 
(j) YAB79::3A4(ADE2), 2C19(HIS3), 2D6(URA3), 
(k) YAB79::3A4(ADE2), 1A2(HIS3), 2D6(URA3) 
The yeast transformation technique used in these experiments was a high-efficiency yeast 
transformation protocol (Amberg et al., 2006). The yeast transformants, obtained from an 
integration of each new CYP gene bearing plasmid, were screened (i.e. selected) for the 
best CYP enzyme producers using fluorogenic substrates that act as substrates for the 
specific CYPs that were used. The best expressing yeast clones were streaked out on SD 
minimum medium agar plates, with the required selection markers. The plates were 
incubated for 3 days at 30°C to ensure that the plasmid had been retained, after 
integration, inside the yeast genome. Scoopful of cells, which grew on SD plates, was 
taken for inoculation in full medium YDP broth (i.e. liquid culture). YPD is a complex 
rich medium that is used for routine yeast growth. It contains 1% bacto-yeast extract, 2% 
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bacto-peptone, 2% glucose, as defined in Chapter 2. YPD medium cannot select for the 
presence of extra-chromosomal plasmids within cells.  
5 ml of YPD broth was transferred into wells of 6-well sterile plastic plates. Then, an 
inoculum (i.e. scoopful of cells) from freshly grown agar plates, containing different yeast 
strains, was added to the different wells of the 6-well plate containing 5 ml of YPD broth. 
2% adenine was added to supplement the small amount of adenine that is present in YPD 
but which is rapidly used up by the cells’ biomass. 
The 6-well plates were transferred to a shaking incubator, set at 30°C, for overnight 
growth of cells. After 12 h, glucose is used up by yeast cells and full induction of the 
ADH2 promoter occurs. This allows expression of the CYP enzyme. The optical density 
at 600 nm (i.e. OD600) was measured from each of the incubated cultures after 18 h of 
(overnight) growth. Cells usually attained an OD600/ml of around 25. The cells were 
transferred into 2 ml Eppendorf tubes and were harvested. The cell pellets were washed 
three times with 500 µl TE buffer (50 mM Tris-HCl, 1 mM EDTA, pH 7.4) by spinning 
down the cells at 13,000 rpm, each time for 1 min. Cells were finally re-suspended in 450 
µl of TE buffer to measure the kinetics of a CYP enzyme reaction with its substrate. 
 
7.6 Assay to determine the activities of CYP 
enzymes  
 
50 µl of cell suspensions were transferred into a sterile 96-well microtiter plate to which 
50 µl of a substrate mixture (depending on the substrate for a specific CYP) was added. 
The parameters for the fluorescence plate reader (Synergy HT BioTek) were set using the 
appropriate extinction/emission filters and appropriate gain sensitivity settings to obtain 
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the best kinetic output from the plate reader. The plate was incubated at 30°C for 30 sec 
before the fluorescence emissions were measured.  
 
7.7 IC50 determinations for inhibition of CYPs, using 
fluorogenic substrates 
 
The protocol for IC50 determinations of compounds inhibiting CYPs has been described 
in Chapter 2 (Materials and Methods). A fluorogenic substrate was used to determine the 
potency with which a test compound inhibits a recombinant human cytochrome P450 
(CYP) enzyme.  
Yeast cells, expressing a CYP enzyme, were incubated in triplicate with a known CYP 
inhibitor, for example, quinidine (a 2D6 inhibitor), furafylline (a 1A2 inhibitor), 
ketoconazole (a 3A4 inhibitor) and ticlopidine (a 2C19 inhibitor) for 30 min. After 
incubation, the kinetic activity of the CYP enzyme was measured in the presence of a 
fluorogenic substrate. All data represented shows n= 3 ± SEM.  
Individual CYP assays were performed using a 96-well microtiter plate. All assays 
included a negative control (i.e. no compound) and eight concentrations of test compound 
in 3-fold serial dilutions; 30 µM, 10 µM, 3 µM, 1 µM, 0.3 µM, 0.1 µM, 0.03 µM, 0.01 
µM. The fluorescent metabolites were measured and the kinetics of metabolic reactions 
is represented graphically in Figures that follow. The bar charts represent comparison of 
fluorescence values obtained at a certain fixed time point of the CYP-mediated reaction 
on its substrate.  
The results may allow us to answer the following questions:  
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(a) Are the enzyme activities of individual CYPs the same when two enzymes are 
expressed together as when they are individually expressed or is there a ‘crowding 
effect’ when two or three enzymes are co-expressed?  
(b) Can co-expression of two CYPs affect the ability of a compound to inhibit one or 
the other?  
(c) Can cells which co-express two CYPs be useful in screening a library of 
compounds for potential CYP inhibition?  
 
7.8 Activities of individual CYPs when co-expressed 
in yeast (a) 2C19 & 1A2, (b) 3A4 & 1A2, (c) 2D6 
& 1A2, (d) 2D6 & 2C19 compared with activities 
of 1A2, 2C19, 2D6, 3A4 which are expressed 
individually from a single integrated copy  
 
For these studies, two separate CYP genes were integrated at the HIS3 and URA3 
chromosomal loci of the yeast strain YAB79 which contains not only a modified gene of 
the human P450 reductase (∆hRDM) but also the gene for cytochrome b5.  
CYP1A2 was co-expressed with another CYP isozyme,  
(a) CYP3A4,  
(b) CYP2C19 and  
(c) CYP2D6,  
in the yeast strain YAB79.  
On the other hand, CYP2D6 was co-expressed with CYP2C19, once again in the strain 
YAB79. This was with the view of confirming that co-expression of cytochrome b5 does 
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not have a deleterious effect on the expression of CYP2D6 enzyme as has been reported 
previously (Henderson et al., 2015).  
The enzyme activities of CYP1A2, CYP3A4, CYP2C19 and CYP2D6 were measured, 
using fluorogenic substrates, when they were co-expressed with another enzyme from 
another chromosomal locus, and were compared with the activities of the same enzymes 
when they were expressed individually from the HIS3 chromosomal locus.  
 
 
Figure 7.2. The graphs show the activities of CYP1A2 andCYP2C19 enzymes 
when co-expressed with a second CYP enzyme, in the strain YAB79. CEC is a 
fluorogenic substrate that primarily measures CYP1A2 and CYP2C19 
activities. The activities are compared with the strains that express single 
copy CYP genes. The graphs represent the average of results obtained from 
three independent experiments. 
 
Figure 7.2 shows that the activities of CYP2D6 and CYP3A4 are not measureable, using 
the fluorogenic substrate CEC. However, the activities of CYP1A2 and CYP2C19 are 
quantifiable. It appears that the CYP2C19 activity is greatly enhanced when co-expressed 















(A) Enhancement of CYP1A2 & CYP2C19 enzyme activity when 











expressed with CYP3A4, CYP2C19 or CYP2D6. This would indicate that co-expressing 
a second CYP enzyme leads to augmentation of activities of CYP1A2 and CYP2C19. It 
would also seem that the second CYP is helping to stabilize the compact native state of 
CYP1A2 and CYP2C19 epitomising the expected effects of ‘molecular crowding’ 
(Benton et al, 2012; Despa, 2005; Kuznetsova et al, 2014).  
 
 
Figure 7.3. The bars mirror the results in Figure 7.2, at the 60 min time point. 
The activities of CYP1A2 and CYP2C19 are clearly much higher when co-
expressed with another CYP than when they are expressed alone. The data 
represent mean ± S.D. of three independent experiments.  
 
Figure 7.3 corroborates the finding presented in Figure 7.2. The CYP1A2 activity 
increases more than 2-fold on co-expression of a second CYP whereas the CYP2C19 


















(B) Enhancement of CYP1A2 & CYP2C19 enzyme activity when 












Figure 7.4. EOMCC is a fluorogenic substrate that can measure the activities of 
CYP1A2, CYP2C19 and CYP2D6. (A) The graphs show the combined activities 
of these enzymes when co-expressed with each other, in the strain YAB79. The 
activities are compared with the strains that express single copy CYP genes. 
The graphs represent the average of results obtained from three independent 
experiments. (B) The bars mirror the results in (A), at the 60 min time point. 
The activities of the CYP enzymes are clearly much higher when co-expressed 
with another CYP than when they are expressed alone. The data represent 














(A) Enhancement of CYP2D6, CYP1A2, CYP2C19 enzyme 





















(B) Enhancement of CYP2D6, CYP1A2, CYP2C19 enzyme 









Figure 7.4 shows that the co-expressed enzymes have improved activity when compared 
with the strains that express the single CYP enzymes. These results would again suggest 
that co-expression of two different CYP enzymes within the same cell stabilizes the 
activity of each of the enzymes because of the ‘crowding effect’ (Benton et al, 2012; 
Despa, 2005; Kuznetsova et al, 2014). For example, the CYP2D6 activity manifested in 
cells which co-express another CYP (i.e. CYP1A2 and CYP2C19) was seen to be 50 and 
30-fold higher than the cells which express CYP2D6 alone.  
These results have another separate significance. It has been reported that CYP2D6 
protein is degraded in the presence of cytochrome b5, that is, when co-expressed with 
cytochrome b5 (Hakki et al., 2008; Zehentgruber at al., 2010). From our results, it would 
seem that this is definitely not the case, at least when CYP2D6 is co-expressed with 
another CYP enzyme.  
The system described in this Section can be used for the simultaneous catalysis of two 
CYP-mediated reactions. The yeast cell has a robust mechanism of distributing electrons 
from the haem proteins and the endoplasmic reticulum to allow more than one mono-
oxygenation reactions to take place efficiently (De Montellano, 2005; Mike et al., 2005; 






7.9 Comparison of CYP1A2, CYP3A4, CYP2C19 and 
CYP2D6 activities when (a) three of them are 
co-expressed with (b) the individual enzymes 
expressed singly  
 
Three different CYP enzymes, from the pool of CYP1A2, CYP3A4, CYP2C19 and 
CYP2D6, were co-expressed in yeast to see if the crowding effect could still be seen. The 
results are shown in Figure 7.5.  
Results show once again that activities of a CYP enzyme increases when it is expressed 
together with another CYP enzyme or other CYP enzymes, as was seen before in Section 
7.8. The crowding effect, seen in Section 7.8, stabilizes a CYP protein structure, in the 
presence of another CYP thereby enhancing both CYP enzymes’ activity.  
Perhaps the crowding effect would be more when three CYP proteins are present, than 
two CYPs, within the same cohort of cells. The crowding effect did not seem to be further 
boosted when three CYP enzymes, 2D6, 2C19 and 3A4, were co-expressed in the strain 
YAB79:: 2D6(HIS3),2C19(URA3),3A4(ADE2) [referred to in Figure 7.5 (A) as 
2D6(HIS3),2C19(URA3),3A4(ADE2)] and their expression was monitored using CEC 
as a fluorogenic substrate. The results were compared with the fluorescence emitted by 
the strain YAB79:: 2D6(HIS3),2C19(URA3) [referred to in Figure 7.5 (A) as 
2D6(HIS3),2C19(URA3)]. Using EOMCC as a fluorogenic substrate, it was clearly seen 
that co-expression of a third enzyme does not show an increase in expression levels. 
Stagnancy in the expression levels was seen when CYP3A4 was expressed in a strain 
which already had the capacity to co-express two enzymes CYP2D6 and CYP2C19. The 
reactions with both CEC and EOMCC, as substrates, may indicate that saturation may 




Figure 7.5. The bar plots show the combined activities of CYP1A2, CYP3A4, and 
CYP2D6 or CYP2C19 enzymes when two or three CYP enzymes are co-
expressed. The fluorogenic molecules CEC (A) and EOMCC (B), which were 
used, can act as substrates for all 4 CYP enzymes. The enzyme activities, from 
strains which co-express 2 or 3 CYPs were compared with strains that express 
only one of the CYP enzymes. The data represent mean ± S.D. of three 














(A) Crowding  effect observed during co-
expression of three CYP enzymes in yeast cells, 
























(B) Possible saturation of crowding  effect observed 
during co-expression of three CYP enzymes in yeast 













The results with CEC and EOMCC as substrates suggest that saturation may have set in 
when the genome of yeast was overcrowded with CYP genes. In Figure 7.5 (B), the 
combined activity of the three CYP enzymes in clones 1 & 2 of the yeast strain 
[YAB79::2D6(HIS3),1A2(URA3),3A4(ADE2)] referred to in Figure 7.5 (B) as 
2D6(HIS3),1A2(URA3),3A4(ADE2)] that co-expresses CYP2D6, CYP1A2 and 
CYP3A4 (the bars with red and purple colour, respectively) is more or less the same as 
the activity in the strain YAB79::2D6(HIS3),1A2(URA3) [referred to in the Figure 7.5 
(B) as 2D6(HIS3),1A2(URA3)]. This would indicate that the strain that has three CYP 
genes can no longer produce any more amount of CYPs (a reflection of CYP activity) 
than the strain which has two different CYP genes.  
Similarly, in the two clones of the yeast strain 
[YAB79::2D6(HIS3),2C19(URA3),3A4(ADE2), referred to in Figure 7.5 (B) as 
2D6(HIS3),2C19(URA3),3A4(ADE2)] that co-expresses the three CYP enzymes, 2D6, 
2C19 and 3A4, when compared with the strain YAB79::2D6(HIS3),2C19(URA3) 
[referred to in Figure 7.5 (B) as 2D6(HIS3),2C19(URA3)] that co-expresses only two 
CYP enzymes, 2D6 and 2C19, it is seen once again that the crowding effect does not 
permit the combined enzyme activity to move beyond the activity seen in 
YAB79::2D6(HIS3),2C19(URA3). Possible explanations of these results are that: 
1. The binding of substrate may alter the optical absorption spectra of a CYP, thereby 
making it difficult for the turnover of the substrate probably because of the 
distances between chromosomal loci, where CYP genes are integrated, that could 
impair turnover (Narasimhulu et al., 1996).  
564 
 
2. The supply of electrons at two different steps in the process of CYP activation 
may not be functioning in tandem and thus may be having a dissociative effect on 
the activation of CYPs (Estabrook et al., 1971).  
The latter point above involves the first electron being supplied to a substrate-bound 
oxidized CYP450 so that it can reduce the haem iron at the CYP450 active site. The 
second electron interacts with the oxygenated P450 to activate the haem-bound oxygen 
molecule by splitting the O-O bond. This results in the formation of superoxide anion as 
a by-product of the oxygenation reaction. Superoxide accumulation is toxic to the cells 
and thereby an inhibitory reaction is triggered. Immediately when the yeast cells sense 
the toxic environment, they stop production of proteins by trying to preserve themselves. 
The conclusions from these observations may also have implications on the inhibitory 
effects of a compound on a CYP enzyme when two or more CYP enzymes are co-
expressed within yeast cells.  
 
7.10 Inhibition of a CYP enzyme in the presence of 
one or two other CYPs which are being co-
expressed within yeast cells  
 
The multiple CYP expressing yeast system described above was then tested using known 
CYP inhibitory compounds to see if it would provide meaningful results in the screening 
of chemical libraries for CYP inhibition. For studies on the impact of co-expression of 
multiple CYP genes within whole yeast cells, FDA-approved CYP-specific inhibitory 
compounds were used for screening.  
Inhibition of a CYP enzyme mostly involves a reversible reaction. To be able to ascertain 
the reliability of fluorescent assays in live CYP expressing yeast cells for screening of 
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CYP inhibitors, several known (FDA-approved) potent inhibitors of CYP2D6, CYP3A4, 
CYP1A2, and CYP2C19 were used. It has been published that the sensitivity of a CYP 
enzyme to an inhibitor is dependent on the fluorogenic substrate (Stresser et al., 2000; 
Wang et al., 2000). In this present study, the following inhibitors were chosen: 
(i) Quinidine for CYP2D6,  
(ii) Ketoconazole for CYP3A4,  
(iii) Furafylline for CYP1A2, and  
(iv) Ticlopidine for CYP2C19.  
Failure of various CYP inhibitors in drug development is due to the lack of drug-like 
features and cellular efficacy (Ibidapo Williams et al., 2017). The advantages of 
expressing CYP enzymes in yeast for drug metabolism studies have been emphasised 
many years ago by Renaud et al (1993). It is because yeast cells allow correct folding of 
CYP proteins on the endoplasmic reticular (ER) membranes. Yeast is a simple eukaryote 
which mimics human cells in many ways. For example, more than 80% of yeast proteins 
are homologous in their primary sequences to human proteins (Pearson et al., 2013). Thus, 
CYP-expressing yeast cells could be considered as a convenient and also appropriate tool, 
which could possibly replace human cells, for early stage drug metabolism studies. 
The results for inhibition of the four CYP enzymes, CYP2D6, CYP3A4, CYP1A2 and 
CYP2C19 expressed within yeast alone, or co-expressed together with one or two other 
CYPs, after pre-incubation of cells, for 45 min, with compound, are shown in Figures 7.6 




(C)  CYP2D6 +CYP(2C19+ 3A4), 
4 µM EOMCC 
(B)   CYP2D6 + CYP2C19,
4 µM EOMCC
(A)   CYP2D6, 4 µM EOMCC 
IC50 = 0.0097 µM
IC50 = 0.007 µM
IC50 = 0.69 µM
 
Figure 7.6. Shows the IC50 values of quinidine for inhibition of CYP2D6, in 
different yeast strains. Inhibition of CYP2D6 in strain that (A) expresses 
CYP2D6 alone, IC50, 0.69 µM; (B) co-expresses CYP2D6 with CYP2C19, IC50, 
0.0097 µM; (C) co-expresses CYP2D6 with CYP2C19  and CYP3A4, IC50, 0.007 
µM. The data represent mean ± S.D. of three independent experiments. 
 
The results in Figure 7.6 would indicate that the expression of a second CYP enzyme, 
CYP2C19, has a great effect on the IC50 value of quinidine. The IC50 value of quinidine 
drops from 690 nM (when CYP2D6 is expressed alone) to ~10 nM (when CYP2D6 is co-
expressed with CYP2C19). However, when the third enzyme, CYP3A4, is introduced 
within yeast cells that already have CYP2D6 and CYP2C19, there is practically no further 
decrease in the IC50 value of quinidine which is 7 nM. It is to be noted that the reported 
IC50 value of quinidine after a ‘brief’ incubation with human hepatocytes, which 
simultaneously co-express multiple CYP enzymes (albeit at very different levels), is 30 
nM ((Peter H. Bui et al. 2008) . Hepatocytes are the predominant cells of the liver and 
constitute 70-85% of the liver’s mass. The difference in the IC50 values seen between 
hepatocytes and cells expressing CYP2D6 with CYP2C19 (30 nM versus 10 nM) could 
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be explained by the different time periods that were used for pre-incubation of inhibitory 
compound with CYP2D6 enzyme (45 min versus ‘brief’ which could be anywhere 
between 0-10 min). It is known that the time period of pre-incubation affects IC50’s of 
compounds (Sekiguchi et al., 2009).  
This would indicate that expression of a second CYP together with CYP2D6 does have 
an effect on the inhibitory potential of quinidine. Introduction of a third CYP has no 
further effect on quinidine’s inhibitory capacity. This could be explained by the fact that 
perhaps expression of a second enzyme together with CYP2D6 already allows the latter 
to manifest its true 3D geometry whereas addition of another enzyme has no further effect.  
The results provide the first indication that the yeast system could be a probable substitute 
for hepatocytes which are obtained from pools of 200 or more human livers of diverse 
genetic background. Hepatocytes are also known to lose all CYP activity within 24 h and, 
therefore, impossible to use for the identification of metabolites of compounds which 
undergo slow metabolism. Human CYPs being expressed by yeast cells should be able to 
provide a stable environment, over a week or longer, for the metabolism of compounds 






(C)   CYP1A2 + CYP(2C19+ 3A4),
4µM CEC 
(B)   CYP1A2 + CYP2C19,
4µM CEC 
(A)   CYP1A2 , 4µM CEC 
 
 
Figure 7.7. Shows the IC50 values of furafylline for inhibition of CYP1A2, in 
different yeast strains. Inhibition of CYP1A2 in strain that (A) expresses 
CYP1A2 alone, IC50, 3.63 µM; (B) co-expresses CYP1A2 with CYP2C19, IC50, 
0.60 µM; (C) co-expresses CYP1A2 with CYP2C19 and CYP3A4, IC50, 0.0227 
µM.  The data represent mean ± S.D. of three independent experiments.  
 
The results in Figure 7.7 show that the co-expression of a second and a third enzyme 
together with CYP1A2 decreases the IC50 value of furafylline for inhibition of CYP1A2 
from 3.63 µM to 0.60 µM (in the presence of the 2nd CYP2C19 enzyme) to 0.023 µM (in 
the presence of the 2nd and 3rd enzymes, CYP2C19 and CYP3A4). The percentage 
inhibition of 1 µM furafylline in hepatocytes, after pre-incubation for 30 min, is reported 
be 71% 
(https://tools.thermofisher.com/content/sfs/brochures/ISSX2010InhibitioninHepatocytes
.pdf). Pre-incubation of HLMs for 30 min showed an IC50 value of 0.586 µM but it is 
reported that this value could vary depending on the NADPH concentrations in the in 
vitro assay system; it seems more the NADPH concentration, lesser the IC50 value 
(http://www.cyprotex.com/admepk/in-vitro-metabolism/cytochrome-p450-tdi-ic50-
shift). In the cellular system that we have used, the ‘crowding effect’ (i.e. stabilization of 
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one protein in the presence of the other) may also play a role in the IC50 decreasing from 
3.63 µM to 0.60 µM which is the value obtained in human liver microsomes (HLMs). 
One could also speculate that expression of CYP3A4 which is likely to be produced at 
high levels within yeast cells, in concert with CYP1A2 and CYP2C19, may be 
metabolizing (i.e. hydroxylating) furafylline into a more potent inhibitor of CYP1A2.  
 
(A)   CYP3A4 with 4 µM DBF  (B)   CYP3A4 +CYP2D6
4µM DBF  
IC50 = 0.24 µM
IC50 = 0.13 µM
 
Figure 7.8. Shows the IC50 values of ketoconazole for inhibition of CYP3A4, in 
two different yeast strains. Inhibition of CYP3A4 in strain that (A) expresses 
CYP3A4 alone, IC50, 0.24 µM; (B) co-expresses CYP3A4 with CYP2D6, IC50, 0.13 
µM. The data represent mean ± S.D. of three independent experiments. 
 
The results in Figure 7.8 show that co-expression of CYP2CD6 appreciably decreases the 
IC50 value of ketoconazole from 0.24 µM to 0.13 µM. The reported IC50 value of 
ketoconazole in hepatocytes is 0.14 ± 0.028 (Timothy et al., 2013) which is very close to 
the value obtained in yeast cells that express CYP3A4 together with CYP2D6. This would 




(A)   CYP2C19,  4µM CEC  (B) CYP2C19 + CYP1A2 , 
4 µM CEC 
(C)   CYP2C19 + CYP(1A2+ 3A4), 
4 µM CEC 
 
Figure 7.9. Shows the IC50 values of ticlopidine for inhibition of CYP2C19, in 
different yeast strains. Inhibition of CYP2C19 in strain that (A) expresses 
CYP2C19 alone, IC50, 0.45 µM; (B) co-expresses CYP2C19 with CYP1A2, IC50, 
0.44 µM; (C) co-expresses CYP2C19 with CYP1A2 and CYP3A4, IC50, 0.38 µM.  
The data represent mean ± S.D. of three independent experiments. 
 
The results in Figure 7.9 show that the IC50 value of ticlopidine does not alter too much 
when two other CYP enzymes, CYP1A2 and CYP3A4 are co-expressed with CYP2C19. 
This would indicate that CYP co-expression has no effect on CYP2C19 stability. The 
IC50 value of ticlopidine in hepatocytes has been reported to be 0.59 ± 0.2 µM (Stresser 
et al., 2009). These results suggest once more that human CYP-expressing yeast cells may 
act as substitute for human hepatocytes.  
All the experiments related to IC50 determinations of known CYP enzyme inhibitors for 
a particular CYP enzyme show that the expression of a second and a third human CYP in 
yeast reveals a new system that could be used in an analogous manner to human 
hepatocytes. It would be expected that the CYP expressing recombinant yeast cells would 




(1) Recombinant CYP-expressing yeast cells would produce reproducible results 
which is very difficult or rather impossible with hepatocytes which are obtained 
from diverse human beings with very different health status and genetic 
backgrounds, and  
(2) Recombinant CYP-expressing yeast cells could be used to identify the metabolites 
of compounds, in development, which are difficult or impossible to metabolise 
with human hepatocytes.  
Pan et al (2011) examined the heterologous expression of human CYP2D6 and CYP3A4 
in E. coli cells. They observed that co-expression increased the level of activities of 
individual CYPs, after they were isolated as bacterial microsomes, compared to the values 
in the literature for CYPs that were expressed alone. This study has produced similar 
results at the cellular level. This was seen when activities of CYP enzymes increased 
dramatically after co-expression of a second CYP. Introduction of a third CYP shows 
only slight increase in overall activity. These observations were made across all CYP 
enzymes that have been expressed until now.  
Besides studying potential inhibitory capacity of test compounds, similar cell systems to 
that which have been described above could also be used to study the possible metabolism 
of compounds in development. Instead of using individual CYPs which are currently 
used, whole yeast cells expressing multiple CYPs could routinely be employed to study 
drug metabolism. This would be analogous to the study that has been reported about 
tamoxifen (Kwon et al. 2014). It seems that tamoxifen can drastically be detoxified when 
exposed to a combination of two or three recombinant enzymes simultaneously, for 




7.11 Conclusions  
 
CYP inhibition assays were successfully set up and performed for CYP1A2, CYP2D6, 
CYP3A4, and CYP2C19 enzymes. The mean IC50 values found for the known inhibitors, 
furafylline, ketoconazole, ticlopidine, and quinidine, in CYP-expressing yeast cells were 
consistent with that reported previously in the literature with human hepatocytes (Crespi 
et al., 1997). Such results with baker’s yeast have never been reported before and are, 
therefore, significant. Moreover, the successful co-expression of more than one human 
CYP enzyme has also not been reported previously. This shows the importance of the use 
of yeast biased codons in the expression of human CYP450 enzymes to obtain stable, 
high-yielding expression of proteins that can be used industrially for larger scale use. 
In summary, the present study describes the use of intact whole yeast cells to study the 
effect of co-production of two or three human CYP enzymes. The expression and 
inhibition of these co-produced enzymes were studied. The results show yeast has the 
ability to express multiple human CYPs of choice. Results from inhibition of CYP 
enzymes expressed within yeast, using FDA-approved CYP-specific inhibitory 
compounds, show that the yeast system can be used in a similar manner to human 
hepatocytes. It may follow from these results that real life drug metabolism studies can 
indeed be performed with human CYP-expressing yeast cells, very early in the drug 
discovery process. Right now, human hepatocytes are used much later in the pre-
clinical/clinical interface. Use of the cheap and reliable yeast system early on could be a 





Chapter 8 Discussion  
 
The aim of my investigation was to devise new systems for expression of cytochrome 
P450 (CYP) enzymes in baker’s yeast, so that they are produced, as ‘intracellular 
membrane bound’ proteins, in high yields and activity. It is essential that CYPs bind to 
intracellular membranes to manifest activity. The goals were to find out the effects on 
‘activity’ and ‘yields’ of CYP enzymes with the use of (1) human CYP genes (~1500 bp 
in length) which were ‘chemically synthesised’ using ‘yeast-biased codons’, and (2) a 
non-toxic variant of the human P450 reductase gene (∆hRDM; ~2000 bp in length; Patent 
WO2007129050A3),. This was to test the concept that ‘codon usage’ is an important 
factor in expression of inherently toxic proteins.  
 
8.1 Cloning and constructing of yeast plasmids for 
expression of 17 human CYP genes (most of 
which are used for Drug Metabolism studies), 
synthesized using yeast-biased codons  
 
In Chapter 3, results show the importance of using yeast biased codons in the expression 
of CYP enzymes. In this Chapter, the advantages of using bakers’ yeast as a heterologous 
expression system were exploited. Yeast has the capability of sheltering CYP enzymes 
and providing them with a strong anchorage to its intracellular (endoplasmic reticular) 
membranes. Attempts have been in the past made to use CYP-expressing yeast cells to 
study drug metabolism in vitro but not at all effectively (Oeda et al., 1985).  
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The composition of phospholipids, sphingolipids, and other sterols in the membranes 
provide a valuable influence on the activities of the protein associated or embedded in the 
lipid bilayer (Rest et al., 1995; Ali et al., 2006). Hence, binding to the yeast endoplasmic 
reticular membranes must have an influence on CYP enzyme activities. All activities of 
CYP enzymes, expressed from synthetic CYP genes (i.e. synthesized using yeast biased 
codons) have shown high activity when expressed in yeast form episomal plasmids. The 
results were compared head-to-head with the enzymes expressed from ‘native’ CYP genes 
obtained from a human liver cDNA library. It was seen that the amount of proteins 
produced by the synthetic genes were far more than that produced by native genes. For 
particular CYPs, the presence of cytochrome b5 enhanced the levels of CYP proteins that 
were produced.  
Customarily, CYP1A2 is expressed in the absence of cytochrome b5. It has been reported 
that cytochrome b5 has no effect on CYP1A2 activity or expression level when it was co-
expressed (Zhang et al., 2015; Duarte et al., 2005). However, during this study, when 
cytochrome b5 was co-expressed with CYP1A2 (i.e. from strain YAB97::CYP1A2), a 
higher activity was observed when compared with the strain YY7::CYP1A2, that 
expressed CYP1A2 in the absence of cytochrome b5 (Figure 4.37; Chapter 4). This 
provides room for further studies on CYP1A2 expression to see if with the use of further 
chromosomal integrations if one could construct a strain that would express even higher 
levels of CYP1A2. This would also provide an insight into the stability of CYP enzymes, 
in general, after their overexpression (see Chapters 4 & 5). 
In addition, a similar study was carried out with the two CYPD2D6 variants, 
CYP2D6(Met374) and CYP2D6(Val374) where the variant enzymes were expressed in the 
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absence or presence of cytochrome b5. Results show that cytochrome b5 has a deleterious 
effect on both CYP2D6 variants (Figures 4.45 and 4.52; Chapter 4).  
It has been reported that the residues at position 374 of CYP2D6’s primary sequence, Val 
and Met, play at an important part in the active site of the enzyme. It has been proposed 
that the residues at this position hep in binding substrates and inhibitors of CYP2D6. It 
was suggested that a mutation at the DNA level that can cause a change from in amino 
acid from Met to Val can form a hydrophobic cleft in the loop between the K helix and β 
l-4 (Ellis et al, 2000), thus altering the rate of enzyme-substrate reaction and also affecting 
CYP2D6’s stereo-selectivity in the metabolism of the drug, metoprolol. In the same 
report, however, it was stated that the kinetics of metabolism of other drugs are totally 
unaffected by this change. The report also reiterated that Val374 is the actual residue in the 
wild-type protein which is in contrast to another report that claims that Met is the residue 
at position 374 of the wild-type protein (Rowland et al., 2006).  
Besides expressing the above two variants, Met374 and Val374, three CYP2D6 SNPs 
(mutants, *2, *10 and *39), were also ‘synthesised using yeast biased codons. Western 
blotting, after expression of the SNP bearing gene constructs in yeast, shows that codon 
bias helps in providing much more CYP2D6 protein for the variants that bear the SNPs 
when compared with the enzyme expressed from the native CYP2D6 gene, isolated form 
a human liver cDNA library (Figure 3.45; Chapter 3). 
Yu et al (2003) have reported the contribution of CYP2D6 polymorphism and has 
described the pharmacokinetic variability of CYP2D6 SNPs in humans. This report 
suggests that CYP2D6(Met374) (i.e. 2D6-2) possesses similar affinity towards the 
fluorogenic substrate as the three enzymes expressed from genes that bear the SNPs. used 
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than any other reported CYP2D6. Chromosomal integration of gene coding for the 
CYP2D6(Met374) (i.e. 2D6-2) and CYP2D6(Val374) (i.e. 2D6-1) variants has led us to 
further quantify expression levels and CYP2D6 enzyme activities (Chapter 5). 
The enzyme aromatase (CYP19A1) is responsible for the conversion of testosterone to 
estradiol in many tissues. Aberrant expression of CYP19A1 is one of the primary causes 
of breast cancer in postmenopausal women (Nadine et al., 2016; Boon et al., 2010). 
CYP19A1 enzyme is also misregulated in prostate and colorectal cancer (Travis et al., 
2009; Slattery et al., 2011. The expression level of CYP19A1 and its enzyme kinetic 
activity was investigated during this study. CYP19A1 shows good level of expression in 
yeast which was independent of the presence/absence of cytochrome b5 (Figure 3.84; 
Chapter 3). Previously published reports did indicate that presence of cytochrome b5 was 
essential for CYP19A1 expression (Akhtar et al., 2015).  
Although CYP2C8, CYP2C9 and CYP2C19 play important role in drugs metabolism, 
factors that mediate and control the activity of the CYP2C subfamily of enzymes are 
largely not well defined. This study has utilised the importance of yeast biased codons to 
clone these CYP genes in baker’s yeast. It was observed that expression levels of 
CYP2C8, CYP2C9 and CYP2C19 were >10, 0.5 and 5.5 fold higher, respectively, than 
that observed in the strains that express the ‘native’ genes cloned from a human liver 
cDNA library (Figures 3.59, 3.14, 3.19; Chapter 3). Microsomal CYP2C9 and CYP2C19 
enzymes were isolated from yeast cells. Results showed that microsomal enzymes, 
isolated from cells which contained integrated copies of CYP genes, could be prepared in 
very high yields and activities compared to what would be possible using strains that 
contained CYP gene-bearing episomal plasmids (Figures 5.20/5.21/5.29 and 
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5.19/5.20/5.30; Chapter 5). Past studies have used cultured human hepatocytes in the 
study of expression of CYP2C enzymes (CYP2C8, CYP2C9, CYP2C18 and CYP2C19). 
The results have shown that deletion of cytochrome b5 is responsible for the reduction in 
the metabolism of drugs. The presence of cytochrome b5 is required for increased 
expression of these CYP enzymes (Henderson et al., 2014). In this study, cytochrome b5 
has been co-expressed with CYP2C8, CYP2C9 and CYP2C19 enzymes. We also see that, 
in the presence of cytochrome b5, expression levels increase dramatically, particularly in 
the case of CYP2C9 and CYP2C19. Contrary to this observation, cytochrome b5 did not 
have any influence on the levels of CYP2C18 enzyme  expressed from the gene 
synthesized with yeast biased codons.  
The human CYP2B6 enzyme participates in the catalysis of several clinically important 
drugs and xenobiotics (Mo et al, 2009). It has been reported that polymorphism affects 
the expression levels of CYP2B6 (Lang e al., 2001). Zhanger et al, (2007) confirmed that 
there are 29 polymorphic alleles of CYP2B6. In this study, the human CYP2B6 gene has 
been synthesized with yeast biased codons and expressed in baker’s yeast. The results 
show that levels of expression in the presence of cytochrome b5 was high (Figure 3.24; 
Chapter 3), although this is in contrast to what has been reported before (Xie et al., 2003). 
This enzyme is involved in the clearance of the drug efavirenz (Hass et al., 2004; Tsuchiya 
et al., 2004; Zanger et al., 2007).  
The CYP isozyme CYP2E1 is involved in the metabolism of alcohol, aldehydes and 
various carcinogens. Upregulation of CYP2E1 has been linked to diseases like diabetes, 
obesity, cancer, liver cirrhosis and non-alcoholic hepatic steatosis (Sumner et al., 1999).. 
The most interesting role of the enzyme is its ability to oxidize ethanol into reactive 
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products, acetaldehyde and 1-hydroxylethyl radical which is a reactive oxygen species 
(ROS). Production of ROS leads to oxidative stress. Large fractions of CYP2E1 are 
located in the endoplasmic reticulum (Bansal et al., 2010). In this study, I have assessed 
the expression in baker’s yeast of human CYP2E1 enzyme using its gene (CYP2E1_yc) 
synthesized with yeast biased codons. The expression of CYP2E1 was higher when 
compared with that obtained from ‘native’ CYP2E1 gene isolated from a human liver 
cDNA library (Figure 3.49; Chapter 3). The initial results obtained were further optimised 
by integrating the CYP2E1_yc gene expression cassette on to the yeast genome at the 
HIS3 chromosomal locus (Figure 4.87, Chapter 4; Figure 5.33, Chapter 5). 
It has been reported that cytochrome b5 has no effect on the activity of the human 
CYP2A6 enzyme. The turnover of the enzyme in the presence or absence of cytochrome 
b5 did not show any difference (Duarte et al., 2005). In this report, the CYP2A6_yc gene, 
synthesised using yeast biased codons, has been used for expression in yeast in the 
presence of cytochrome b5. The expression level was much higher when compared with 
the one obtained from native gene (Figure 3.54; Chapter 3). A Western blot confirmed 
the initial observations (Figure 3.55; Chapter 5). The results again showed that expression 
of a gene with yeast biased codons influences expression levels of a CYP enzyme.  
It has been reported that inhibitors of CYP1 (CYP1A1 and CYP1B1) enzymes may play 
a vital role in the prevention of cancer (Androutsopouos et al, 2009) and overcoming 
chemo-resistance to anticancer drugs (Williams et al., 2017) in human cells that 
overexpress CYP1A1 or CYP1B1. Also in Chapter 6 of this study, CYP1A1 mediated 
more than 90% conversion of chrysin to baicalein. Whole yeast cells stably expressing 
CYP1A1 was used for this conversion (Williams et al., 2017). The use of yeast biased 
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codons has provided an avenue to optimise the expression of CYP1A1 and CYP1B1 to 
produce high yields of these enzymes. When protein expression was compared with 
strains expressing native genes, isolated from a human liver cDNA library, results showed 
that there was a lot higher expression in strains containing genes synthesised with yeast 
biased codons (Figures 3.64, 3.69; Chapter 3). 
CYP2J2 is also known as unsaturated fatty acid epoxygenase. It has attracted much 
attention to its metabolism of arachidonic acid (AA) (Wu et al, 1996) to four different 
epoxyeicosatrienoic acid metabolites (EETs) (Xu et al, 2013; Morrison et al., 1981). N-
terminal truncation of CYP2J2 was reported to be the only way to express this enzyme 
(Park et al, 2014). But in this study, the synthetic CYP2J2 gene with yeast biased codons 
when expressed in baker’s yeast has shown good expression (Figure 3.89; Chapter 3). 
Results from a Western blot show that the amount of CYP2J2 protein obtained is more in 
the presence of cytochrome b5 result than in its absence Figure 3.90; Chapter 3).  
CYP4F3A and CYP4F3B are generated via the selection of different transcription start 
sites (Christmas et al. 1999)  resulting from an alternative splicing of exons. CYP4F3A 
mediates the production of human eosinophil (Kikuta et al., 2007). In the presence of 
cytochrome b5, there is a good level of expression of the CYP4F3A enzyme (Figure 3.74; 
Chapter 3). Microsomal enzyme has been isolated from yeast. Our results show that the 
activity of the yeast-produced enzyme is considerably better than the only commercially 
available enzyme from Corning-Gentest (Figure 5.34; Chapter 5).  
The CYP17A1 enzyme was expressed from a CYP17A1_yc gene, synthesised with yeast 
biased codons, in the presence and absence of cytochrome b5. Level of expression in the 
presence of cytochrome b5 was much higher than in its absence (Figure 3.79; Chapter 3). 
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Western blot analysis confirmed that the expression level was higher in the presence of 
cytochrome b5 in all the CYPs (Figure 3.80; Chapter 3). The membrane haem protein 
cytochrome b5 can enhance or inhibit the catalysis of CYP450 proteins but this depends 
on the specific CYP450, the substrate, and reaction conditions. But the structural basis 
for enhancement or inhibition is still unclear (Estrada et al., 2013, 2105). CYP17A1 is a 
critical enzyme in steroidogenesis, and acts between the points of glucocorticoid synthesis 
and androgen synthesis (Duggal et al., 2016). Cytochrome b5 is known to be the chief 
regulator of CYP17A1 reactivity in vivo (Auchus et al., 1998). Like the observations we 
have during this study, cytochrome b5 is known to enhance the CYP17A1 mediated lyase 
reactions 5 to 10 fold (Gurvey et al., 2001). Although the specific role of cytochrome b5 
is not yet clear, but in a study recently published it was deduced that cytochrome b5 is 
likely to play the role of a second electron donor (Duggal et al., 2016). The results 
obtained in this study confirm that expression of CYP17A1 requires co-expression of 
cytochrome b5 for production of high levels of protein. 
Overall, all expressions with CYP genes, synthesised with yeast biased codons have 
shown a great improvement in the levels of CYP proteins over those produced from the 
native genes isolated from a human liver cDNA library. The use of yeast biased codons 
has produced a platform for the experiments performed in the following Chapters.  
In Chapter 4, the synthetic CYP_yc genes, synthesized with yeast biased codons, have 
been used for integration into the yeast genome with the aim of constructing stable yeast 




8.2 Construction of yeast strains that would stably 
produce cytochrome P450 (CYP) enzymes from 
genomic copies of the CYP genes 
 
We have already seen the role yeast biased codons play to enhance the activity of the 
seventeen CYP enzymes that have been described in this study (Chapter 3). All 
experiments in Chapter 3 were performed with yeast strains containing episomal 
plasmids. Maintaining these plasmids (i.e. extra-chromosomal entities) within yeast cells 
requires a selective medium which is, firstly, not nutritious enough to provide healthy 
growth and, secondly, cannot maintain the plasmid over many generations. Minimal 
media growth is seldom prolonged beyond 48 h which equates to 32 generations of 
growth (yeast cell division occurs every 90 min).  
In this context, it was thought that if the CYP_yc gene expression cassettes (containing 
the CYP_yc gene sandwiched between the ADH2 promoter and the SUC2 terminator) 
were to be integrated into the yeast genome, the problems related to loss of genetic 
information from the cells would not exist. Hence, all CYP_yc expression cassettes were 
integrated into specific chromosomal loci afforded by the auxotrophic markers of the 
yeast strain (i.e. BC300) that had been chosen for expression of the CYP enzymes. The 
loci available for integration (after having integrated a mutant human CPR and, in some 
cases, cytochrome b5) were at the locations where the ADE2, HIS3 and URA3 genes lay 
on particular chromosomes of the yeast genome.  
It was also thought that use of the ADH2 promoter would be of great help. To the best of 
our knowledge, it is the only yeast promoter that naturally allows a slow and gradual 
582 
 
induction of expression of foreign proteins when cells are grown in glucose, the beast 
carbon source for growth of all living cells. 
 
8.3 Human CYP enzyme expression from a single 
chromosomal location of the yeast genome  
 
The yeast integrative plasmids, containing a CYP gene expression cassette, used the 
ADE2, HIS3, or URA3 genes as a yeast selection marker. The integrative plasmids were 
linearized within these marker genes. The linear DNA is flanked at either end by the 5’-
end and the 3’-end of the marker genes. These flanking regions allow homologous 
recombination at the chromosomal sites of the yeast genome which bears the 
dysfunctional ade2, his3 and ura3 genes. If homologous recombination were to occur, a 
CYP_yc gene expression cassette introduced into the yeast genome would allow the cells 
to become ADE2, HIS3, or URA3 (i.e. the genes would become functional again), 
depending on the integration plasmid used. This would allow initial selection of cells that 
contain an integrated CYP_yc expression cassette in minimal SD medium that lacks 
adenine, histidine or uracil, again depending on the integration plasmid used. Once the 
integration is confirmed in SD medium, the cells harbouring an integrated gene 
expression cassette or gene expression cassettes could be propagated indefinitely, without 
any selection, in full complete YPD medium.  
Integration of a single copy of various CYP_yc gene expression cassettes and further 
biochemical analysis of the expressed enzymes are described in Chapter 4, Sections 4.6 
to 4.16.  
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Yeast strains for the following human CYP enzymes were constructed with a CYP_yc 
gene copy at the HIS3 or URA3 locus: 1A2, 3A4 3A5, 2D6-1(Val374), 2D6-2(Met374), 
2C9, 2C19, 2E1 and 4F3A. In the case of 3A4, the CYP3A4_yc  gene was also integrated 
at the ADE2 locus.  
Cellular assays were developed from scratch to assay each of the human CYP enzymes 
that were expressed in baker’s yeast. This had to be done since such type of cells have 
never been reported before. Fluorogenic substrates, which are non-fluorescent to start off 
with but which fluoresce when a product is formed, were used to set up the enzyme 
assays. These substrates were also very helpful in selecting high producing clones from 
each strain. Often 50 clones were screened to obtain a high CYP enzyme producer which 
could be later used for (a) isolation of microsomal enzyme and (b) biotransformation 
reactions.  
Results with all CYP enzymes tested show that chromosomal integrations of a CYP_yc 
gene provides much higher levels of a CYP than a strain containing CYP_yc gene bearing 
episomal plasmid, even after 18 h of growth which was quite unexpected. Minimal 
plasmid loss should occur during an 18 h period of yeast cell growth. The results indicate 
that chromosomal integrations provide stability to the foreign genetic information which 
yeast cells propagate during cell division. 
In general, it was observed that the HIS3 chromosomal location provided the highest 
levels of a functional CYP enzyme. As discussed in Chapter 4, this may be due to the 
neighbouring proteins within chromosome XV, where the HIS3 gene lies, that may be 
acting in trans to regulate the expression of CYP genes under the control of the inducible 




8.4 Expression of a CYP enzyme transcribed 
simultaneously from two or three gene 
expression cassettes, located at different 
chromosomal loci  
 
The importance of a chromosomal integrated copy of a human CYP gene expression 
cassette has been described in the above Sections. The development of one copy yeast 
strains overcomes the problem of stability encountered when using episomal plasmids. 
To explore further, a second copy of a CYP gene was added to an existing copy contained 
within yeast strains. It may be logical to assume that a second copy will provide better 
levels of functional CYP enzymes than from a single copy. However, CYP enzymes are 
inherently toxic because of their redox properties allowing them to generate high levels 
of ROS during overexpression. Since already it has been seen that a chromosomal 
integrated copy produces a lot more CYP enzyme than from an episomal plasmid, even 
at 18 h of growth, it may have been unrealistic to expect that there would be more CYP 
protein produced if expression occurred simultaneously from two separate chromosomal 
locations.  
The HIS3 gene belongs to yeast chromosome XV and the URA3 gene is an integral part 
of chromosome V. It may be possible that transcription of two independent copies of a 
CYP_yc gene from two different chromosomal locations may be able to enhance levels 
of proteins made through ‘neighbouring effect’ or ‘crowding effect’ (Benton et al., 2012 
; Despa, 2005).  
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The results in Chapter 5 show that a strain bearing two copies of a CYP gene does produce 
more CYP enzyme than the strain containing a single copy.  
The microsomal CYP enzymes were isolated from strains containing (a) two integrated 
copies of the CYP_yc gene and (b) an episomal plasmid which encodes the CYP_yc gene. 
The amounts of functional CYP enzymes were measured via carbon monoxide (CO) 
difference spectroscopy as was described in Chapter 2. It involves binding of CO to 
CYP450 to measure the amounts of CYP450 produced. The results show that amount of 
an enzyme produced from 400 ml of cells, cultured from strains containing two integrated 
copies of a CYP_yc gene, are a lot more than the enzyme produced from the same number 
of cells containing a CYP_yc gene bearing episomal plasmid. The Western blots show a 
clear difference in the amounts of CYP enzymes produced within the two types of cells. 
The IC50 values of know inhibitory compounds, using the Sacchrosomes (yeast derived 
microsomal CYP enzymes) show that the values obtained are close to those published for 
human liver microsomes (HLMs) indicating that the CYP-Sacchrosomes possess active 
sites that are similar to the native enzymes produced in human liver cells. This indicates 
that instead of depending on expensive HLMs, Sacchrosomes can reliably be use for rapid 








8.5 Roles of yeast bias codon synthesised 
recombinant CYPs in biocatalysis 
 
In Chapter 6, biotransformation reactions were performed using whole yeast cells. Three 
CYP enzymes, CYP1A1, CYP2D6, and CYP3A4, contained within whole yeast cells 
have been used for the biocatalysis of interesting substrates, as a proof of principle that 
whole yeast cells can be used for efficient biotransformation. 
CYP1A1 was used for the conversion of chrysin to baicalein. More than 90% of chrysin 
was converted to baicalein after 144 hrs of incubation with whole cells. The conversion 
involved selective hydroxylation at the C6 position of chrysin. Molecular modelling 
(PDB ID: 418V) has explained this selectivity.  
Whole yeast cells expressing CYP2D6 variants have been used to study the metabolism 
of codeine to morphine. A novel CYP2D6 variant (P34S/A122V/S486T) has been 
identified serendipitously. It converted > 60% of codeine to morphine whereas the other 
two variants (Met374 and Val374), both of which have often been referred to as wild type, 
convert < 30% of codeine to morphine. The Met374 and Val374 variants produce a lot more 
nor-codeine through N-demethylation than the other variant which predominantly 
catalyses O-demethylation to morphine.  
Whole yeast cells expressing CYP3A4 have been used to follow the biotransformation of 
a medicine in phase II/III clinical trials. It had been disclosed that all commercially 
available CYP3A4-based test systems were able to convert < 10% of the compound AZD-
2014 to its metabolites. We have shown that approximately 80% of AZD-2014 was 




8.6 Crowding effect through the co-expression 
different CYP enzymes within whole yeast cells  
 
The activities of CYP1A2, CYP2D6 and CYP3A4 were analysed after c-expression, 
using fluorogenic substrates CEC and EOMCC. The results show that the CYP2C19 
activity is greatly enhanced when co-expressed with CYP2D6. In parallel, CYP1A2 
activity is remarkably improved when it is co-expressed with CYP3A4, CYP2C19 or 
CYP2D6. This would indicate that co-expressing a second CYP enzyme leads to 
stabilization of the 3D structure, thereby activities, of CYP1A2 and CYP2C19. This may 
be an indication that ‘molecular crowding ‘or ‘neighbouring effect’ is playing a role in 
stabilisation. 
The CYP inhibition assays were successfully set up and performed for CYP1A2, 
CYP2D6 and CYP3A4 enzymes. The aim was to determine whether there are any 
differences in IC50 values of the co-expressed CYPs in comparison to the values reported 
in hepatocytes.  The mean IC50 values found for the known inhibitors, furafylline, 
quinidine and ketoconazole were consistent with that reported previously (Crespi et al. 
1997). These inhibition studies demonstrated that CYP-expressing whole yeast cells can 




In summary, we have devised various yeast systems that produce functionally active 
human CYP enzymes. The CYP genes that were used were chemically synthesised using 
yeast biased codons. It has been shown clearly in the early part of the thesis that these 
biased codons definitely facilitate expression of human CYP enzymes in yeast. The use 
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of yeast biased codons has allowed us to achieve our goal of improving expression levels 
for all human CYPs that have been studied.  
The key findings of this thesis are listed below: 
1. Expression of high levels of CYP proteins from episomal plasmids encoding 
genes with yeast biased codons. It allowed us to answer the question whether 
chemically ‘synthesized’ CYP genes produce active CYP enzymes that are as 
good as the enzymes produced from the ‘native’ genes. It was found that genes 
with yeast biased codons produce a lot more protein than the native genes. 
2. CYP genes integrated on a chromosomal locus have a huge effect on the yields 
and activities of all CYP enzymes produced. The HIS3 locus was the best for 
expression.  
3. The integration of two or three CYP genes produced higher yields than the single 
copy integrated strain. This allowed us to create improved systems that may allow 
convenient (a) drug metabolism studies and (b) bioorganic synthesis of high-value 
chemicals via biotransformation.  
4. Human CYP microsomal enzymes isolated from yeast were far superior to 
commercially available CYP microsomal enzymes from the three leading 
manufacturers of these enzymes which are isolated from insect and bacterial cells. 
Furthermore, multiple enzymes co-expressed within the same yeast cell produced much 
higher yield when compared with the individual CYP enzymes expressed from yeast 
cells. This allowed us to create a system which on further development could possibly be 




8.8 Future prospects 
 
In this study, we have established the role of the yeast biased codons and integration of 
genes containing these codons into the genome of yeast cells provides proteins with high 
yield and activity. Nonetheless, there is more that needs to be done to establish the reasons 
why cytochrome b5 is more selective towards certain CYP enzymes. If we can change 
the locus of cytochrome b5 in the parent yeast, maybe we could establish this reason. 
Also, in 1999, Zhao and colleagues studied the crystal structure of the FMN binding 
domain of human cytochrome P450 reductase (CPR). Their findings indicate that the 
FMN domain has an unusual surface charge distribution, leading to a very strong dipole 
which may be involved in docking a CYP into place for electron transfer (Zhao et al. 
1999). This could be a clue for future optimisation of production of CYP450 enzymes in 
large scale. If we can create an artificial electron donor in some of the strains that are 
already producing CYP450, maybe the time scale for production could be cut down and 
a higher yield would be achieved. As we understand, all CYPs have different sites in their 
binding surface for receiving of necessary electrons from NADPH. This would be 
achieved using methods that will mimic the surface of cytochrome b5. This will prevent 
competition from cytochrome P450 reductase for binding to the site of some CYP450 
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